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2PREFACE
When a patient embarks on pregnancy, she expects to remain in good health and, 
after the minimum of interference, to deliver unaided a healthy, well grown and 
vigorous child. Reproduction is a natural function, bu t experience has shown that, in 
many instances, a  pregnant woman suffers from some abnormality of pregnancy or 
labour, increasing the risk for both her and her child. Hypertension in pregnancy is 
one such abnormality with well recognised risks for both m other and baby. The 
cause of the blood pressure rise is unknown bu t appears to be related to an  inability 
of the m other to adapt to the normal changes of pregnancy, with a  deficiency of 
plasma volume expansion and an increased peripheral resistance. The reason for the 
failure in  the physiology of a given pregnancy may be genetic or hereditary in origin, 
an  abnormal reaction to a given pregnancy or may have its primary source in  some 
feature of the environment.
While the incidence and the presentation of any disease is easily studied, aetiological 
factors and the risks to mother or baby are more difficult to assess. With changes in 
the environment, improvement in antenatal care and improved general health, 
there has been a reduction in most major complications of pregnancy, including 
severe preeclam psia/eclam psia. As the incidence of the condition falls, the  
im portance of the rarer atypical forms increases. This m akes the study  and  
management of the condition more problematical as the num ber of patients seen by 
an  average obstetrician is greatly reduced. Despite the fall in  the incidence of the 
severe condition, the overall incidence of all types of preeclampsia has not altered, 
remaining at around 25% in primigravid and 10% in multigravid patients. The 
m aternal death rate associated with it has not changed for over 20 years. This has led 
to a call for specialised teams to be set-up to study and manage the condition.
One such team was formed at the beginning of 1981 in the Glasgow Royal Maternity 
Hospital under the direction of the author. The aim of the group was to study the 
aetiology, presentation, assessm ent of risk and morbidity and m anagem ent of 
hypertensive disorders in pregnancy. There has been an attem pt to develop methods 
of screening, of prevention and of treatm ent that could then be used in other centres. 
The basis of this thesis is the history of the formation and workings of this group.
The team consisted of obstetricians, midwives, haematologists and biochemists. All 
clinical and research work was conceived, instigated, directed and largely carried out 
by the author who saw and assessed all hypertensive patients attending the GRMH 
over the nine year period.
Much of the previous work carried out in hypertension in pregnancy has been done
3retrospectively after the pregnancy is over and the outcome known. Retrospective 
analysis does not help the assessm ent of risk to a patient at the time of presentation 
of the problem during the pregnancy and does not help in the m anagement of the 
case. The main objective of the work was to look at the problems of hypertension in a 
prospective way.
Although the concept, planning, direction and organisation of the studies were the 
author's, m uch of the laboratory and some of the ward work was carried out by other 
members of the team. A sincere debt is owed to many people.
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After a critical review of the literature, it was decided to study the risks, presentation 
and m anagement of patients with pregnancy hypertension in  our population, the 
role of antihypertensive drug therapy on disease stabilisation and progression and 
the causes of the prostaglandin/thromboxane imbalance and the increased platelet 
consumption.
The incidence of eclampsia has fallen from the mid 1930's to the early 1980's. The 
largest reduction occurred at around 1950. There were 74 maternal deaths in the first 
decade, 14% of all eclamptics. There was only 1 m aternal death in  the last two 
decades, 5% of the eclamptics. Therefore, not only has the incidence of eclampsia 
fallen, bu t also the incidence of maternal death from eclampsia. Perinatal survival 
has improved over the five decades. However, from 1973 to 1982 one-third of the 
babies bom  of m others with eclampsia died, dem onstrating th a t a  high risk  
rem ains. Delivery, with various m ethods of sedation, was the  m ost common 
management. Only since 1973 have antihypertensive drugs have been used regularly. 
Investigation of blood pressure variation showed th a t over 60% of patients had a 
blood pressure variation of more than  5 mmHg in both systolic and diastolic blood 
pressure when 2 m easurements were taken 10 minutes apart. An average of 4 blood 
pressure readings taken between 30 and 60 m inutes appeared to give an  accurate 
estimate of a patient's blood pressure. Automated blood pressure monitoring showed 
similar variations, bu t the Dinamap automatic blood pressure recorder tended to 
m easure the diastolic blood pressure about 8 mmHg lower than  the nursing staff. A 
single blood pressure reading was not used for diagnosis or for making management 
decisions.
At Daycare, it was found tha t if the 3 param eters of blood pressure, uric acid and 
platelet count were all normal, 95% of the patients would remain normal throughout 
the rest of their pregnancy without the need for any specialised care. This constituted 
over 50% of the patients who attended daycare. If any of these param eters were 
abnormal, 40% of the patients would progress to a more severe form of the disease. 
Most the patients referred to day care attended only once, and then  returned to the 
antenatal clinic for routine care. This has reduced the num ber of admissions and 
num ber of inpatient days spent because of hypertension.
Using multiple regression analysis of the various param eters, it was found th a t 
proteinuria was associated with earlier gestations, and growth retardation with later 
onset disease. Uric acid was associated negatively with platelet count and positively 
with abnormalities of liver enzymes and diastolic blood pressure, suggesting th a t it 
may be a  marker of systemic involvement. The causes of the changes in  albumin are 
multiple and not related only to proteinuria.
An increase of platelet size was only seen if severe hypertension developed after 34
17
weeks. This suggests tha t those developing severe preeclampsia later in pregnancy 
would appear to have a more chronic onset with a prolonged stim ulus to platelet 
activation and increased platelet turnover.
Associated studies were carried out on prostacyclin levels. Studies in hypertensive 
patients showed th a t patients with severe disease all had unrecordable levels of 
prostacyclin (<5 ng/ml), and that about 50% of those with moderate disease also had 
unrecordable levels. Thromboxane did not appear to be elevated in  most patients. 
Although the prostacyclin/thromboxane balance is disturbed, it is mostly due to 
deficiency of prostacyclin rather than  an  elevation of thromboxane.
A serial study of prostacyclin showed th a t levels fell below the lower limit of the 
assay before the onset of hypertension. This suggests tha t the ability to produce 
prostacyclin was exhausted prior to the development of the hypertension.
Studies of antihypertensive drugs in acute hypertension showed th a t hydrallazine, 
oral labetalol and oral nicardipine could adequately reduce the diastolic blood 
pressure over a  period of 30 minutes to 1 hour. This reduction was m aintained over 
the next 2 hours.
A randomised study of labetalol against bed rest in mild to m oderate pregnancy 
hypertension showed th a t bed rest alone did not lower blood pressure or slow the 
progression of the disease, whereas labetalol therapy significantly reduced blood 
pressure and appeared to slow the progression of certain disease param eters. 
However, there was no difference in the outcome of the pregnancies between the two 
groups. If the diastolic blood pressure was below 100 mmHg, there did not appear to 
be any benefit from early therapy. There is no evidence tha t these medications are 
harmful to the mother or baby.
A further study of 186 primigravidae with severe proteinuric preeclam psia was 
carried out. Adequate reduction of blood pressure was achieved in 95% patients using 
either labetalol alone or in combination with a  vasodilator drug. The average length 
of treatm ent was 15 days. There was no change in the fetal heart rate patterns or 
blood flow param eters as measured by Doppler velocimetry with commencement of 
therapy. Maternal monitoring, including uric acid, blood pressure, proteinuria and 
platelet count did not relate to fetal wellbeing. Gestation at presentation was the 
m ost significant parameter. After 30 weeks almost all the babies did well. In the 
group presenting before 30 weeks, outcome was associated with evidence of fetal 
compromise. If the results of fetal monitoring were satisfactory, the outcome was 
good irrespective of maternal disease severity.
Over the last 9 years 3,885 hypertensive patients have been reviewed. Prophylactic 
anticonvulsants were not used unless there were obvious signs of severe progressive 
hypertension with evidence of imminent eclampsia. The incidence of eclampsia in
IS
these patients was low suggesting tha t there is no need for routine anticonvulsant 
therapy.
It is concluded th a t a stepwise approach to the management of hypertension in 
pregnancy is possible. Most patients can be managed as outpatients without the need 
for intervention. Patients who have blood pressure persistently greater th an  100 
mmHg can be treated safely with antihypertensive therapy as long as the baby is 
well. This is associated with a  reduction of hospital adm ission, reduction of 
intervention and a general reduction in the perinatal mortality rate.
CHAPTER 1
INTRODUCTION
TO
THE THESIS
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There is m uch confusion concerning the condition of hypertension and convulsions 
in pregnancy, although the association of convulsions and m aternal death has been 
known since ancient times. The word "eclampsia" comes from the Greek verb 
"eclamptien" m eaning "to flash out". This relates to its sudden onset or to the 
flashing hallucinations experienced in the prodromal phase. Hippocrates described 
the condition in  "On The Sacred Disease". Unfortunately he did not distinguish 
eclampsia from epilepsy, bu t stated th a t "it proves fatal to women in the state of 
pregnancy" (Chesley, 1980). Over the centuries, it was noted th a t the presence of 
convulsions and coma were ominous signs in the presence of difficult labour and 
often resulted in the death of both mother and fetus (Chesley, 1980). In the sixteenth 
century, Gabelchoverus noted tha t pregnancy was a cause of epilepsy and described 
the epigastric pain associated with this. He felt that the pain was a sign tha t the cause 
of the convulsion came from the uterus (Chesley, 1980). Mauriceau (1668), refers to 
eclampsia as does Denman (1768) in a book dedicated to the problem along with 
puerperal fever. He recognised eclampsia as a major cause of morbidity and 
m ortality.
Once it was realised tha t the condition was specific for pregnancy, it was thought by 
m any to be a form of renal disease. In 1843 Lever found that patients with eclampsia 
had proteinuria (Lever, 1843). Although he realised th a t eclampsia was different 
from renal disease since the proteinuria disappeared after delivery, others thought 
th a t the condition was very similar to th a t seen in glomerulonephritis. Simpson, 
who found proteinuria at about the same time, saw contracted kidneys in  one of his 
patients and felt that this was the cause of the problem (Simpson, 1843). This became 
the popular opinion for some time. It was not until the development of methods of 
assessm ent of renal function and finally the renal histology studies of Sheehan 
(1950) and McCartney (1964), that the timing of the stages of the disease was realised. 
Both Sheehan and McCartney stated tha t renal lesions were present only when the 
patient had proteinuria and since this was a late m anifestation of the condition 
called preeclampsia, it could not be a primary cause of the condition.
It was not until the late nineteenth century tha t hypertension was first noted to be 
associated with eclampsia (Ballantyne, 1885; Cook and Briggs, 1903). In 1896, 
essential hypertension was first differentiated from renal hypertension. However, as 
it was originally called 'senile plethora1, many obstetricians felt th a t none of their 
(mostly young) patients could have this condition (Chesley, 1980). It was not until the 
1940's th a t the possibility of essential hypertension as a cause of hypertension in 
pregnancy was accepted. From this time it was realised tha t renal disease was a 
relatively rare cause of hypertension in pregnancy. Although pregnancy could occur 
in  a patient with preexisting essential hypertension, renal disease or o ther
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hypertensive disorder, there was a specific hypertensive syndrome arising in  
pregnancy tha t disappeared when the pregnancy was over and apparently carried no 
long term sequelae (Chesley, Annitto and Cosgrove, 1976).
The realisation th a t th is  pregnancy "associated" hypertension often antecedes 
convulsions, led to the term  "preeclampsia". This term  was initially used for the 
immediate prodromal stage of eclampsia but now is applied to patients with milder 
forms of the disease. Although eclampsia is associated with hypertension, it is not 
an  obligatory endpoint of the condition. Convulsions are independent of the severity 
of the disease. 'Mild' preeclampsia may be associated with convulsions and 'severe' 
may not. Between 15 and 20% of the patients suffering from "eclampsia" had no 
record of hypertension prior to the seizure (Cruickshank, 1923; Cruickshank, Hewitt 
and Couper, 1927) Although these early findings could partly be due to inadequate 
records, the results have been confirmed by more recent workers (Sibai et aL, 1981b). 
Modem thinking appears to simplify classification of hypertension in pregnancy. 
However, hypertension in pregnancy is not a single disorder, b u t has m ultivariant 
causes, dependent on different aetiologies and on the m other’s varying response to 
the stimuli. It is often not possible to be sure to which group a patient belongs at the 
time of presentation. Postnatal followup may dem onstrate, for example, renal 
pathology causative of the hypertension.
Over 100 nam es have been used in the past to define the  different forms of 
hypertension in pregnancy and efforts have been made to simplify th is (Rippman, 
1968; Hughes, 1972; Nelson, 1955b) The m odem  term  of "pregnancy induced 
hypertension" is no great improvement, as it implies aetiology.
Until the underlying aetiology is understood, however, the disease will continue to be 
described in the clinical way it presents or develops. The "Organisation Gestosis", or 
EPH-Gestosis, was the first international organisation formed for the study of this 
clinical condition. It uses the clinical signs of Edema, Proteinuria and Hypertension 
as the basis of the diagnosis. The presence of any two of these signs is all th a t is 
required for the diagnosis of 'gestosis’ bu t the dominance of the oedema as the 
presenting sign is over-stressed and the hypertension is given little prominence 
(Rippman, 1968). The "International Society for the Study of Hypertension in 
Pregnancy" (ISSHP) is devoted to the study of all aspects of the pregnancy conditions 
associated with hypertension. The emphasis is on hypertension arising for the first 
time during pregnancy and its various m anifestations (Davey and MacGillivray, 
1988). These m ethods of classification lead to confusion, as some patien ts with 
"gestosis" do not have "preeclampsia". It is important to realise th a t these societies 
are describing different groups of patients, although there is a considerable degree of 
overlap.
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The problem s with the definitions of the condition make com parison of the 
apparent incidence and risks difficult. It would appear tha t hypertension in hum an 
pregnancy occurs in around 25% of primigravid and in  10% of the multigravid 
m others, b u t the incidence varies with the experience of different au thors 
(Chamberlain et a l, 1978b; Nelson, 1955b; MacGillivray, 1958; Common Services 
Agency., 1986). In Western society, despite improved environmental conditions, 
improved m aternal health , greatly improved an tenatal care and  reduction in 
perinatal loss in association with hypertensive syndromes, the rate of m aternal 
death attributed to pregnancy hypertension has not changed for twenty years (DHSS, 
1969; DHSS, 1974; DHSS, 1979; Turnbull, 1987; Turnbull et aL, 1989; Scottish Home 
And Health Departm ent, 1978; Scottish Home And Health Departm ent, 1987; 
Scottish Home And Health Department, 1989). In 75%-81% of the m aternal deaths, 
avoidable factors were found. Most of these were associated with failure to recognise 
warning signs. There was a failure to initiate proper therapy rather th an  the use of 
inadequate or wrong therapy. The reduction in the incidence of the severe forms of 
hypertensive disease in pregnancy in the United Kingdom has led to reduction in  the 
exposure of obstetricians to the problem and a lowering of their ability to manage the 
severe cases as they arise. The m odem  clinician is caught in a  clinical dilemma. 
Because the incidence of severe forms of the condition appears to be reducing, while 
the overall incidence of all forms of hypertension appears to be unchanged, the risk 
of the hypertension in pregnancy to the m other and baby would appear to be 
diminishing. Therefore, it is difficult to justify continued admission to hospital for 
all cases of hypertension in pregnancy, especially when the risks appear to be small 
and the patient feels so well. As the rate of m aternal death has not changed and 
hypertension in  pregnancy is still a  significant contributor to the  perinatal 
m ortality rate (Common Services Agency., 1986; Scottish Home And Health 
Departm ent, 1989), the more cautious approach of adm ission to hospital for 
observation might also seem reasonable. Since pregnancy has a finite length and the 
admission to hospital will be only for a short stay, the price to pay for admission is 
small and the rewards of success appear to be great. Every satisfactory outcome 
following admission to hospital for the management of th is condition leads to a 
further positive reinforcement that it is the best approach (De Sweit, 1985). A logical 
approach to the management of pregnancy hypertension is difficult because of the 
emotional and deep seated feelings it can produce (De Sweit, 1985; Hodgson, 1985). 
Anything that is thought to put the mother or baby at risk is rejected in return  for the 
tried and tested 'status quo'. However, there has been no randomised study carried out 
proving th a t admission to hospital is beneficial to m other or baby (Crowther and 
Chalmers, 1989). Since the situation is confused, and experience limited, there has
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been a call for the setting up of specialised team s of clinicians to manage and study 
all patients who present with hypertension in pregnancy (Turnbull et aL, 1989).
In 1980, the author initiated a programme to study hypertension in pregnancy. This 
consisted of investigations into the incidence of hypertensive problems in  the 
hosp ita l practice, the  m aternal and fetal m orbidity associated  w ith the  
hypertension, specific aspects of aetiology, the  role of screening te s ts  for 
hypertensive risk, the role of early intervention therapy using hypotensive regimes 
in  both mild to moderate and severe pregnancy hypertension and the development of 
standardised protocols to simplify patient management. It was hoped th a t the 
majority of the screening, monitoring and treatm ent could be achieved as an  
outpatient th u s  reducing the need for hospitalisation and allowing more intensive 
care to be provided to those who would m ost benefit from it. Initially these 
investigations were carried out on patients cared for by the academic unit, bu t with 
increasing acceptance and cooperation from consultant colleagues, all patients 
attending the GRMH were included.
CHAPTER 2
THE OBJECTIVES 
OF THE THESIS 
AND
GENERAL METHODOLOGY
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Since 1980, the au thor has initiated a programme of clinical and scientific 
assessm ent of the hypertensive patient in the Glasgow Royal Maternity Hospital. He 
has assumed the role of “research director” in the initiation and development of this 
programme, raised the necessary research money and engaged research fellows to 
undertake the studies primarily designed and selected by himself. Some of these 
projects were developed further by these fellows some of whom have obtained 
secondary degrees. The programme is continuing and some of the projects are 
incomplete and will be reported in due course in scientific journals. They will be 
alluded to in Chapter 11.
This thesis describes the completed clinical and research projects conceived, 
initiated and directed by the author under the following headings.
2.1 A Critical Review of the Current State of Knowledge
Every attempt has been made to review the relevant literature. It was important tha t 
new studies should be aimed at answering gaps in the knowledge or clearing up 
confusion rather than  repeating reliable studies already well documented.
This critical review is in separate parts.
1) The D efinition of pregnancy hypertension.
2) The Aetiology of pregnancy hypertension.
3) The Risks of pregnancy hypertension to both mother and baby.
4) The current thoughts on Management of pregnancy hypertension.
This work is presented in Chapter 3.
2.2 Assessment of Risk to Glasgow patients.
Although the risks of pregnancy hypertension in general are described in Chapter 3, 
it was im portant to investigate the current risk to patients attending the Glasgow 
Royal Maternity Hospital (GRMH) as treatm ent protocols would be directed a t th is 
group of patients.
The GRMH has been at the centre of Glasgow Obstetrics for 150 years. Over 550,000 
Glaswegians have been bom  within its walls and an  similar num ber delivered 
within its districts. It would appear to be a perfect place to study the changing 
incidence of a condition over time and its concomitant risks. The medical records 
are available in some form going back over 50 years. Some of the records themselves 
are accessible and the hospital reports also give full information on the problems of 
each year. It was decided to use eclampsia as a marker of disease change over time as 
it is a  hard end point where the accuracy of the diagnosis over time would not be 
questioned.
The questions that were asked were:-
1) What is the change in the incidence of eclampsia?
2) Has there been a change in the presentation and tim ing of eclampsia?
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3) Has there been a change in the outcome for the mother and baby?
4) What have been the changes in the management of the condition?
5) What pointers can be found for the development of management protocols.
This work is presented in Chapter 4.
2.3 Studies on disease presentation and diagnosis.
Little in  obstetrics has been studied or assessed by randomised clinical trial (Yusuf, 
Collins and Peto, 1984). Antenatal care, blood pressure m easurem ent, weight 
estimation and clinical examination all were established at a time when widespread 
m aternal and fetal death was a  recent memory. In many parts of the world, it is still 
a fact of obstetric life. However, it is now accepted that many patients presenting with 
hypertension in pregnancy are not a t m ajor risk, and th a t the outcome for the 
m other and baby of hypertension in  pregnancy is ho worse th an  in the / - 
normotensive patient, unless severe disease occurs. If it were possible to distinguish 
the low risk  from those who may progress, it might be possible to attenuate the 
progression to the more severe form and so reduce the risks to m other and fetus. It 
would also allow the low risk patients to be treated as normal pregnancies, reducing 
the chance of obstetric interference.
Modem obstetrics has given the obstetrician a wide armoury of tests and equipment 
for monitoring the wellbeing of the m other and her fetus. Many of them  are 
expensive to use in equipment cost and staff. These techniques are not particularly 
transportable to other centres with fewer resources. Many have not been fully 
evaluated and are accepted because they are ‘clever’ rather th an  because they are 
useful. Tests that are associated with a given disease state might be useful in the study 
of the aetiology, b u t may be of little value if they add nothing to the  clinical 
evaluation of the condition. The aims in this thesis were to study the various routine 
tests available and choose the simplest tha t would give the most useful information. 
The questions asked were:-
1) How accurate is the measurement of blood pressure?
2) W hat is the normal variation in blood pressure m easurem ent throughout 
pregnancy?
3) Which of the ‘routine’ tests give the best information concerning disease 
diagnosis and progression?
4) How m any women progress from a mild form to a severe form of the  
condition?
5) Can signs of disease progression be found and be used as an  accurate disease 
predictor?
6) Can the patient be categorised into a low risk group to be allowed to re tu rn  to 
normal antenatal care?
7) Can simple protocols be drawn up for the investigation of a  hypertensive 
patient and implemented easily on an  outpatient basis?
This work will be presented in Chapters 4-7.
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2.4 Aetiology of pregnancy hypertension
The aetiology of th is condition is still largely unknown. Although it could never be 
hoped tha t this work would answer this perplexing problem, there were certain areas 
tha t were investigated closely to try and increase the understanding of the causes of 
the  condition. It was hoped th a t th is might help design potential m anagem ent 
protocols.
As will be discussed in the review chapters, one of the most persistent findings in 
preeclampsia is platelet consumption. This may be part of the disease process or 
caused by it. Studies were carried out into the incidence of platelet consumption and 
its relationship to disease progression.
The questions asked were:-
1) What are the changes in mean platelet volume in hypertensive disease in 
pregnancy?
2) Do the changes demonstrate signs of platelet activation?
3) When does platelet activation take place and does it antedate the presentation 
of the clinical signs?
This work was based mainly on changes in platelet size and will be described in 
Chapter 8.
Control of platelet activation involves the prostaglandin system. Abnormalities of 
prostacyclin/throm boxane balance may be responsible for any abnorm ality of 
platelet function. Another abnormality th a t has been found in preeclam psia is 
vascular reactivity. Prostacyclin is a potent vasodilator and throm boxane is a 
vasoconstrictor. Therefore, an  imbalance of prostacyclin/throm boxane balance 
may be responsible for these vascular findings. Therefore, studies of the blood levels 
of the metabolites of prostacyclin and thromboxane were carried out in  normal and 
abnormal pregnancy. The assay work was carried out at the authors request by the 
University Department of Medicine in the Glasgow Royal Infirmary. An integral part 
of these studies was the development of the assay techniques. These have been 
published (McLaren et a l, 1985) and will only be commented on in the methodology 
sections and the discussion.
4) What are the normal changes of prostacyclin and thromboxane m etabolite 
levels in normal pregnancy?
5) What changes are seen in patients with preeclampsia?
6) What is the tim ing of these changes?
This work will be described in Chapter 9.
2.5 Treatment of the condition
Delivery of the preeclamptic patient is the m ainstay of treatm ent, a s  it leads 
(eventually) to the cure of the patient. Traditionally medical therapy h as been 
restricted to the use of anticonvulsants and the acute use of antihypertensive drugs in 
severe hypertension. At the time of commencement of th is  work, stud ies were
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beginning to report the benefits and the harm  of antihypertensive drugs in 
pregnancy hypertension. Over the time of th is work, newer drugs have become 
available. These have allowed a wider investigation of the role of blood pressure 
lowering drugs.
The questions asked were:-
1) Are antihypertensive drugs effective in pregnancy?
2) How do they compare with traditional bed rest?
3) What effect do they have on the disease process?
4) What side effects are seen in the mother?
5) What effect do they have on the fetus?
6) What patients, if any, benefit from therapy?
This work will be described in Chapter 10.
2.6 Project goals
The project goals were:-
1) To try  and gain a  greater understanding of how the  disease develops, 
progresses and how it causes its harmful effects.
2) To increase the m onitoring for patients at particular risk.
3) To reduce the mortality and morbidity especially for the baby.
4) To clarify the role of antihypertensive drugs.
5) To develop a logical and individual approach to the m anagem ent of the 
condition.
These objectives will be taken in tu rn  and Chapter 11 will discuss whether any of the 
project goals have been met.
2.7 General Methodology.
Methodology will be discussed in each chapter where it is relevant bu t there are some 
general methods used which will be outlined here.
The pa tien t population
In any study of incidence and m anagement, it is im portant to study  a ‘to ta l’ 
population. This prospective investigation of hypertension in the Royal Maternity 
Hospital in Glasgow was based on all the patients presenting to the hospital from 
January, 1981 until December, 1989. The patients were seen on admission to hospital 
or a t attendance at the Daycare Assessment unit by the au thor or by one of the 
hypertensive team. The records department also provided lists of all patients who 
were coded as hypertensive and th is  w as checked against ou r records. 
Computerisation of the Daycare attenders and the admitted patients was carried out 
to allow full analysis of the total patient group. As will be discussed in  Chapter 3, 
preeclampsia is thought to be mainly a disease of the primigravida. Therefore studies 
of aetiology and monitoring were confined to primigravidae. M anagement studies 
also included parous women, but the patient groups will be clearly documented.
29
The Hypertensive team
The work with the hypertensive patients was conceived, initiated and directed by the 
author. However, with the increasing work load, help was required. As part of the 
expanding research programmes, grants were obtained and a series of research 
registrars were appointed. These registrars helped form the ‘Hypertensive Team’. All 
the hypertensive patients were seen on admission by a member of th is team. The 
m embers of the team  reported directly to the author. There was a  weekly team  
meeting when all the outpatient and inpatient problems were discussed. This allowed 
all the studies and management protocols to be coordinated.
Developing protocols
The m ain aim s of th is  thesis was to study the aetiology, p resentation  and 
progression of hypertension in pregnancy. However, various treatm ent regimes were 
also developed. All were designed and altered by the author and are described in 
Chapter 10.
The development o f a  microcomputer database.
There has been much interest in the use of computers in obstetrics, mostly using 
mainfram e or m inicom puters with the ability of collecting and storing large 
quantities of information. These systems are expensive and controlled by hospital 
adm inistrators. Because of this, the design of the database is largely orientated 
towards the adm inistrators' needs. There is little clinical data except the basic 
inform ation concerning an ten a ta l v isits and b irth  details. A lthough th is  
information is important to collect, it has little value to the clinical researcher with 
a specific area of interest. Large system s are inflexible, have relatively fixed 
databases and limited access points. Often only a few terminals can be active a t any 
one time and the access time is limited during office hours when demand is highest. 
The advantages of microcomputers is th a t they are cheap, locally controlled, and 
data handling is more flexible and can be tailor made to the needs of the user. A 
m icrocom puter can be linked to m ini's or m ainfram es to transm it or collect 
information, and to laboratory and clinical equipment to collect 'hands off data. Its 
use can be variable, as it can be used for different databases, as a word processor, 
spreadsheet or statistics calculator. ,
As part of the development of the projects into the study of hypertension in 
pregnancy, it was im portant to develop computerised data collection system s to 
allow accum ulation of patient information and resu lts  to ease analysis and 
followup. All th is work was carried out personally by the author. The first area 
computerised was the Daycare Assessment Unit for high risk  pregnancies. The 
microcomputer was used to collect and display the information in 'real tim e’ in  the 
unit itself. The computer calculated the average blood pressure readings. On screen,
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all abnormal results were highlighted in red to make sure tha t they were not missed. 
At the end of the day, a printout of the data was produced for insertion into the case 
notes for a permanent record of the attendance. The data was stored on disc to allow 
calculation and study of the data on a regular basis.
Equipment used
The equipment tha t suited this purpose best was the BBC 'B' microcomputer, despite 
its recognised limitations. It was fast, had good graphics, fast disk access and could 
easily be interfaced with other equipment. A further advantage of the system was 
th a t it can  be relatively easily programmed. The necessity of th is  becam e 
increasingly obvious when it was realised tha t few commercial systems allowed the 
freedom of data input, analysis or display th a t we desired. Although commercial 
packages such as Dbase and Viewstore are useful, a specific database system was 
developed allowing a custom  designed ’front end’, display and  s ta tistica l 
programmes. These files could be transferred into Viewstore or Dbase compatible 
files to allow manipulation of the data via the commercial packages b u t it was not 
necessary to have these programmes in the machine to use the system.
Methods
The initial equipment of a BBC microcomputer, twin disk drive, monitor and printer 
cost less than  £1,000 and gave word processor as well as database facilities. A 
programme was written in BASIC to collect the data in 'real time' (see Appendix). 
Care was taken to make sure the data was verified a t input. The programme was 
menu driven (Fig. 2.1) and required no computer experience to use. Student midwives 
were competent in using the system within the first day of being in the unit. All the 
information was in numerical form or from a choice list, no free text was allowed. 
This helped to confine the information to the expected values for analysis. The 
information was stored immediately on disk, so even if the system  crashes, all 
information is retrievable. Data was backed up weekly and indexed under patient 
name, num ber and date of attendance, allowing easy access to stored data. The file 
was compact so that one year's visits or 2,000 attendances could be stored on one side 
of a floppy disk as one file. This is approximately 276 Kilobytes. The information 
stored is shown in Table 2.1. All th is information was known on the day of 
attendance. The average blood pressure, uric acid and platelet count were used for 
patient assessment as described in Chapter 7. At the end of the day the information 
can be displayed on screen for analysis (Fig. 2.2) and printed out for case records 
(Table 2.2). At the end of each week sum m ary sheets were printed of patients 
belonging to a specific consultant or specific results value (e.g., platelets between 
100,000 - 200,000). This information was assessed by a separate access programme. 
Further equipment was purchased because of increasing demands for data storage.
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Initially th is was more BBC microcomputers bu t as prices of com puter equipment 
began to fall, IBM compatible machines were used with the Dbase 3+ database 
programme and then  Macintosh equipment with FileMaker Pro, Foxbase, Statworks 
and Cricket Graph programmes. All data collected on any machine can easily be 
transferred to any other machine to allow full analysis and display.
All the systems have been developed 'in house'. There is now 6 years of data on 
Daycare attendances allowing analysis of daily, weekly and monthly attendances, 
num ber of new patients and return visits, serial results for any patient and selection 
by data group. Inpatient and followup data have also been collected on separately 
developed systems.
The connection o f  a  BBC microcomputer to a  Dinamap blood pressure recorder/or  
collection o f ‘hands off* blood pressure data.
As part of the blood pressure studies, the autom atic blood pressure machine, 
Dinamap, was used. This work is described in Chapter 5 . To aid data collection, the 
Dinamap was connected to the computer to collect 'hands off data. It was hoped tha t 
this system would eventually help to reduce the nurses' workload.
BBC/Dinamap Interface
The BBC has multiple interface ports. The Dinamap has various outputs of its BP and 
pulse readings, either from the printer port or a 'standard' RS232 port. The BBC 
RS423 domino socket was used to connect with the Dinamap. With the original 
Dinamap the printer output was easily used, bu t with the newer Dinam aps the 
information is transm itted at 600 BAUD from the RS232 output and the  BBC can 
only read th is data if there is a software alteration in clock time readings. This can 
be done by a specific 'FX' call. The information is presented as a stream  of ASCII 
characters, giving BP, pulse and machine estimated m ean arterial pressure (MAP). 
These are read from the RS423 input buffer and the components split into their 
separate parts. The information is stored on disk and displayed in graphical form in 
colour and in numerical form. An average blood pressure and pulse are updated after 
each reading. The graphical display is in *bar’ format, the scale is self-correcting bu t 
starts with a  range between 150 and 50 mmHg. It moves up and down by 10 mmHg as 
necessary. An arbitrary figure of 90 mmHg diastolic is taken as abnorm al and all 
readings above this are displayed in red. The information on disk is indexed under 
name, num ber and date. The average BP reading is transferred to the day care file to 
allow display of this figure as well the nurses’ readings. The Dinamap programme 
can be used separately as a BP screening method or as part of an  ‘intelligent’ patient 
monitor.
2JB Statistics
All statistics carried out were done by standard commercially available packages,
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mostly Statworks on the Macintosh microcomputer. The methods used were 
the Student *T Test to study differences between the means of groups, 
the Fishers Test and the Chi Square Test to look for differences of the 
occurrence of events between groups,
the Wilcoxon Rank Sum Test to investigate within patient changes,
the Spearman Test of correlation was used to investigate the association
between various parameters and
m ultivariant regression analysis was used to study the independent
relationship between parameters. A stepdown procedure was used to check the 
validity of the significant results. This involves the removal of the  non­
significant results in a stepwise fashion until only the significant results are 
left. Advice was gratefully received from Dr Pravn in  the  University 
Department of Statistics.
The thesis was typed and all graphics were done by the author using MacWrite II, 
Cricket graph 1.3 and MacDraw II on a Macintosh microcomputer and printed on a 
LaserWriter IINT.
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CHAPTER 3
A Critical R eview and D iscussion
o f the
Old and Current Literature
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3.1 The Definition of Pregnancy Hypertension
(Lot. Definvre: to se t limits to)
Accurate disease definition is important to allow assessm ent of the risk  th a t the 
disease entails and for comparison between investigating centres. It is im portant to 
set the limits of the disease groups under study. The definition should be partly 
related to the aetiology of the condition and partly to the ' clinical presentation. It is 
im portant th a t the method of defining the problem is easy to implement and is 
reproducible in  any environm ent w ithout need for specialist knowledge or 
equipment.
Over 100 different nam es have been used to define hypertension in  pregnancy 
(Rippman, 1968). This is because the aetiology is largely still unknown and the 
clinical picture is so variable. If the classification is based on clinical presentation 
alone it becomes less specific and more like a syndrome th an  a disease state. 
Hypertension in pregnancy is largely defined using the m ain presenting signs of 
hypertension, oedema, proteinuria and convulsions. More recently ’subdefinitions’ 
have been produced based on laboratoiy findings. HELLP syndrome (Weinstein, 1982; 
Weinstein, 1985) consisting of Haemolysis, Elevated Liver enzymes and  Low 
Platelets, is one such example which has done little to ’help* the understanding of the 
problem (Greer, Cameron and Walker, 1985).
There h as been some improvement over the centuries. When Hippocrates first 
described eclam psia, he did not differentiate it from epilepsy. Similarly, 
Gabelchoverus, in the sixteenth century, felt tha t pregnancy was a cause of epilepsy. 
This is because the clinical presentation of epilepsy and eclampsia can  be very 
similar if other factors such as blood pressure and proteinuria are not taken into 
account (Chesley, 1980). By the end of the 18 th  century, there was a  realisation tha t 
the condition was specific to pregnancy and the term  “Toxaemia” of pregnancy was 
introduced (Beker, 1948). This further confused the situation as it implied the 
presence of a toxin causing the condition. Years of fruitless research followed but no 
toxin has been found despite the recent description of the 'worm* (Lueck et oL, 1983a; 
Aladjem, Lueck and Brewer, 1983; Lueck et a l, 1983b; Sibai and Spinnato, 1983; 
Perkins and Cauchi, 1983). Another problem was tha t several conditions came under 
the term 'toxaemia' including hypertension and eclampsia, albuminuria alone, acute 
yellow atrophy and hyperemesis gravidarum (Munro Kerr, 1933). This m akes the 
interpretation of studies reported from tha t time difficult. When Lever (1843) and 
Simpson (1843) found proteinuria in the urine in the 19 th  century, they wrongly 
assigned the blame for the condition to the kidney. It was not until the histological 
findings of Baird and Shaw Dunn (1933), Sheehan (1950), Sheehan and Lynch (1973) 
and McCartney (1964) tha t the separation of renal disease from the preeclamptic
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lesion became accepted.
It, therefore, became obvious tha t there were two main groups with hypertension in 
pregnancy (Chesley, Annitto and Cosgrove, 1976):-
1) Hypertension occurring for the first time during the pregnancy, labour or 
puerpeiium and returning to normal after the end of the pregnancy.
2) Pregnancy occurring in patients with preexisting essential hypertension, 
renal disease or other hypertensive disease diagnosed by previous history 
prior to pregnancy, high blood pressure at the booking clinic or persistent 
hypertension after the pregnancy is over.
The problems do not stop here. What is hypertension ? What is the relevance of the
other two m ain clinical signs of proteinuria and oedema? Where does eclampsia fit 
into the criteria? If a patient has preexisting disease, is it renal in origin or has the 
patien t essential hypertension? Can such a patien t develop 'superim posed' 
preeclam psia?
What is Hypertension ?
Blood pressure is not an  absolute value but a variable physiological measurement. In 
a large population it forms a normal Gaussian distribution. Pickering (1968) stated 
th a t arterial pressure is a quantity and should be treated as such. The diagnosis of 
hypertension is fairly arbitrary and there should not be a  rigid cutoff point taken to 
diagnose abnormality. Hypertension is not a disease in itself b u t a reflection of an 
individual’s response to an  underlying stimulus. It can therefore be used as a m arker 
of risk. Obviously, in any disease situation, the risk tha t a given value produces is an 
im portant param eter in determining whether th a t value is abnorm al or not. It 
should be remembered tha t discovery of an  association of high blood pressure and a 
detrimental outcome does not imply cause, only a relationship.
Studies by Friedman and Neff (1975) and Page and Christianson (1976) suggested that 
the risk to the baby increased significantly once the diastolic blood pressure was 
above 95 or 90 mmHg respectively (Table 3.1). Friedman and Neff (1975; 1976; 1978) 
found tha t this was true a t all gestations. This finding is surprising. In m any women, 
the diastolic blood pressure rises to above 90 mmHg as they approach term  when 
blood pressure reaches prepregnancy levels. These patients are a t low risk  of fetal 
loss (MacGillivray, 1961; Friedman and Neff, 1978). These studies confirmed the 
findings of the British Birth Survey of 1958 (Butler and Bonham, 1963, Butler and 
Alberman, 1969) th a t a single diastolic blood pressure above 90 mmHg was 
associated with an  increased perinatal mortality rate. However, the more recent 
British Births Survey 1970 (Chamberlain et a l, 1978b) did not demonstrated this, as 
a rise in perinatal mortality rate was not associated with diastolic blood pressure 
until it was either above 110 mmHg, or above 90 mmHg with significant proteinuria 
(Table 3.2). Similar findings were seen if the end point was neonatal neurological
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complications. The report concluded th a t raised arterial pressure in pregnancy, 
whether due to preexisting hypertension or to preeclampsia, increases the risks tha t 
the fetus will grow poorly, die in utero or be delivered prematurely (Chamberlain et 
a l, 1978b). This would appear to be an  over statem ent from their data as it would 
seem th a t in the absence of severe disease, the outcome is no worse th an  in the 
normal population. Differences in the outcome of pregnancies between these studies 
may well be due to management variations rather than  disease disparity.
The risks to the mother are more difficult to assess. Pregnancy hypertension is one 
of the largest causes of maternal death in England and Wales in the last twenty years. 
Cerebral vascular accident (CVA) was the commonest mode of death in  th is group 
(DHSS, 1969; DHSS, 1974; DHSS, 1979; Turnbull, 1987; Turnbull et a l ,  1989; 
Scottish Home And H ealth D epartm ent, 1978; Scottish Home And H ealth 
Department, 1987; Scottish Home And Health Department, 1989). It was often 
difficult to discover the maternal blood pressure before this event occurred as many 
patients presented only after the occurrence of the CVA. It can, however, be assumed 
tha t the risk is associated with a rise of blood pressure to abnormally high levels for 
th a t given patient. Blood pressures of 170-180/110-120 mmHg or greater are 
equivalent levels to those tha t produce vascular damage in experimental animals 
(Goldby and Beilin, 1972). The association with other complications is not so clear.
In m any studies there has not been an absolute correlation between blood pressure 
rise and eclampsia. Cruickshank (1927) in a review of patients in  the Glasgow Royal 
Maternity Hospital, showed th a t 18.5% of the eclamptics had a systolic blood 
pressure below 140 mmHg. In the John  Hopkins Hospital between 1924 and 1943 in 
2,418 cases of preeclampsia only 92 (3.2%) of the patients developed eclampsia 
(Chesley, 1971). Therefore, the risk of eclampsia would appear to relatively low for 
the preeclamptic.
In the 1930's, over 75% of all cases of abruptio placenta were associated with 
preeclampsia (Munro Kerr, 1933). More recent studies suggest tha t tha t is no longer 
true since now more than  two thirds of the cases occur in patients with normal blood 
pressure (Chamberlain, 1981). Although the British Birth Survey 1970 shows a slight 
increase of abruption in hypertensive patients (1.38%) compared with normotensive 
patients (1.05%) (Chamberlain et a l, 1978b), there was no increase in the perinatal 
mortality rate in these cases unless the abruption accompanied severe hypertension. 
Again, hypertension should not be classified as a risk factor for abruption.
Therefore, in summary, diastolic blood pressure of above 110 mmHg appears to  
increase the risks of morbidity and mortality particularly to the mother and can be 
taken as abnormal meriting some form of management decision. A diastolic blood 
pressure above 90 mmHg may constitute a slightly increased risk especially in the
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presence of proteinuria but th is risk is m ostly to  the fetus implying the need for 
increased monitoring.
The absolute level of blood pressure m easured may be less im portant th an  the 
absolute rise and the temporal aspect of that rise. Some workers believe th a t a  rise of 
blood pressure of 3 0 /20  mmHg to whatever level is sufficient for a diagnosis of 
preeclampsia (Chesley, 1978; Zuspan, 1966). Redman states that the sudden increases 
of blood pressure th a t occurs in severe preeclampsia and eclampsia are the most 
likely cause of the associated neurological signs and cerebral pathology (Redman, 
1980).
Therefore, a rise in diastolic blood pressure to levels above 90 mmHg would appear to 
put a patient into an ‘at risk’ group. A diastolic BP of above 110 mmHg would signify 
a more severe risk, particularly to the mother. It would be reasonable to use these 
m easurem ents as differential m arkers of disease severity. If the rise in  the blood 
pressure has been acute, the risk is consequently higher. However, it is important to 
remember tha t maternal risk does not necessarily represent a fetal risk and the risk 
is not absolute as most of the patients will have a successful outcome.
Blood Pressure Measurement
All these studies presume that the measurement of the blood pressure is accurate. 
Some workers take one reading only to classify the patients. There is a wide degree of 
inherent variation in the blood pressure itself (Munro Kerr, 1933; Pickering, 1968; 
Redman, Beilin and Bonnar, 1977a). There is also a variation found in  the 
methodology and it is probably im portant to standard ise  the  m ethod of 
m easurement to allow comparison between centres (O'Brien; and O’Malley, 1979). In 
the non-pregnant patient the fifth Korotkoff sound corresponds to the intraarterial 
m easurem ent (Kirkendall, 1967). However, in pregnancy, the fifth sound may 
continue down to zero because of the hyperdynamic circulation, and the fourth 
Korotkoff sound is more reproducible (MacGillivray, Rose and Rowe, 1969) This is 
taken by m ost centres to m easure the diastolic blood pressure in the pregnant 
woman. Many of the older studies used the fifth sound and this is still recommended 
in some texts. This often leads to false comparisons, as obviously more patients will 
have a diastolic blood pressure over 90 mmHg if measurement is by the fourth sound 
rather than  by the fifth sound.
MacGillivray (1961) in his study of blood pressure throughout pregnancy showed 
th a t there was no difference in the diastolic blood pressure with the patient in  the 
lying position or sitting at an angle of 30-45 degrees from the horizontal (Fig.3.1) 
(MacGillivray, 1961). The blood pressure should be taken in the right arm  with the 
sphygmomanometer at the level of the heart. The patient should be rested prior to the 
measurement. The practice of lying the patient on their left side to rest and then
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taking the blood pressure in the right (upper) arm, can produce a BP tha t is falsely 
low by as much as 15 mmHg because of the hydrostatic pressure differences between 
the sphygmomanometer cuff and the heart.
Most workers use a single diastolic blood pressure reading above 110 mmHg as being 
adequate for a diagnosis of severe preeclampsia (Hughes, 1972; Nelson, 1955b; Gant 
etoL, 1980). For the diagnosis of mild or moderate hypertension, two readings above 
90  mmHg diastolic at least 6 hours apart are accepted. It is im portant th a t these 
readings are close enough together to imply a definite relationship (Nelson, 1955b). 
Proteinuria
The definition of "proteinuria" depends on the methods used. Protein excretion goes 
up in pregnancy from a level of around 18 mg in 24 hrs in the non-pregnant to over 
300 mg total protein. Albumin represents about 55% of this. The Committee on 
Terminology of the American College of O bstetricians and  Gynaecologists 
recommend th a t a total daily protein excretion over 300 mg should be taken  as 
abnormal (Hughes, 1972). When 'dip' sticks are used, the false positive rate is around 
25% with 'a trace’ and 6% with 'one + '. This is probably due to the fluctuation in the 
concentration of protein in the urine and the presence of vaginal contam ination or 
urinary infection. Therefore, if proteinuria is suspected, 24 hour urine collections 
should be made.
The importance of proteinuria has been known since the 19 th  century b u t renal 
disease was initially not differentiated from preeclampsia. Nelson in his clinical 
study of preeclampsia (Nelson, 1955b) used the presence of proteinuria as his main 
differentiate of mild and severe disease. Friedman and Neff (1977), in their study of 
over 32000 pregnancies, showed th a t proteinuria is associated with increased 
perinatal mortality even in the absence of hypertension (Table 3.3). Unfortunately 
they defined hypertension as blood pressure above 95 mmHg diastolic. It is possible 
th a t some of these proteinuric non-hypertensive patients had  a diastolic blood 
pressure of above 90 mmHg and would be defined by many as preeclamptic. In the 
sam e patien t group, they showed th a t, in  com bination w ith hypertension, 
proteinuria increases the risk of perinatal loss, neonatal cerebral signs and in tra  
uterine growth retardation (Table 3.4) (Friedman and Neff, 1975). It is difficult to 
explain why proteinuria is associated with th is increased risk to the fetus. It is 
almost always associated with the 'pathognomonic' preeclamptic glomerular lesions 
(Fig 3.2) (Sheehan and Lynch, 1973). Rather than  being associated with a  worsening 
disease risk, it may be th a t the presence of proteinuria increases the probability of 
the patient having ‘true’ preeclampsia. The risk to the fetus is therefore higher 
because the pregnancy is complicated by preeclam psia ra th e r th a n  ‘sim ple’ 
hypertension.
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Although proteinuria is associated with increased risk to the baby, there is less 
evidence tha t it is associated with an  increased risk to the mother. Gibberd is quoted 
as presenting a series 300 patients with album inuria out of 8000 pregnancies 
(Gibberd, 1928). Only 3.7% of these patients developed eclampsia. These results are 
similar to those found with raised blood pressure alone. However, the few m aternal 
deaths seen in the United Kingdom are almost always associated with proteinuric 
hypertension. This again may be due to the presence of proteinuria confirming the 
diagnosis.
These studies suggest that the presence of proteinuria implies a specific renal lesion  
confirming the diagnosis o f preeclampsia. It is associated with an increased risk to  
the fetus of both IUGR and death. The effect on the risk to the mother is less clear but 
it is an obvious sign that increased vigilance is required.
Oedema
Oedema is a common finding in normal pregnancy. 64% of norm al women have 
oedema of the face and hands (Dexter and Weiss, 1941)and this is associated with no 
adverse affects (Chamberlain etaL, 1978b; Dexter and Weiss, 1941) Although Hamlin 
(1952) reported oedema in the fingers of almost every primigravida who developed 
PIH six weeks later, the additional presence of oedema does not increase the risk of 
hypertension (MacGillivray and Campbell, 1980).
Conclusions
Therefore, although hypertension in pregnancy is indeed polysymptomatic, high 
blood pressure is the primary sign of danger to the mother. Proteinuria is significant 
as a risk factor to the fetus and oedema appears to have no significance a t all. It 
would seem reasonable to classify the problem for the m other on the  basis  of 
hypertension and the fetal risk on the presence of proteinuria or some more specific 
method of fetal monitoring.
There is one further problem in the definitions of hypertension in pregnancy, and 
tha t is the role of parity.
Parity
'Pure' preeclampsia is defined by Nelson as a diastolic blood pressure over 90 mmHg 
with proteinuria of over 300 mg in 24 hours occurring in a primigravid patient where 
there is no evidence of preexisting hypertensive disease (Nelson, 1955b) This 
definition is widely accepted and was validated by the biopsy studies of McCartney 
(1964). This study showed that the majority of primigravid patients with proteinuric 
preeclampsia had the pathognomonic renal lesion (Fig 3.2). However, the results also 
showed that although most of the multigravid patients with proteinuric disease had 
underlying renal disease, some patients did have the classic renal lesions. Therefore, 
the diagnosis of pure preeclampsia is more likely in primigravidae b u t it cannot be
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excluded In a later pregnancy (McCartney, 1964). If It does occur it tends to be less 
severe (Table 3.5). Therefore, multigravid women are unlikely to develop the disease 
for the first time bu t the diagnosis of preeclampsia is still possible. If a  patient has 
preeclampsia in her first pregnancy, she is more likely to have problems in her next 
pregnancy (Table 3.6). However, if apparent "mild preeclampsia" is found in a 
multigravid patient, the patient may be demonstrating a tendency towards ’latent’ 
hypertension which recurs in subsequent pregnancies and she will have an increased 
chance of developing hypertension in later life. Such women often have a strong 
family history of essential hypertension (Chesley, 1980; Nelson, 1955b; Chesley, 
1978; Gibberd, 1928). Nelson, in  a study of 5251 booked m arried primigravidae 
between 1948-1953, showed th a t this ’latent hypertension' increased in incidence 
with increasing age (Fig 3.3) (Nelson, 1955b). This was not true of 'pure' preeclampsia. 
Proteinuric hypertension occurring for the first time in pregnancy in  a  primigravid 
pa tien t is  alm ost certainly preeclam psia. To be su re r of th is  diagnosis, 
postpregnancy followup is also required to make sure tha t normality returns. 
Therefore, if  a “pure group” is to be studied for the aetiology o f preeclam psia, a 
primigravid proteinuric group should be chosen.
Although preeclampsia can occur in the multigravid patient, the diagnosis is less 
accurate. Mild or moderate preeclampsia will often be confused with laten t or 
essential hypertension in any pregnancy.
In order to study the effect of therapy, all groups can be investigated. However, care 
should be taken to separate them into their component groups prior to study as they 
may differ in their responses to treatment.
Eclampsia
Eclampsia can be defined as a  convulsive state  occurring during pregnancy 
associated with hypertension prior to or after the fit has taken  place. Although 
eclampsia is often associated with severe preeclampsia as the nam e suggests 
(Hamlin, 1952; Dawson, 1953) this is not always so. Convulsions may occur in  the 
presence of mild preeclampsia and most severe cases of preeclam psia are not 
complicated by eclampsia (Cruickshank, 1923; Nelson, 1955a). The seizure threshold 
of the patient probably has as much to do with the occurrence of the seizure as the 
hypertension (Nelson, 1955a; Macintosh, 1952). In Nelson's studies (1955b; 1955a), 
all the baby deaths associated with eclampsia occurred in patients with severe 
preexisting preeclam psia, and none in  the  pa tien ts  where the  preexisting 
preeclampsia was mild. In fact, he states that a case of eclampsia occurring with mild 
preeclampsia was probably less dangerous to mother and baby than a case o f severe 
preeclampsia with no convulsions. The grading of the patient should be related to 
preexisting preeclampsia rather than  an automatic inclusion in the severe group or a
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separate group (Nelson, 1955a).
Preexisting Hypertensive Disease
Once it was accepted tha t young women could have essential hypertension it was 
realised tha t renal disease was not as common as once thought. If the blood pressure 
w as known to be elevated prior to pregnancy, the diagnosis of preexisting 
hypertension was obvious. However, as m ost patients presenting in  their first 
pregnancy will probably never have had their blood pressure checked before, this 
may not be known. If the blood pressure is found to be elevated in the first half of 
pregnancy, a  diagnosis of preexisting hypertension can be assumed. But since the 
diastolic blood pressure may fall by as m uch as 15 mmHg in the second trim ester 
(MacGillivray, 1961), a diastolic of 85 mmHg at 16 weeks may hide a nonpregnant 
equivalent of 100 mmHg. This patient may have been diagnosed correctly if she had 
presented earlier in the pregnancy. Therefore, only a normal first trim ester blood 
pressure can be used to exclude essential hypertension accurately. With the rise of 
blood pressure towards term, a false diagnosis of preeclampsia may be made if the 
diastolic rises over 90 mmHg on its way back to prepregnancy levels (MacGillivray, 
1961). Many of the 'latent' hypertensive group probably fall into th is category. If the 
blood pressures remain in the mild to moderate range, th is will have little clinical 
relevance bu t would interfere with any 'pure' group studies.
Most pa tien ts  with renal disease are known prior to pregnancy b u t the  
differentiation between renal disease and essential hypertension has been made 
easier with the development of m ethods of assessm ent of renal function. The 
presence of proteinuria in early pregnancy should alert the obstetrician to possible 
renal problems which can be confirmed by plasma creatinine estimation, urinalysis 
for infection and casts, and ultrasound of the kidneys.
‘Superimposed' preeclampsia
This is described as an  exacerbation of hypertension or the development of 
proteinuria in previously observed hypertension or a rise in  uric acid to high levels 
in a patient with known essential hypertension (Redman, Beilin and Bonnar, 1977b). 
These criteria are useful in cases of essential hypertension but it is more difficult to 
differentiate ‘superimposed’ preeclampsia from a deterioration in renal disease. 
Whatever the reason for the worsening of the underlying cause of the hypertension, 
the risk to both the mother and the fetus is significantly increased (Chamberlain et 
a l, 1978b).
Conclusions
It is clear tha t there are major problems in the clinical diagnosis of hypertension in 
pregnancy. Proteinuric hypertension, occurring for the first tim e, in a primigravid 
pregnancy can be accurately diagnosed as preeclam psia. All other form s o f
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hypertension could be due to other aetiologies.
Even if a diagnosis can  be made, there is a fu rther complication of disease 
nomenclature.
Nomenclature
Over the years many names have been used to describe hypertension in  pregnancy 
(Rippman, 1968). Although much effort has been made to simplify the problem, the 
situation is still confused.
The Organisation Gestosis was set up to attempt to clarify the diagnosis. Since they 
decided to use a symptomatic method of nomenclature based on oedema as the 
cardinal sign (Table 3.7), their recommendations have not been universally accepted. 
The full name of their condition is EPH-Gestosis using the signs Edema, Proteinuria 
and Hypertension as the method of diagnosis. Each sign is classified numerically 
according to the severity and the diagnosis is made. e.g. E1P2H2 -Gestosis for a  patient 
with mild oedema, moderate proteinuria and moderate hypertension. The method is 
simplistic and relatively reproducible and transferable. Its m ain drawback is the 
im portance placed on the oedema. The presence of oedema and proteinuria 
constitutes "gestosis" even in the absence of hypertension. There is also a further 
category of 'imminent' eclampsia.
The other m ain international group studying hypertension in  pregnancy (The 
International Society for the Study of Hypertension in Pregnancy or ISSHP) 
concentrates on hypertension as the main diagnostic factor along with proteinuria 
bu t ignores the presence of oedema (Table 3.8) (Davey and MacGillivray, 1988). This 
is similar to Nelson's criteria (Nelson, 1955b). This is the m ost widely accepted 
nom enclature. It is clear th a t "true preeclampsia" should be used only for the 
prim igravid patien t with no preexisting disease who develops pro teinuric  
hypertension in the second half of pregnancy. This would imply th a t hypertension 
occurring in pregnancy without proteinuria is not preeclampsia b u t some other kind 
of "pregnancy induced hypertension". This is unlikely to be true. Some of the 
primigravida, with nonproteinuric hypertension, will also have preeclam psia. 
Moreover, preeclampsia can exist in the multigravid patient, although its diagnosis 
is less sure. In these situations, the term  Pregnancy Induced Hypertension (PIH) is 
generally used. The main criticism of this term  is the implication of aetiology which 
is unproven. Pregnancy Associated Hypertension (PAH) is a similar term  without the 
aetiological suggestion. "Gestational hypertension" is the sam e a s  "latent" 
hypertension and implies late onset mild to moderate PIH in a multigravid patient. 
The assumption is that the patient is demonstrating a hypertensive tendency which 
will become apparent in later life (Nelson, 1955b; Chesley, Annitto and Cosgrove, 
1976; Dieckmann, 1952).
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Despite the simplification of the classification it is often difficult to define the 
condition at first presentation. All forms of definition include an  unclassified group 
of patients who present too late or are "unbooked" a t the time of admission making 
accurate diagnosis impossible. Also, many patients classified under one group may 
need to be reclassified as pregnancy continues since the condition may worsen or 
preexisting disease may become apparent after delivery.
Discussion
All these problems of diagnosis and nomenclature are only relevant if “pure studies” 
are required for study or comparisons are to be made between groups. For th is 
reason, all aetiological studies on preeclampsia are generally limited to proteinuric 
hypertension, occurring for the first time, in  a  primigravid pregnancy. All other 
patien ts can  be grouped together as pregnancy induced hypertension unless 
preexisting disease is known. However, trials of management m ust be open to all 
patients as that is how the disease presents to the clinician.
If it is difficult to diagnose and name the condition, studies of aetiology m ust be 
reviewed with a healthy skepticism. If there are many disease types, there may be 
multiple aetiologies.
3.2 The Aetiology of Pregnancy Hypertension
"In summing up this section, it is evident that the cause o f eclampsia has not been 
discovered, and that the peace o f mind o f all concerned would have been increased, 
had many o f the so-called contributors never written, or at least had withheld  
their contributions sufficiently long to subject them to ordinary self-criticism."
Whitridge Williams (1931)
In order to understand the disease process and the relevance of the clinical signs at 
presentation, it is im portant to understand the aetiology of the condition. If the 
aetiology were elucidated, early diagnosis and potential prevention may be possible. 
Unfortunately, in hypertension in pregnancy the aetiology is still largely unknown. 
There has been m uch confusion over the role of many pathological findings in th is 
condition. It is important to distinguish the signs caused by disease progression from 
those tha t are markers of the underlying process. If this can be done and ,if there are 
recognisable stages in the disease process, it may be possible to use these changes as 
predictors of patient risk.
Since the 18 th  century, when the term 'toxaemia of pregnancy' was first used, it has 
been known th a t there was a specific disease of pregnancy which could be 
characterised by oedema, hypertension, album inuria and convulsions (Chesley, 
1980). Much has been written concerning the aetiology of preeclampsia. The m ain 
problem is th a t many of the theories tha t have been pu t forward for the cause of 
eclampsia describe the pathological features found a t end stage disease (Chesley,
1976). These may be the result o f the disease process rather than th e cause.
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Hypertension in pregnancy may not lead to eclampsia. Therefore signs found after 
m aternal death from eclampsia may have little relevance to the earlier stages of the 
preeclampsia.
In 1916, Zweifel first termed it the disease of theories (Zweifel, 1916). Zweifel states 
tha t any cause of preeclampsia m ust explain the following points
1) The predisposing influence of nulliparity, multiple pregnancy, hydatidiform 
mole and hydramnios.
2) Higher incidence in certain geographical areas.
3) Increasing incidence as term  approaches.
4) Rarity of repeated problems in subsequent pregnancies.
5) Improvement after death of the fetus.
6) Hypertension, oedema, proteinuria, convulsions and coma.
7) The hepatic and renal lesions.
The predisposing influence o f nulliparity, multiple pregnancy, hydatidiform mole
and hydramnios 
N ulliparity
Until the histological studies in the 1950’s and 1960’s (Sheehan, 1950; McCartney, 
1964; Sheehan and Lynch, 1973) there was no clear method of accurate diagnosis. It 
was already known th a t hypertension was more common in the primigravida 
(Nelson, 1955b; Munro Kerr, 1933; MacGillivray, 1961) b u t the renal histological 
studies showed th a t the majority of the primigravidae with proteinuria had  a 
specific renal lesion while many of the multigravidae were found to have renal 
disease (Sheehan, 1950; McCartney, 1964; Sheehan and Lynch, 1973). This suggested 
th a t preeclampsia is mostly a disease of the primigravida and  a norm al first 
pregnancy can be seen to protect the patient from any future preeclampsia (Chesley,
1978). Even an earlier abortion protects the patient (MacGillivray, 1958). However, if 
the patient changes partner the incidence increases to tha t of a primigravida. If the 
patient has had a prior blood transfusion, she is also protected from developing 
preeclampsia (Feeney, Tovey and Scott, 1977). There is no evidence tha t blood group 
incompatibilities or sex of the child make any difference.
All these findings suggest tha t the condition is associated with the patien t’s first 
exposure to certain antigens carried by the fetus. Prior exposure to these antibodies 
would appear to protect the patient from disease development. This implies an  
immunological factor in the aetiology of the condition.
Hyperplacentosis
Another factor influencing the development of preeclampsia is hyperplacentosis 
(Jeffcoatte and Scott, 1959). This may occur with hydatidiform mole, diabetes, 
multiple pregnancies, erythroblastosis fetalis and tripliody. Polyhydramnios has 
also been suggested as a risk factor bu t the association of polyhydramnios in  the 
absence of other accepted risk  factors is probably unlikely (Jeffcoatte and  Scott,
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1959). Polyhydramnios due to fetal abnormality alone is not associated with a 
higher incidence and is only associated with preeclampsia if there is another 
influencing factor involved (Desmedt, Henry and  Beischer, 1990). Diabetic 
pregnancies have a higher incidence of the disease especially if there is poor control 
(Siddiqi etaL, 1991). Hydatidiform mole is associated with classic preeclampsia and 
eclampsia, bu t it rarely develops before 16 weeks (Page, 1939; Chesley, Cosgrove and 
Preece, 1946). Twins are reported to cany  a four fold increase in incidence compared 
to singleton pregnancies. However, there is no difference in the incidence between 
monozygotic and dizygotic twins (Campbell, MacGillivray and Thompson, 1977). 
Therefore, it would appear th a t it is the presence of the placental tissue ra ther than  
polyhydramnios th a t is associated with preeclampsia. This again suggests an  
immunological basis to the disease as both m olar and multiple pregnancy will 
produce a higher immunological load than  normal pregnancy.
Immunological factors
These findings suggest tha t immunological factors may be involved with some form 
of m aternal and fetal incompatibility producing an  abnorm al immunological 
response. This may be due to an imperfect m aternal response to pregnancy which 
improves in  the next pregnancy or an  inability to recognise paternal antigens 
displayed by the fetus. The first pregnancy would then help to 'immunise’ the patient 
for any future pregnancy to the same partner (Sutherland et aL, 1981). If this is true, 
there may be differences found in  immunological investigations. No increase in 
ABO, HLA or Y-linked compatibility was found in  couples with a preeclamptic 
pregnancy by Scott and Beer (1976). Redman et al (1978) showed a higher incidence of 
HLA homozygosity. This would reduce the chances of antigen sharing  by 
preeclamptic women and their husbands. They postulate tha t m aternal recessive 
immune-response genes contribute to the development of preeclampsia (Redman et 
a l,  1978). Therefore, there is evidence of an  immunological abnorm ality in 
preeclampsia interfering with the normal m aternal response to her fetus, b u t the 
mechanism is still obscure (Petrucco, 1981). The abnormality may be either an  
increased response to fetal antigens or a reduction in the suppressive effect normally 
seen in pregnancy. The greatly increased incidence of preeclam psia in  twin 
pregnancies without any difference between monozygotic and dizygotic pregnancies 
(Campbell, MacGillivray and Thompson, 1977) suggest increased immune-response 
suppression rather than  increased matemal-fetal incompatibility.
It has been postulated tha t blocking antibodies are formed by the reaction of the 
m other to trophoblastic tissue. These antibodies then  suppress T-lymphocyte 
activation (Currie and Bagshawe, 1967). Schmorl and Veit showed the presence of 
placental villi in the circulation as early as 1933. Therefore, antibody production
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would be expected. Insufficient production of blocking antibody could lead an  
increased m aternal immunological activity, placental damage and preeclampsia. 
However, although circulating antibodies to the placenta have been found in 
preeclamptic pregnancies (Currie and Bagshawe, 1967), this has not been confirmed 
by all workers (Currie and Bagshawe, 1967). Various studies have shown complement 
activation in the placenta (Faulk, Carbonara and Jeannet, 1973; Kitzmiller and 
Benirschke, 1973) bu t no definitive findings of immunological damage have been 
described. There may also be a role for some of the placental proteins, such as PAPP- 
A, in immunosuppression, as they are known to have an  immunodepressant effect 
(Bischof, 1981).
Therefore, although there is strong circum stantial evidence of an  immunological 
basis to preeclampsia, its exact mechanism and site of action is still unclear. A 
further complication is that, as will be discussed later, the placental lesion is not 
specific to preeclam psia. Sim ilar findings are found in in trau terine  growth 
retardation (IUGR) (Sheppard and Bonnar, 1981). This may imply th a t both the 
placental lesion and the immunological lesion may not be unique to preeclampsia. 
Higher Incidence in certain geographical areas.
Differences have been seen between racial groups. In Israel, Jew s have a higher 
incidence th an  the African or Asian (Table 3.9) However, different geographical 
incidence of the condition and its severity may be due to environmental differences, 
particularly diet, and other factors including the standard of health care and the 
timing of presentation (Davies, 1971). There are also problems with the accuracy of 
case recording and diagnosis of hypertension in the Third World. Many studies are 
based on hospital reports which suggest a higher incidence in the u rban  areas. This 
could be explained by the differences in the reporting of the condition, in  the 
standard of antenatal care available and the access patients have to medical help. 
This makes the assessm ent of the incidence in racial groups difficult. Despite this, 
differences obviously exist, and the explanation of th is could be related to the 
environmental and familial factors discussed later (Chesley, Annitto and Cosgrove, 
1961; Chesley, Annitto and Cosgrove, 1968; Cooper et a l, 1988; Cooper and Liston, 
1979).
Increasing incidence as term approaches
The blood pressure rises towards term in most pregnancies (Fig 3.1) (MacGillivray, 
1961) and Nelson found tha t mild or ‘latent’ hypertension is more common in the 
later stages of pregnancy (Nelson, 1955b). The epidemiology of hypertension without 
proteinuria has several characteristic features which suggest th a t it should not 
always be regarded as mild preeclampsia (MacGillivray, 1961). The incidence rises 
sharply over the age of 30 at a time when essential hypertension is also becoming
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more common (Fig 3.3) (Nelson, 1955b). The risks to mother and baby of late onset 
mild to moderate hypertension are much lower when compared with hypertension in 
pregnancy as a  whole (Nelson, 1955a). Mild hypertension occurring during late 
pregnancy has no depressive effect on fetal growth (Baird, Thomson and Billewicz, 
1955). Women who had hypertension without proteinuria were found to have a higher 
risk  of hypertension in  later life compared with those with true  preeclam psia 
(Chesley, 1978; Browne and Dodds, 1939). These findings suggest th a t the finding of 
an  increasing incidence of preeclampsia towards term  may be a reflection of the 
demonstration of the ’latent* hypertension described by Dieckmann (1952), Nelson 
(1955b) and Browne and Sheumack (1956). This is supported by the lack of pathology, 
the  association with increasing age and the  higher incidence of essential 
hypertension in later life.
Rarity o f repeated problems
MacGillivray showed th a t if the first pregnancy was normal, the incidence in  a 
subsequent pregnancy was low (Table 3.5). If the first pregnancy was complicated by 
severe preeclampsia, the incidence was found to be similar to th a t of a primigravida 
(Table 3.6) (MacGillivray, 1981). The protection in the multipara may be related to 
the immunological factors previously mentioned. The first pregnancy im m unises 
the woman against her husbands antigens and reduces the reaction. This argument is 
supported by Feeney, who found that, after a blood transfusion, a woman had a lower 
incidence of preeclampsia (Feeney, Tovey and Scott, 1977) However, Lopez Ilera 
followed up 110 patients with a history of eclampsia. In the next pregnancy 35.4% of 
the patients had repeated preeclampsia although he was less specific in his diagnosis 
(Lopez Llera and Hernandez Horta, 1974). Therefore, the protection of a first 
pregnancy is not absolute and appears to be most effective if preeclampsia does not 
develop. This suggests a degree of susceptibility in those patients in whom the disease 
is manifest. Therefore, ra ther th an  protect against the disease, a  norm al first 
pregnancy may ‘screen out’ those who are not susceptible. This susceptibility may be 
related to the familial tendencies already alluded to.
Improvement after death o f the fetus.
Beker states th a t "if the foetus dies in utero the general condition of the m other 
generally improves" (Beker, 1948) However, fetal death is not always followed by 
immediate clinical improvement. Dexter and Weiss found this in  less th an  one third 
of cases (Dexter and Weiss, 1941). Therefore, although there may be an  improvement, 
it is not absolute and the susceptibility remains.
Hypertension, oedema, proteinuria, convulsions and coma.
The clinical hallm arks of preeclam psia in  the  m other are hypertension , 
proteinuria, oedema and the tendency to convulsions and coma. The physiological
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characteristics are an increase in peripheral resistance (Larkin etaL, 1980; Lim and 
Walters, 1979) exaggerated responses to pressor agents (Talledo, Chesley and Zuspan, 
1968; Gant etaL, 1973; Gant etaL, 1980; Zuspan, 1979), activation of the coagulation 
system (Howie, Prentice and McNicol, 1971), a  reduced platelet count (Redman, 
Bonnar and Beilin, 1978) and decreased uteroplacental blood flow (Lunell et al., 
1982). There is also an  impairment of the normal increase of plasm a volume and 
cardiac output (Lim and Walters, 1979; Gallery, Hunyor and Gyory, 1979). Before 
these abnormalities are discussed, a short review of the normal cardiovascular 
changes in pregnancy will be presented.
Changes in the cardiovascular system  in normal pregnancy
Normal pregnancy is associated with a num ber of alterations in the cardiovascular 
system which start to occur early in pregnancy. Cardiac output increases by around 
40% during the first trim ester and th is increase is m aintained during the th ird 
trim ester. However, if cardiac output is m easured in the supine position a fall in 
output is noted in the third trimester as the venous return  to the heart is obstructed 
by the gravid uterus. Blood pressure starts to fall in the first trimester, reaches a 
nadir in mid-pregnancy, then  slowly rises during the th ird trim ester to levels 
comparable with those in the non-pregnant state (MacGillivray, Rose and Rowe, 
1969) (Fig. 3.1). As arterial pressure is determined by cardiac output and total 
peripheral resistance, the decrease in blood pressure m ust be due to a  fall in the 
latter. Since these changes occur early in pregnancy, they m ust reflect a  change in 
systemic vascular resistance, as the uteroplacental circulation is not sufficiently 
large to account for such a reduction in  peripheral resistance a t th is  stage of 
pregnancy.
The fall in peripheral resistance in normal pregnancy is associated with a relative 
insensitivity to the pressor effects of exogenous angiotensin II (All) (Fig. 3.4) (Gant et 
a l ,  1973), which is detectable as early as 8 weeks gestation and reaches a peak in 
mid-pregnancy. The mechanism underlying th is insensitivity may be prostaglandin 
dependent. The pressor effects of angiotensin II may be balanced in  norm al 
pregnancy by prostaglandin E2 and prostacyclin which have vasodilator effects. It is 
obvious th a t changes in these vascular reactivity may be a t the centre of the 
hypertension changes in preeclampsia.
Vascular sensitivity as a cause o f hypertension
Beker postulated tha t 'toxaemia' of pregnancy was not due to a toxin bu t was related 
to an upset in the circulatory system (Beker, 1948). Hertig suggested tha t the disease 
was one of widespread vasospasm (Hertig, 1945). However, this vascular constriction 
would only contribute towards the vascular hypertension as the blood flow to the 
major organs, apart from the uterus, liver and kidney, would continue to be normal
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unless there is severe cardiac compromise. There is not a general reduction in 
peripheral blood flow. Burt showed increased blood flow to the hand and the forearm 
in preeclampsia, bu t this may be related to muscle blood flow rather th an  the true 
periphery (Burt, 1950). Since tha t time, there has been much work on the causes of 
the hypertension. Studies have shown th a t the vascular system in preeclampsia is 
hypersensitive to several pressor agents. The first studies used various pituitary 
extracts (De Valera and Kellar, 1948; Browne, 1946). Browne showed th a t th is 
sensitivity disappeared after delivery. Raab et al (1956) found it with norepinephrine 
(noradrenaline) and Talledo et al (1968), Chesley et al (1965) and Zuspan (1979) found 
it with noradrenaline and angiotensin. Gant et al (1973), Wallenburg et al (1986) and 
Deker et al (1990) have shown th a t the angiotensin infusion test can select out 
patients who are destined to develop preeclampsia by demonstrating sensitivity at 
16-18 weeks (Fig. 3.4). This suggests that the sensitivity is present prior to the disease 
presentation, implying susceptibility to the condition. It is now widely accepted tha t 
vasoconstriction is the basic cause of the hypertension in preeclampsia (Gant et al., 
1980; Hardy and Williams, 1988; Gilstrap and Gant, 1990). However, since the 
hypertension develops later in the pregnancy, a further stim ulus would seem to be 
required and the vasoconstriction would then be a secondary effect following this 
stimulus.
Salt and water retention
Sodium and water retention could be an  explanation for the arterial hypertension. 
Sodium is retained in preeclampsia (Chesley, 1966; Plentl and Gray, 1959). Harding 
and Van Wyck (1930) gave sodium solutions to preeclamptic women with disastrous 
results: one patient developed fulminating preeclampsia within 24 hours with a  BP 
rise from 128/100 to 200/140. Dieckmann (1952) showed that a  high salt intake in 
preeclamptic women produced a deterioration of the symptoms and there was a 
reduced ability to concentrate salt in the urine. However, spironolactone, a drug 
useful in other salt retaining conditions, has no effect on the blood pressure in 
preeclamptic women (MacGillivray, 1981). Salt restriction as a therapy is common, 
particularly in Holland, but prophylactic salt restriction has little benefit on the 
development of the disease but may have an  effect on the sensitivity of the peripheral 
vasculature by altering All receptor activity. This has led on to the interest in  the 
renin-angiotensin system.
The Renin-angiotensin system
Salt excretion is controlled by the renin-angiotensin system. As already stated, the 
response to a angiotensin infusion is abnormal in preeclampsia (Chesley et oL, 1965; 
Gant et a l, 1973; Gant et a l, 1980). Gant feels th a t if levels of angiotensin are low, 
receptor site occupancy will be low and sensitivity to angiotensin will be raised. The
50
resu lts  of studies of blood levels are confusing. M assiani e t al (1967) found 
angiotensin levels normal, Weir et al (1973) found them  severely depressed and 
Symonds, Broughton Pipkin & Craven (1975) found them to be raised. All the studies 
were on patients of apparently similar severity.
Both adrenaline and noradrenaline can cause vasoconstriction and increased 
sensitivity to infusions of these substances have been dem onstrated (Talledo, 
Chesley and Zuspan, 1968; Chesley et a l ,  1965; Zuspan, 1979) b u t levels of 
noradrenaline have been found to be low (Tunbridge and Donnia, 1981).
Broughton Pipkin (Broughton Pipkin, 1976) has dem onstrated th a t the fetal 
placental unit can produce angiotensin II and the levels in the cord venous blood of 
babies from mothers with preeclampsia are found to be significantly elevated above 
levels seen in norm al pregnancy. Symonds (Symonds, Broughton Pipkin and 
Craven, 1975) found tha t the levels of All in plasm a in late pregnancy in over 50 
primigravidae were in direct relationship to diastolic blood pressure. He feels tha t 
the fetal placental unit produces angiotensin in response to hypoxia. This, in turn , 
can produce hypertension in susceptible patients. This production of angiotensin II 
may act as the trigger. The susceptibility of the patient to respond to this stimulation 
may be related to prostaglandin activity.
The role o f the prostaglandins
There is mounting evidence tha t the local effects of the prostanoids, prostacyclin 
and thromboxane, may have a role to play in the pathophysiology of th is  disease. 
Prostacyclin (PGI2) is the major product of the arachidonic acid cascade in vascular 
tissue, and is a potent vasodilator and inhibitor of platelet aggregation (Moncada et 
al., 1977; Ritter e ta l, 1983). It has a short half life and is usually m easured as one of 
its stable metabolites, such as 6-keto-PGFla. In preeclampsia, production of PGI2 
from both maternal and fetal vascular tissue has been shown to be reduced (Downing, 
Shepherd and Lewis, 1980; Remuzzi et al., 1980; Jogee, Myatt and Elder, 1983) and 
lower levels of amniotic fluid prostacyclin compared to normal pregnancy have also 
been found (Bodzenta et a l, 1980; Ylikorkala and Makali, 1985). High levels of 
prostacyclin stimulating factor have also been found in patients with pregnancy 
induced hypertension suggesting a reduced end organ response (Remuzzi e ta l,  1981) 
Thromboxane A2 is a powerful vasoconstrictor and platelet aggregating agent 
(Ylikorkala and Makali, 1985). It is the m ajor product of the arachidonic acid 
cascade in platelets, and is synthesised and released when platelets aggregate. 
Increased TxA2 production from placentas and platelets has been shown to occur in 
pregnancy induced hypertension (Makila, Viinikka and Ylikorkala, 1984; Fitzgerald 
e ta l,  1990; Walsh, 1989).
Thromboxane A2 and prostacyclin oppose each other through regulation of
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adenylate cyclase (Tateson, Moncada and Vane, 1977). The proaggregatory substances 
thromboxane A2 and the endoperoxides PGG2 and PGH2 inhibit adenylate cyclase
allowing free intraplatelet Ca++ to rise. They also have a direct effect, promoting
Ca++ release from intracellular storage sites (Gerrard et a l ,  1977). Platelet
inhibitory prostaglandins stimulate adenylate cyclase, increasing cyclic AMP and
reducing Ca++ (Tateson, Moncada and Vane, 1977; Gorman, Bunting and Miller,
1977). An increase in intracellular calcium would increase the sensitivity of smooth 
muscle cells to contract and platelets to aggregate. An increase in intracellular 
calcium has been found in pregnancy induced hypertension (Kilby et aL, 1990).
It has been suggested that normally a balance exists between PGI2 and TxA2 , and that 
th is balance may be upset in pregnancy induced hypertension (Walsh, 1985). A 
reduced prostacyclin/ thromboxane ratio would account for the increased platelet 
consum ption and the increasing sensitivity to vasoconstrictors and peripheral 
co n stric tio n  found in  p a tien ts  w ith p regnancy induced  hypertension . 
Experimentally, th is increased sensitivity to angiotensin II can  be produced in 
norm al pregnancy by the  adm inistration of indom ethacin, a p rostag landin  
synthetase inhibitor (Everett et aL, 1978).
An imbalance between PGI and TxA could lead to platelet aggregation and the 
formation of platelet throm bi and fibrin deposition in the kidney and placenta 
causing impairment of these organs. The renal effects of sodium retention and 
reduced glomerular filtration rates seen in pregnancy induced hypertension could 
also be due to the lack of vasodilator and naturetic PGE2 and PGI2 in the kidney. 
Therefore, pregnancy induced hypertension could be largely a consequence of a 
prostaglandin deficiency. This could be either from a deficiency of precursors, 
reduced production or defective action. O’Brien et al (1979) showed that, in pregnant 
rabbits, a restriction of the dietary essential fatty acid precursors of prostaglandins 
leads to an  increased sensitivity towards angiotensin II. However, studies have 
shown tha t only about 50% of the patients sensitive to All infusions will develop 
preeclampsia (Gant et al., 1973; Wallenburg et a l, 1986) (Fig 3.5). This suggests tha t 
PGI2 deficiency may not be the primary cause of the disease b u t may play an 
im portant role in the pathophysiology of the condition by altering the patients 
response to vasopressor agents.
Prostacyclin infusions have been used successfully in severe pregnancy induced 
hypertension (Fidler e ta l ,  1981) where both its vasodilator and anti-platelet effects 
have been of value. However, PGI2 requires a continuous intravenous infusion and 
has not been shown to be an efficient antihypertensive agent.
Other prostaglandins have been implicated bu t the picture is less clear. Demers and
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Gabbe (1976) showed that PGF20C was elevated and PGE2 low in preeclampsia. Hiller 
and Smith (1981) found no change and Robinson et al[1979) found both PGE and PGF 
to be reduced.
There is no doubt th a t there is an  upset in the prostaglandin biochemistry, most 
likely to be related to changes in production of prostacyclin. F urther work is 
required bu t it is unlikely tha t these abnormalities will be more th an  a part of the 
pathophysiological process..
Changes in Rheology
Preeclam psia and in trau terine  growth retardation  are both  associated  with 
abnormal haem ostasis which may be related to histological evidence of placental 
intravascular changes (Bonnar, McNicol and Douglas, 1971; Sheppard and Bonnar, 
1976; Brosens, Dixon and Robertson, 1977; Howie et a l, 1976). Blood flow, and 
changes in blood rheology which may reduce blood flow, are im portant factors in 
determining the am ount of oxygen and nutrients transferred across the placenta. 
Abnormal blood rheology has been found in both preeclampsia and IUGR (Inglis et 
a l, 1982; Buchan, 1982; Hobbs et a l, 1982; Thorbum et a l, 1982). Lang et al (1984) 
showed th a t blood viscosity was increased at high shear rate, due in part to high 
haematocrit. Blood viscosity was also increased at low shear rate. Some studies 
(Thorbum et aL, 1982) have found reduced red cell deformability when filtration of 
cells was performed in native plasma bu t not in donor plasma. This would imply 
tha t a plasma factor may be responsible (Inglis et al., 1982). Whole blood viscosity (ie. 
red cells in  native plasma) a t high shear was still elevated after correction to 
standard  haem atocrit (Lang et a l, 1984). This suggests th a t red cells are less 
deformable in  preeclampsia, since high shear viscosity is influenced by red cell 
deformation under high shear conditions. Therefore, the consensus of opinion is 
th a t blood viscosity is increased and red cell deformability in native plasm a is 
decreased in preeclampsia (Thorbum e ta l,  1982; Lang e ta l,  1984).
As regards tests of haem ostasis, the levels of Factor VIII coagulant activity and 
antigen were increased in pregnancy hypertension (Lang et a l, 1984), although the 
ratio of activity to antigen was not altered. Hypofibrinogenaemia has been noted in 
severe preeclampsia (Birmingham Eclampsia Study Group, 1971). There is also 
reduced fibrinolytic activity (Bonnar et a l, 1969; Birmingham Eclampsia Study 
Group, 1971), increasing the chance of fibrin deposits. Fibrin degradation products 
(FDP’s) were found to be raised (Bonnar, McNicol and Douglas, 1971; Condie, 1976) 
with a reduction of platelet count. It is difficult to know whether these changes are 
prim aiy or secondary to the disease process. Since activation of the coagulation 
system is a feature of preeclampsia, changes in the levels of these substances is no 
great surprise.
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Platelet activity
Platelet studies in normal pregnancy have yielded conflicting results, Giles et al 
(1981) reported no alteration in platelet num bers or Mean Platelet Volume (MPV) in 
1087 norm al pregnant women compared to non-pregnant controls. Harrison, 
Bramich and Collins (1982) also found no change in the platelet count in normal 
pregnancy. In contrast, Hsieh and Cauchi (1983) reported a fall in MPV in normal 
pregnancy, most profound in the first trim ester bu t sustained throughout normal 
pregnancy. Fay, Hughes and Farron (1983) have reported a  significant drop in 
platelet numbers in the last 8 weeks associated with a rise in the MPV in the last four 
weeks of normal gestation, and Still, Lind and Walker (1985) have recently reported 
increased MPV and Platelet Distribution Width (PDW) between 34 and  37 weeks. 
Many studies in  women with pregnancy induced hypertension and preeclampsia 
have reported changes in platelet numbers, platelet survival and MPV which have 
been interpreted as evidence of increased platelet consumption (Redman, Bonnar and 
Beilin, 1978; Wallenburg and Rotmans, 1980; Giles, 1981; Hsieh and Cauchi, 1983). 
Thrombocytopenia is a common finding (Birmingham Eclampsia Study Group, 
1971), is associated with progressive disease (Redman, Bonnar and Beilin, 1978; 
Trudinger, 1976) and has been shown to be related to disease severity (Howie, Prentice 
and McNicol, 1971). Platelet life span is known to be reduced in PIH (Rakoczi et al., 
1979) and this is thought to be secondary to intravascular platelet aggregation and 
increased adhesion to damaged vascular endothelium. If platelets are activated, 
betathrom boglobulin (BTG) and serotonin are often increased in  the  plasm a. 
Increased betathromboglobulin has been found (Douglas et al., 1982; Socol et al., 
1985) bu t Lang (1984) found no increase. Serotonin levels have been found to be 
raised (Jelen, Fananapazir and Crawford, 1979) in pregnancy induced hypertension 
and intraplatelet serotonin levels are decreased (Whigham et al., 1978). Page (1972) 
suggested tha t there is varying activation of the coagulation system  and platelet 
aggregation but the trigger to this activity is unknown. It is also not known whether 
th is is a primaiy or secondary effect. The differences seen may be related to differing 
disease severities in the study groups.
The relevance o f Oedema
As already discussed oedema is found in  85% of women with preeclam psia 
(Thomson, Hytten and Billewicz, 1967) and may be severe. The oedema fluid is an 
ultra-filtrate of plasma and is associated with reduced plasma albumin and osmotic 
pressure, and with retention of sodium and potassium. However, it has little value as 
a specific diagnostic sign as oedema occurs in 64% of normal pregnancies (Thomson, 
Hytten and Billewicz, 1967; Dexter and Weiss, 1941) and is associated with no 
increase in perinatal mortality (Thomson, Hytten and Billewicz, 1967; Chamberlain
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e ta l,  1978b). Although Hamlin (1952) found that all patients who developed PIH had 
been noted to show oedema during the preceding 6 weeks, others have found th a t 
patients with oedema had an incidence of PIH which was similar to patients without 
oedema (MacGillivray and Campbell, 1980). In fact, retention of fluid is associated 
with heavier babies (Duffus e ta l,  1969). There are other signs of loss of intravascular 
volume. Haemoconcentration also occurs (Zangemeister, 1903). Dieckmann in his 
m onograph “Toxaem ias of Pregnancy” (1952) s ta te s  th a t  serum  pro tein  
concentration rises at least two days prior to the development of eclampsia as does 
the  haem atocrit and haemoglobin. This dem onstrates the association of the 
hypertension with a reduced plasm a volume (Gallery, Hunyor and Gyoiy, 1979). 
There is controversy over whether the cardiac output is increased, unchanged or 
reduced (Werko, 1950; Assali and Vaughn, 1977; Rafferty and Berkowitz, 1980). Most 
studies have been done on patients where various treatm ent regimes have already 
been instigated and this may explain the differences found.
Proteinuria
As already discussed, proteinuria in pregnancy induced hypertension is related to 
disease severity (MacGillivray, 1961; Nelson, 1955b). The proteinuria is moderately 
selective in term s of size of the filtered proteins, bu t can be heavy with more th an  5 
grams of protein per day being lost. It is due to a glomerular protein leak, signifying 
glomerular involvement in the disease process. As th is is always associated with the 
pathognomonic renal lesion, this will be discussed under renal pathology. 
Convulsions and coma
Severe hypertension causes arterial damage and th is has been dem onstrated in 
anim als (Goldby and Beilin, 1972). This arterial damage m ay explain the 
convulsions and cerebral haemorrhage seen in untreated severe preeclam psia . 
Cerebral haemorrhage is the commonest cause of death in pregnancy induced 
hypertension (DHSS, 1969; DHSS, 1974; DHSS, 1979; Turnbull, 1987; Turnbull et 
a l, 1989). Postmortem studies of the brain show oedema, hyperaemia, focal lesions, 
thrombosis and haemorrhage (Sheehan and Lynch, 1973; Smorl and Veit, 1933). As 
these lesions were found at postmortem, they may be end stage changes ra ther than  
causal lesions. The length of time after death tha t the studies were carried out also 
m ay contribute. Sheehan (1950) studied 48 cases within one ho u r of death. 
Haemorrhages were the most common findings. There was little oedema at th is time. 
Govan (1961) showed that the cause of death in 39 of 110 women who died of PIH was 
cerebral haemorrhage. In a further 47 it was cardiorespiratory failure with small 
haemorrhages found in 85% of them. Fibrinoid changes were regular findings in  the 
walls of the cerebral vessels. Because of the lymphocyte reactions around the lesions 
with infiltration by pigmented macrophages, they appeared to have been present for
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some time. This could suggest that these lesions antedate the fit and are not caused by 
the seizure itself. Whether these lesions are the cause of the neurological symptoms 
and the fits is more difficult to discover. The relevant factor concerning whether a 
patient does or does not convulse, appears to be her own fitting threshold (Nelson, 
1955b). The degree of pathological damage found may well be related to the amount of 
prodromal preeclampsia. Only some of the pathological signs may result from the 
damage due to the seizure itself.
Hepatic lesions.
The most characteristic feature of the hepatic lesion in eclampsia is its variability 
in  extent and severity. Many cases are described with no hepatic necrosis a t all 
(Acosta Sison, 1931; Bell, Dieckmann and Eastm ann, 1940; Theobald, 1933). The 
changes seen within the liver are not related to severity, although the pathological 
damage can be quite extensive (Sheehan and Lynch, 1973; Dieckmann, 1929). 
Therefore, it is thought th a t the lesions are caused by the condition and do not 
contribute to the aetiology of the disease. In biopsies of five patients who survived 
eclampsia, a normal liver was found in two. In a further two patients, the lesions 
were found to be worse th an  those found in the patients who died (Ingerslev and 
Teilum, 1946). The hepatic findings are mostly related to end stage disease and are 
found at postmortem. Because most of the early studies were carried out on patients 
who had died, this led to the opinion held in the 1930's tha t haemorrhagic necrosis 
in  the periphery of the lobules is the characteristic lesion of eclampsia (Acosta 
Sison, 1931).
The lesions are most commonly found in the right lobe of the liver. The areas of 
haemorrhage begin around a periportal space and are usually associated with 
extensive throm bosis in  the smallest vessels in the periportal connective tissue. 
Sheehan and Lynch (1973) thought that the primary lesion was the escape of blood or 
plasm a into the peripheral base of the hepatic cell cords. Focal fibrosis is usually 
seen. Lesions of the centre of the hepatic lobule are also seen (Acosta Sison, 1931). 
Haemorrhage beneath the liver capsule may be so extensive as to cause rupture of the 
capsule with massive haemorrhage into the peritoneal cavity (Golan and White,
1979). Therefore, hepatic lesions are patient specific rather than  related directly to 
disease severity.
Renal Lesions
In normal pregnancy there is an increase in the glomerular filtration rate (GFR) of 
50%. This leads to a  reduction in the plasma urea and creatinine concentrations.
In preeclampsia there is a reduction in the GFR leading to a  rise in plasma creatinine 
and urea and a fall in the creatinine clearance rate. In severe preeclampsia there is a 
characteristic increase in the am ount of protein excreted by the kidney into the
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measurable range (above 300 pg/1). In the presence of proteinuria, renal lesions are 
usually found (Sheehan, 1980; McCartney, 1964)
Altchek, Albright and Sommers (1968) showed that the typical biopsy lesions are:-
1) Glomerular Lesions.
2) Juxtaglomerular cellular hyperplasia.
3) Lesions of the loop of Henle.
4) Afferent arteriolar spasm.
Glomeruli are enlarged by 20% with cellular swelling and glom erular capillary 
endotheliosis (Fig. 3.2). All glomeruli appeared affected bu t the distribution within 
the  glomeruli was patchy. There was an  increase of the num ber of cells and 
thickening of the capillary endothelium between the capillaries explaining the 
appearance of the splitting of the basem ent membrane seen by light microscopy. 
This is really an  increase in the mesangial matrix. Capillary endothelial cells were 
swollen and many lumina appeared empty or absent. Deposition of fibrin protein 
strands were seen within Bowmans capsule. Vassalli, Morris and McClusky (1963) 
have found fibrinogen within these lesions. Immunofluorescent studies suggested 
th a t the deposits seen on the basement membrane are fibrinogen derivatives. This 
supports the view th a t preeclampsia is an  upset of the coagulation system. The 
epithelium of Henle's loop was severely desquamated with fragments of nuclei and 
cells evident. In other areas regeneration was apparent. Afferent arterioles showed 
marked vasospasm.
Tubular lesions are also common and casts are seen in the urine. Chesley (1971) 
showed that the kidney has a decreased ability to secrete uric acid in preeclampsia, 
hence the increase in the concentration of uric acid and a fall in bicarbonate 
concentration. Uric acid is filtered completely by glomeruli, reabsorbed completely 
by proximal tubules and then secreted by distal convoluted tubules. Therefore, in 
preeclampsia, the initial filtering may be reduced by glomerular impairment or the 
secretion may be deficient due to tubular damage. In support of the latter possibility, 
Altchek, Albright and Sommers (1968) have reported a lesion in the Loop of Henle, 
the severity of which is related to the level of uric acid. They and Poliak and Nettles 
(1960) have shown hyperplasia of the juxtaglomerular apparatus (JGA) and apparent 
cellular hyperactivity. The JGA was swollen with an  increase in the num ber of cells 
and vacuolation. There is an increase in renin, angiotensin and aldosterone activity. 
This could lead to retention of sodium and water. However these lesions appear to be 
progressive with the disease and may be secondary to the volume depletion ra ther 
th an  being an aetiological factor. Dieckmann (1952) has reported the rare lesion of 
cortical necrosis which was fatal although it can now be managed by renal dialysis. 
The lesion is caused by spasm of the renal arteries and anaemic infarcts. This lesion 
is not specific to pregnancy.
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After delivery the changes disappear with occasional traces of increased mesangial 
matrix. Petrucco et al (1974) did not see the changes of the JGA or the Loop of Henle 
b u t their samples were taken from the recovery phase post delivery while the 
findings of Altchek’s (1961; 1964; 1968) and other's came from renal biopsies taken 
during the active phase. Sheehan showed that the renal changes regress quickly after 
delivery (Sheehan, 1950).
These findings were summarised by Zuspan (1978) as
1) Disease of arterioles.
2) Increased vascular sensitivity and reactivity.
3) Sodium retention.
4) Decreased glomerular filtration rate.
5) Decreased intravascular compartment.
6) Increased irritability of the central nervous system.
7) Negative nitrogen balance.
Placental lesions
The fetus depends on the placenta for its survival. The ability of the placenta to 
exchange nutrients and gases with the fetus is largely dependent on blood flow, both 
in the mother and in the fetus. It has been known for some years th a t the blood flow 
to the placenta is reduced in maternal hypertension (Browne and Veall, 1953; Dixon 
and Robertson, 1958; Assali et a l, 1954). More recently, Campbell (1983) has show 
abnormalities in the uterine artery velocity wave form as early as 18 weeks in 
patients who are destined to develop preeclampsia and IUGR.
These observations might be explained by the pathology in the terminal segments of 
the uterine spiral arteries. Within the placenta, these become obstructed by fibrin 
and platelet aggregates. Placental infarcts are also seen. However, these 'so-called' 
infarcts are found in about 60 per cent of normal pregnancies. Tenney and Parker 
(1940) believe tha t the characteristic placental change is one of prem ature aging. Fox 
(1978) disregards th is term  and calls the lesions ischaemic villus necrosis. Tenney 
and Parker (1940) found tha t in preeclampsia m ost of the villi show syncytial 
degeneration, a finding in only 10 to 50% of normal pregnancy. Extensive infarcts of 
more than  5% of the placental area are not found in normal pregnancy (Fox, 1978) 
bu t are found in increasing frequency in patients with worsening hypertension. This 
lesion is not specific to preeclampsia and occurs in essential hypertension without 
evidence of superimposed preeclampsia. It is likely tha t these changes are those of 
hypertensive damage of whatever cause (Fox, 1978). The work of Dixon & Robertson 
(1958), Brosens et al (1970; 1977), Robertson and Dixon (1967) and Robertson (1976) 
showed the obvious differences between normal and preeclamptic pregnancies (Fig. 
3.6). The fundamental lesions are in the spiral arteries of the placental bed. There is 
a failure of the normal invasion of the m aternal spiral arteries by the trophoblastic 
cells. This invasion is necessary to destroy the musculo-elastic tissue in the media to
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allow vasodilatation of the spiral arteries. There is then  failure of the norm al 
vasodilatation of these arteries leading to a reduced placental blood flow. The trigger 
for failure of the normal physiological changes in the m aternal blood vessels is 
unknown b u t could be due to immunological reaction similar to graft rejection. An 
immune aetiology has been previously discussed. More recent studies by Sheppard 
and Bonnar (1981) suggest tha t these lesions are not specific to preeclampsia bu t are 
found in the vessels from pregnancies with intrauterine growth retardation, with or 
without hypertension.
These placental changes give rise to interference with fetal growth and oxygenation. 
B astiaanse and Mastboom (1950) claimed th a t uteroplacental ischaem ia was 
responsible for preeclampsia. Therefore, the m aternal changes seen in pregnancy 
induced hypertension may be secondary to placental ischaemia. Animal models of 
the disease depend on procedures which cause placental ischaemia (Cavanagh et al.,
1977). This theory would support Symonds belief tha t uteroplacental stimulation of 
the renin/angiotensin system secondary to placental ischaemia plays a central role 
in  the development of hypertension (Symonds, 1981).
Hereditary factors
There is increasing evidence tha t severe preeclampsia is a  familial disease (Adams 
and Finlayson, 1961; Chesley, Annitto and Cosgrove, 1968; Cooper and Liston, 1979). 
Chesley, Annitto and Cosgrove (1986) traced 96% of the grown daughters of the 
women who had had eclampsia at the Margaret Hague M aternity Hospital. The 
incidence of preeclampsia in daughters was 26%. It was 32% in sisters and 16% in 
granddaughters. Adams and Finlayson in a study of sisters found a strong family 
association. Humphries (1960) looked at the mothers of women who had eclampsia 
in the Johns Hopkins Hospital in Baltimore. There was an  incidence of 28% in the 
m others compared with 13% in other random  patients. Sutherland et al (1981) 
studied the mothers and mothers-in-law of patients with severe preeclampsia. The 
study showed tha t mothers-in-law did not have an  incidence higher th an  expected 
(4%) bu t mothers did (14%). So the condition appears to be passed from m other to 
daughter and is not transmitted by the husband. Therefore, a single recessive gene in 
the m other and not the fetus could be responsible for the development of pregnancy 
induced hypertension (Cooper and Liston, 1979). This is unlikely to be true as other 
factors are undoubtedly involved. It is more likely th a t the hereditary factors are 
dom inant in natu re  with only 50% penetrance. This would allow for the other 
factors to influence the disease penetration and reduce the incidence of the carrier 
gene required in  the population to support the single recessive gene theory. 
Incomplete penetrance is very difficult to d istinguish  from m ultifactorial 
inheritance.
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Similar inherited tendencies are not found in mild preeclam psia or late onset 
disease. This implies th a t th is condition may have a different aetiology, th a t it 
represents a mixed group or tha t it is the adaption to the disease process tha t is 
related to inheritance.
Miscellaneous factors
The condition is thought to be more frequent in the obese (Oats et a l, 1983) and it 
appears to be related to the weight a t the s ta rt of pregnancy (Peckham and 
Christianson, 1971). However, fat women have higher blood pressure  and it is 
difficult to measure as the arm is too big for a normal sphygmomanometer cuff.
There are no differences in  the incidence of preeclampsia in the different social 
classes (Duffus and MacGillivray, 1968) except for a slight increase found in social 
class III. Women who smoke have a lower incidence of disease (Duffus and 
MacGillivray, 1968) but if preeclampsia develops, it tends be of a more severe form 
th an  average. Although it has been advocated tha t eclampsia was partly due to 
dietary deficiencies (MacGillivray and Johnstone, 1978), there is little evidence for 
this. Brewer (1969) agreed bu t based his argument on the fact tha t the incidence of 
preeclampsia was higher in underprivileged black groups. This difference found in 
social groups is not universal (Duffus and MacGillivray, 1968) and some of the 
changes may be racial rather than  social. Others found tha t diet has no effect on the 
incidence bu t may affect outcome (MacGillivray, 1981).
Discussion
Much of what has been described are epiphenomena tha t relate to each other. They 
are not in  themselves causes of preeclampsia. There are however two basic 
abnormalities tha t are persistently found.
1) Abnormalities of placentation, evidence of which can  be found early in 
pregnancy before the clinical manifestations of the disease are apparent. 
Preeclampsia is also associated with excessive placentation, as in twin and 
molar pregnancies.
2) Abnorm alities of p latelet/vessel wall interaction, leading to increased 
vascular sensitivity and platelet consumption. The vascular activity also 
appears to antedate the clinical signs of preeclampsia. These changes may be 
mediated through the prostaglandin system.
As already stated there appears to be no difference between the placental changes 
found in preeclampsia and IUGR. The reason tha t some patients present with high 
blood pressure probably depends on their vascular reactivity (Fig. 3.7). The risk of 
convulsion appears to be related to the patient’s seizure threshold as it is not directly 
related to the blood pressure alone.
It is obvious tha t patients may carry the susceptibility to vascular reactivity, as 
described by Wallenburg (1986), without developing preeclampsia. What is required is
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a further trigger which would come from the placenta. This stim ulus may be 
mediated through the renin/angiotensin system but this is liable to be a  messenger 
ra ther th a t a  cause. The stim ulus would be produced either from the ischaemic, 
small, poorly implanted placenta of classic preeclampsia or from a large placenta 
found in a multiple pregnancy. The vascular reactivity is also associated with other 
vessel wall functional abnormalities such as increased platelet activation.
Most of the other signs found in this condition could be explained from these two 
m ain “prim ary” problems.
This does not explain why these events occur.
There is strong evidence tha t there is an im m unological role in preeclampsia.The 
immunological influence is most likely to be involved in the initial im plantation 
abnorm alities leading to the spiral artery  pathology re la ted  to p lacental 
insufficiency.
There is also strong evidence of an  hereditary role. This could be involved in  the 
vascular sensitivity seen by Gant and Wallenburg. If this was true, it could not be an 
autosomal recessive disorder bu t is more likely to be an autosomal dom inant with 
incomplete, around 50%, penetrance. This would fit the resu lts described by 
Wallenburg (1986) (Fig 3.5)
3.3 The risks of pregnancy hypertension
Hypertension in pregnancy is not a disease in itself bu t a reflection of a m aternal 
response to an  underlying disease. It can however be used as a m arker of risk  for the 
mother or the baby. The risks associated with any measurement can be used in the 
assessm ent of whether that measurement is abnormal or not. Since preeclampsia is 
a m ultisystem  disorder, blood pressure alone may be inadequate for assessing 
absolute risk. The disease affects different organs in different ways and to different 
degrees. The risks to the m other and baby depend on how the disease affects the 
patient and which organs are involved. Not all patients with the same abnormalities 
of disease param eters will necessarily have the same risks. The problems for the 
mother and the baby are different and they will be treated separately.
Risks to the mother
In m odem  obstetric practice, hypertension in pregnancy produces a m anagem ent 
dilemma. The risks to the m other are difficult to assess.. The figures from the 
Scottish m aternal mortality report show tha t the vast majority of the patien ts do 
well (1987). The risk of maternal death associated with hypertension is only 1:11000 
which is not m uch different from the rate for pregnancy as a whole. However, the 
recent confidential inquiries into m aternal deaths in England and Wales, have 
shown th a t hypertension in pregnancy rem ains the biggest killer of pregnant 
women. 20.5% of m aternal deaths are associated with pregnancy induced
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hypertension and another 8.3% related to other hypertensive related factors 
(Turnbull et al., 1989). A look at the rates over the last four reports show th a t there 
has been little change over the last 20 years (Table 3.10) (Turnbull, 1987). The figures 
for Scotland are less clear as the numbers are smaller. PIH is the second biggest killer 
w ith pulm onary throm boem bolism  (PTE) first (Scottish Home And Health 
Department, 1989). If the cause of death within the hypertensive group is studied it 
can be seen that the main cause of death was cerebral haemorrhage and other types of 
cerebral damage (Table 3.11). The more traditional causes of mortality, such as  renal 
failure, are now less common, partly due to improved medical support available. 
Even if patients with eclampsia are studied, cerebral haemorrhage still appears to be 
the main cause of mortality. The risk to both mother and baby appears to relate to 
the degree of preeclampsia preceding the seizure, ra ther th an  the seizure itself. 
Therefore, in the United Kingdom, although eclampsia is the main preoccupation of 
therapeutic approach, CVA is the main maternal risk of hypertension in pregnancy. 
As already stated, the level and the degree of the rise of the blood pressure correlates 
more closely to the risk of CVA than  the risk of eclampsia. In most studies, about 
30% of the patients who suffered seizures, had diastolic blood pressures of less than  
90 mmHg. The chances of eclampsia occurring may be more related to the patient’s 
seizure threshold th an  to the level of blood pressure (Nelson, 1955a). The risk  of 
vascular damage with hypertension correlates with the animal studies th a t showed 
vessels are damaged when the diastolic blood pressure rises above 110 mmHg (Goldby 
and Beilin, 1972). Therefore, the main risks to the mother would appear to occur only 
after the blood pressure has reached 110 mmHg diastolic. Although convulsions may 
occur below this level, the maternal mortality and morbidity appear to be related to 
the  vascular damage associated with the hypertension, ra th e r th a n  to the  
convulsions unless repeated convulsions occur. There are m any cases in  the 
literature showing tha t patients still die with enough anticonvulsants ‘on board’ to 
stabilise the seizures.
Because of the dramatic presentation, it was eclampsia tha t was recognised before 
the hypertension (Chesley, 1980). Even with m odem  methods of blood pressure 
measurement, it is often eclampsia that brings the patient to the attention of medical 
care. This is particularly true in the third world where there is less antenatal care 
available. This has lead to a preoccupation with the prevention and treatm ent of 
eclampsia. The risk  of seizures in a hypertensive patien t is greatly overrated. 
However there is little good evidence of the true risk. In the Johns Hopkins Hospital 
in the 1930’s, less than  1 in 300 preeclamptics became eclamptic (Chesley, 1971). 
There were similar figures from Guys hospital at the same time (Gibberd, 1928). In 
Scotland, th e  incidence of eclam psia is 1 in  300 of the  to ta l of the
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preeclamptic/eclamptic patients (Scottish Home And Health Department, 1989). 
Since m any of the eclamptics show acute onset or are in trapartum /post partum  
patients with no prodromal preeclampsia, the incidence of eclampsia occurring in 
any hypertensive patient m ust be even lower th an  1/300. Therefore the risk of 
eclam psia for the average hypertensive patient is  low, and the m ain risks of 
mortality is from the hypertension itself leading to CVA.
A common belief is tha t delivery cures the patient with preeclampsia. If the Scottish 
figures are reviewed, it can be seen tha t all the patients that died, did so after delivery 
(Scottish Home And Health Department, 1989). Therefore, although the removal of 
the trophoblast will eventually remove the stim ulus to the disease, th is  is not 
immediate and continued vigilance is required after delivery.
Delivery in the unstable patient is probably more dangerous than  a delay in  order to 
stabilise the situation. Intubation causes a further rise in BP of between 20 and 30 
mmHg in both systolic and diastolic (Lavies et a l, 1989; Ram anathan et al., 1988). 
This is associated with CVA's occurring under anaesthetic leading to postpartum  
death. Adequate therapy with antihypertensives a n d /o r  narcotics p rior to 
intubation reduces this risk (Ramanathan et aL, 1988). Pulmonary edema is the next 
major cause of m aternal mortality. This is often due to fluid overload partly caused 
by overenthusiastic replacem ent. Plasm a protein solutions are particu larly  
dangerous (Duncan, 1989). Although there may be depletion of the plasm a volume, 
the vascular tree is contracted, reducing the capacity for fluid replacement. Some 
workers suggest th a t Swan-Ganz catheters are required to m onitor the  fluid 
replacement in  order to reduce th is iatrogenic cause of m aternal m ortality and 
morbidity (Wasserstrum and Cotton, 1986). The classical risks of renal and liver 
damage are rarely seen in present day practice in the United Kingdom, although they 
are still encountered in other parts of the world.
The reason for the reduction in renal risk is partly due to the availability of renal 
dialysis, bu t with adequate attention to the fluid balance and the careful monitoring 
of the urine output, renal failure should not occur. Coagulation abnorm alities 
associated with elevated liver enzymes and haemolysis have recently been described 
and termed the HELLP syndrome (Weinstein, 1982). This may not be anything new as 
low platelets, liver problems and haemolysis are well recognised complications of 
preeclampsia (Pritchard, Cunningham and Mason, 1976). The realisation th a t these 
signs highlight a high risk patient is important however, as the assessm ent of risk in 
preeclampsia has often been arbitrary in the past.
Despite these well accepted risks to the mother, it should be remembered tha t the vast 
majority of these patients do well with little or no morbidity.
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Risks to the fe tu s  and neonate
The effects of hypertension on the fetus depend on the degree of Involvement of the 
placenta, acute occurrences such as abruption, and the gestation at delivery (Scottish 
Home And Health Department, 1989).
Although preeclampsia is thought by many to be a placental disease (Robertson, 
Brosens and Dixon, 1967), it is plain tha t not all the pregnancies are equally badly 
affected. The incidence of intrauterine growth retardation is not absolute and many 
babies are well grown with no apparent placental insufficiency (Nelson, 1955b).
The classic pathology seen with preeclampsia consists of two parts. First there is the 
failure of the spiral arteries to dilate and lose their m uscular coat and then  there are 
secondary changes of infarction and thrombosis (Robertson, Brosens and Dixon, 
1967; Fox, 1978). The first changes are probably present in most, if not all of the true 
preeclamptic patients, bu t the secondary changes are not universal and may not be 
present in all parts of the placenta in the same patient. It is the secondary changes 
tha t therapies, such as low dose aspirin, may prevent, thus reducing the effects of the 
disease. Many workers believe th a t it is the placental damage th a t leads to 
ischaemia. Such damage stim ulates the release of vasoactive substances such as 
angiotensin II. These, in turn, produce the vasoconstriction and hypertension found 
in preeclampsia (Symonds and Broughton Pipkin, 1978). The secondary changes are 
similar in essential hypertension and may be partly an effect of hypertension. The 
primary changes in the spiral arteries are absent in essential hypertension bu t IUGR 
is associated with this form of disease.
Therefore, the effect on the baby depends not only on the presence of the disease but 
the degree of placental involvement. Although diastolic blood pressure above 95 
mmHg is associated with an  increased perinatal mortality (Friedman and Neff,
1975), the level of blood pressure does not appear to be a  good m arker in clinical 
practice. The Scottish Perinatal mortality statistics show that the percentage of the 
perinatal mortality rate associated with preeclampsia is around 18% (Scottish Home 
And Health Department, 1989). The percentage associated with severe disease is 5% 
and 13% are associated with mild disease. This implies th a t the overall risk  of 
perinatal death in the patient with preeclampsia is less than  the overall perinatal 
mortality rate. This is still true for patients with severe disease (Table 3.12).
So, if blood pressure does not necessarily help in the prediction of perinatal 
outcome, is there anything tha t is better. Redman (1976) showed tha t uric acid was a 
better predictor of poor perinatal outcome than  blood pressure. The increasing uric 
acid level is thought to be a sign of the renal involvement in the disease. The platelet 
count also falls in patients with progressive disease before the increasing severity 
becomes apparent (Redman, Bonnar and Beilin, 1978). Platelet consum ption is
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thought to be associated with placental deposition and fibrin formation (Robertson, 
Brosens and Dixon, 1967). This could be a sign of impending placental insufficiency. 
There is a higher incidence of IUGR in cases of perinatal mortality associated with 
hypertension compared to the other causes of perinatal mortality (Scottish Home 
And Health Departm ent, 1978; Scottish Home And Health D epartm ent, 1987; 
Scottish Home And Health Department, 1989).
Therefore the risks to the fetus are associated with changes found in placental 
insufficiency.
In the presence of a normally functioning placenta, is hypertension any problem to 
the fetus at all? If the hypertension remains mild or moderate, the risk  to the fetus 
appears to be less than  normal (Nelson, 1955a).
In cases of eclampsia, the risk to the fetus relates to the degree of preeclampsia that 
existed prior to the convulsion rather than the convulsion itself.
There is a small increase in the incidence of abruption (Chamberlain et a l, 1978a), 
bu t the risk only appears to rise when the systolic blood pressures is above 200 
mmHg (Dunlop, 1966).
One of the significant causes of perinatal mortality in pregnancies complicated by 
pregnancy hypertension is prem aturity. Many workers have shown the  poor 
outcome of hypertensive pregnancies in the second and early third trim esters (Sibai 
et al., 1985). Some have suggested tha t it is a different disease (Moore and Redman, 
1983).
The reason for th is is obvious. If the patient h as severe disease in  the  early 
gestations, delivery of the fetus carries a poor outcome whereas severe preeclampsia 
occurring at 34 weeks can easily be treated by delivery with an excellent prospect of a 
satisfactory  fetal outcome. In la te r pregnancy, the  presence of placental 
insufficiency increases the risk of fetal mortality and morbidity irrespective of the 
degree of blood pressure rise.
Therefore, the need to deliver the baby in the maternal interest is only a  risk to the 
fetus in the earlier trimesters when, despite good growth and wellbeing, the fetus may 
well die because of prematurity. The other risk is of placental insufficiency and IUGR 
which can cause problems at any gestation and with any severity of hypertension. 
This can be seen in the Scottish perinatal mortality figures which show th a t the 
perinatal loss associated with PIH is mostly postnatal prior to 32 weeks and 
antenatal after 32 weeks (Scottish Home And Health Department, 1989)
As the risk to the fetus varies with gestation, in order to reduce th is  loss, a  two 
pronged approach is required; attempt to prolong the pregnancies to allow improved 
fetal viability in the early gestations; and increase fetal m onitoring to reduce 
intrauterine death in the later pregnancies.
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3.4 The Management Of Hypertension In Pregnancy
Historical Perspective
Eclampsia was the first presentation of th is disease th a t was recognised (Chesley,
1980). It is not surprising tha t the treatm ent was directed a t th is symptom of the 
disease (Stroganoff and Davidovitch, 1937). Even today, when the whole spectrum  of 
the disease is known, the m ainstay of most protocols is anticonvulsant therapy 
(Menon, 1961; Zuspan, 1966; Pritchard and Pritchard, 1975; Sibai etal., 1981a). This 
is despite the fact th a t more m others die without convulsion th a n  die following 
convulsion (Turnbull, 1987). It was also realised th a t delivery was the definitive 
treatm ent as the condition only occurs in  the presence of a placenta and resolves 
after removal of the placenta (Chesley, 1980). Therefore, most therapeutic regimes 
were based on sedating of the mother and expediting deliver of the fetus.
Methods o f therapy in hypertension o f pregnancy
Prevention would be the best form of treatment, bu t as we do not know the cause we 
therefore do not know how to prevent this condition. Early studies of m anipulation 
of the prostaglandin/thromboxane balance look encouraging, b u t the results of the 
CLASP (Collaborative Low dose Aspirin Study for the Prevention of preeclampsia 
and growth retardation) study controlled from Oxford and the large American study 
are awaited. Early detection of the condition would help provide an  opportunity for 
early treatm ent tha t might alleviate the worst effects of the condition. Various tests 
such as the cold pressor test, the flicker fusion test and the roll over test have been 
tried to detect the very early changes of preeclampsia, bu t they have not been found to 
be of practical value. However, even if early detection is achieved, w hat are the 
therapeutic options?
Hospitalisation and bed rest
If the blood pressure is found to be raised to a diastolic pressure of over 90 mmHg or if 
there is protein in more than  trace amounts in a m idstream specimen of urine, most 
obstetricians felt th a t the patient should be admitted to hospital (Hamlin, 1952; 
Chamberlain et a l, 1978a; Cunningham and Pritchard, 1984). Bed rest is probably 
one of the m ost widely used m ethods of treating th is  condition, although no 
randomised study has proven its value (Matthews, 1977a; Crowther and Chalmers, 
1989). If the blood pressure remained ju s t below 90 mmHg or fell below 90 mmHg on 
resting, the patient would then  be allowed to rest at home. Sedation was often 
prescribed, e.g. Sodium Amytal, 200 mg or Diazepam (Valium) 5 mg (Chamberlain et 
aL, 1978a). It has been shown that bed rest increases the placental blood flow b u t it is 
not known whether this is necessarily beneficial. It also reduces the venous pressure 
in the lower extremities and allows a reabsorption of a considerable am ount of the 
oedema. This can give a false impression tha t the condition is improving.
66
Matthews, in  a randomised trial, showed that management at home was as good as 
hospitalisation in nonproteinuric preeclamptic patients (Matthews, 1977b). There 
appeared to be no need to admit to hospital. If patients are admitted, the blood 
pressure is often found to be normal and more than  half the patients admitted with 
hypertension were found to be wrongly diagnosed (Hall, Chang and MacGillivray,
1980).
If the blood pressure remained up and particularly if proteinuria was present the 
patient would normally stay in hospital. She may be allowed up  to the toilet bu t 
otherwise bed rest would be complete. Sedation was often increased (Chamberlain et 
al, 1978a).
Salt restriction and D iet
Since a patient with preeclampsia has salt and water retention, salt restriction and 
the use of diuretics might initially appear attractive. However, changes in dietary 
salt have no effect on the clinical course of preeclamptic patients (MacGillivray,
1981).
Low calorie diets have been tried in an  attem pt to prevent or to treat preeclampsia, 
bu t a controlled trial has shown th a t there is no difference in the incidence of 
proteinuric preeclampsia in primigravidae given a low calorie diet compared with 
matched controls, although the weight of the babies was reduced (Campbell and 
MacGillivray, 1975). Therefore, diets do not appear to reduce the  incidence of 
preeclampsia or improve the condition once it is established.
Sedation
M agnesium sulphate was popular as part of the  Stroganoff trea tm en t which 
originated from Russia in the early part of the century (Stroganoff and Davidovitch, 
1937) and its use has continued mainly in North America, in  the treatm ent of 
eclamptic convulsions or as a sedative in the severe form of preconvulsive state. 
Large doses of magnesium sulphate may produce depression of the vital centres. The 
margin of safety is small bu t it remains the regime of choice in eclampsia and severe 
preeclam psia in  the USA (Pritchard and Pritchard, 1975; Sibai, G raham  and 
McCubbin, 1984; Lee, Todd and Bowe, 1984; Zuspan, 1966; Dinsdale, 1988). Even 
there, it is not universally accepted (Kaplan et a l, 1988; Dinsdale, 1988; Donaldson, 
1988).
Many other methods of sedation have been used. The so-called 'Lytic cocktail’ was 
composed of 25 mg of chlorpromazine, lOO mg of pethidine and 50 mg of 
promethazine. It was extensively used in the treatm ent of eclampsia by Menon (1961) 
in Madras. Although a good anticonvulsant, it could cause respiratory depression in 
the babies.
Morphia has been used in the treatment of fulminating preeclampsia and eclampsia.
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Amylobarbitone sodium (Sodium Amytal) was given in a dose of 200 mg nightly or 
four- to six-hourly depending on the severity of the condition (Chamberlain et a l, 
1978a). Paraldehyde was popular in some places bu t it was usually given rectally and 
w as not a very efficient anticonvulsant. Diazepam (Valium) is an  efficient 
anticonvulsant and it is still widely used. It h as some hypotensive effect b u t 
overdosage is relatively easy and  respiratory depression m ay be encountered 
particularly if given in conjunction with barbiturates.
Chlormethiazole (Heminevrin) given by continuous intravenous infusion is a 
commonly used anticonvulsant. The perinatal mortality with chlormethiazole was 
only half tha t found with bromethol or paraldehyde (Duffus et a l, 1969).
The use o f antihypertensive drugs in pregnancy.
Antihypertensive drugs reduce blood pressure. The pharmacological action of many 
of these drugs is still not fully understood. They may act in different ways b u t the 
results of the action are the same. All antihypertensive drugs have side-effects, some 
of which may produce further benefits and others harmful results (De Sweit, 1985; 
Lubbe, 1984). Since they are powerful cardiovascular agents, it would be surprising if 
they did not have some adverse fetal effect (Schoenfeld et a l, 1989). The obstetrician 
m ust balance any potential benefit of antihyp extensive therapy against any 
potential side-effect th a t might occur. There is no consensus about therapy for 
pregnancy hypertension and the role of antihypertensive drugs (Lubbe, 1984; Rubin, 
1981; Chamberlain e ta l, 1978a; Trudinger and Parik, 1982).
Which drugs are available?
Drugs exist tha t can alter the responses of every known blood pressure control 
system. They can be divided into five main groups:- centrally acting drugs, drugs that 
alter cardiac output, drugs tha t effect the peripheral vascular resistance, angiotensin 
converting enzyme inhibitors and diuretics.
Centrally acting drugs
The m ain centrally acting drugs are methyldopa and clonidine. They act by central 
inhibition of the sympathetic drive (Frolich, 1980; Houston, 1981). All drugs tha t act 
in th is way are associated with troublesome side effects and have led to the move 
away from these products in the non-pregnant patient (Reid and Elliot, 1984). 
Clonidine, an  alpha-adrenoceptor agonist, has been used successfully in  pregnancy 
to control blood pressure, bu t the experience is limited (Horvath et a l, 1985).
Methyl dopa is still the m ost widely used  drug for pregnancy hypertension 
throughout the world. This is partly due to its relative inexpensiveness b u t also its 
apparent safety (Leather et a l, 1968; Redman et a l, 1976). Its mode of action is not 
fully understood. Oral absorption is poor with oral bioavailability of less th an  30%.
Methyl dopa
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An oral dose of 250-1000 mg will reduce blood pressure within 2-3 hours, with a peak 
effect at 4-8 hours and lasting 10-12 hours. There is a small degree of bradycardia but 
little or no alteration in cardiac output. The hypotensive effect appears to be related 
to a  reduction in the peripheral resistance following a reduction in  sympathetic 
drive. The use of methyl dopa is associated with a relatively high degree of m aternal 
side effects. The most common are sedation, diy mouth, nasal congestion, depression 
and postural hypotension (Redman et aL, 1976).
Drugs that alter cardiac output
The mode of action of beta adrenoceptor blockers is not fully understood bu t the 
consistent haemodynamic feature of beta-adrenergic blockade is a reduction in the 
cardiac output (Lund Johansen, 1980). In the non-pregnant hypertensive patient, the 
cardiac output is often increased and the peripheral resistance is normal. Therefore, 
beta-blockers are well suited for the treatment of chronic hypertension.
Not all these drugs act in the same way. They can be subdivided into those th a t are 
blockers to both pi and p2 receptors, selective pi receptor blockers, those with 
intrinsic sympathomimetic activity (ISA), different lipid solubility and membrane 
stabilising effects. These different properties can  alter both the beneficial and 
harmful effects of these drugs. Widely used in the non-pregnant patient, their initial 
use in pregnancy was associated with some degree of hesitation. They were thought to 
have depressant effects on the fetal circulation and uterine tone. In addition, studies 
had suggested tha t they might be associated with adverse effects such as neonatal 
hypoglycaemia (Haraldsson and Geven, 1989), neonatal hypotension, depression of 
fetal heart rate  (Ingemarsson et a l, 1984), impairment of the stress  response 
(Dagbjartsson et a l, 1985) and intrauterine death (Lieberman et a l, 1978). Most of 
these studies, however, have been anecdotal or stem from animal research ra ther 
than  hum an experience (Dagbjartsson e ta l,  1985). They have not been confirmed in 
prospective studies. Adrenoceptor antagonists are now widely used in the treatm ent 
of preeclam psia in  Europe and A ustralia (Rubin, 1981; Dubois et a l ,  1982; 
Pontonnier, 1984). They are widely accepted as being safe to use although those 
w ithout in trin sic  sym pathom im etic activity m ay increase the  chance of 
intrauterine growth retardation (Dubois et aL, 1982; Lardoux et al, 1983b). The drugs 
tha t have been studied the most are the non-selective blockers pindolol (Kahhale et 
a l, 1985; Dubois et al., 1982) and oxprenolol (Gallery et a l, 1979; Gallery, Ross and 
Gyory, 1985; Fidler et al., 1983), the selective blockers atenolol (Rubin et a l, 1983; 
Lardoux e ta l,  1983b; Dubois e ta l, 1982) and metoprolol (Sandstrom e ta l ,  1983) and 
the combined alpha/beta blocker labetalol (Lardoux e ta l, 1983b).
Labetalol
Labetalol is a  unique adrenoceptor antagonist as it has both a  1-adrenoceptor
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antagonist and non-selective p-adrenoceptor antagonist properties. The p-blocking 
effect of labetalol is four times less potent than  th a t of propranolol. It appears to 
produce its hypotensive effects without compromising the m aternal cardiovascular 
system by producing peripheral vasodilation (Lund Johansen, 1984). This may help 
to m aintain renal and uterine blood flow. The acute adm inistration of labetalol 
causes a  reduction in blood pressure, heart rate and peripheral resistance, bu t there 
is no change in the cardiac output in standing and supine positions (Lund Johansen, 
1980).
Drugs that effect the peripheral vascular resistance
These drugs act on the vascular wall to reduce peripheral resistance. The m ain 
examples are among the oldest and the newest antihypertensive drugs.
Diazoxide
Diazoxide is a benzothiadiazine derivative th a t is closely related to the thiazide 
diuretics. It has no diuretic activity and has a direct action on the arteriolar smooth 
muscle (Koch Weser, 1976). In large doses it is associated with acute fetal distress and 
intrauterine death (Ayromlooi et a l, 1982). Small intermittent doses of 30 mg would 
appear to be safe and efficient in lowering blood pressure in the acute situation 
(MacLean e ta l,  1981).
Hydrallazine
Hydrallazine is the oldest antihypertensive drug still in regular clinical use. It acts 
directly on the vascular wall requiring an intact endothelium to produce its effect 
and acts best with the patient lying flat in  bed. Although its action is not fully 
understood, it may be mediated by prostaglandins. The fall in blood pressure results 
from vasodilation. Used as monotherapy, hydrallazine produces side-effects such as 
tachycardia, flushing, nasal congestion, tremors, headaches, nausea and vomiting 
(Koch Weser, 1974). A few subjects may be unusually sensitive to hydrallazine because 
of a reduced capacity to metabolise the drug. The use of hydrallazine is usually 
restricted to single or short term use. Prolonged use leads to both the stimulation of 
the renin-angiotensin-aldosterone system and the reduction in  renal perfusion 
pressure. This can cause fluid retention with blunting of the drug's hypotensive effect 
and increasing the chances of cardiac failure. It is more effective in  lowering 
diastolic blood pressure th an  systolic blood pressure. Acute adm inistration is 
associated with reduced placental blood flow (Lipshitz, Ahokas and Reynolds, 1987) 
and fetal distress (Vink, Moodley and Philpott, 1980). The effect of a single dose of 
hydrallazine wears off in about 2 /3  hours. Orally, the effect is minimal b u t can be 
used as an adjunct to beta-blocker therapy (Bott Kanner et aL, 1980).
Nitroprusside
Sodium nitroprusside is an  effective intravenous drug for the management of acute
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hypertension in the non-pregnant patient. It has been used in pregnancy bu t there is 
concern about the effects on the placental blood flow and the potential toxic effects 
(Shoemaker and Meyers, 1984; Stempel e ta l, 1982). Because it is light sensitive, it is 
difficult to give. There are easier and as effective drugs which are preferable to use. 
Calcium channel blockers
Calcium channel blockers act primarily by inhibiting extracellular calcium influx 
into cells through slow calcium channels. They reduce peripheral resistance and 
their action is proportional to the am ount of vasoconstriction (Olivari, Bartorelli 
and Polese, 1979). They are antagonistic against any form of vasoconstrictor and 
have a mild tocolytic effect (Ulmsten, 1984). The drugs which are m ost used in 
primary hypertension are nifedipine, nicardipine and verapamil. They are potent 
orally and are used alone (Barton, Hiett and Conover, 1990; Seabe, Moodley and 
Becker, 1989; Walters and Redman, 1984) or in  combination with p-adrenergic 
blockers (Constantine et a l, 1987).
They can be used in the acute situation or chronically. Animal studies have suggested 
th a t placental blood flow is reduced by nicardipine (Parisi, Salinas and Stockmar, 
1989b) and there is an  increase in fetal hypoxia (Parisi, Salinas and Stockmar, 
1989a). Other studies do not support this (Ahokas et a l, 1988) and hum an experience 
suggests tha t with therapeutic dosage, calcium channel blockers are safe (Hanretty 
e ta l, 1989; Lindow e ta l ,  1988).
Angiotensin converting enzym e (ACE) inhibitors
ACE inhibitors are relatively new, very effective drugs for treatm ent of hypertension 
in  the non-pregnant patient. They act by inhibiting the action of the angiotensin 
converting enzyme. This reduces the production of angiotensin II and reduces 
peripheral vascular resistance (Cody et a l, 1978). There is no reflex tachycardia. 
This action may seem attractive for use in preeclampsia with its abnormalities of 
angiotensin II (Symonds, Broughton Pipkin and Craven, 1975). However, the original 
ACE inhibitor, captopril, has been found to have unacceptable side effects both in 
animal experiments and clinical practice (Broughton Pipkin, Turber and Symonds, 
1980). Fetal deformity, neonatal renal failure, intrauterine death and a significant 
reduction in placental blood flow have all been reported. When captopril was given to 
pregnant sheep and rabbits, there was an appallingly high fetal and neonatal death 
rate in  both species. It was concluded tha t th is treatm ent should not be used in 
hum ans (Broughton Pipkin, Turber and Symonds, 1980). Enalapril is a  newer drug 
with less side effects but adverse reports have begun to appear in the literature (Scott 
and Purohit, 1989). For these reasons their use in pregnancy m ust be restricted. 
However, they may be used in the postpartum period when blood pressure control is 
difficult to achieve.
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Diuretics
The mechanism of action of diuretics is not definitely known bu t they probably act 
by a mild vasodilator action (Morgan, Mendelsohn and Doyle, 1980) and by reducing 
plasm a volume by altering sodium balance (Winer, 1961). The thiazide diuretics are 
the m ost commonly used often in combination with other drugs (Finnerty et al., 
1979). Thiazides do not significantly lower the blood pressure in  pregnancy (Gray, 
1968; Kraus, Marchase and Yen, 1966) and have proved dangerous by induction of 
severe hyponatraemia (Pritchard and Whalley, 1961) and causing acute pancreatitis 
in the mother (Menzher and Prystowsky, 1967) and the fetus (Minkowitwitz et al., 
1964). A rise in  blood u rea  and uric acid (Breckenridge, 1966), neonatal 
thrombocytopenia (Rodriguez, Leikin and Hiller, 1964) and hyperglycaemia and 
glycosuria in  diabetic or prediabetic patients (Goldman et al., 1969) can all be 
produced by the use of thiazide diuretics. There is some evidence to indicate tha t they 
can decrease placental function (Campbell and MacGillivray, 1975). A double blind 
study of the continuous prophylactic use of hydrochlorothiazide, 50 mg daily, in 
1030 obstetrical patients demonstrated tha t there was no alteration in the incidence 
of preeclampsia, hypertension, prem aturity, congenital anomalies or perinatal 
mortality (Kraus, Marchase and Yen, 1966). However, Collins reviewed the available 
literature and concluded that there was not enough evidence to prove th a t diuretics 
are dangerous (Collins, Yusuf and Peto, 1985) and Sibai (1983) showed th a t patients 
with chronic hypertension on diuretics can have the normal blood volume changes 
of pregnancy. In conclusion, diuretics have a relatively weak action and their de 
nouveau use in pregnancy cannot be recommended. Patients already on diuretic 
therapy will probably have chronic hypertension mild enough to allow cessation of 
therapy for the duration of the pregnancy.
What beneficial effect will treatment bring?
Since these drugs have varying modes of action, beneficial results achieved with one 
p reparation  m ay not be seen with ano ther and failure of action of one 
antihypertensive drug does not m ean tha t all will fail to work. Side effects seen with 
some m edications will not be seen with others. Before giving any patien t 
antihypertensive therapy, the obstetrician m ust assess whether the patient would 
benefit from the medication and which drug would be best to use. A diastolic blood 
pressure of above 110 mmHg appears to increase the risks of morbidity and 
mortality particularly to the m other and should m erit some form of m anagem ent 
decision (Turnbull, 1987; Mabie et al., 1987). A diastolic blood pressure above 90 
mmHg may constitute a slightly increased risk, especially in the presence of 
proteinuria (Friedman and Neff, 1975; Butler and Bonham, 1963; Chamberlain et 
a l, 1978b; Naeye and Friedman, 1979; Benedetti, Benedetti and Stenchever, 1982),
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but this risk is mostly to the fetus implying the need for increased monitoring. There 
is not a direct relationship between fetal compromise and blood pressure level.
One therapy, two patients.
In the nonpregnant patient, the potential benefits are balanced against the potential 
risks of therapy. With the advent of safer drugs with fewer side effects, the use of 
antihypertensive therapy has greatly increased without any clear evidence of benefit 
to the patients. In pregnancy, the situation is complicated by the presence of the 
fetus. Although the benefits of therapy may be directed at the mother, the side effects 
may be experienced by both the m other and her unborn child. The fear of 
teratogenicity and other fetal complications has m eant th a t m ost new drugs are 
contraindicated for use in pregnancy although there is no evidence of their harm. 
With the increasing cost of litigation and the relatively low profits from pregnancy 
use, few companies support or fund antihypertensive studies in pregnancy. This has 
led to contradictions and other difficulties in th is area of research. Labetalol is a 
drug licensed for use in pregnancy in the United Kingdom but is contraindicated for 
use in the United States. Both these decisions were based on the same available 
evidence.
Chronic hypertension
As far as the obstetrician is concerned, chronic hypertension is a  non-progressive 
disease. In the absence of superimposed preeclampsia, there is little increased risk to 
m other or baby (Redman, 1980; Sibai, Abdella and Anderson, 1983). No study has 
dem onstrated a reduction in the incidence of superim posed preeclam psia by 
prophylactic antihypertensive therapy. Therefore, the risks of therapy are relatively 
greater as the  benefits are less easily dem onstrated. However, th e  use  of 
antihypertensives in these patients is widely accepted, probably because the patients 
are often on therapy by the time they are seen by the obstetrician. It is in  th is 
situation tha t the need for treatm ent should be closely scrutinised. There are some 
drugs that should be avoided if it is at all possible.
Most of the studies in hypertension in pregnancy have been conducted on chronic 
hypertensive patients. Methyldopa was assessed in  hypertension occurring in 
pregnancy as long ago as 1968 (Leather et a l, 1968). The most comprehensive study of 
its use in pregnancy was performed by Redman et al (1976). They concluded tha t it 
was safe and tha t it appeared to reduce fetal loss from m id-trim ester abortions. 
There was no difference in perinatal mortality rate or the incidence of superimposed 
preeclampsia. The children of the women who took part in this study were followed 
up for seven years, and there was no obvious difference between the children from the 
treatm ent group, and those from the control group in term s of physical and mental 
handicaps, behaviour, vision, hearing and intellectual ability, th u s  emphasising the
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drug's safety bu t also the lack of measurable benefit (Cockbum et al., 1982). These 
results have led the authors to state that methyl dopa should be the drug of choice in 
pregnancy as it is proven to be safe. It should be remembered th a t the other drugs 
have not been shown to be unsafe. In th is  study, m aternal side effects were 
troublesome enough to cause 15% of the women to be withdrawn. Another study 
showed th a t methyl dopa was associated with reduced neonatal blood pressure 
(Henderson Smart et aL, 1984).
In the 1970’s increasing studies have been carried out into the use of p-blockers. 
Initially, studies with propranolol demonstrated fetal side effects (Lieberman et al.,
1978), bu t more recent work has shown increasing safety (Rubin, 1987; Tcherdakoff 
and Goupil Colliard, 1983; Tcherdakoff et al., 1978). p-blockers are now well 
established in the management of chronic hypertension. Metoprolol (Sandstrom et 
a l, 1983), oxprenolol (Gallery et al., 1979; Gallery, Ross and Gyory, 1985; Fidler et 
a t, 1983), labetalol (Lamming and Symonds, 1979; Lardoux et al., 1983b), sotolol 
(O’Hare e ta l ,  1980), pindolol (Dubois etal., 1982; Lardoux e ta l ,  1983b) and atenolol 
(Dubois et aL, 1982; Lardoux et a l, 1983b) have all been used in pregnancy, singly or 
in  combination with vasodilators. Although blood pressure control was achieved 
with all, few studies showed any measurable benefit to the mother or baby.
Oxprenolol has been compared with methyldopa (Gallery et al., 1979; Gallery, Ross 
and Gyory, 1985; Fidler et al., 1983). Both drugs had similar effects on blood pressure 
control, bu t one study showed tha t the oxprenolol group had a better outcome in 
term s of fetal and placental weight (Gallery et al., 1979; Gallery, Ross and Gyory, 
1985). These findings were not confirmed by the other study (Fidler et al., 1983). 
Labetalol was also compared with methyldopa and was found to be as efficient at 
lowering blood pressure and reducing the progression to proteinuria (Lamming, 
Broughton Pipkin and Symonds, 1980). There were less side effects found with the p- 
blockers.
Different p-blockers have been compared. Both pindolol and labetalol have been 
compared with atenolol in pregnancy (Dubois et al., 1982; Lardoux et aL, 1983b). All 
drugs controlled blood pressure but birth weights were significantly higher in  the 
pindolol and labetalol groups, possibly due to increased uteroplacental blood flow. 
Atenolol has been associated with intrauterine growth retardation and fetal heart 
rate abnormalities (Ingemarsson et al., 1984; Dubois et al., 1982; Lardoux et al., 
1983b).
Therefore, no great benefit has been shown by the treatm ent of chronic hypertension 
in pregnancy. If treatm ent is desired, no drug appears to be significantly superior, 
although methyldopa has a high incidence of side effects and the vasodilator p- 
blockers, oxprenolol, pindolol and labetalol may allow increased fetal growth as
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compared to the others.
Preeclampsia (PET)
In preeclampsia, the mother is at risk of vascular, renal, hepatic and neurological 
damage, all of which are related partly to the hypertension itself (Turnbull, 1987). 
Therefore, antihypertensive therapy may be of benefit to the m other by reducing 
these risks. The fetus is at risk from placental damage leading to intrauterine growth 
retardation and in trauterine death (Chamberlain et al.f 1978b). The placental 
pathology is not directly related to the hypertension as a patient with mild disease 
may have placental insufficiency and those with severe disease may have a fully 
functional placenta. Lowering blood pressure is unlikely to improve placental 
function. However, in these milder forms of hypertension the disease may progress 
and histological glomerular lesions typical of preeclampsia have been found in 
pregnant women with only mild hypertension. In pregnancies complicated by 
hypertension the physiological changes of pregnancy seem to be restricted to the 
decidual segments of uteroplacental spiral arteries (Robertson, Brosens and Dixon,
1976). These arteries may retain the capacity to respond to vasoconstrictor stimuli. 
Fibrinoid necrotic lesions are also seen in these arteries after relatively short 
exposure to high blood pressure (Brosens, Robertson and Dixon, 1970). These lesions 
are generally worse in women with prim ary hypertension and superim posed 
preeclampsia, a situation which carries the highest risk of fetal hypoxia (Robertson, 
Brosens and Dixon, 1976). All these findings suggest that the rate of progress of the 
hypertensive disorders in pregnancy may be attenuated by the antihypertensive 
therapy, allowing prolongation of the pregnancy and greater fetal maturity. 
Therefore, the purpose of antihypertensive treatm ent is; to control the blood 
pressure, in order to protect the m other from the effects of hypertensive crisis, 
especially during labour; and to prevent or slow the progression of the disease and 
prolong the pregnancy sufficiently to avoid the complications of prem aturity for the 
fetus, without increasing the risk to the mother.
Can this be achieved? Are there unacceptable side effects of therapy?
There is controversy about w hat effect antihypertensive drugs have on 
uteroplacental blood flow. There is disagreement concerning the ability of the 
placenta to autoregulate the blood flow (Moawad and Lindheimer, 1982). There is 
experimental data in rabbits which has shown autoregulation of uteroplacental 
blood flow throughout a large range of maternal blood pressure (Venuto, Stein and 
Ferris, 1976). This suggests not only tha t the placenta can protect itself from the 
effects of hypertension bu t also tha t the blood flow can be m aintained after blood 
pressure reduction.
The effects on the placental flow and the fetus may be dependent on other changes in
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the cardiovascular system rather than  purely a blood pressure effect. Patients with 
p reeclam psia  have a lte ra tio n s  in  th e ir  ca rd io v ascu lar system . Since 
vasoconstriction with reduction in the plasma volume is a common finding, it would 
seem logical to use vasodilator drugs, p-blockers which tend to reduce cardiac output 
and are beneficial in  chronic hypertension may not be as safe in preeclampsia. 
However, if the plasma volume is low, vasodilators may produce large falls in  blood 
pressure due to the inability of the cardiovascular system to adapt. This would lead to 
tachycardia and reduction in placental blood flow producing fetal distress. This has 
been described following the intravenous use of hydrallazine and diazoxide, potent 
vasodilators (Vink, Moodley and Philpott, 1980; Lipshitz, Ahokas and Reynolds, 
1987; Rabau Friedman et aL, 1980). Side effects may be reduced by using multiple low 
doses (MacLean et aL, 1981; Nissen, 1982) and concomitant (^-blocking agents. 
Therefore, in patients with preeclampsia, antihypertensive drugs should be used 
with care and understanding of the underlying problems. Lowering the blood 
pressure does not cure the disease and continuing vigilance of the mother and fetus is 
required, usually as an  inpatient. Preeclampsia is a progressive disease and 
antihypertensive drugs will only slow the progress at best. Although there is now a 
wide experience of drug therapy in preeclampsia there are still conflicting views on 
their benefits.
Severe hypertension.
There h as been no random ised study th a t has evaluated treatm ent in  severe 
hypertension although there is general consensus about starting  hypotensive 
treatm ent when diastolic blood pressure is above 110 mmHg. This is to protect the 
m other from cerebral vascular accident, the largest cause of m aternal death in 
hypertensive disease of pregnancy. Many centres manage severe hypertension with 
prophylactic anticonvulsant therapy, particularly magnesium sulphate. As m any as 
18% of all patients may be given this therapy although magnesium sulphate also has 
not been evaluated by controlled trial (Pritchard and Pritchard, 1975). Its role in 
established convulsions would appear to be beneficial. However, outside the United 
S tates, m agnesium  sulphate is not so widely used, with less th a n  20% of 
obstetricians in the United Kingdom having any experience with it (Chamberlain et 
aL, 1978a). Sedation with valium and chlormethiazole is often used in the UK.
If antihypertensive drugs are to be used, hydrallazine is still the m ost commonly 
used in acute hypertension, given intravenously by injection or infusion (Garden, 
Davey and Dommisse, 1982). Diazoxide has largely been superseded by more recent 
antihypertensives because of its recognised side effects. Satisfactory control of the 
blood pressure was easily achieved with intravenous infusion of labetalol in severe 
hypertension in pregnancy (Michael, 1979; Michael, 1986). There were no m aternal
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hypotensive episodes or side effects. A slow intravenous injection of 50 mg of 
labetalol is an  effective treatm ent of severe hypertension. It has  been shown to 
minim ise the norm al hypertensive effect of in tubation  a t caesarean  section 
(Ramanathan et aL, 1988).
Nifedipine has also been proven effective in pregnancy and the puerperium (Walters 
and  Redman, 1984; Barton, Hiett and Conover, 1990). On com parison with 
hydrallazine, nifedipine has been found to be as effective in lowering blood pressure 
and has the advantage of being an oral therapy (Seabe, Moodley and Becker, 1989). 
One possible serious problem is the possible interaction between calcium channel 
blockers and magnesium sulphate leading to sudden excessive fall in blood pressure 
(Waisman et aL, 1988).
Mild to Moderate hypertension
It is less well accepted tha t treatm ent should be started with diastolic blood pressure 
between 90 and 100 mmHg. There is no universal agreement as to whether drug 
treatm ent is preferable to; doing nothing,; bed rest; or delivery, in  women with mild 
to moderate preeclampsia. However, the use of drugs to control blood pressure in 
pregnancy is gradually increasing, due to the greater knowledge about the drugs and 
their safety in pregnancy.
Despite the initial reservations, adrenoceptor antagonists have now been studied 
fairly extensively in preeclampsia, and they have been shown to be both safe and 
effective in controlling blood pressure. They are also relatively free of side effects, 
making them  acceptable to patients.
The first random ised controlled s tudy  of an  adrenoceptor an tagon ist in 
preeclampsia was performed with atenolol, a  selective p-receptor antagonist (Rubin 
et aL, 1983). This was a study of 120 women. Atenolol effectively controlled blood 
pressure and reduced the subsequent development of proteinuria, suggesting a 
possible beneficial effect on the disease process. It is not a surprise, however, if 
antihypertensive therapy reduces the incidence of proteinuria (Rubin et aL, 1983; 
Lamming, Broughton Pipkin and Symonds, 1980), as this is probably a result of the 
reduction in the perfusion pressure to the kidney.
There was no difference in fetal and neonatal complications such as intrauterine 
growth retardation, neonatal hypoglycaemia or hyperbilirubinaemia between the 
two groups. Respiratoxy distress was seen only in the control group. However, 
neonatal bradycardia was more common in the atenolol group, although there was 
no effect on neonatal blood pressure. The children from this study have all been 
followed up for one year and atenolol has not been shown to have any adverse effects 
on their development. Other studies have confirmed these findings. Some workers 
recommend the use of a vasodilator like nifedipine as concom itant therapy to
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overcome the vasoconstriction of preeclampsia (Constantine et aL, 1987). Labetalol, 
which has built in vasodilator ability, has also been shown to be effective.
It would seem from these studies tha t adrenoceptor antagonists are both safe and 
effective in the treatm ent of preeclampsia, and may have some beneficial effects on 
the disease process. W hether any particular adrenoceptor antagonist is more 
effective than  the others is not certain. Labetalol has been shown to be as good as or 
superior to methyl dopa (Lamming, Broughton Pipkin and Symonds, 1980), while 
both labetalol (Lardoux et aL, 1983a) and pindolol (Dubois etaL, 1983) appear to have 
advantages over atenolol.
Hydrallazine is frequently used as a "second line" drug to augment the effects of 
adrenoceptor antagonists and methyldopa when satisfactory control is not achieved 
with a single agent. Erratic metabolism yields unpredictable responses by the oral 
route and nifedipine has largely superseded hydrallazine.
Metabolism o f drugs in pregnancy
Pregnancy is associated with major changes in the m aternal metabolism. Various 
studies have shown that there is an alteration in the way a pregnant woman handles 
antihypertensive drugs. The plasma half life appears to be altered and the length of 
time the drug is effective is shortened (Rubin et al., 1983; Rubin et al., 1987; Rogers, 
Sibai and Whybrew, 1990). This may lead to the need for different dosage regimes for 
the pregnant compared with the non-pregnant.
Other effects antihypertensive drugs may have.
Very few drugs are used for the reason for which they were first produced. The 
antihypertensive action is often stumbled upon during evaluation studies. Therefore, 
it is not surprising when other effects are discovered. The m ost consistent is an 
antiplatelet action shown by propranolol, pindolol and labetalol (Greer et a l, 
1985b). Labetalol has also been shown to reduce thromboxane production (Greer et 
a l, 1985a). This result is probably not a beta-blocker effect as the nonhypotensive 
isomer of propranolol is associated with the anti-platelet effect.
Discussion
There is no doubt tha t hypertension in  pregnancy is associated with an  increased 
risk to the mother and fetus. However, there appears to be no consensus concerning 
the best treatm ent regimes. It appears clear tha t many of the patients do not require 
special care bu t vigilance is probably required to distinguish those th a t do from 
those th a t do not. Hospitalisation is not necessary for all. Lowering blood pressure 
appears to be possible and easy to achieve. But does it bring benefit?
As therapy during pregnancy is directed at the mother, there is concern that the fetus 
might be subjected to adverse effects without benefit to itself. If antihypertensive 
therapy prolongs pregnancy, the fetus will indirectly benefit from this and th is may
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counter balance any harmful effects. Not all therapies would appear to be beneficial 
and some drugs have greater side effects than  others. Close monitoring is required 
for any fetus of a hypertensive mother and th is need is heightened if she is given 
antihypertensive therapy. It is difficult to distinguish between side effects produced 
by therapy and the problems of the disease itself. All drugs will cross the placenta to 
a greater or lesser degree. It has been reported tha t some babies have a prolonged 
clearance of labetalol after delivery (Haraldsson and Geven, 1989). Atenolol has a 
prolonged neonatal clearance. It would be surprising if these drugs produced no side 
effects in the neonate.
The ACE inhibitors appear to produce direct complications tha t are harmful to the 
fetus and neonate. There would have to be strong reasons for their use in  pregnancy. 
Diuretics have only a weak effect and the potentially harmful changes to placental 
blood flow would count against their use.
Atenolol is a very effective drug in pregnancy, especially in those with an  increased 
cardiac output, bu t there are reports of fetal heart rate abnormalities, high levels of 
cord blood drug concentration and a slow neonatal clearance. One of the main fears 
concerning antihypertensive drugs is the effect they might have on the placental 
blood flow. Labetalol has been shown in both animal and hum an studies to lower 
blood pressure and m aintain placental blood flow. Hydrallazine and nicardipine 
have been shown to reduce placental blood flow but nifedipine does not. It is difficult 
to know whether these findings are clinically relevant bu t it would appear advisable 
to use drugs that have not been shown to have adverse effects.
All the p-blockers are known to be associated with hypoglycaemia, bradycardia, and 
hypotension in some infants. This does not appear to be clinically significant. These 
problems are also common in babies bom  of hypertensive mothers not on therapy. It 
is difficult, therefore, to distinguish the side effects of drugs from manifestations of 
the disease process. If widespread use of medication is to be carried out, close 
monitoring is required.
3.5 Conclusions
1) The majority of hypertensive patients are at relatively low risk and do not 
require therapy.
2) Antihypertensive drugs are mostly safe in  pregnancy b u t th e ir role is 
unproven.
3) Drug treatm ent may be beneficial to lower blood pressure and minimise the 
risks for the mother.
4) The combined alpha/beta blocker labetalol appears to be well tolerated and 
may have some benefits over the others.
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5) Lowering the blood pressure may moderate the progression of the disease bu t 
it does not stop it.
6) Care should be taken to m onitor closely the mother and the fetus.
7) Delivery remains the only cure for established preeclampsia.
8) Side effects o f beta-blockers for the neonate include hypoglycaemia and 
occasionally bradycardia.
9) Once delivery has been carried out the therapy may need to be continued in  
some patients for a number of weeks.
10) If blood pressure does not settle following delivery the diagnosis may need to 
be altered and the patient referred for further assessment.
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CHAPTER 4
The Changing Face o f Eclam psia
in
The Glasgow Royal M aternity H ospital
1933-1983
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4.1 Introduction
In eclampsia, mortality and morbidity for both m other and infant have been 
reported as being high (Wightman, Hibbard and Rosen, 1978; Pritchard and 
Pritchard, 1975; Lopez Llera, Linares and Horta, 1976; Zuspan and Ward, 1965). The 
cause of maternal death was usually cerebral vascular accident (Lopez Llera, Linares 
and Horta, 1976). Abruptio placentae and prem aturity were the m ain causes of 
perinatal death (Wightman, Hibbard and Rosen, 1978; Pritchard and Pritchard, 
1975). Much of the work tha t has been published is from parts of the world where 
eclampsia is still commonplace. It would appear that, in the UK, the num ber of cases 
seen each year has been falling and the prognosis for both m other and infant has 
improved. It would appear logical to assess the risk in our own population, and 
design management protocols accordingly.
The Glasgow Royal Maternity Hospital (GRMH) is a large maternity hospital which 
has served Glasgow for over 150 years. It serves a large catchm ent area consisting 
mainly of social class IV and V patients. Any obstetric problems such as eclampsia 
have always been referred to the hospital. Detailed hospital records for the last 50 
years are available, giving the num ber of deliveries and outcome of the pregnancies, 
including all those patients delivered within the surrounding district and not within 
the hospital. It provides an ideal centre to investigate the changing incidence of 
eclampsia and its concomitant m aternal and fetal morbidity and mortality. To 
study the effect of eclampsia on m aternal and fetal morbidity in  GRMH, it was 
decided to review all the cases of eclampsia presenting to the hospital over the 50 
year period 1933-1982.
4.2 Methods
The case records of all the patients presenting with eclampsia over the fifty year 
period of 1933-82 were studied if they were available. If no case records were 
available, information was taken from the yearly hospital reports. These reports 
contained all the relevant information about the patients presenting with eclampsia 
during the year. The statistics concerning num ber of deliveries, the m aternal death 
rate and perinatal mortality for the hospital and district were noted. The total 
num bers of eclamptics, m aternal deaths and deliveries for the whole district were 
available throughout the time period. Although the catchment area has changed with 
the opening of other maternity hospitals, there is no reason to believe th a t those 
patients lost to the catchment area would be any different th an  those remaining. 
Therefore, although the actual num ber of patients delivered under direct supervision 
of the hospital has decreased over the study period, th is should have little effect on 
the incidence of eclampsia in the patient group within the area of Glasgow served by 
the hospital.
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4.3 Results
Over the  study period 271,752 infants were delivered w ithin the hospital or 
surrounding district. The num ber of deliveries occurring in the hospital remained 
almost constant for each decade, whereas deliveries in the district decreased since 
1943 (Table 4.1).
1,118 cases of eclampsia were managed by the hospital staff over th is time. The 
num ber of cases and the incidence of eclampsia has significantly fallen over the 
period of the study (Table 4.1). The ratio of primigravidae to m ultiparous patients 
with eclampsia rem ained sim ilar throughout each decade studied (Table 4.2). 
Overall, antepartum  eclampsia was the most common type of presentation seen. This 
was followed by intrapartum  and post partum  cases (Table 4.3). There has been a 
change in the proportion of these presentations between the first two decades and the 
last three. (Fig.4.4) The relative proportion of postpartum  cases has significantly 
increased (p<0.001) and the proportion of both antenatal (p<0.05) and intrapartum  
cases reduced (p<0.05). This implies th a t there has been a smaller reduction in  the 
postpartum cases than in the others.
If the overall incidence of preeclampsia is assumed to be 15%, there would have been 
around 11036 preeclamptics in the first decade, giving an incidence of one eclamptic 
patient per 20 cases of eclampsia. In the last two decades, there will have been around 
14120 preeclam ptics, giving an incidence of one eclamptic pa tien t per 152 
preeclamptics. In the last decade, the figure is 1 per 292 preeclamptics. Although this 
is only an estimate of the incidence, it does suggest tha t the risk of eclampsia is now 
m uch reduced from the levels seen previously.
Management
From Table 4.5, it can be seen that treatm ent of eclampsia altered considerably over 
the fifty year study period. In the first decade studied, the mainstay of treatm ent was 
delivery of the patient, and this often included induction of labour using cervical 
bougies under full anaesthesia. Sedation was achieved by chloroform, morphine and 
phenobarbitone. Stomach and colonic lavage with magnesium sulphate was used to 
clear the patient of ‘toxins’. Various medical therapies were instituted in  the ensuing 
years, including Stroganoff therapy and bromethol. It is only in the m ost recent 
years th a t true anticonvulsants and antihypertensives have been employed in the 
management of eclampsia.
In the last decade studied 78% of patients received diazepam, 94% chlormethiazole 
and 78% received a hypotensive agent, usually hydrallazine. Only six patien ts 
received treatment prior to the onset of seizures and in only one of these cases did the 
patient receive an antihypertensive drug.
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Maternal Mortality and Morbidity
The m aternal mortality rate associated with eclampsia has reduced dramatically 
from the first to the last decade (Table 4.6). Since 1952, there has been significant 
reduction in the m aternal mortality rate (Table 4.7) This is true not only for the 
absolute numbers but also for the incidence of death in eclamptic patients. There has 
been no maternal death from eclampsia since 1964.
The causes of death in 116 of the women who died from eclampsia during the period 
studied was previously reported (Govan, 1961). There were 68 primigravidae and 48 
multiparous patients. 69 patients were less than  30 years of age and 47 were over 30 
years of age. The actual cause of death was established in  110 of the 116 cases. 
Cerebral lesions accounted for 39 cases, 32 of which showed a large haemorrhage in 
the pons and basal nuclei. In 47 cases the cause of death was due to cardiorespiratory 
failure. Sometimes the cardiac failure occurred during or immediately after the 
eclamptic phase bu t frequently death was due to subsequent pneumonia. Massive 
adrenal haemorrhage was found in 3 cases , sepsis caused death in 4 cases, delayed 
chloroform poisoning following Stroganoff treatm ent accounted for four and signs 
of shock a further eight. Renal impairment was a relatively rare case with uraem ia 
occurring in only 5 cases. Analysis of the cardiorespiratory group and comparison 
with those dying of cerebral haemorrhage revealed a difference between the onset of 
convulsions and death. In the cerebral group the average time lapse was 23 hours 
compared with 43 hours in the cardiorespiratory group. It was also found th a t the 
incidence of prodromal symptoms did not differ and both groups had an average of 7 
seizures. Another interesting finding was tha t chronic pyelonephritis was a frequent 
complication in these patients.
Clinical Findings 1973-82
The 19 cases of eclampsia in the last decade were studied more closely. The most 
common premonitory symptoms were those of headache, visual disturbance and 
abdom inal pain. However, only nine patien ts dem onstrated these prodrom al 
symptoms. Five patients arrived at the hospital in a semiconscious or unconscious 
state and nine patients had their seizures outside the hospital. These included fits in 
other Casualty Departments, a t home or in the general practitioners surgery. The 
other ten  patients seized for the first time in the hospital b u t only one of these 
occurred prior to delivery.
Only eight of the nineteen patients had documented evidence of hypertension prior 
to convulsing. Four of the 10 antepartum  cases had a documented rise in  blood 
pressure prior to the seizure. Two of these patients were noted to be hypertensive at 
the antenatal clinic but refused admission and were later admitted unconscious from 
home. One patien t had essential hypertension and was on trea tm en t with
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methyldopa bu t had seizures at home. The other patient was in  hospital with severe 
pregnancy induced hypertension. She was not treated with antihypertensive therapy 
and convulsed while in the hospital. Three of the intra and post partum  eclamptics 
had documented rises of blood pressure prior to the seizure and none were treated 
with antihypertensives although two were given sedative agents.
Of the 19, only 2 had significant morbidity. One patient who had been known to have 
essential hypertension was later diagnosed as having Conn's syndrome. Another 
patient who delivered a fresh stillbirth after intrapartum  eclampsia subsequently 
developed low grade disseminated intravascular coagulation and acute renal failure 
which resolved after treatm ent. This was the only patient in the last decade of the 
study who had evidence of abruptio placentae.
Fetal Outcome
There has been a steady decrease in perinatal mortality due to eclampsia (Table 4.8). 
This reaches statistical significance after 1963 (table 4.9). The perinatal mortality 
rate  of eclamptics per 1000 hospital b irths has also reduced. The proportion of 
stillbirths to the eclamptic perinatal mortality rate fell during the fifty year period 
and neonatal deaths now form a larger percentage of perinatal mortality rate (Table 
4.9).
Fetal Outcome 1973-1982
There were 21 infants, including two sets of twins, bom  to the 19 eclamptic patients. 
Three infants were stillborn and there were four neonatal deaths. 14 infants 
including both sets of twins survived. Six of the seven fetal losses occurred in 
patients with antepartum  eclampsia. The m ean gestation of the two stillbirths which 
occurred in the antepartum group was 28 weeks and the mean birth weight was 1.5 kg. 
The m ean gestation of the four neonatal deaths in the antepartum  group was 29 
weeks and the m ean birth weight was 1.33 kg. The one other fetal death was a 
stillbirth in a patient a t term with intrapartum  eclampsia. This patient had a seizure 
while a fetal blood sample was being performed for fetal distress. There was delay in 
performing a caesarean section and a fresh stillbirth weighing 3.18 kg was delivered. 
There were no losses in patients with postpartum eclampsia.
The m ean gestation of the 14 surviving infants was 39 weeks and the m ean birth 
weight was 2.8 kg. None of the 21 babies were below the 10 th  centile for birth weight 
for their gestational age.
4.4 Discussion
In any retrospective case record study, there is a risk that changes seen can be due to 
factors other than  disease changes. Great care was taken to include all the sources of 
information available on the deliveries in the hospital and the district. Therefore, 
the author is sure tha t the denominator of total deliveries is accurate. Although, the
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exact area of referral has altered of the last fifty years, this is inevitable in a shifting 
population and developing health care system. It is only in the last decade tha t 
particular referrals to the Glasgow Royal Maternity Hospital have been made from 
other hospital areas because of particular facilities available. Therefore, there is no 
reason to believe tha t the population cared for has significantly changed in type over 
the fifty years. It is difficult to know whether the referral of eclamptics into GRMH 
was always 100% in the early years. Some may not have been counted. This would 
tend to underestimate the rate in the earlier decades making the changes seen even 
more significant. Therefore, it is felt tha t both the value of the denominator and the 
total num ber of eclamptics are reasonably certain. It is therefore possible to 
calculate the changing rates of eclampsia over the last fifty years.
Cruickshank (1923) reported the high incidence of the toxaemias of pregnancy in 
Glasgow. At tha t time, no other centre in the United Kingdom, Europe or the United 
States of America reported such a high incidence of those conditions. Over the study 
period, the incidence of eclampsia fell from 729/100,000 to 51/100,000 deliveries 
from the first to last decade studied. This later figure is compatible with other 
publications (Campbell and Templeton, 1980).
The ratio of primigravidae to m ultipara was similar throughout the decades of 
between 2 and 3 to 1. This has been reported by other authors (Wightman, Hibbard 
and Rosen, 1978; Campbell and Templeton, 1980; Cruickshank, 1923). This suggests 
th a t multigravid women are also at risk, albeit lower. Since th is constant ratio is 
seen against a background of reducing proportion of multigravid deliveries, it would 
imply tha t the relative risk to the parous woman may be increasing. Accurate figures 
for piimigravid and multigravid delivery num bers were not available, and th is 
change in incidence could not be studied. The long term prognosis for multigravidae 
who develop eclampsia, has been shown to be worse than  in those women developing 
eclampsia in their first pregnancies. In a study of longterm follow up, a m uch higher 
proportion of those who had eclampsia as a multigravida were found to have died 
from cardiovascular disease th an  did those women who had  eclam psia as 
primigravida. Cardiovascular causes accounted for only 29% of the remote deaths of 
the  primigravid eclamptic women, as compared with 82% of those who were 
multigravid (Chesley, Annitto and Cosgrove, 1976).
The highest m aternal mortality occurred in patients with antepartum  eclampsia
and this has been reported by other workers (Lopez Llera, Linares and Horta, 1976).
Chronic renal disease, particularly pyelonephritis was a common finding in  fatal 
eclampsia. In patients over the age of 30, chronic vascular disease was a  frequent 
occurrence and massive cerebral haemorrhage was more common in th is age group. 
(Govan, 1961). The prognostic importance of age has previously been noted (Davies,
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1971; Hibbard, 1973; Lopez Llera, 1967; Lopez Llera, Linares and Horta, 1976). It is 
suggested tha t either age reduces the adaptability of vital systems to various types of 
pathogenic influences and stress or th a t older women are more likely to have 
preexisting disease that predisposes to eclampsia.
The falling m aternal death rate was one of the striking features in  th is study. The 
reduction in  the incidence of the condition has resulted for several reasons. The most 
dramatic changes in incidence and mortality from eclampsia occurred in the 1950's. 
Around th is time there was a gradual move towards hospital based obstetric care. 
There were major improvements in social circum stances and the National Health 
Service was developed leading to improved antenatal care and hospital facilities. 
The introduction of bromethol as a eclamptic therapy, also occurred in the m id/late 
forties. Therefore, the falling incidence is likely to be related to a  combination of 
improved social conditions, better antenatal care, increased intervention therapy 
and earlier delivery leading to less progression to eclampsia.
Treatment of eclampsia has altered considerably over the 50 year study period. The 
m ost common drugs used in recent years were diazepam and chlormethiazole. 
Antihypertensive agents were not frequently used. Only one of the 19 eclamptic 
patients in the final decade received an antihypertensive drug prior to seizing. In two 
cases, if hypotensive therapy had been commenced then seizures may have been 
prevented. The lack of use of hypotensive agents h as been reported by others 
(Wightman, Hibbard and Rosen, 1978) when only 12% of eclamptic patients received 
a hypotensive drug and 25 permutations of drugs were used to treat 43 patients. The 
recent reports on m aternal death in England and Wales also noted the lack of 
antihypertensive therapy (Turnbull et al., 1989). Although, in in th is triennium , 
cerebral vascular accident (CVA) was still a m ajor cause of m aternal death, 
cardiopulmonary problems were now the biggest cause. If CVA was to blame, th is 
tended to happen early following the convulsion. Cardiopulmonary problems 
occurred later. This would suggest that antihypertensive drugs may be an  important 
first line therapy but problems of fluid balance follow this. Renal failure occurred in 
less than  5% of cases.
Eclampsia continues to be a major cause of perinatal death worldwide (Wightman,
Hibbard and Rosen, 1978; Turnbull etaL, 1989; Sibai, 1990). Despite an  overall fall
in  perinatal mortality due to eclampsia, the disease is still associated with a  fetal 
loss of 182/1000 in the relatively few cases seen in the last twenty years. Over the 50 
year study period, the ratio of stillbirths to neonatal deaths has been reversed, with 
the latter now representing a larger percentage of the perinatal mortality. In the last 
decade, of the seven infants who died, four were neonatal deaths all occurring in 
patients with antepartum  eclampsia. The m ean gestation at time of delivery was 29
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weeks, reflecting th a t prematurity was a significant contributor to fetal loss. With 
the improvement in neonatal care over recent years, m any of these infants would 
now be expected to survive in a tertiary care neonatal unit. Of the three stillbirths, 
two would now be potentially preventable. One was a  term ination of pregnancy 
because of severe hypertension and the stillborn infant weighed 1.1 kg. Such a case 
would be managed differently now with antihypertensive therapy and delivery by 
caesarean section if further deterioration occurred. A favourable outcome could be 
anticipated in an  infant of th is birth weight. The other stillbirth could have been 
avoided, had a caesarean section been performed earlier. One case resulting in a 
stillbirth was probably unavoidable. The patient presented at another hospital in an 
unconscious state. By the time of transfer to the maternity hospital no fetal heart 
was detected. It was interesting to note tha t this patient's m other had a history of 
having a cerebrovascular accident during pregnancy, attributable to eclampsia. 
Overall, the perinatal loss in the last decade of the study is disturbing. However, the 
majority of the fetal loss was related to prem aturity and in current day practice, 
m any of these infants would probably have survived.
None of the surviving nor the fetal loss cases showed evidence of growth retardation 
as m easured by birth centile. This perhaps reflects the acute presentation of the 
majority of the patients and the fact th a t a preceding preeclamptic process with 
resultant placental insufficiency was not seen in any of the patients during the last 
10 years of the study. The lack of evidence of growth retardation is contrary to the 
experience of other authors (Sibai, 1990; Wightman, Hibbard and Rosen, 1978). and 
may reflect the inaccuracy of the methods of diagnosis rather th an  lack of growth 
retardation. A properly designed case control study might help to answ er th is 
question.
Evidence of abruptio placentae was rare in the eclamptic patients during the last 
decade of the study. The incidence was similar to tha t reported by Sibai when 9 of 67 
patients had evidence of abruption (Sibai, 1990).
The falling incidence of eclampsia is probably due to multiple causes, including 
im provem ent of general health , an ten a ta l care, reduction  in  parity  and  
improvement in the treatm ent of hypertension. However, despite a  low m aternal 
mortality and morbidity, fetal loss from eclampsia is still relatively high, due 
mainly to prem aturity. The general trend in  improved neonatal survival for the 
prem ature infant should lead to better prognosis for infants bom  to eclamptic 
m others.
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4.5 Conclusions
The m ain conclusions are:
1) The incidence and therefore the risk of eclampsia has dramatically fallen.
2) Multigravid patients are also at risk of developing eclampsia.
3) There has been a relative increase in the rate o f postpartum  eclam psia 
compared with ante and intrapartum  eclampsia.
4) The risk  related to postpartum  eclampsia is less th an  th a t related to 
antenatal eclampsia.
5) Renal failure is a rare cause of maternal death.
6) Cardiopulmonaiy problems occur between 40-48 hours after convulsions
7) Despite the steady reduction, there is still a high rate of fetal loss tha t may be 
preventable.
8) There was sometimes a failure to deliver the baby in  the best possible 
condition and the best possible way.
9) The risk of abruptio placenta and coagulation defects would appear to be low.
CHAPTER 5
89
STUDIES INTO THE CHANGES OF BLOOD
PRESSURE
AND
BLOOD PRESSURE VARIATION DURING
PREGNANCY
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5.1 Introduction
Hypertension in pregnancy has well recognised complications of morbidity and 
m ortality for both m other and baby. It also constitu tes a high percentage of 
antenatal admissions. However, there is a gross overdiagnosis of the condition with 
almost 60% of patients being found not to be hypertensive when admitted to hospital 
even though the blood pressure was elevated at the outpatient clinic (Hall, Chang and 
MacGillivray, 1980).
Blood pressure is not a precise physiological m easurem ent b u t a continuum  
(Pickering, 1968). In any given individual, it varies on a minute to minute and hour 
to hour basis. It is also known to vary throughout pregnancy (MacGillivray, Rose and 
Rowe, 1969). Despite these recognised changes, arbitrary values are used as m arkers 
of abnormality and hence for management decisions. These levels have been decided 
partly following statistical analysis of normality and partly related to the adverse 
outcome associated to the elevation of blood pressure (Friedman and Neff, 1975; 
Friedman and Neff, 1977; Friedman and Neff, 1978).
These arbitrary values are widely accepted. Many obstetricians would wish to admit 
to hospital, patients whose diastolic blood pressure has reached 90 mmHg. Others 
would intervene with either antihypertensive drugs an d /o r delivery if the diastolic 
blood pressure reached 110 mmHg (Chamberlain et a l, 1978a; Trudinger and Parik, 
1982; Turner, 1981; Redman, 1987).
Many of the patients with blood pressures above 90 mmHg do not have any problem. 
Therefore, using a diastolic of 90 mmHg as the cutoff point for the diagnosis of 
hypertension in pregnancy would appear to be an overdiagnosis (Hall, Chang and 
MacGillivray, 1980). There could be several reasons for this. Despite the known 
blood pressure variation (Mumaghan, 1987; MacGillivray, Rose and Rowe, 1969), 
single blood pressure readings are often used to make the diagnosis. Alternatively, 
the m easurement is repeated until a value is obtained which is below the arbitrary 
action level. This is then taken as the “true” level. There are no guidelines available 
th a t would let clinicians know the accuracy of a single blood pressure, the value of 
repeated readings or whether an average of these readings would be more useful.
There are changes in the blood pressure levels throughout pregnancy. It would appear 
to be illogical to use the same blood pressure level as abnormal at all times during 
pregnancy.
These doubts concerning the accuracy of the diagnosis of hypertension in pregnancy 
has led to the development of outpatient Day Care Assessment units (Walker, 1987; 
Rosenberg and Twaddle, 1990), various outpatient tests  using autom ated blood 
pressure monitoring (Mooney and Dalton, 1990) or home visiting of community 
midwives (Matthews, Patel and Sengupta, 1971; Rosenberg and Twaddle, 1990) as a
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method of assessing the risk to the individual patient. The purpose of these regimes 
is to tiy  and differentiate between those who require hospital admission and those 
who do not. Clear guidelines at the initial point of diagnosis might reduce the overall 
workload.
5J2 Aim s
The aims of the studies described in this chapter were to investigate the variation of 
blood pressure during pregnancy, the accuracy of a single blood pressure reading, 
how many times this reading would have to be repeated to get a reproducible average, 
and whether automatic blood pressure equipment gave a more accurate result.
5.3 Blood pressure changes throughout pregnancy.
MacGillivray (1969) showed that blood pressure fell in the first and second trimester 
and rose again towards term (Fig.3.1). This study was done on primigravida only. In 
order to confirm these changes and compare them  with the changes found in 
multipara, the blood pressures in 186 primigravida and 115 m ultiparous randomly 
selected patients attending the antenatal clinic a t the Glasgow Royal Maternity 
Hospital were measure serially throughout pregnancy.
Methods
All patients were resting for 10 minutes prior to the m easurement and sitting at 45 
degrees. The blood pressure was taken in the right arm using a London School of 
Hygiene random  zero sphygmomanometer a t the level of the heart. Phase four 
diastolic was used throughout. All the readings were carried out by one of two 
investigators. All patients were included in the results and were not excluded if their 
diastolic blood pressures rose above 90 mmHg.
All measurements were carried out between the hours of 9 a.m. and 12 noon to tiy  
and standardise the patient groups and to make sure the variations were not related 
to the diurnal rhythm (Mumaghan, 1987).
Results
The demographic data of the two groups are shown in Table 5.1. As would be expected 
the m ultiparous group were older than  the primigravida. The results are shown in 
Figure 5.1. The graph confirms the fall in blood pressure in the second trim ester with 
a rise towards term  as previously described (MacGillivray, Rose and Rowe, 1969). 
However, it was found tha t the parous women had a significantly lower systolic and 
diastolic blood pressure in mid-pregnancy as compared to the  prim igravida 
(Significance shown in Table 5.2). This difference persisted until the last weeks of 
pregnancy.
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Discussion
These findings were not expected. There was no difference between the groups a t the 
beginning or the end of pregnancy, bu t there was a significant difference from 24 
weeks onwards. It is surprising th a t the m ultiparous patient had lower blood 
pressures than  the primigravida as blood pressure normally rises with age. Since the 
fall in blood pressure is associated with vasodilation (Easterling et al., 1990), these 
findings suggest tha t the multiparous patient has greater vasodilation and for longer 
th an  the primigravida. This would imply a greater adaption to pregnancy in  the 
m ultiparous patient which may help to partly explain the reduced incidence of 
preeclampsia.
Since the blood pressure alters throughout pregnancy and between primigravida and 
multipara, it is difficult to decide on any particular blood pressure level th a t may 
offer a simple cut-off point between normal and abnormal. The level m ust have a 
different significance in different parities and at different gestations.
5.4 Blood pressure variation at the outpatient clinic.
M anagement decisions are often based on a single blood pressu re  reading. 
Alternatively, the measurement is repeated to assess the “true” value after rest. There 
is little information on the repeatability of blood pressure readings and whether this 
second reading is any more accurate than  the first. The purpose of this study was to 
study the reproducibility of an outpatient blood pressure reading.
Methods
Three hundred and sixty five randomly selected primigravidae in the th ird trim ester 
attending the routine antenatal clinic were asked to volunteer for the study. All 
patients were lying semi-recumbent on the examination couch and the blood 
pressure was taken in the right arm using a London School of Hygiene random  zero 
sphygmomanometer at the level of the heart. Initial blood pressure was taken  and 
this was repeated within 10 minutes. All estimations were carried out by the same 
observer. Both values were noted and used for analysis of variation. Primigravidae 
in the third trim ester were used as this is the patient group where the diagnosis of 
blood pressure is seen as the most relevant.
The difference between the two readings was noted and whether it was higher or 
lower than  the first reading.
Results
The range of systolic blood pressures is shown in Figure 5.2. and the range of 
diastolic blood pressures in Figure 5.3. There is a normal distribution in  both 
systolic blood pressures and no difference between the means or ranges of the two 
readings. Therefore there was no difference between the readings when the group was 
looked at as a whole.
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If the individuals were studied, there was marked differences found. Less th an  40% of 
the patients had a repeated systolic or diastolic measurements within 5 mmHg of the 
original blood pressure reading (Figure 5.4). In some, the difference was considerable. 
This measurement could be either higher or lower than  the original m easurement. 
Discussion
These findings have considerable significance. If the blood pressure of different 
groups are being studied, a single blood pressure from each individual is adequate to 
calculate the blood pressure mean. However, if an individual is being studied, a  single 
blood pressure only gives an  approximation of the patient’s blood pressure. If the 
first is found to be elevated, a repeat sample may be lower. This appears to be signs of 
the normal fluctuation and not an  effect of rest. There is no evidence to suggest tha t 
the second reading is any more ‘correct’ than  the first. Similarly, if a patient with a 
‘normal’ blood pressure is checked again, the level may be higher. It would appear 
th a t repeated measurem ents may give a  better idea of the patient’s blood pressure 
range. From this an average could be calculated and used as the ‘true’ blood pressure.
5.5 Blood pressure variation in the patients attending Daycare.
What is not known from the above study is the effect of the level of the initial blood 
pressure on the variation seen. Also, if an  average of several blood pressures are to 
used, what is the num ber of blood pressure readings required to give a m ean which 
would be a  reasonable estimation of the patient’s ‘true’ blood pressure. In order to tiy  
and answer these questions one thousand primigravidae attending the Daycare 
Assessment Unit (see Chapter 7) for the first time in the third trimester were studied. 
Methods
Five separate blood pressure readings were taken between 9 and 12 noon on the 
morning of attendance by the attendant nursing staff. All patients were resting for 10 
minutes prior to the measurement and sitting at 45 degrees. The blood pressure was 
taken in the right arm using a mercury sphygmomanometer at the level of the heart. 
These were part of the routine monitoring of the Daycare patients by the attendant 
nurses who were not aware tha t a study of the variation was to be carried out. 
Therefore, there was no bias due to the nurses trying to achieve equality of readings. 
The diastolic blood pressure was assessed using the phase four Korotkoff sound. The 
5 blood pressure readings were compared for degree of variation, the effect of the 
starting blood pressure on this variation, whether there was a trend from the first to 
last blood pressure and for the number of blood pressure readings required to give a 
mean which would be a reasonable estimation of the patient’s ‘true’ blood pressure. 
Results
The blood pressures in this study were higher than  in the normal study. This is not 
surprising as the patients were originally referred because of hypertension. The
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ranges found with the first and second readings of both systolic and diastolic blood 
pressure were similar (Figures 5.5 and 5.6). There was a small b u t significant 
difference in the means of the readings suggesting a small reduction between the first 
and second readings. These differences were only 2.5 mmHg for the systolic blood 
pressure and 1.3 mmHg for the diastolic blood pressure. This does not appear to be 
clinically significant. Similarly to the previous study, the blood pressure readings 
showed a veiy wide variation (Fig 5.6). In less than  50% of the patients was the 
second blood pressure within 5 mmHg of the first. The differences could be either up 
or down. There is always a risk tha t there is a bias towards readings ending in 5 or 0 
when the blood pressures are carried out using an  open method. In this study there 
was an  predominance to readings ending in 0 and 5 (Figure 5.8) bu t there was a 
reasonable scatter of results. It would appear tha t generally the midwifery staff took 
care to take an accurate reading.
The degree of variation was compared with the level of the first m easurem ent (Figure 
5.9 and 5.10). The results demonstrate tha t for the higher initial blood pressures 
there is a tendency for the blood pressure to fall (a positive difference) and the lower 
blood pressure to rise (a negative difference). These are highly significant differences 
(p<0.001). This would appear to demonstrate “a tendency towards the m ean” where 
repeated values would tend towards the mean of the group as a whole. If the second 
and third, third and fourth or fourth and fifth readings are studied, the results are 
fundam entally the same with similar variations found. There is no evidence of 
“stabilisation” over these five readings.
If the complete group was studied, there was no trend from the first reading to the 
fifth reading apart from the small bu t significant difference between the first and 
second readings previously mentioned. (Fig. 5.11). This does not support the 
argument that patients’ blood pressure will fall as they get used to the person taking 
it. This confirms the findings of the previous study where the results of the group as a 
whole showed no change despite the variations seen in the individual.
If the single reading does not give an  accurate assessm ent of the patient’s blood 
pressure, is an average of several readings any better.
In order to try and answer this question, the first two and subsequent blood pressure 
readings were averaged and compared (Fig. 5.12). The average difference between the 
first two readings was 7.4±8.3 mmHg. If a third reading was added to the first two and 
averaged, the difference between this result and the average of two readings was 2.9± 
4.8 mmHg. The addition of a fourth and fifth reading further reduced difference 
although these changes did not reach statistical significance.
Although the average difference may not be great, what is more im portant is the 
num ber of patients where the difference is still significant. Figure 5.12 shows th a t
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with the increasing num ber of blood pressures used to calculate the means, the 
standard  deviations got sm aller implying a reduced num ber of patien ts with 
persistent larger differences. If an arbitrary difference of less than  5 mmHg is taken 
as acceptable, The percentage of those with a persistently higher difference was 
noted. The results are shown in figure 5.13. If the first two readings are compared, 
over 40% of the patients had a difference of 5 mmHg. If the average of the first two 
readings is compared with the average of the first three, there are still 10% of the 
patients with a difference of more than  5 mmHg. This means th a t an  average of two 
readings is only accurate in 90% of the patients. If the difference between three and 
four readings are compared, 98% of the patients had a difference of less th an  5 
mmHg. An addition of five readings appeared to give little benefit. Therefore, an 
average of three readings appears to give reasonable accuracy in most patients and 
four readings in  almost all.
Discussion
This study confirms the findings of the outpatient study. There is no difference in 
the m eans of the repeated blood pressure readings in the given group of patients 
although the blood pressure in any individual patient can vary considerably. The 
direction of the variation is related to the starting blood pressure. Therefore, it would 
not be surprising if a patient who is found to have a high blood pressure reading is 
found to have a lower blood pressure reading on repeating the m easurem ent. 
Similarly a  patient with known elevation may be found to have a lower reading bu t 
the next reading will probably be elevated again. The blood pressure fluctuates 
around a given mean. However, this might not always be true as some patients will 
get worse and others get better. A series of three or four m easurem ents should give 
th a t information and the m ean of the readings will be a reasonable estimate of the 
“true” blood pressure. Future readings will vaiy round this mean. This study suggests 
th a t the m ean of three readings is the minimum th a t should be used and four 
readings is preferable. Management decisions should not be taken on single high or 
low levels. The more often a blood pressure is taken, the more likely the extremes of 
the range will be found. Therefore, in a patient with moderately high blood pressure, 
if the readings are repeated often enough, a ‘normal’ reading of less th an  140/90 
mmHg will be achieved. This is not the true, rested blood pressure b u t the lower 
extreme of the range. Similarly, a single reading of 160/110 mmHg will probably be 
the upper extreme of the range. Only persistent elevation or an elevated average blood 
pressure should be taken as significant. Nelson stated th a t two readings of the 
diastolic blood pressure above 110 mmHg are required before a  diagnosis of severe 
preeclampsia can be made (Nelson, 1955b).
If an  average blood pressure is clinically useful, can an automated blood pressure
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recorder be used to calculate it?
5.6 Blood pressure variation using the Dinamap automatic blood pressure 
recorder.
The same 300 patients attending Day Care also had blood pressure monitored using a 
Dinamap autom atic blood pressure machine. This was interfaced into a BBC 
microcomputer for analysis as previously described (Chapter 2). Ten blood pressure 
readings were taken over a 10 minute period. Similar analysis to those above were 
carried out to see whether there was any trend from beginning to end and how many 
blood pressure readings were required using a Dinamap to give an  average which 
would then  no longer vary. The average of the Dinamap readings were then  also 
compared with the average of the nurses' readings taken in Day Care.
Method
All the patients were sitting in a comfortable chair, the right arm was used for blood 
pressure m easurem ent and care was taken  to make sure th a t the  cuff of the 
sphygmomanometer was a t the level of the heart. The Dinamap used a diastolic 
which is automatically assessed by the machine which lies somewhere between 
Phase 4 and Phase 5. It was therefore expected th a t the Dinamap blood pressure 
recorder would produce results which were lower than  those found by the nursing 
staff. The variation, however, should have been the same.
Results
As predicted the Dinamap readings were found to be on average 8 mmHg lower for 
diastolic blood pressure compared with the nurses readings (Fig 5.14). When the 
average of the first two Dinamap diastolic blood pressures were compared, there was 
a significant reduction (Fig. 5.15). bu t no difference following this. This might imply 
tha t the patients were initially anxious bu t the pulse rate showed a gradual rise over 
the first four readings (Fig 5.16). If anxiety was the cause of the change of blood 
pressure readings, the pulse rate would have been expected to fall, not rise.
The variation found between the first two readings is shown in figure 5.17.
If this is compared results from the nurse’s readings (Fig 5.7), it can be seen th a t the 
degree of variation was similar.
When the end digit was studied, there was no obvious predominance found (Fig. 5.18). 
This is to be expected as there is no reason for the machine to favour any given result. 
When these results are compared to the results found with readings by the nursing 
staff (Fig, 5.8), no significant difference was found (Chi square test). This suggests 
tha t the nursing staff were taking reasonable care to read an accurate result.
When the serial averages were compared, there was little difference found after six 
readings were used (Fig.5.19). After this, a persistent average (a change of less th an  5 
mmHg) was achieved in 97% of the patients (Fig. 5.20). After 8 readings, th is rose to
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99%. The difference between this result and that found with the nurses readings is 
probably related to the fact tha t there is a significant fall in the first two blood 
pressure readings.
Discussion
The Dinamap appears to give similar findings to the previous studies. This suggests 
tha t the variation in blood pressure is on a m inute to minute basis and is a genuine 
physiological finding and not due to hum an error. Averaging the Dinamap readings 
gives an  accurate m easurem ent of blood pressure range bu t the level of diastolic 
blood pressures appears to be lower when compared with the nurse’s readings. This 
finding was expected as the Dinamap m easures a diastolic blood pressure between 
Phase 4 and 5. There is no reason that the Dinamap blood pressure recorder could not 
be used for the assessment of hypertension but a lower cut off point for abnormality 
is probably required. An average of 8 readings would appear to give an  accurate result 
in 99% of patients.
5.7 Discussion
The accurate diagnosis of hypertension is critical, as it is associated both with 
increased morbidity and mortality for mother and baby (Friedman and Neff, 1975; 
Friedman and Neff, 1976; Friedman and Neff, 1978). It is also a  reason for a large 
percentage of antenatal admissions to hospital (Hall, Chang and MacGillivray,
1980). It is also important tha t if a patient is at risk, she should be monitored closely. 
On the other hand, overdiagnosis of hypertension is common and one of the reasons 
for this could be the variability of blood pressure in the normal pregnant patient. 
These studies confirm the wide variation of blood pressure readings tha t occur on a 
minute to minute and hour to hour basis. This appears to be true irrespective of the 
blood pressure level although there is a trend towards the group mean. The repeated 
blood pressure reading may be higher or lower th an  the initial blood pressure 
reading. If the variation is as m uch as 15 mmHg, it m eans th a t patients with an 
average blood pressure in the low 80's could occasionally get a  blood pressure reading 
of over 90. The more often tha t blood pressure is measured in a given patient, the 
more often she attends the outpatient clinics, the more likely she is to have a single 
hypertensive reading.
The idea that blood pressure will settle after a  period of rest is not supported by this 
study. Although the Dinamap study showed a fall from the first reading to the next 
one taken 1 minute later, there is no obvious trend of blood pressure levels from high 
to low over repeated readings over time. In both the clinic and the Daycare study, 
blood pressure was equally likely to rise with the second reading as it was to fall. It is 
not surprising tha t if a blood pressure reading of 90 mmHg diastolic was repeated 
within 10 minutes tha t a lower blood pressure would be found bu t similarly it would
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be possible if you repeated a blood pressure reading of 85 mmHg th a t a  reading over 
90 mmHg might be found. Therefore, any given blood pressure reading will be a 
sample of a range of blood pressures. The limits of this range may be as much as 15 
mmHg above or below th a t reading. Two readings would improve on th is, bu t an 
average should be taken, not the lower reading. There is no obvious sense of using the 
lowest blood pressure reading any more than  of using the highest blood pressure 
reading. If repeated blood pressure readings are taken, an average of 4 would appear 
to give a  reasonably accurate assessm ent of the ‘true’ blood pressure, with the 
confidence limits of around 98%.
If th is method of blood pressure assessm ent is used, it may help to reduce the 
diagnosis of hypertension compared to a method using a single blood pressure 
reading. It may be found tha t 4 blood pressure readings over half an  hour, resting in 
the clinic, and averaged , would reduce the need for the patient to attend Daycare or be 
admitted to hospital. This study was not designed to answer th is question. O ther 
workers have suggested that the use of automatic blood pressure recorders may do the 
same job (Mooney and Dalton, 1990). Care is needed to make sure tha t the machine is 
measuring the same as the midwife. The Dinamap study showed th a t although it 
could be used, a lower cut off point is required as the diastolic blood pressure found is 
lower than  the phase four normally used.
Since there is so much variation in the blood pressure, it may be tha t blood pressure 
alone is not an  accurate method of diagnosing preeclampsia. The addition of 
biochemical testing may well help to increase the accuracy of the diagnosis.
5.6 Conclusions.
The main conclusions from these studies are:
1) Blood pressure variability is normal and should not be seen as abnormal.
2) Blood pressure does not settle with rest over a few hours.
3) A single blood pressure measurement should not be used for m anagem ent 
decisions.
4) A repeated measurement is not a more accurate result.
5) An average blood pressure of a t least four readings should be used for 
diagnosis and management.
6) Single blood pressure readings can be used in group studies.
7) Since there is so much variation, it may be that blood pressure alone is not an 
accurate method of diagnosing preeclampsia and should be used as a 
screening test only.
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CHAPTER 6
THE EVALUATION OF THE ‘ROUTINE’ 
INVESTIGATIONS 
USED IN THE ASSESSMENT
OF
PREGNANCY HYPERTENSION
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6.1 Introduction
The diagnosis of preeclam psia is not straightforward. The prim ary sign of 
presentation is a rise in the blood pressure to a specific level. The studies in the 
previous chapter demonstrated th a t the blood pressure is variable and th a t no 
absolute measurement can be taken as the ‘correct’ one. This may explain why there 
is an  overdiagnosis of the condition (Hall, Chang and MacGillivray, 1980). It is 
known that, in preeclampsia, various biochemical and haematological changes also 
occur (Redman, Beilin and Wilkinson, 1976; Redman, Bonnar and Beilin, 1978). 
These param eters could be used to help in the diagnosis of ‘true’ disease, and the 
monitoring of disease progression. If all param eters are normal, it would seem 
probable tha t the high blood pressure is transient in nature and is of less concern. If 
any are abnorm al, it would suggest th a t the diagnosis is more likely to be 
preeclampsia. If there is a worsening of the values, it may predict the progression 
from moderate to severe disease.
The author considers tha t most obstetricians fail to make an accurate diagnosis in 
cases of pregnancy hypertension and tend to manage all cases as being in the same 
risk  category. Once a diagnosis is made, there is often a failure to m onitor the 
progressive nature of the disease in both the mother and fetus. To try to correct these 
deficiencies a stepwise approach to the management of hypertension in pregnancy 
was developed. The initial management was based on m aternal monitoring. This 
concentrated on the changes found in blood pressure, renal function, including uric 
acid levels (Redman, Beilin and W ilkinson, 1976), liver function te s ts  and 
haematological param eters, including platelet count (Redman, Bonnar and Beilin, 
1978). Fetal monitoring consisted of cardiotocography and ultrasound. This chapter 
describes the results of these tests, their relationship to each other and  to the 
pregnancy outcome.
6.2 Patient group
To study the relevance of these tests, 335 consecutive primigravida who had a 
diastolic blood pressure below 90 mmHg in the first trimester and presented after 24 
weeks with a diastolic blood pressure persistently above 90 mmHg were reviewed 
(Table 6.1). None had a history of hypertension prior to pregnancy. These criteria 
were used in an attempt to select as ‘pure’ a group as possible for investigation. The 
relationship between the booking parameters, the param eters a t the time of the 
hypertension and the measurements of pregnancy outcome were studied.
Statistics
As many of the changes seen in these param eters may be interdependent, it was 
decided to u se  m ultiple regression analysis to look for any independent 
relationships between the selected measurements. A stepdown procedure was used to
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check the validity of the significant results. This involves the removal of the non­
significant results in a stepwise fashion until only the significant results are left. 
For convenience, only the full results will be displayed with the significant values 
highlighted. This was carried out with the help of Dr Pravn of the  University 
Department of Statistics a t Glasgow University.
6.3 Booking parameters
The mean and range of the parameters studied are shown in table 6.1. Tables 6.2 and
6.3 show the results of multiple regression analysis which demonstrates evidence of 
an  independent relationship between the parameters. The results show th a t systolic 
and diastolic blood pressures are closely related. There is also a  relationship between 
m aternal weight and both systolic and diastolic blood pressure. It would appear tha t 
a rise of 10 Kg in weight will change the blood pressure by 1 mmHg. This may appear 
to be a relatively small effect. However, a t the extremes of weight the difference is 
more significant, 8 mmHg between weights of 40 Kg and 120 Kg. If the patient was 
heavier, a larger width blood pressure cuff was used. Therefore, it is felt th a t these 
differences are real. It is difficult to know whether these changes imply th a t the 
heavier patient is at increased risk because of this difference or less risk because the 
blood pressure is less elevated for them. There is no relationship with patient height, 
booking haemoglobin, haematocrit or blood pressure measurem ents. The Adjusted 
Coefficient (RA2) is only 0.4 for both the systolic and diastolic blood pressure 
suggesting th a t these particular parameters contribute to around 40% of the blood 
pressure changes.
Later parameters
The mean, standard deviation and range of the values obtained when the patients 
were hypertensive are seen in Table 6.4. The results used were either the last 
m easurem ents carried out before delivery or before antihypertensive therapy was 
given, whichever was the later. Since, for each individual patient, they were taken at 
the same time point, they can be compared with each other. Although less accurate 
than  creatinine as a measure of renal function, urea (Redman et aL, 1973) was used in 
the study as the creatinine values were not available for all patients. The birth 
weights were also converted into the birth centile for the delivery gestation in  order 
to standardise the values. The following sections discuss the results of th is analysis.
6.4 Blood Pressure
As already stated, although elevation of blood pressure constitu tes the m ain 
m aternal risk, it is very variable and may be a relatively inaccurate m easure of 
disease severity. The average of four blood pressure readings taken in one day was 
used for these studies. Therefore, some patients had an average blood pressure of less 
th a n  90 mmHg (Table 6.4), although all were hypertensive with a t least two
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individual blood pressure readings over 90 mmHg on the day of assessm ent. All the 
other param eters show a wide range from well within the normal range to  grossly 
abnormal.
Systolic Blood Pressure
Table 6.5 dem onstrates the independent relationships with the  systolic blood 
pressure. It is not surprising th a t there is a relationship with the booking blood 
pressure, bu t the effect is small. For every 10 mmHg change in the booking systolic, 
there is only a  change of 2 mmHg in the last systolic. The only other results th a t are 
significant are the last haemoglobin and last haematocrit. The size of the coefficient 
depends on the actual value of the results. Therefore, the absolute value of the 
coefficient for haematocrit is considerably larger than  tha t for haemoglobin because 
the absolute value of the haematocrit (e.g. 0.33) is usually around 35 times lower than 
th a t for the equivalent haemoglobin (11.5). The direction of effect is different for 
these parameters. This means that a higher systolic blood pressure is associated with 
a lower haemoglobin and a higher haematocrit. This implies the development of a 
relative macrocytic anaem ia. This could be explained by chronic haem olysis 
(Weinstein, 1982) and a relative reticulocytosis. More studies are required into th is as 
it could be an early sign of HELLP syndrome, an accepted serious complication of the 
condition (Weinstein, 1982). There is no correlation with any of the other disease 
markers such as urea, uric acid, and platelet count.
Diastolic Blood Pressure
Diastolic blood pressure is related to the booking diastolic bu t the coefficient is only 
0.1 so the effect is even smaller than  tha t for systolic blood pressure (Table 6.6). 
There is a significant independent relationship with the accepted m arkers of disease 
severity, urea (Redman etal., 1973), uric acid (Redman, Beilin and Wilkinson, 1976) 
and platelet count (Redman, Bonnar and Beilin, 1978). There is also a  significant 
relationship with haemoglobin. The direction of effect is opposite to th a t found with 
the systolic blood pressure implying th a t a rise in  diastolic blood pressure  is 
associated with a rise in haemoglobin.
Discussion
These results suggest tha t diastolic blood pressure and not the systolic appears to 
relate to the accepted parameters of disease severity such as uric acid and platelet 
count. This may imply tha t the rise in diastolic blood pressure is more relevant in 
pregnancy induced hypertension. This would be logical as the  diastolic blood 
pressure is associated with the increased peripheral resistance seen  in  th is  
condition. The factors tha t relate to rises in systolic blood pressure are different. 
Therefore, the rise in  the systolic blood pressure may demonstrate a different aspect 
of the disease process. The changes seen with the haemoglobin and haematocrit are
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confusing and require further study.
6.5 Studies o f renal function.
Renal involvement is pathognom onic in  preeclam psia and  it is  norm ally 
dem onstrated by the presence of proteinuria (McCartney, 1964). There may be 
elevation of urea (Redman et aL, 1973) and creatinine (Zlatnik, Burm eister and 
Beach, 1982) as further evidence of impairment of renal function. Elevation of uric 
acid is associated with severe preeclampsia. Redman suggested th a t it was more 
closely correlated with fetal compromise th an  blood pressure (Redman, Beilin and 
Wilkinson, 1976). Uric acid is thought to correlate with renal tubular damage, bu t it 
may be elevated for reasons other th an  renal impairment alone (Beaufils et al.,
1981).
Urea
In th is study creatinine was not available in all patients and was not used in the 
analysis. It is realised tha t urea is not as accurate as creatinine as a m arker of renal 
impairment bu t an  elevation of serum urea is suggestive of impaired renal function. 
In normal pregnancy, there is an increase in creatinine clearance leading to a  fall in 
the serum  urea. This m eans th a t the levels of urea found in  pregnancy are 
approximately half those found in the non-pregnant. Very few of the patients studied 
had an  abnormal level for pregnancy, suggesting tha t renal function is m aintained 
in the majority of cases of pregnancy hypertension.
Multiple regression analysis shows th a t changes in urea relate independently to 
urate, Alt and booking haemoglobin (Table 6.7). Since the coefficients are small and 
the  Adjusted Coefficient is only 0.3, changes in  these param eters are only 
responsible for around 30% of the changes in urea. These results suggest th a t 
changes in renal function are relatively independent of the other changes in  the 
disease parameters.
UricAcid.
Uric acid is thought to correlate more closely with placental and fetal involvement 
th an  blood pressure (Redman, Beilin and Wilkinson, 1976). Multiple regression 
analysis shows tha t it is independently associated with diastolic blood pressure, Ast, 
serum albumin and urea (Table 6.8). This suggests that uric acid elevation is not only 
related to renal impairment but to some of the other systemic changes as well. These 
changes are related to cellular damage of the vascular endothelium and liver cells. 
Uric acid may be a m arker of systemic involvement in  preeclampsia ra th e r th an  
simply a m arker of renal impairment. The rise in uric acid could be partly due to an 
increased production of urate associated with cellular damage. The relationship with 
renal function and tubular damage is not surprising since, when produced, urate is 
excreted by the renal tubule.
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Proteinuria.
Proteinuria is associated with a higher incidence of fetal loss (Friedman and Neff, 
1975). The majority of these patients did not have protein in the urine. Since so few 
babies are now lost, correlation of proteinuria with fetal survival is difficult to 
confirm .
Using m ultiple regression analysis, proteinuria w as found to  have a direct 
independent relationship only with albumin, and booking haemoglobin (Table 6.9). 
As would be expected, serum  albumin was negatively related to urinary protein. 
There was no relationship between proteinuria and blood pressure  or other 
parameters of disease severity, such as uric acid, urea or platelet count. This suggests 
tha t proteinuria is a specific marker of preeclampsia due to the presence of the renal 
lesion rather than  a sign of disease ‘severity’.
Discussion
The three ‘renal’ m arkers appear to have a degree of independence. The lesion 
associated with proteinuria is well recognised (McCartney, 1964) and is probably a 
specific primary lesion in the disease. It would appear to be independent of blood 
p ressure  level and is probably an  absolute m arker of the presence of ‘tru e ’ 
preeclampsia. The absence of proteinuria does not m ean tha t the patient does not 
have preeclampsia, bu t many of those without proteinuria will have a more benign 
form of hypertension. This could be partly explain why proteinuria is associated 
with a less successful outcome.
Although the changes in uric acid are m ost strongly related to signs of renal 
impairment, it also appears to be independently associated with changes of diastolic 
blood pressure, and the m arkers suggestive of liver function abnormality, Ast and 
serum  Albumin. This suggests that the elevation in uric acid is at least partly related 
to signs of the systemic effects of the disease and may be a more accurate m arker of 
progressive pregnancy induced hypertension th an  blood pressure alone. Renal 
impairment, as measured by urea, may or may not be present.
6.6 Haematological tests.
Haemoglobin
Haemolysis is recognised as a late, worrying sign in preeclampsia (Weinstein, 1982). 
There has been a suggestion that haemolysis may be an early sign in the development 
of the disease (Sarrel et al., 1990). Multiple regression analysis shows the 
independent relationship of the last haemoglobin with the booking haemoglobin 
and haematocrit, the last haematocrit and the last blood pressure (Table 6.10). The 
direction of the association between the haemoglobin and the systolic blood 
pressure is negative but is positive with the diastolic blood pressure. This suggests 
th a t changes in  the systolic and diastolic blood pressures are associated with
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different effects on the haemoglobin levels.
Haematocrit
Multiple regression analysis shows an  independent relationship with the booking 
haemoglobin and haematocrit, the last systolic, last haemoglobin and last albumin 
bu t not the last diastolic (Table 6.12). These associations appear to be in the opposite 
direction than  those found with haemoglobin. This suggests tha t factors tha t reduce 
the haemoglobin will tend to increase the haematocrit. This can only result from a 
relative macrocytosis.
Platelets
Platelet consum ption is thought to be an  early abnorm ality in  preeclam psia 
(Redman, Bonnar and Beilin, 1978). In the study group, the range of platelet counts 
was wide from 62 to 669 (Table 6.4). Platelet consumption is thought to relate to 
platelet and fibrin deposition in the placental and renal circulation. Multiple 
regression analysis demonstrated an independent relationship with booking weight, 
diastolic blood pressure, and Ast (Table 6.13). These results suggest th a t platelet 
consumption is linked to a diastolic rise rather than  a rise in systolic blood pressure. 
However, since the Adjusted Coefficient (RA2) is only 0.2, these factors would appear 
to influence only 20% of the changes seen in platelet count.
Discussion
There appear to be few obvious relationships between haemoglobin, haematocrit and 
the other disease parameters. Where relationships are seen, the influences appear to 
have an  opposite effect on haemoglobin compared to haem atocrit. Low grade 
haemolysis could lead to a  fall in haemoglobin and a rise in haem atocrit due to a 
relative reticulocytosis. There are other influences such as haemoconcentration 
which would further complicate the relationships. These findings are confusing and 
require further study.
Changes in the platelet count are independently related to diastolic blood pressure 
and Ast. This suggests tha t the changes in platelet count are associated with damage 
to cell membranes and the liver mitochondria (Torbergsen et a l, 1989; Berkowitz et 
a l, 1990).
6.7 Combination of Blood Pressure, Uric Acid and Platelet Count.
As will be described fully in Chapter 7, the majority of the patients referred to the 
Daycare u n it are found to be normotensive. Most of th is  group rem ained 
normotensive for the rest of their pregnancy, b u t some developed persisten t, 
worsening hypertension. Since the purpose of Daycare is to screen out those who are 
and will remain normal, it is in the group tha t are normotensive a t first visit th a t 
further tests of normality or abnormality will be potentially useful. If there were 
signs tha t signify increased risk, these patients could be monitored more closely.
106
Since blood pressure, uric acid levels and platelet count all appear to be associated 
with different aspects of the disease, it may be possible to use changes in these 
param eters as a method of diagnosis and assessm ent of risk. All three param eters 
were measured at the Daycare Assessment Unit (Chapter 7) and the predictive value 
of an  individual result, or a combination of the three results, on the development of 
moderate to severe hypertension later in the pregnancy was studied. All these results 
were available on the day of attendance at Daycare.
One thousand and eighty seven consecutive primigravidae referred to the Daycare 
Unit because of elevation of blood pressure were studied. These patients attended 
between January  1985 and December 1989. The results obtained at the first daycare 
assessm ent were compared with the long term  outcome of the pregnancy. The 
definitions of outcome, that were used, are listed in table 6.14.
Diastolic blood pressure alone
When the diastolic blood pressures were studied, it was found th a t 78% of the 
patients had an average pressure below 90 mmHg, 17% between 90-100 mmHg and 
the rest over 100 mmHg (Table 6.15). If the diastolic blood pressure was above 90 
mmHg, no patient settled in the long term and 33% progressed to severe disease. 
Therefore, the average diastolic was an  accurate method of diagnosing those patients 
with a  persistent problem and at risk of progression.
Of the 846 patients with an  average blood pressure below 90 mmHg, 86% remained 
either normal or mildly hypertensive for the rest of their pregnancy, while 13% 
developed moderate disease and 1% severe disease (Table 6.15).
Uric acid alone
Arbitrary values of normality and abnormality for uric acid were chosen. Only 14% 
of the patients had a uric acid of less than  250 umol/1, 72% between 250-370 umol/1 
and only 14% were in the highest abnormal range (Table 6.16). If the long term  
outcome is studied, there is a scatter of results in both the lower two ranges. This is 
not surprising since not all patients with an elevation of blood pressure will have an 
elevation of uric acid. However, if the uric acid was above 370 umol/1, all the patients 
developed at least moderate hypertension in their pregnancy (Table 6.16). As so few 
patients fell into this category, it was decided that, in future studies, 350 umol/1 
would be used as the cutoff point of normality.
Platelet count alone
When the platelet count was used, a count greater than  250xl09/m l was taken  as 
completely normal, 150-250xl09 /m l as borderline and less th an  150xl09/m l as 
abnormal. The majority of the patients had levels above 150xl09/m l with a  scatter of 
outcomes (Table 6.17). This is not surprising since many of the hypertensive patients
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will have normal platelet counts. All patients with a count less th an  150xl09/m l 
developed hypertension of some degree during the rest of their pregnancy. Since 
using 150xl09/m l selected so few patients, a level of 200xl09/m l was used as the 
cutoff point of normality in future studies.
Combined results
Since these three parameters appear to be relatively independent, it was decided to 
study the effect of combining the results. Normal values were arbitrarily chosen as 
stated previously. The diastolic cutoff level of ‘normality’ was taken as 90 mmHg, the 
uric acid cutoff level as 350 umol/1 and platelet count cutoff level as 200xl09/ml. 
Diastolic Blood pressure alone
As already shown, 846 (78%) were assessed as normal (Table 6.18). Of these, only 293 
(35%) remained completely normal, 434 (51%) developed mild disease which implies 
further blood pressures of 90 mmHg but no clinical problem. That left only 109 (13%) 
who developed moderate and 10 (1%) severe disease. Therefore, 78% of the attending 
patients were assessed as normal bu t 14% of these would progress to moderate or 
severe disease often requiring hospitalisation and treatment.
The addition o f Uric Acid
If a uric acid of less than 350 umol/1 was added to a normal blood pressure, 630 (58%) 
were classified as normal. In these patients, the predictability of the long term  
outcome of the pregnancies increased with 281 (45%) of the patien ts remaining 
normal, 276 (44%) becoming mildly hypertensive, 65 (10%) m oderate and 8 (2%) 
progressing to the severe state (Table 6.18). This implies that 216 (26%) of the 846 
patients were selected to be at higher risk because of an  elevated uric acid. Of these, 
only 12 (5%) remained normal, 158 (73%) developed mild disease, 44 (20%) moderate 
and 2 (1%) severe disease. Therefore, a fewer num ber of patients are assessed to be 
low risk but the diagnosis is more accurate.
The addition o f platelet count
If the first two param eters were associated with a platelet count greater th an  
200xl09/m l, 537 (49%) were diagnosed as normal. Of these, 264 (49%) remained 
normal, 245 (46%) mild, 22 (4%) moderate and 6 (1%) to severe disease. Therefore, a 
combination of these 3 parameters has a 95% predictive value of relative normality 
for the rest of the pregnancy.
This m eans th a t 83 (13%) of patients with normal diastolic blood pressure and 
normal uric acid were thought to be a t risk because of a low platelet count. Of these 
patients 17 (20%) remained normal, 31 (37%) mild, 33 (40%) moderate and 2 (2%) 
became severe.
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Discussion
It should be noted tha t the diagnosis of disease and severity was based on blood 
pressure with or without proteinuria. No attem pt was made to verify the type of 
hypertension. It was felt tha t since it is the hypertension tha t normally triggers the 
change of management, tha t it should be the basis of diagnosis. What is clear from 
these results is tha t it is possible to improve the prediction of normality using tests 
which are simply done and assessed. It is also clear th a t the prediction is not 
absolute. Although there is an  overall reduction of the selected patients progressing 
to moderate or severe disease, no m atter what combination of tests  are used, around 
1-2% of the patients will develop severe disease. Therefore, even if the patients are 
assessed as normal, care should be taken as this does not exclude their progression to 
severe disease. Because of these findings, any patient assessed as normal is seen 
within 10 days of the Daycare appointment. This will be discussed more fully in 
Chapter 7.
6.8 Liver Function Tests.
Alkaline phosphatase, Alt, Ast and yGT are generally taken together as part of ‘liver 
function tests’. This is largely inaccurate as they are elevated when liver cell damage 
or bile stasis occurs. Liver cell function is better assessed by m easurem ent of 
bilirubin, album in and a ‘coagulation screen’. Therefore, abnorm alities of these 
param eters are more likely to be associated with liver cellular damage which may 
also cause liver function problems. Abnormalities of liver enzymes are associated 
with severe disease (Weinstein, 1982). Abnormalities of liver pathology are found in 
fatal cases (Acosta Sison, 1931). Because of these accepted changes, various markers 
of liver abnormality were studied to see if they were related to the other param eters 
already discussed (Table 6.22).
A lka lin e  Phosphatase
Alkaline phosphatase is a series of isoenzymes which are present in liver, bone, 
kidney, placenta and intestinal mucosa. Levels are elevated in situations of bile 
stasis  b u t various other factors also effect it. However, since it is presen t in  
abundance in liver cells, elevation in the serum is generally presumed to be caused by 
liver function abnorm ality. M ultiple regression analysis dem onstra tes  an  
independent relationship with yGT and albumin only (Table 6.19). The Adjusted 
Coefficient is only 0.2. Therefore, only around 20% of the changes in  alkaline 
phosphatase can be explained by these parameters. This would suggest th a t changes 
in alkaline phosphatase cannot be used as a m easure of disease activity as other 
factors are involved in alterations of its levels. This may be largely due to changes in 
placental alkaline phosphatase.
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Alt and Ast
Alt Is a cytosolic enzyme present in abundance in liver cells but is also present in the 
kidney, heart and skeletal muscle. Ast comes from the mitochondria of cells and is 
the mostly widely used marker of liver cell abnormality. It is also elevated in cases of 
myocardial infarction secondary to cardiac cell damage.
Multiple regression analysis shows the independent relationship of Alt with urea, 
Ast and yGT (Table 6.20). This suggests tha t the Alt rise may be partly due to renal 
impairment which could be explained by its known presence in  renal tissue. A 
relationship was also seen with the booking haemoglobin.
Ast relates to urate, platelet count and Alt (Table 6.21). Ast appears to relate to the 
recognised m arkers of disease severity rather than  the other liver parameters. Since 
Ast is a mitochondrial enzyme, a rise in Ast would appear to be more fundamental to 
cellular damage than  the other liver markers. This is also the reason why Ast rises 
after myocardial infarction. Other signs of mitochondrial damage have been found 
in preeclampsia (Torbergsen et a l, 1989; Berkowitz et al., 1990; Shanklin and Sibai, 
1990). 
yGT
yGT is commonly elevated in cirrhosis of the liver where there is damage to the liver 
cells. It can be seen as a non-specific sign of liver cell abnormality. However, apart 
from the relationship with booking height, it is independently related only to 
alkaline phosphatase and Alt (Table 6.22). As it is only related to the other factors of 
liver damage and not independently with anything else, yGT would appear to reflect 
liver involvement alone.
Albumin
Albumin is synthesised in the liver. Therefore, liver function abnormality may be 
reflected by lower serum albumin levels. In preeclampsia, proteinuria would also 
tend to result in lower levels of serum albumin. Multiple regression analysis shows 
th a t album in has an  independent relationship only with urate , Hct, alkaline 
phosphatase and proteinuria (Table 6.23). The relationship with Hct is positive, 
suggesting tha t this may be evidence of the haemoconcentration seen in worsening 
disease. The other relationships show th a t changes in  album in are linked to 
systemic changes in disease activity and not simply a loss of album in from the 
kidney. The Adjusted Coefficient is only 0.3 suggesting only 30% of the changes in 
albumin can be explained by these changes. Therefore, the reason for serum  albumin 
changes is multifactorial.
Discussion
It is clear th a t the different ‘liver’ param eters are affected by different things. 
Although, a  rise in Ast is generally accompanied by rises in Alt and yGT, yGT appears
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to be a  ‘purely’ liver parameter, Alt related to renal function abnormality and Ast 
related to the systemic disease parameters.
Albumin is affected by a m ultitude of factors. Some will tend to increase the level 
and others reduce it. Low albumin will lead to increased interstitial fluid. In its most 
benign form th is is oedema, bu t if severe, it could lead to pulmonary problems with 
respiratory embarrassment. This is now an increasing cause of m aternal mortality 
and morbidity. The causes of low albumin would be a useful area of further research.
6.9 Outcome parameters
It would be useful if simple blood tests could correlate well with the outcome of the 
pregnancy. Three main outcome parameters were studied, the gestation of delivery, 
the birth weight and centile and the Apgar score.
Delivery Gestation
Delivery gestation is a param eter of significant importance. Epidemiology studies 
demonstrate th a t fetal survival a t earlier gestations are greatly reduced (Friedman 
and Neff, 1975). Factors th a t influence the gestation at delivery, will, therefore, 
influence the survival of the fetus.
There w as an  independent relationship between delivery gestation and  urea, 
platelets, and proteinuria only (Table 6.25). During the time of th is  study, the 
presence of proteinuria was not used as a sole criteria for delivery. This suggests tha t 
earlier gestation of delivery is associated with the presence of proteinuria, renal 
impairment, as m arked by elevated serum  urea, and platelet consumption. The 
reasons for th is could be multiple but it does suggest tha t the earlier the disease 
presents, the more severe it appears to be with the presence of proteinuria and a low 
platelet count. Studies presented in Chapter 8 also show that platelet num bers were 
lower in patients presenting earlier in pregnancy.
Birth weight
The birth weight of the baby is dependent on the placental function and the gestation 
at delivery. To counteract the effect of gestation, the birth centile was also calculated 
based on normal figures for Scotland.
There was an  independent relationship with the m other’s booking height and 
weight, urea, alkaline phosphatase , albumin and delivery gestation b u t not blood 
pressure (Table 6.26). It is interesting to note that the weight increased on average by
171.3 gms per week. If the weight centile is studied, there was an  independent 
relationship with booking haemoglobin and haem atocrit, delivery gestation and 
birth weight (Table 6.27). Since the relationship with gestation is negative, it would 
appear tha t growth retardation is more likely at later gestations. There do not appear 
to be any other param eters th a t relate to weight centile apart from booking 
haematology. This would imply tha t it is the length of time the disease is present that
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influences the weight centile, not disease severity itself.
Apgar score
Assessment of the fetus at delivery is based on the Apgar score despite its recognised 
limitations. There was an independent relationship between the one m inute score 
and urea, delivery gestation, birth weight and weight centile (Table 6.28). The five 
m inute scores are related to the systolic pressure and the one m inute score only 
(Table 6.29). These results suggest that the state of the baby at birth is mostly related 
to gestation and weight of the baby rather than  the disease severity.
6.10 Tests o f Fetal Wellbeing
Over the years, various tests of fetal wellbeing have been employed. In 1980, the main 
tests used were the biochemical ‘placental function* tests, hum an placental lactogen 
and estriol. For a num ber of reasons, these were not thought to be immediate enough 
and more direct tests of fetal wellbeing were sought. Over the time of the study, the 
m ain test used was the cardiotocograph with ‘descriptive’ ultrasound estimations of 
fetal weight and liquor volume. Doppler u ltrasound of both m aternal and fetal 
vessels have been added more recently.
In m ost of the hypertensive patients, the babies did well. A close evaluation of 186 
proteinuric primigravidae was carried out and the results of monitoring tests  were 
correlated with fetal outcome. These patients were those managed between January  
1981 and December 1989. They include all those where full monitoring was carried 
out before delivery. The results used were the last carried out before delivery. S /D  
ratio is the ratio of the systolic and diastolic Doppler flow velocity m easurem ent in 
the assessed blood vessel. This param eter is an  m easurem ent independent of the 
angle of the Doppler transducer to the vessel being investigated. It widely used in 
m atem al/fetal assessm ent (Fitzgerald and Drumm, 1977; Campbell et al., 1983; 
Cam eron et a l ,  1988). Abnormalities are thought to relate to dim inished 
fetal/m atem al blood flow leading to fetal compromise.
Of the 186 patients, 57 presented before 30 weeks and 129 presented in or after the 30 
th  week (Table 6.30). These two groups were compared. None of the param eters 
relating to m aternal disease, except proteinuria, showed any significant difference. 
These findings confirm the finding that proteinuria is independently related to the 
gestation a t delivery. All the param eters of fetal wellbeing showed a significant 
difference between those presenting below and after 30 weeks. There was a  higher 
incidence of abnormal m arkers of fetal wellbeing seen in the earlier group. This 
suggests tha t the earlier the presentation, the worse the fetal condition. Of the 129 
pregnancies presenting after 30 weeks, 123 (95%) resulted in  a  surviving baby 
compared with only 36 out of 57 (63%) presenting prior to 30 weeks. It would appear 
tha t this was partly because of prematurity and partly because those presenting at an
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earlier gestation showed evidence of increased fetal compromise.
If only those pregnancies tha t presented before 30 weeks are studied (Table 6.31), it 
can be seen tha t fetal survival is associated with satisfactory signs of fetal wellbeing, 
such as a reactive cardiotocograph, normal Doppler u ltrasound and good fetal 
growth. Traditional tests of disease severity, including proteinuria, did not correlate 
with fetal survival. If pregnancies could be prolonged until after thirty  weeks, the 
survival was better, as would be expected. A reactive cardiotocograph would appear to 
be the best predictive test for fetal survival. However, even a decelerative tracing is 
associated with a  surviving fetus in over 60% of cases and there was no significant 
difference in  th is  respect between the survivors and those th a t died. Similarly, 
normal Doppler results were also associated with a good fetal outcome. Normal 
amniotic fluid volume was associated with a better outcome. If growth retardation 
was present or if delivery was due to fetal compromise, the incidence of fetal loss was 
significantly higher.
Discussion
These results suggest that markers of maternal disease do not influence the perinatal 
outcome. If proteinuria is present, the level of proteinuria does not influence the fetal 
outcome. This would support the idea tha t the presence of proteinuria m arks ‘true’ 
preeclampsia, and, therefore, increased risk. The risk does not increase with the 
level of protein. The most important parameter as far as the fetus is concerned is the 
gestation at presentation. After 30 weeks, the fetus almost always survives. This is 
probably due to the fact that delivery is possible bu t also tha t the fetus would appear 
to be in better condition if the presentation is after 30 weeks. It is obvious tha t signs 
of fetal compromise increase the chances of fetal loss, bu t it is not inevitable. Even in 
the presence of a premature, growth retarded fetus with abnormal CTG or Doppler, 
fetal loss is not certain and the fetus should not be ‘written off.
6.11 Discussion
These results confirm that preeclampsia is a systemic disease and effects can be seen 
even in the mild to moderate patients. Abnormalities of liver enzymes are not 
present only in the severely affected group. The liver abnormalities are affected by 
different influences. Ast may be the most sensitive marker of liver cell involvement. 
Uric acid levels appear to be related m ost closely to urea b u t also to the other 
‘systemic’ m arkers of diastolic blood pressure, albumin and Ast. Therefore, uric acid 
is related to other signs suggestive of cellular damage. These changes may be present 
even in the milder forms of the disease. The severe signs of HELLP syndrome may 
simply be a continuum and not a different disease entity (Greer, Cameron and Walker, 
1985). The changes seen in haemoglobin and haematocrit could be due to chronic 
haemolysis bu t there is no direct evidence of this and further studies are required.
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The renal Involvement is not due purely to the glomerular lesion as the changes in 
uric acid and Alt suggest the possibility of fundamental cellular damage, particularly 
in the tubules.
It is clear th a t low album in is due to a m ultitude of factors including liver cell 
damage and proteinuria. There are conflicting influences on it, with Hct positively 
related demonstrating the effect of haemoconcentration and increasing proteinuria 
tending to produce a reduction in serum albumin.
Proteinuria does not relate to any other disease parameter and is probably not a sign 
of ‘severity’ bu t confirmation of the ‘true’ diagnosis. It is related to the gestation of 
delivery, suggesting tha t it is more often present when the patient presents a t earlier 
gestation.
Therefore, this is a multisystem disease and in any given patient different systems 
are affected to different degrees. It would appear th a t by using diastolic blood 
pressure, uric acid and platelet count most areas of potential disease involvement are 
being investigated. Using these three param eters for m aternal monitoring, it is 
possible to improve the differentiation of normality from abnormality. However, it 
is not absolute and some patients will progress to more severe disease without clear 
early signs. The param eters would appear to be better at predicting progression to 
moderate than  to severe disease.
The fact th a t the outcome for the fetus appears to be independent of the m aternal 
disease state, accentuates the need for the fetus to be monitored separately. In the 
presence of satisfactory tests of fetal wellbeing, the fetus can do well even in the 
presence of severe m aternal disease. This may allow aggressive antihypertensive 
therapy to prolong pregnancies. If the pregnancy is prolonged beyond 30 weeks, the 
outcome is improved. Although this may be due to the prolongation of the pregnancy, 
it may be due purely to the fact that the fetus is in good enough condition to allow 
continuation of the pregnancy, so increasing the chance of survival.
The condition of the baby at birth is related to the delivery gestation and birth 
weight. The only maternal parameter which appears to affect it is urea and possibly 
systolic blood pressure. This is difficult to explain unless urea is raised only in 
severe disease. However urea appears relatively independent of disease severity. It is 
possible tha t diminished renal function is responsible for suppression of the fetus at 
birth because of an increase of a ‘toxic’ substance.
Birth weight was related to booking height and weight which is not surprising bu t the 
relationship is lost when centiles are used. The centile is related to the  booking 
haemoglobin and haematocrit. This suggests tha t the fitness of the m other and her 
adaption to her pregnancy will effect the outcome for the baby. It is already known 
that a booking weight of less than 50 Kg increases the chances of low birth weight and
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other pregnancy complications. Birth weight was affected by the level of albumin in 
a negative way; the lower the albumin the higher the birth weight. Low albumin is 
known to be related to maternal oedema. Oedema is associated with larger babies 
(MacGillivray and Campbell, 1980). The larger baby weight may be due to increased 
fetal fluid because of reduced maternal osmolality due to low albumin. There was no 
recording of oedema in th is study. This finding is lost when looking at birth centile. 
This is strange as albumin does not appear to be related to gestation at delivery.
It w as disappointing th a t booking param eters were not clearly re la ted  to 
development of the disease. It was hoped that the studies would suggest a  potential 
screening test for the risk of pregnancy hypertension. However th is  is a selected 
group who had all developed a degree of hypertension and the results cannot exclude 
an  association between booking parameters and preeclampsia in an  unselected group 
of normal booking patients. Booking haemoglobin and haem atocrit do relate to 
birth centile, which suggests an interesting area of further study.
6.12 Conclusions
The main conclusions in  th is chapter are:
1) Preeclam psia is a system ic disease w ith evidence of m ultiple organ 
involvement.
2) D iastolic blood pressure, uric acid and platelets can be used to monitor 
patients successfully and can be used as predictors of outcome.
3) Proteinuria is due to a specific renal lesion and is not associated with other 
disease parameters. It is probably a marker of true disease.
4) Albumin levels are effected by multiple factors and are not simply related to 
renal loss.
5) Liver abnorm alities are common at all stages of disease severity.
6) The fetus requires specific m onitoring as its problems are not predicted by 
m aternal disease parameters.
7) The gestation at clin ical onset is the m ost relevant param eter for fetal 
outcome.
8) Growth retardation is associated with disease presentation a t a later 
gestation.
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CHAPTER 7
THE DAYCARE ASSESSMENT UNIT
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7.1 Introduction
As already stated, hypertension is a common problem of pregnancy and occurs in 
between 12 and 15 % of pregnancies (Scottish Home And Health Department, 1989; 
Chamberlain et a l, 1978b) and is associated with increased risk both to the mother 
and the fetus (Kirshon et al., 1990; Page and Christianson, 1976; Turnbull, 1987; 
Turnbull et al., 1989). When found to be hypertensive, most patients are admitted for 
observation and bed rest. (Chamberlain et a l, 1978a; Trudinger and Parik, 1982). 
This management dates from the 1950’s (Hamlin, 1952) and has led to approximately 
25% of all an tenatal adm issions being due to hypertension. Overdiagnosis is 
common and over 50% of patients admitted as hypertensive are found to be 
normotensive on admission (Hall, Chang and MacGillivray, 1980).
Despite th is  policy, m aternal and perinatal m ortality from hypertension in 
pregnancy did not change over a twenty year period (Turnbull, 1987; Turnbull et al., 
1989). However, the majority of patients do well, with the m aternal mortality from 
hypertension being 1/11000 in Scotland and the perinatal m ortality related to 
hypertension being 12/1000 hypertensive pregnancies, which is not m uch greater 
th an  the national average of 10.2/1000 (Scottish Home And Health Department, 
1989). The routine admission of patients with hypertension has been challenged 
(Matthews, Patel and Sengupta, 1971) as there appears to be no evidence to show that 
bed rest is of benefit (Matthews, 1977; Crowther and Chalmers, 1989). However, it is 
accepted that there is a need to monitor the pregnancies closely.
Chapter 5 demonstrated tha t blood pressure is very variable and the diagnosis may 
be inaccurate. There may not be a need to admit all patients, bu t further assessm ent 
is probably required. This has led to the concept of developing an  inpatient 
monitoring system delivered on an  outpatient basis. The aim of the project was to 
develop an  outpatient daycare management system where the degree of the blood 
pressure problem could be assessed and the need for admission decided. The unit 
would act as a filter for the need for hospital admission. It was predicted th a t the 
system would increase the access to full monitoring bu t reduce the  num ber of 
admissions. This would allow the targeting of in-patient care to the patients who 
would most benefit from it.
7.2 Methods 
Patients selection
The aim was to monitor all patients thought to be a t risk of a hypertensive problem. 
No firm guidelines for patient selection were issued as it w as felt th a t each 
obstetrician would have different criteria of risk. General guidelines of risk  factors 
were given and the reasons for referral are listed in Table 7.1. The consultan t 
obstetrician was free either to refer the patient to daycare or admit to hospital as he
117
saw fit. Patients referred from the antenatal clinic were seen in day care either on the 
same day or on a day suitable to the patient within the next four days.
This project was started in the summer of 1981 before the analysis described in the 
previous chapters. Therefore the protocols did not take into account the findings 
previously described.
Investigations
A protocol was developed to provide full monitoring for the m other and  for 
assessm ent of fetal wellbeing (Table 7.2). The patient attended between 9.00 and 9.30 
in  the morning. Venesection was performed and a blood sample taken (Table 7.2). The 
urine was tested for presence of protein. As blood pressure was known to vary, it was 
decided to use five blood pressure readings taken over three hours. Surveillance of 
fetal wellbeing was m ade by subjective assessm ent of fetal m ovem ents and 
cardiotocograph over 40 m inutes. U ltrasound exam ination for fetal weight 
estimation (Jeanty et a l, 1984) and liquor volume was performed if fetal growth 
deficiency was suspected and in  those patients referred for a second time with 
moderate hypertension. Since August 1984, all data was collected and entered into a 
BBC microcomputer using specially designed software (Chapter 2). This has provided 
continuing audit and greater ability to analyse the data.
Patient assessm ent
All results were available by 12.30 pm and displayed on the computer screen (Fig 2.3). 
The patient was then interviewed and further management was discussed. Although 
the referring consultant was able to assess the patient if he wished, m ost of the 
assessm ents were carried out by the attendant medical staff. During the early years 
of this study th is assessm ent was carried out by the author, but, latterly, help in 
running the un it was provided by a specially trained registrar. Patients were 
classified as being of normal/low risk, mild/m oderate risk or of high risk  of blood 
pressure problems using the 4 m ain param eters: blood pressure (average of 5 
readings), platelet count (Redman, Bonnar and Beilin, 1978), uric acid (Redman, 
Beilin and Wilkinson, 1976) and urinalysis (Friedman and Neff, 1975) (Table 7.3). 
The results of the assessm ent of fetal wellbeing was also taken into consideration 
regarding further management. A normal cardiotocograph was taken  as one with 
four accelerations within the 40 minute period, beat to beat variation of a t least 20 
bpm and the absence of decelerations.
The choices of management were based on these three risk categories provided fetal 
well being was confirmed by cardiotocograph an d /o r ultrasound. If norm al or low 
risk the patient was referred back to the antenatal clinic. This re tu rn  appointm ent 
m ust be within 10 days of their Daycare appointment. If moderate risk, the patient 
was brought back for a re turn  visit at the day care unit, either the same or the
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following week to assess any progress of the disease. If the risk was high, the patient 
was admitted to hospital the same day or the next when further observation and 
management would be carried out. At all times, the system allowed flexibility to 
overrule the protocol and bring the patient back to daycare or to adm it them  to 
hospital if there was any doubt about the safety of the mother or the fetus.
Since computerisation of the data, a full display of the patients previous attendances 
and assessm ent of any change in the param eters has been possible (Fig. 2.3). A 
printed copy of the results was inserted in the case notes and the consultant received 
a summary of all the attendances of their patients each week.
Facilities
The unit initially used the day area of one of the antenatal wards and then  gradually 
took over a  larger area. It is presently housed in a ward area adjacent to the 
ultrasound department. It comprises 3 separate rooms; a sitting area where patients 
stay most of the time, a  centre room for the nursing station, computer centre and 2 
cubicles for counselling. The third area is used for monitoring with 4 beds, each with 
a cardiotocograph monitor.
The unit has been open for 5 days a week from 8 a.m. until 5 p.m. since August 1981. 
Initially, the antenatal ward staff ran  the unit. From 1983 a dedicated midwifery 
sister was allocated and the present staffing level comprises 2 midwifery sisters, a 
staff midwife and a student midwife. The need for this level of nursing staff had 
become necessary because of the increasing utilisation of Daycare for other areas of 
high risk antenatal monitoring.
Assessm ent o f the effect o f Daycare
All patients who attended Daycare were followed up until delivery and the outcome 
noted. Hospital admissions, numbers and diagnoses were obtained from the hospital 
records department and from the Information Services Department of the Scottish 
Home and Health Department. Antenatal inpatient nights were counted for every 
April and averaged as confirmation of the reduction of antenatal bed occupancy. 
Statistical comparisons of the changes seen were carried out using Fishers exact test.
7.3 Results 
Number o f referrals
Daycare first started in a small way with referrals from 2 consultant units in August 
1981. Only 25 patients were seen before the end of the first year. The num ber of 
attendances has steadily risen and by the end of 1989 a total of 3156 patients had 
attended (Table 7.4). Most patients seen were primigravida (1641). The diagnosis at 
time of referral was mostly pregnancy induced hypertension (2793) b u t 221 had 
essential hypertension and 142 were seen because of past history and were normal at 
the time of referral. The average gestation a t referral was 33+6 weeks and m ost
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patients (1925) were between 32 and 40 weeks. However, 568 presented before 28 and 
190 after 40 weeks. Most referral diastolic blood pressures (DBP) were between 90 and 
100 diastolic (68%) b u t 5% of the referrals had a DBP above 110 mmHg (Table 7.5). 
The average DBP found at Daycare was 10 mmHg lower than  the referral DBP and the 
majority of the patients had an average DBP of below 90 mmHg. Of the patients with 
referral DBP of over 90 mmHg only 25% came under the same category at Daycare 
assessm ent (Table 7.5). The Daycare Unit was primarily an  assessm ent unit, and the 
majority of the patients were seen only once (62.4%) (Fig 7.1). However, the average 
num ber of visits was 2 .1±0.7 and 461 patients had more than  3 visits. If continuous 
Daycare was used, no patient was seen more than  twice in one week. If the patient was 
thought to require more frequent attendances, she was admitted to hospital.
At the first Daycare attendance, patients were grouped into 3 risk categories (Table 
7.3) with the majority of patients being assessed as normal or low risk (Table 7.6). 
Overall, 67.9% were referred back to antenatal clinic and only 4% were admitted to 
the antenatal ward (Fig 7.1). The assessm ent a t Daycare appeared to be accurate in 
the majority of patients bu t 26% of those referred back to the an tenatal clinic 
returned to daycare at a later date. Overall 16% of the patients eventually required 
admission bu t this was delayed in around 75% of cases (Table 7.6) Therefore, of 
patients referred back to the antenatal clinic a significant num ber developed 
worsening hypertension highlighting the need for continuing vigilance and the need 
to reassess risk factors. No patient who was assessed as high risk reduced their risk 
at a later date.
Maternal Outcome
Three patients developed severe hypertension with symptoms prior to their next 
appointment, one of whom had failed to re tu rn  for follow-up. Apart from these 
events, all patients did well and there were no cases of maternal death or eclampsia. 
Fetal Outcome
The outcome of all pregnancies is given in Table 7.6. Overall perinatal mortality was 
3.5/1000. The outcome was worse in patients admitted compared to those managed as 
outpatients due to the selection of severity. There were three perinatal deaths in  the 
outpatients group (no admission at all = Return to Antenatal clinic + R eturn to 
Daycare). One patient was seen on a Friday, was of moderate risk, bu t returned after 
the weekend with an  intrauterine death. Another perinatal death was due to a 
placental abruption and the third due to a  congenital heart defect. The overall 
perinatal mortality rate was 1.1/1000 for the 2650 patients managed totally as 
outpatients.
The effect o f Daycare
Over the last five years all consultants in the hospital have utilised the service and
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the num bers have remained constant. Since 1985, the average num ber of Daycare 
referrals was 113/1000 deliveries (Table 7.4). The percentage of patients, who were 
diagnosed as hypertensive, changed little over the study period but the total num ber 
of patients monitored (daycare + admission) has risen (Fig. 7.2). Although some 
patients come into both categories, this would imply tha t a greater percentage (85%) 
are monitored in  1988-89 compared with 1980-81 (62%) (P<0.0001). The most 
significant change has been in the num ber of inpatient days due to hypertension. In 
the years 1980-81 there were over 2000 inpatient days as compared to under 750 for 
1988-89. This is a highly significant reduction of 70% (p<0.0001).
The average antenatal bed occupancy for April for the year 1981 was 57/night and 
this had fallen to 20/night in 1989 (p<0.0001). This is not purely due to a reduction in 
the admission of hypertensive patients but also the increasing use of Daycare for all 
high risk monitoring.
A comparison with the 4 other large maternity hospitals in Central Scotland which 
did not have a Daycare Unit is shown in Table 7.7. These hospitals were chosen as 
those being nearest the Glasgow Royal Maternity Hospital and delivering around the 
same num ber of patients. The figures are for 1986 and 1987 and are taken from the 
Information Services Department of the Scottish Home and Health Departm ent 
(Rosenberg and Twaddle, 1990). There is wide variation between the hospitals bu t the 
Glasgow Royal Maternity Hospital had fewer admissions and inpatient days per 1000 
deliveries than  any of the other hospitals. The size of the difference ranged from 41% 
to over 60%.
7.4 Discussion
As a common disorder, hypertension has been a burden on the health  services 
resources in  term s of manpower and hospital accommodation (Hall, Chang and 
MacGillivray, 1980) The high prevalence of the condition with its potential harmful 
effects for the m other and baby, makes it a difficult management problem for the 
obstetrician.
Pregnancy hypertension is thought to be unpredictable and most obstetricians would 
admit the hypertensive patient for closer monitoring of both m other and baby 
(Chamberlain et al., 1978a; Trudinger and Parik, 1982), This "play safe approach" 
can cause m uch inconvenience to the patient and her existing family (Hall, Chang 
and MacGillivray, 1980). Mild to moderate disease carries little risk unless there is 
progression to the more severe form (Collins and Wallenburg, 1989). Therefore, the 
majority of the patients can be safely managed at home if there is access to adequate 
fetal and m aternal monitoring. The idea of outpatient m anagem ent is not new 
(Matthews, Patel and Sengupta, 1971), and Matthews showed tha t in  the absence of 
p ro te inuria, non-adm ission to hospital had  no detrim ental effect on the
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hypertensive patient (Matthews, 1977). Inpatient management may vaiy between 
different hospitals bu t the cornerstone is to keep the patient in to allow serial 
monitoring of blood pressure. Strict bedrest has been suggested as having therapeutic 
value bu t never been substantiated (Crowther and Chalmers, 1989) As some of these 
patients will progress to more severe forms of the disease, it is important tha t there 
is early recognition of any signs of progression (Collins and Wallenburg, 1989) 
Daycare was envisaged as a system of reducing admissions to the hospital by 
providing a third option of antenatal care for the ‘at risk’ patient. The aim was to 
provide inpatient monitoring facilities on an outpatient basis. This would allow an 
increased access to monitoring for all the hypertensive patients.
Other forms of monitoring have become available tha t allows closer monitoring of 
the fetus to be carried out on an outpatient basis. Home cardiotocography (Dawson et 
a l, 1989), district midwives measuring blood pressure at home (Willis and Sharp, 
1982) and home blood pressure monitoring using battery sphygmomanometers 
(Dawson, Middlemiss and Vanner, 1989) have all been advocated. All these methods 
do not use  adjunctive biochemical and haematological investigations th a t are 
normally available in the hospital setting. Studies have shown the predictive value 
of platelet count (Redman, Bonnar and Beilin, 1978) and uric acid (Redman, Beilin 
and Wilkinson, 1976) estimations for the assessm ent of ongoing risk. The protocol 
tha t was developed used all the facilities that can be used for inpatient management 
and made them available for outpatients. As previously discussed in Chapter 5, blood 
pressure has an inherent variation (Mumaghan, 1987; Redman, Beilin and Bonnar, 
1977a). The unit was set up before the results from Chapter 5 were available. 
Therefore, it was decided tha t five blood pressure readings were to be taken  and 
averaged to tiy  and overcome the problems of variation.
Daycare has developed rapidly due to the management flexibility it offers and the 
increasing faith th a t has developed among consultants in the hospital. This is 
reflected by the steadily increasing num ber of referrals. A greater percentage of the 
hypertensive patients are now fully monitored. There has been a fall in hypertensive 
admissions by nearly 70%. This has allowed a targeting of inpatient care to those 
requiring intensive monitoring and treatm ent. There is no evidence th a t the 
m others or babies have suffered from non-adm issions after introduction of the 
Daycare system.
The advantage of Daycare is that more than  two thirds of the patients were diagnosed 
as normal and were returned back to the routine antenatal system after the first 
visit. Follow up of the patients shows tha t there is a chance th a t the patient may 
develop worsening hypertension. In those with increased risk of this, Daycare also 
allows continuous close monitoring as an outpatient.
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Initially, all the patients were assessed by the main author but more recently, other 
members of staff have been trained in Daycare management. We have found tha t it is 
important to provide relatively senior medical cover for Daycare to make sure tha t 
there is adequate surveillance of the patients. This is important, not only for patient 
safety, bu t for the confidence of the consultants in the hospital. This confidence was 
successfully built up, after some initial resistance, when the benefits of Daycare were 
appreciated by both doctor and patient.
Daycare units are now well established in Scotland, with over 50% of the hospitals 
now having a designated daycare area (Rosenberg and Twaddle, 1990) The use of these 
areas varies widely. In the Glasgow Royal Maternity Hospital, all forms of intensive 
monitoring are now offered as an  outpatient. This has helped to further reduce the 
inpatient load. The Unit also provides facilities for other specialist clinics such as 
diabetic, twin, epileptic, recurren t m iscarriage, prepregnancy, and  p renatal 
diagnosis.
Three problems remain before Daycare can be recommended as the main method of 
management of the ‘at risk’ antenatal patient.
Is it safe?
This was not a  controlled trial. Daycare evolved out of a desire to improve the 
monitoring and diagnosis of hypertensive patients. Many obstetricians were wary of 
allowing patients home with a diastolic above 90 mmHg. A controlled trial has been 
carried out in Leeds but it is too small to show evidence on safety. Since, in  the GRMH 
study, there were only 11 perinatal deaths in 3156 patients, it would be difficult to 
show tha t admission to hospital is any safer for the mother or baby or th a t Daycare 
was more dangerous.
Is it cost effective?
With nearly 70% reduction in inpatients days one would predict considerable saving 
on running costs. This, however, is difficult to prove. The hospital still needs most of 
the midwifery staff as it delivers the same num ber of patients. The most significant 
saving would be on capital cost when designing a new m aternity hospital with a 
purposely built daycare facility or for larger num ber of deliveries to be managed 
through the existing facilities. A cost comparison study has been carried out between 
The Glasgow Royal Maternity Hospital and Aberdeen Maternity Hospital which uses 
Domiciliary Midwifes to check the patient’s blood pressure at home. The results are 
not fully analysed bu t initial assessm ent suggests th a t Glasgow is cheaper on a 
patient cost basis (Rosenberg and Twaddle, 1990). There is a suggestion th a t a 
Daycare unit may increase the overall hospital workload despite reducing admission 
days. This was found in  a study of before and after the introduction of a Pregnancy 
Assessment Day Unit in the Queen Mothers Hospital in Glasgow (Rosenberg and
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Twaddle, 1990).
Are all these tests necessary?
The Daycare Unit was set up to provide blanket monitoring to make sure tha t the 
system did not miss any potential problem. It became obvious th a t m any of the 
patients could have been diagnosed of being a t low risk w ithout m any of the 
adjunctive tests. The problem is tha t it was not possible to know which patients 
would fall into this category prior to the daycare appointment. It is hoped to use the 
daycare experience to develop the optimal protocols for the management of all high 
risk pregnancy.
7.5 Conclusions
The main conclusions from this chapter were:
1) The majority of referred patients were not found to be truly hypertensive.
2) Most patien ts can be safely managed as outpatients with supportive 
outpatient monitoring.
3) Hospital admissions can be reduced.
4 The outcome can be predicted using tests outlined in Chapter 6.
5) To ru n  a Daycare probably, dedicated trained medical staff are required.
Chapter 8
Changes in  P latelet Size
in
Norm al
and
H ypertensive Pregnancy
125
8.1 Introduction
The m easurem ent of platelet size has been greatly facilitated by the generation of 
m ean platelet volume (MPV) and a size distribution param eter (platelet distribution 
width; PDW) by the latest automated haematology laboratory equipment.
Platelet studies in pregnancy have, to date, yielded conflicting results. Giles (1981) 
reported no alteration in platelet num bers or MPV in 1087 normal pregnant women 
compared to non-pregnant controls and Harrison, Bramich & Collins (1982) also 
found no change in the platelet count in normal pregnancy. In contrast Hsieh & 
Cauchi (1983) reported a fall in the MPV in normal pregnancy, most profound in  the 
first trim ester bu t sustained throughout normal pregnancy. Meanwhile Fay, Hughes 
& Farron (1983) have reported a significant drop in platelet num bers in the last 8 
weeks associated with a rise in the MPV in the last 4 weeks of normal gestation, and 
Sill, Lind & Walker (1985) have more recently reported increased MPV and PDW 
values between 34 and 37 weeks.
Many s tud ies  in  women with pregnancy-induced hypertension  (PIH) and 
preeclampsia have reported changes in platelet numbers, platelet survival and MPV 
which have been interpreted as evidence of increased platelet consumption (Redman, 
Bonnar and Beilin, 1978; Wallenburg and Rotmans, 1980; Giles, 1981; Giles and 
Inglis, 1981; Hsieh and Cauchi, 1983). However, since a decrease in platelet count is 
not inevitable, even at the onset of an  eclamptic episode (Pritchard, Cunningham 
and Mason, 1976), it may be possible to show increasing platelet consum ption in 
these patients by demonstrating an increase in platelet size, even though the platelet 
count remains within the normal range. Also, since Redman suggests th a t the fall in 
platelet count occurs before the rise in serum  urate (Redman, Bonnar and Beilin, 
1978), a change in m ean platelet volume occurring prior to the fall in platelet count, 
may predict the progression of preeclampsia before it is clinically apparent.
These studies were to determine which (if any) of the reported platelet changes occur 
in normal pregnancy and abnormal pregnancy, with a view to the evaluation of the 
MPV as a parameter to identify women at risk of preeclampsia.
8.2 Patients and methods 
Cross-sectional studies
Group A:- A control group of 20 non-pregnant females of similar age to the pregnant 
groups were studied.
Group b:- Blood samples from 208 healthy pregnant women were obtained during 
routine antenatal clinic attendances for a cross-sectional of norm al pregnancy. 
Group C:- Forty women with normal antenatal histories were studied sequentially in 
the third trimester, early labour and on day 5 postpartum. Twenty of these were also 
sampled 6 weeks postpartum. (Table 8.1)
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Prospective studies
Four prospective studies on the predictive value of platelet size was carried out.
Group D:- Three hundred primigravid patients were studied between 28 and 30 weeks. 
A single blood sample was taken and the results obtained from these patients were 
compared with the outcome of their pregnancies.
Group E:- Samples were also obtained from 141 patients with pregnancy-induced 
hypertension (PIH).
Group F:- Forty patients with moderate PIH were followed serially from the gestation 
th a t the condition was first diagnosed. None of these patients were on any form of 
antihypertensive therapy when first selected for this study.
Group G:- Thirty-four patients with essential hypertension were followed from 24 
weeks with serial blood sampling to study changes in platelet size. (Table 8.2) 
Definitions used
In the studies of disease development or progression, mild PIH was defined as a 
persistent diastolic blood pressure greater than  or equal to 90 mmHg, moderate PIH 
was defined as a persistent diastolic blood pressure greater th an  or equal to 100 
mmHg. Severe PIH (preeclampsia) was defined as a persistent diastolic blood 
pressure of greater than  or equal to 110 mmHg. Proteinuria was not used in the 
disease classification but was present in most cases of moderate and severe disease.
8.3 Sample handling
Blood samples were obtained from a large vein using a syringe and 19 G needle b u t no 
tourniquet. Blood was immediately mixed with K2 EDTA (1.5 m g/m l blood) and 
maintained at room temperature for 90-120 min. before analysis. Previous studies 
have dem onstrated a time dependent change in  platelet volume with a  relative 
plateau between 60 and 150 min. after sampling (Rowan and Fraser, 1991). Analysis 
was carried out on a Coulter Counter Model S-Plus (Coulter Electronics Ltd., Luton, 
Beds, UK) which was subject to continuous quality control. Channel calibration with 
latex particles (Platelet Volume Calibration Latex, modal volume 8.6 fl; Coulter 
Electronics Ltd.) was carried out initially daily and later weekly to ensure sample 
comparability with respect to MPV and PDW values generated.
8.4 Results
Cross-sectional Study (Groups A&J3)
The platelet count was unchanged throughout normal pregnancy when compared to 
non-pregnant controls (Table 8.3). However, both MPV (p < 0.05) and PDW (p < 0.001) 
increased in the third trimester. The increase in the MPV occurred after 34 weeks 
gestation (p < 0.05) whilst the PDW appears to increase throughout the third trimester 
(p < 0.05).
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Serial Study o f normal pregnancy (Group C)
Serial exam ination of forty healthy women from the th ird  trim ester to the 
puerperium (Table 8.4) revealed a similar increase in MPV (p < 0.05) and PDW (p < 
0.05) in early labour and a striking fall in the MPV (p < 0.005) on the fifth postpartum 
day accompanying a rise in the platelet count (p < 0.005) and a fall in  the PDW (p < 
0.005). At the sixth post-natal week, the platelet count, MPV and PDW had returned to 
non- pregnant levels.
Prospective Primigravid Study (Group D)
Of the 300 normal primigravid pregnancies, 216 patients had no hypertensive 
problems throughout the rest of their pregnancy and 84 developed hypertension. 
When all param eters for these patients were compared, although a trend upwards 
could be seen, there was no significant difference found in any of the param eters 
measured (Table 8.5). However, if the MPV of this group was split into those who had a 
value above the m ean and those below the mean, it can be seen tha t nearly all the 
patients who developed severe preeclampsia had MPV greater than  the m ean for the 
population a t 28 and 30 weeks. (Table 8.6). Only one of the patients, who had a MPV 
below the mean, went on to develop severe preeclampsia, although others did go on 
and develop mild or moderate disease. This gives a high sensitivity of 88.9% but low 
specificity and predictive value. Therefore, it was felt tha t platelet volume could not 
be used as a screening test in this low risk population.
It can be noted from Table 8.5 tha t the haem atocrit similarly did not show any 
predictive value.
Cross Sectional Studies in PIH (Group E)
No change in these platelet parameters was seen in women with moderate PIH when 
compared to gestation matched controls (Table 8.7). A fall in  platelet count (p < 
0.001), bu t no change in MPV or PDW was seen in women with severe PIH under 34 
weeks. Women presenting with severe PIH after 34 weeks had a smaller reduction in 
platelet count (P < 0.05) b u t a markedly increased MPV (p < 0.001) compared to 
controls. Women with PIH displayed similar postpartum  changes in  platelet count, 
MPV and PDW to those seen in healthy pregnant women with resu lts returned to 
normal by six weeks postpartum.
In the serial studies, of the 34 patients with essential hypertension, 14 patients had 
worsening hypertension (Table 8.8) In the 8 patien ts, who had  w orsening 
hypertension but did not become severe, there was little change in the m ean platelet 
volume bu t in the 6 patients who developed severe superimposed preeclampsia the 
MPV was significantly increased at least one week before it became clinically 
apparent (Table 8.8). The platelet count did not significantly fall when compared 
with the patients who remained stable. Similar findings were found in the mild PIH
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group (Table 8.9). In the patients where there was a significant increase in  MPV, 
suggesting an  increased platelet turnover and platelet deposition w ithin the 
placenta, there was an  increased incidence of intrauterine growth retardation, with 7 
of the 16 babies being smaller than  the 10 th  centile for birthweight. This is further 
evidence tha t it is in these progressive patients with platelet consumption tha t most 
of the pathology in PIH, particularly for the fetus, will be found.
8.5 Discussion
Giles (1981) found no change in platelet count or MPV in  norm al pregnancy. 
However, he did not analyse his patients according to trimester. The findings in these 
studies confirm the rise in MPV in late third trimester described by Fay et a l  (1983) 
and Sill et a l  (1985). These two groups also reported a progressive rise in PDW 
throughout normal pregnancy and Fay et al. (1983) found a reduced platelet count in 
the last 8 weeks of normal gestation.This study confirms a rise in the PDW only in 
the third trimester, bu t no change in platelet count was seen. The time-dependent 
changes in platelet volume and shape induced by EDTA anticoagulant (Rowan and 
Fraser, 1991) may explain differences in  MPV and PDW between studies. The 
importance of analysing samples at a consistent time after venesection is clear. Even 
then , it is not established th a t norm al and abnorm al platelets respond to 
anticoagulants in the same way. The analysis of samples up to 18 hours after 
venesection as performed by Fay et al. (1983) may also affect platelet numbers.
As the majority of patients with PIH present in the third trimester, when normal 
pregnancy appears to induce changes in MPV and PDW it is im portant to compare 
these patients with gestation-matched controls. When this is done, no change is seen 
in platelet parameters in moderate PIH.
This study has dem onstrated different patterns of platelet changes in patients 
presenting with severe PIH (preeclampsia) before and after 34 weeks. This has not 
previously been reported. However, Moore & Redman (1983) have suggested tha t PIH 
presenting before 34 weeks is more severe and may have a different natural history 
from late PIH. These findings are consistent with this suggestion. Patients with early 
severe PIH displayed a low platelet count, bu t normal MPV. The progression of the 
PIH in these patients may be so rapid that the patient presents before compensatory 
platelet changes can occur. An increase in MPV has been described in association 
with a 'compensated thrombocytolytic state’ in  a variety of clinical disorders (Garg, 
Lackner and Karpatkin, 1972) Patients presenting later with severe PIH may have a 
less rapid disease-process and display compensation with a less severe fall in 
platelet numbers bu t a rise in MPV suggesting an increase in platelet turnover.
Giles & Inglis (1981)described a rise in platelet num bers and a fall in MPV after 
delivery in patients with severe PIH. This study also demonstrated these changes in
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PIH patients postpartum, but also revealed a similar rise in platelet count and fall in 
MPV and PDW after delivery in normal pregnancy. The marked fall in  MPV occurs 
w hether the MPV was previously in the normal range or elevated. An ergometrine 
effect on MPV can be excluded as many of the patients who displayed the postpartum  
reduction in MPV had not received ergometrine at delivery. Iron deficiency, in which 
increased small platelets have been described (Harker, 1968) was also excluded in 
these women. All values had returned to normal by 6 weeks. The rise in  platelet count 
may be a  response to blood loss during delivery but it seems strange that, if these are 
new platelets, the MPV became smaller.
The increased MPV in late third trimester of normal pregnancy followed by a fall to 
subnorm al levels postpartum  might suggest th a t com pensated mild platelet 
consumption occurs in the last weeks of normal pregnancy. However, diminished 
platelet lifespan has not been detected in studies of normal pregnancy using an 
acetylsalicylic acid labelling technique (Wallenburg and Van Kessel, 1978). Events 
during thrombocytopoiesis appear to be the most important determ inant of platelet 
size (Paulus, 1975) and a hormonal alteration in thrombocytopoiesis may explain 
the changes seen in pregnancy. Whichever explanation applies, large platelets appear 
to be more active th a n  small platelets, irrespective of age. This s tudy  has 
dem onstrated changes in platelet volume in the final weeks of normal pregnancy 
which represent a continuum with the changes seen in PIH. The platelet alterations 
reported in  PIH may therefore not all be secondary bu t may be a  factor in  the 
pathogenesis or persistence of the condition. It obviously requires time for these 
changes to occur. The alterations probably occur in  parallel to th e  disease 
development and the degree of progression may depend on the patient’s ability to 
compensate for the disease changes. The patients tha t present in the late second or 
early third trimester of pregnancy, may be those with little ability to respond to the 
insult of the disease. This may be influenced by the ability to produce prostacyclin 
(see next chapter).
It is not surprising, therefore, tha t the prospective study did not give evidence of a 
significantly increased platelet consumption remote from the onset of the clinical 
disease. However, the fact tha t the MPV tended to be higher in  the patients who 
progressed does suggest tha t there may be an  early increase in platelet consumption 
in this group. It is, however, of no value as a screening test. Similarly, there was no 
evidence of an  increased haem atocrit being associated with the  patien ts who 
developed serious hypertension as has previously been suggested. The serial study did 
confirm th a t there was increasing platelet consum ption in  the  patien ts who 
developed moderate and severe PIH and the changes relating to th is  increased 
platelet consumption did antedate the appearance of clinical signs by at least one
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week. Since there are other methods of investigation, such as uric acid (Redman, 
Beilin and Wilkinson, 1976), which can be used to help to monitor patients at risk of 
developing progressive PIH it is difficult to know whether m ean platelet volume is 
necessarily any better than  monitoring serial platelet counts and uric acid levels. It 
does, however, support the argument for the use of low dose aspirin in patients 
thought to be a t risk as, if this reduces the degree of platelet consumption that occurs, 
it may slow or stop the progression of the disease to its more severe form, and reduce 
the chance of placental insufficiency.
8.6 Conclusions
The main conclusions from this chapter are:
1) Platelet size increases in normal pregnancy towards term.
2) There are larger increases in preeclampsia, bu t only in the later onset group.
3) The patients response to the disease may influence the gestation of onset.
4) Early onset disease may be a sign of poor patient response.
5) Platelet activity is a part of the disease process but not the cause.
6) Antiplatelet therapy may help to attenuate the disease process.
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Chapter 9
Studies on  
Prostacyclin  and throm boxane
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9.1 Introduction
As discussed in  C hapter 3, prostaglandins have long been known to have 
physiological roles in pregnancy and parturition. Many of the changes seen in PIH 
and IUGR, such as platelet consumption, vasoconstriction and low renin secretion 
may result from PGI2 deficiency, as PGI2 is a potent vasodilator, platelet inhibitor 
and  renin  secretion stim ulant (Miyamori et a l,  1979) TxA2 is produced from 
activated platelets and is a PGI2 antagonist, having platelet aggregatory and 
vasoconstric to r p roperties (Hamberg, Svensson and  S am uelsson , 1975). 
Prostacyclin's major metabolite is 6-keto-PGFla. Thromboxane A2 is converted to 
its  stable hydration product throm boxane B2 (TxB2). M easurem ent of PGI 
metabolites has been, and remains a subject of great controversy. Initial work on 6- 
keto-PG Fla by radioimmuno- assay (RIA) suggested that levels in normal subjects 
were of the order of 70-100 pg/m l (Mitchell, 1978), and this was supported by gas 
chromatography-mass spectrometry (GCMS) which suggested similar levels (Hensby 
et a l, 1979). However, Blair et al (1982) using negative ion GCMS, showed th a t the 
absolute values for 6-keto-PGFl a  were <5 pg/ml, and they concluded that PGI2 could 
not be a  circulating hormone in m an as previously thought. This does not preclude a 
role for PGI2 functioning as a local hormone in the regulation of platelet-vessel wall 
interaction. Changes in levels of its stable metabolites m ust reflect changes in 
production. It is still valuable to measure these metabolites to elucidate the role of 
prostacyclin in disease. RIA has also been discredited by varying 'normal' values due 
to differences in methodology and antibody sensitivity (Viinikka and Ylikorkala, 
1982). While RIA cannot give absolute values for PGI2 metabolites, the assay can still 
produce accurate comparative values.
Much improved RIA methods have been developed recently with sensitivities and 
normal levels m uch closer to tha t obtained by GCMS. RIA, therefore, can  still yield 
m uch valuable and accurate data provided proper controls are included and 
validation performed (Salmon, 1983). It has many advantages over GCMS as it is 
relatively sensitive, specific, and can cope with large num bers of samples. For these 
reasons RIA is probably the method of choice for routine measurem ents (Belch et aL, 
1983; Salmon, 1983). There is little information on the normal levels of PGI2 and 
TxAz in  pregnancy and since they may be implicated in disease processes, it is 
necessary to know the normal ranges. Lewis et al. (1980) published levels of 6-keto- 
PG Fla and showed an elevation in late normal pregnancy and the puerperium . 
Bolton et al. (1981) recorded serial m easurem ents th roughout 12 norm al 
pregnancies, and found a peak at 18-22 weeks gestation with a subsequent reduction 
towards term. Both of these studies were carried out before the work by Blair et al. 
(1982) and suggested normal ranges of 80-200 pg/m l for 6-keto-PGFloc. These studies
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are still quoted as normal ranges despite subsequent advances in knowledge and 
assay techniques. In view of these advances and the conflicting reports of Lewis et al.
(1980) and Bolton et al. (1981), the aim of the studies reported here was to determine 
the  comparative values of PGI2 and TxA2 metabolites throughout norm al and 
abnormal pregnancy and the puerperium, using a RIA which has been shown to be 
sensitive, specific and reproducible for PGI2 metabolites (McLaren et aL, 1985).
9.2 Patients and methods 
Three separate studies were set up.
Normal cross-sectional Study
The study included 155 women; 44 normal nonpregnant, 29 women in the first 
trim ester of pregnancy, 31 in the second trimester, 29 in the third trimester, and 21 
women on the third day following delivery. All pregnancies were uncomplicated and 
no subject had taken any aspirin or similar preparations for a t least 2 weeks before 
blood sampling.
Hypertensive Study.
Twenty-six patien ts w ith m ild/m oderate PIH, 15 patien ts w ith severe PIH 
(preeclampsia) and 40 normal pregnant women in the third trimester, were studied, 
the latter group acting as controls (Table 9.1). Mild/moderate PIH was defined as a 
persistent diastolic blood pressure greater than  or equal to 90 mmHg after 3 days 
hospital bed rest in women who had been normotensive in the first trimester. Severe 
PIH (preeclampsia) was defined as a persistent diastolic blood pressure of greater 
th an  110 mmHg in women who had been normotensive in  the  first trimester. 
Proteinuria was not used in the disease classification but was present in  most cases. 
(Table 9.1)
Serial study
Fourteen randomly selected patients were studied, all were primigravida and had no 
history of any hypertensive or medical disorder. No subject took any aspirin  or 
similar preparation for a  minimum of two weeks prior to each venepuncture. Blood 
sampling was performed in the late first trimester (9-12 weeks gestation), the second 
trimester (17-24 weeks gestation) and in the 3rd trimester (32-36 weeks gestation). In 
the patients who became hypertensive further samples were obtained where possible 
between 36 weeks and term.
Sample Handling and Assays
Venous blood was taken without stasis into an anticoagulant mixture consisting of 
3.8% w /v trisodium citrate containing 3 x l0 '5 M indomethacin and 10'4 M adenosine
(9 volumes of blood to I volume anticoagulant), and then centrifuged at 4°C for 20 
min. a t 3000 r/m in . Plasma prostacyclin metabolites (PGI2 M) were m easured on
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unextracted plasm a by radioimmunoassay as described previously (Belch et a l, 
1983; McLaren et a l, 1985). Lower limit of sensitivity of the assay is 5 pg/m l, 
recovery of added 6-keto-PGFla was 95% (SD 9), intraassay variation is 4% and 
interassay variation 9%. TxB2 was measured in unextracted plasma, by a  RIA with a 
lower limit of sensitivity of 20 pg/ml, intraassay variation was 4%, and interassay 
variation 10%. It is a debatable subject in the field of RIA, whether plasm a samples 
should be extracted or not, since m any extraction procedures can  add further 
impurities (Greaves and Preston, 1982), which can produce detectable levels of PGI2M 
in distilled water blanks subjected to the same procedure. The assay we used has been 
shown to be sensitive, reproducible and specific for m easurement of PGI2M directly 
in unextracted plasma, avoiding the technical difficulties associated with extraction 
procedures (McLaren et al, 1985).
9.3 Results
Normal cross-sectional Study
Results for PGI2 M and TxB2 are shown in Table 9.2. There w as a  significant 
difference in PGI2M levels in the first trimester (p<0.01) when compared with those in 
the non-pregnant group. While there were no significant differences between non­
pregnant values and those in the second or third trimesters, a trend towards lower 
concentrations of PGI2M on the third postnatal day was noted, bu t this also did not 
reach significance. Levels of PGI2M were significantly lower in the second and third 
trimester and the puerperium than  in the first trimester group (p<0.05). There was a 
progressive reduction in  plasma TxB2 concentrations from the second trimester, 
through the third trimester and into the puerperium.
Hypertensive study
The description of the patient groups in the cross-sectional study of PGI2 M in 
m ild/m oderate and severe PIH (preeclampsia) compared to normal th ird  trim ester 
pregnancy is seen in Table 9.1. The PGI2M results are shown in Fig. 9.1 and the TxB2 
in Fig. 9.2. As can be seen, 11 of the 26 patients with mild/moderate PIH and 13 of the 
15 patients with severe PIH had unrecordable levels (<5 pg/ml) of PGI2 M. No patient 
in the normal third trim ester pregnancy group had unrecordable levels of PGI2M. 
The levels of PGI2 M in both the m ild/m oderate and severe PIH groups were 
significantly different from those in the normal group. The majority of the patients 
in the severe group had unrecordable levels. The level of PGI2 M in patients with PIH 
was not related to parity, with both primigravida and parous women having 
unrecordable levels of PGI2M. There appeared to be a trend towards a  negative 
correlation of PGI2M with proteinuria and a positive correlation with intrauterine 
growth retardation bu t this did not reach significance.
The TxB2 resu lts show th a t thromboxane appears to be increased only in  the
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mild/moderate group and not the severe group. (Fig. 9.2)
Serial Study
Of the 14 patients studied, 8 remained normotensive while 6 developed mild to 
moderate PIH in the 3rd trimester, defined as a persistent diastolic blood pressure of 
90 mm of mercury. 5 were treated conservatively, while one required treatm ent with 
an  antihypertensive agent (labetalol). None developed significant p latelet 
consumption or proteinuria. All patients had vaginal deliveries either spontaneous 
or induced at term, and all infants were healthy with birth weights above the 10 th  
centile for their gestational age. The proportion of patients who became hypertensive 
was unexpected and extraordinarily high. There was no apparent reason for th is as 
all were apparently normal patients at a routine antenatal clinic. The high incidence 
in the study group appears to be totally coincidental.
Results are shown in figures 9.3 and 9.4 with a fuller statistical analysis in tables 9.3 
and 9.4.
In the normal patients PGI2 M was significantly higher in the first than  in the second 
and third trim esters, while TxB2 levels fell significantly in the second and third 
trim esters as compared with the first trimester. There was no significant difference 
for either PGI2M or TxB2 between the second and third trim esters of the normal 
group, although there was a trend towards lower levels of TxB2 in the third trimester. 
These results agreed with the previous cross-sectional study.
In the first and second trimesters, the PIH group was not significantly different from 
the normal group for either PGI2M or TXB2. All hypertensive patients developed 
unrecordable (<5pg/ml) levels of PGI2M in the third trim ester w hen they were 
hypertensive. In 3 of the 6 PIH patients hypertension had developed prior to the 
sample showing unrecordable levels, therefore it could not be determined whether 
undetectable PGI2 M levels preceded the development of hypertension or vice-verse. 
In the other 3 patients, however, unrecordable levels were m easured prior to the 
development of the hypertension.
Owing to the small num bers and differing times of development of PIH it was not 
possible to compare statistically the th ird  trim ester m easurem ents in  the  PIH 
patients with the normal group. The late (36-40 weeks gestation) third trim ester 
measurement in the PIH group was significantly different from the first and second 
trimester measurements within the group. There was a significant reduction in TXB2 
in the second and early (32-36 weeks gestation) third trimester compared to the first 
trim ester in the PIH group and a significant increase in TXB2 was noted in the late 
third as compared to the early third trimester. There was no significant difference 
between normal and PIH groups for TXB2, and no correlation existed between PGI2M 
and TxB2 in either group.
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9.4 Discussion
Despite using larger num bers the cross-sectional study did not confirm the work of 
Lewis et al. (1980) who showed a higher concentration of 6-keto-PGFla in  late 
pregnancy and the puerperium. It also could not confirm the work of Bolton et al.
(1981) as the peak levels of PGI2M occurred in the first trimester, and not in mid­
pregnancy as they reported, although they did not record levels before 14 weeks 
gestation. We found a significant difference in the first trim ester compared with 
values in the nonpregnant and second and third trimesters. This early increase may 
be involved in the physiological vasodilation and insensitivity to angiotensin II 
(Gant et a l, 1973) which are characteristic of early pregnancy. It has recently been 
shown th a t trophoblast from early pregnancies has a high capacity to synthesise 
PGI2 , and it has been suggested th a t colonisation of m aternal blood vessels by 
trophoblast is facilitated by PGI2 . which may prevent platelet aggregates from 
halting this process (Lewis, 1982) This theory might explain the findings of elevated 
PGI2M levels in early pregnancy. Theoretically one might expect high levels of PGI2 
in late pregnancy, due to the potential for increased production from the u terus and 
fetoplacental circulation unit. This study did not show any increased levels a t this 
stage. This may be explained by the findings of Remuzzi et al. (1981) who found a 
reduced level of prostacyclin stimulating factor in late normal pregnancy, possibly a 
homeostatic mechanism. Since the capacity to produce PGI2 is increased a t th is 
stage, less prostacyclin stimulating is required. In the postnatal group a trend 
towards reduced levels was found which contradicts the work of Lewis et al. (1980). 
The sampling was performed only on the third postnatal day, while Lewis et al.
(1980) sampled between the first and seventh postnatal days. If many of the samples 
were obtained soon after delivery they may have had a high 6-keto-PGFla level due 
to vascular injury or the recognised rise of PGI2 during labour (Ylikorkala, 
Makarainen and Viinikka, 1981). Since the fetoplacental unit, which has enormous 
capacity to synthesise PGI2 , is removed at birth, a reduction in 6-keto-PGFla levels 
postnatally might be expected. There is also a fall in  PGI2 levels after suckling 
(Ylikorkala and Viinikka, 1981). There was a progressive fall in  plasm a TxB2 
concentrations throughout pregnancy and into the puerperium. This may reflect 
increased platelet stability, or the diversion of TxB2 precursors into the formation of 
other prostaglandins, such as PGD2 or PGEi. Other possible explanations of this may 
be related to a change in activity of thromboxane synthetase or decreased substrate 
availability, bu t further studies are required to elucidate this.
The results in the patients with PIH confirm tha t low levels of PGI2M occur in PIH, 
with over 50% of patients in this study having unrecordable (<5 pg/ml) levels of this 
metabolite, a feature not seen in  the normal group. This did not appear to be
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absolutely related to disease severity as 11 of 26 patients with mild/moderate disease 
and 13 of the 15 patients with severe disease had unrecordable levels. However, many 
patients in the mild/moderate group and 2 patientsin the severe group had PGI2M 
levels within the normal range, suggesting th a t very low levels of PGI2 M are not 
always found in PIH.
These findings are consistent with other studies. Yamaguchi and Mori (1985) studied 
15 women with PIH and found them  to have relatively lower levels of plasma 6-keto- 
PG Fla th an  normal pregnant women. However, the levels they reported were veiy 
high and bring the validity of their assay into question. Moodley et al (1984) also 
reported lower levels of plasm a 6-keto-PG Fla in  women with eclam psia or 
impending eclampsia compared to normal pregnancy, bu t again they reported very 
high levels of this substance although they were taken from central lines. Not all 
reports on plasma PGI2 metabolites in PIH have been consistent. Ylikorkala et al.
(1981) found no change in 22 patients with PIH compared with normal pregnancy. 
Strickland et al. (1984) reported higher levels of 6-keto-PGFla in PIH. The findings 
of the present study are in keeping with the work of Goodman et al., (Goodman et aL, 
1982) who studied 6 patients with PIH and found them to have lower levels of urinary 
PGI2 metabolites. The reports of reduced amniotic fluid PGI2 in PIH and reduced PGI2 
production from both maternal and fetal vascular tissue are also in  keeping with the 
findings of the low PGI2M in PIH seen in the present study. Low levels of PGI2 m ay 
well play a role in the pathophysiology of PIH, as a deficiency of this vasodilator and 
an tip la te le t prostag land in  m ight allow the  vasoconstric tion  and  p la te let 
consumption, which are characteristic of PIH, to go unchallenged. PGI2 may also be 
im portant in balancing the pressor effects of angiotensin II in  normal pregnancy 
(Broughton Pipkin, Morrison and O'Brien, 1984), although similar effects have been 
found for PGE2 (Broughton Pipkin et a t ,  1984) and PGEi (Broughton Pipkin, 
M orrison and O'Brien, 1987). Therefore, prostacyclin may be an  im portant 
vasodilator during pregnancy. The reduced levels of PGI2 in PIH seen in  the present 
study may explain the All sensitivity seen in PIH. This is another m echanism  by 
which PGI2 deficiency could contribute to the disease process in PIH. A cause and 
effect relationship between low PGI2 and PIH cannot be concluded from th is present 
study and other prostaglandins may also be involved. PGI2 deficiency is unlikely to 
be the prim ary cause of the disease, b u t may occupy a pivotal role in  the 
pathophysiology of PIH, by increasing v ascu lar sensitiv ity  and  allowing 
vasoconstriction and platelet consumption to occur unopposed.
The resu lts  from th is  small prospective longitudinal s tudy  show increased 
concentrations of plasm a PGI2 M in the first trimester, and falling levels of plasm a 
TxB2 in the second and third trim esters of normal pregnancy. This confirms the
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results found in the cross sectional study. Prostacyclin may play an  important role 
in implantation and establishment of normal pregnancy.
All hypertensive patients developed unrecordable levels of PGI2 M and th is  is 
consistent with the cross-sectional study. As three patients had unrecordable levels 
of PGI2 M prior to development of PIH, this suggests tha t falling levels of PGI2 M may 
antedate the development of hypertension, and may possibly act as a  marker, 
heralding the development of the disease. Thromboxane A2 did not seem to be related 
to PIH. A significant increase in the late third trim ester of the hypertensive group 
was noted. It is not possible to comment as to whether this was related to the disease, 
due to subclinical platelet aggregation, or was a normal finding as we did not have a 
late third trim ester sample in our normal control group. It would appear th a t the 
change of prostacyclin /throm boxane balance is more re la ted  to a fall in  
prostacyclin than  a rise in thromboxane.
The fact th a t prostacyclin levels are higher in the second trim ester in the patients 
who developed PIH compared to those who did not, suggests th a t there may be an 
increased demand on PGI2 production at tha t time. This could be due to increased 
vasoconstrictor activity. It is when this ability to respond is lost tha t PIH develops. 
The earlier th is ability is lost or the greater the demand, the earlier the disease 
develops. This theory would fit the data in these studies. The severe early disease 
group almost always had unrecordable levels whereas the later more moderate group 
had mixed results. These results also fit those found in the platelet size studies 
(Chapter 8) where the early disease group had no changes in platelet size and the later 
onset disease had larger platelets. These are the patients who can compensate for the 
disease stimulus. However, there will be an  increase in their platelet consum ption 
leading to changes in platelet size.
Therefore, prostacyclin deficiency is unlikely to be the cause of preeclampsia, bu t 
may be the factor that effects the way the disease presents and how severe the patient 
becomes. This would imply that there are two factors involved, a stim ulus or trigger, 
and the response or susceptibility. The factors affecting prostacyclin production 
would contribute to the susceptibility to the disease. The stim ulus could possibly be 
mediated through the renin/angiotensin system as postulated by Symonds et al 
(1978) and discussed in Chapter 3.
9.5 Conclusions
The main conclusions from this chapter are:
1) In patients with severe preeclampsia, prostacyclin production is deficient.
2) This low level of prostacyclin can be seen in  som e o f those w ith m ilder 
disease.
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3) The low level of prostacyclin may be due to an absence or a loss of production 
ability.
4) The response a patient has to the disease process may depend on their ability  
to produce prostacyclin.
5) Some factor appears to reduce the ability to produce prostacyclin.
6) Thromboxane elevation is a late manifestation of the disease.
7) The alteration in the prostacyclin/thromboxane balance is mostly due to loss 
of prostacyclin.
8) These findings appear to agree with the platelet size studies.
Chapter 10
Studies o f M anagement 
o f
Pregnancy H ypertension
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10.1 Introduction
The results of the daycare studies suggest that the risk of hypertension in pregnancy 
is greatly overestimated. The majority of patients who are diagnosed as having mild 
to moderate hypertension remain relatively stable and at low risk  for the rest of 
their pregnancy. By close monitoring of th is group, it appears to be possible to 
determine those who will remain low risk from those who will progress to the 
moderate or severe stage. Therefore, the development of severe preeclampsia with 
proteinuria may be predicted, or perhaps prevented. If a significant num ber of 
patients progress from milder stages to more severe forms, it may be possible to 
develop systems of early recognition and intervention in th is condition. However, 
there will rem ain patien ts in whom severe preeclam psia appears w ithout a 
previously recognised mild stage.
Therefore, it would seem logical tha t, if patients are thought to be a t risk  of 
development of severe preeclampsia, they should be monitored closely for signs of 
progression of disease and signs of placental insufficiency which may interfere with 
fetal growth and wellbeing. If all param eters rem ain stable and fetal growth is 
satisfactory, the patients may be allowed to continue their pregnancy and so reduce 
prematurity, even though they have obvious stigmata of developing preeclampsia.
At the  initiation of these studies, the m ain risk  to the m other w as of the 
hypertension itself since the m ain cause of m aternal death was cerebrovascular 
accident (Turnbull, 1987). The risks to the baby, however, consists of prematurity due 
to iatrogenic delivery because of the m aternal condition, placental abruption or 
placental insufficiency and in trauterine growth retardation (Common Services 
Agency, 1986).
Most patients could be managed by close monitoring, with delivery if there are signs 
of fetal compromise, or concern about m aternal wellbeing. If placental function is 
adequate, antihypertensive drugs may help to reduce the maternal risk and further 
prolong the pregnancy.
To try  and establish th is system of surveillance, a stepwise approach to the 
m anagement of hypertension in pregnancy has been developed. The aim was to 
monitor closely those a t risk, develop guidelines for management and delivery and 
investigate the role of antihypertensive drugs.
10.2 Methods
All patients who were seen at the antenatal clinic and found to have an elevation of 
blood pressure above 140/90 mmHg were referred initially to a day assessm ent unit. 
At this attendance, an assessment was made of the risk to both m other and baby as 
previously described in Chapter 7. If the risk was thought to be low, the patient was 
referred back to the care of her obstetrician at the antenatal clinic. If the risks were
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assessed as moderate the patient continued to be monitored a t the day assessm ent 
unit. If the risk  was assessed as high, she was admitted to hospital for closer 
monitoring and stabilisation of her condition.
If blood pressure was persistently elevated, various studies into the  effect of 
antihypertensive drugs were carried out. Following these studies, general protocols 
of management were developed.
10.3 Acute studies
The use of antihypertensive drugs in pregnancy has generally been within the ‘fire- 
station’ approach, tha t is only when the blood pressure is severe (Garden, Davey and 
Dommisse, 1982; Thien et a l,  1980). The traditional drugs used have been 
hydrallazine (Reti et al., 1987; Joyce and Kenyon, 1972) and diazoxide (MacLean et 
al., 1981; Rabau Friedman et a l, 1980). A study was set up to look at oral alternatives 
to these parental drugs.
Methods
Thirty patients, in  the th ird  trim ester of pregnancy, who had  diastolic blood 
pressures above 105 mmHg on 2 measurements after 30 m inutes of bed-rest were 
random ised to treatm ent either with 200 mg oral labetalol or w ith 10 mg 
intram uscular hydrallazine. A separate study of 10 mg of oral nicardipine, the 
calcium channel blocker, was carried out in 20 patients with the entiy same criteria. 
(Table 10.1)
Pulse and blood pressure were monitored every 15 minutes for 2 hours after the drug 
was given. No other drugs were used during the period of observation. Measurements 
on individual patients were carried out by one observer. Phase four Korotkov sounds 
were used for the diastolic measurements in all cases, and the blood pressure taken 
in the left arm with the patient sitting at 45 degrees throughout the 2 hours.
Results
The studies into the use of labetalol, hydrallazine and nicardipine demonstrate tha t 
all three drugs produce a smooth predictable fall in diastolic blood pressure (Fig.
10.1). The blood pressure effect is seen within 10 m inutes with the full effect seen at 
30 minutes. The effect is still apparent at 2 hours. Both nicardipine and hydrallazine 
produced an initial rise in the systolic blood pressure compared with their own 
baseline, bu t there was no statistical difference between the three drugs and the 
effects were similar by 90 minutes. The effect on the pulse rate was also different 
(Fig. 10.2). Labetalol produced a small initial rise in pulse rate bu t overall there was 
no change. There was a significant rise in the pulse rates seen with nicardipine and 
hydrallazine at 30-60 m inutes bu t there was no difference after 90 m inutes. (Fig.
10.2).
More patien ts given labetalol or nicardipine subjectively felt be tte r following
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medication compared with those given hydrallazine. Also, fewer complained of side 
effects (Table 10.2).
Six patients given hydrallazine complained of headache, nausea or tremor. The rise 
in  pulse rate, combined with the increased pulse pressure, could explain the 
headaches seen with hydrallazine. However, only 2 /2 0  patien ts experienced 
headache or other side effects after nicardipine despite sim ilar cardiovascular 
actions.
10.4 Early treatment of Pregnancy Induced Hypertension.
After admission to hospital, the traditional treatm ent consists of bed rest (Turner, 
1981b). The benefit of this has been questioned (Hamlin, 1952; Matthews, 1977a). 
A ntihypertensive d rugs are norm ally only u sed  in  severe hypertension  
(Chamberlain et a l, 1978a). In order to study whether earlier more active blood 
pressure reduction would have more benefit than bed rest alone, an  open randomised 
study of traditional bed rest against antihypertensive treatm ent using oral labetalol 
(± hydrallazine) was set up. An open study was chosen instead of a  placebo controlled 
study because, at the time, there was little information on the dosage required to 
control blood pressure. It was expected tha t a certain num ber of the patients would 
need maximum doses of labetalol plus hydrallazine.
Methods
A total of 126 patients were recruited to the study, 74 primigravida and 52 parous 
patients. The criteria for entry was an average daily blood pressure of over 95 mmHg 
after four days of hospital bed rest in the third trimester. All patients had had a 
norm al first trim ester blood pressure. Primigravida and parous women were 
randomised separately. Both groups were prescribed “Bed Rest”. This consisted of 
“UTTAM” - Up To Toilet And Meals.
Treatment with labetalol was started a t 100 mg. twice a day and increased in stages 
to 1,600 mg per day or until blood pressure control was achieved.
If control was not achieved or was lost a t the maximum dosage, hydrallazine was 
added at a starting dose of 25 mg three times a day and increased until control was 
achieved to a maximum dose of 200 mg. a day.
Control was defined as either a fall in the average diastolic blood pressure to below 
90 mmHg or a drop of 10 mmHg, from the starting diastolic blood pressure.
Loss of control was defined as a rise in the diastolic blood pressure to over 5 mmHg 
above the pretreatment diastolic blood pressure.
All patients entering the trial were closely monitored before and after starting 
treatm ent. The m others were fully monitored and the effects, if any, on the 
cardiovascular, renal and coagulation systems were assessed. Placental function and 
the influences on the fetus and the newborn were also monitored as previously
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described in Chapter 7..
Results
The patient groups were evenly matched (Table 10.3). Not only was the average 
diastolic above 90 mmHg, bu t the average blood pressures rise was above the 15 
mmHg diastolic criteria of the  American College used in  the definition of 
preeclampsia (Hughes 1972). The average levels of uric acid and platelet count were 
not outwith the normal range for the gestation.
Oral labetalol at a dosage of 100 mg bd failed to control the blood pressure in any of 
the patients and although 100 mg tid efficiently lowered the blood pressure in some 
patients, the majority required 200 mg to achieve adequate control (fig 10.3). Overall, 
the treated group achieved blood pressure reduction within the first seventy-two 
hours and sooner than  tha t once the starting dose was increased to 200 mg tid 
(fig. 10.4). Fifty nine of the patients (92%) treated with labetalol had a blood pressure 
tha t fell into the normal range or remained at or around 90 - 95 mmHg (Table 10.4). 
Five of the patients showed signs of progressive disease, with a rise of diastolic blood 
pressure of more th an  5 mmHg, requiring increasing doses of labetalol w ithout 
complete satisfactory control. Of these, 2 patients developed severe preeclampsia 
with blood pressures over 110 mmHg and 4 of the patients developed proteinuria of 
greater th an  0.3 gm /24 hours. In the control group the blood pressure remained 
elevated in the majority of the patients although the blood pressure did fall back into 
the normal range after continuous hospital bed rest in 9 patients. A further 20 of the 
patients remained with blood pressures within the moderate range and did not 
progress to worsening disease. However, 33 of patients had a steadily increasing 
blood pressure, and 20 were given intervention therapy at a  later date. Of 33 patients 
with worsening disease, 13 developed severe hypertension with blood pressure rising 
over 110 mmHg and 9 patients developed proteinuria (Table 10.4). A significant 
improvement (p<0.005) was seen in the creatinine clearance in  the treated group 
compared with the control group in which there was a slight b u t insignificant fall. 
(Fig 10.5). There was no difference seen in the changes in the levels of uric acid which 
rose in around 50% of both groups. There was a significant reduction in  platelet 
count in the control group which not seen in the treated group (p<0.005) (fig. 10.6).
The side effects seen were all in the treated group, but there were only 4 withdrawals, 
1 for bronchospasm, 2 for tremor and one at patient request, no reason given. (Table 
10.5)
Fetal monitoring, as assessed by fetal movement counts, cardiotocographs and 
ultrasound estimation of fetal growth, showed no difference between groups.
There was no difference seen between groups in any aspect of labour, delivery or fetal 
wellbeing (Table 10.6).
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It is to be remembered that many of the patients in the control group who progressed 
to more severe disease were then  started on labetalol therapy to control the blood 
pressure. This may have helped to prolong the pregnancies in the control group. 
Discussion
This study suggests tha t labetalol can be safely used in pregnancy. It can lower blood 
pressure successfully and appears to attenuate some of the progressive changes tha t 
are normally seen in PIH. However, since others still progress, the underlying disease 
process is still continuing. The changes seen in the creatinine clearance were not 
reflected in changes seen in uric acid levels, suggesting tha t uric acid abnormalities 
are not completely associated with renal function disturbances. The maintenance of 
the platelet num bers might suggest reduction in platelet consumption. In parallel 
studies, it was shown th a t labetalol does appear to have an  affect on platelet 
aggregation (Greer et aL, 1985b; Greer et a l, 1983; Greer et a l, 1987) and this has been 
confirmed by others (Anfossi et a l, 1988). This finding might suggest a beneficial 
effect of labetalol apart from lowering blood pressure (De Sweit, 1985).
However, since the outcome in both groups was the same, there is no evidence to 
support starting treatm ent in mild disease. It would appear to be possible to closely 
monitor these patients in  the daycare unit and delay intervention until patients 
have persistent blood pressures above 100 mmHg before commencing therapy.
10.5 Severe Study
If antihypertensive therapy can reduce or slow some of the disease changes, can 
pregnancies complicated by severe preeclampsia be stabilised and maintained safely 
with the help of antihypertensive drugs? A randomised study of drug therapy against 
non-treatm ent or placebo was considered. However, as antihypertensive therapy is 
commonly given if the diastolic blood pressure rises above 110 mmHg (Chamberlain 
e ta l,  1978a; Mabie e ta l,  1987; Garden, Davey and Dommisse, 1982; Michael, 1979), 
it was felt th a t it was unethical to withhold antihypertensive therapy from the 
majority of these patients. Therefore, the study was specifically designed to discover 
whether lowering blood pressure alters the disease process, allowing prolongation of 
the pregnancy and improving the outcome of the mother and baby.
Methods
To investigate the benefit of antihypertensive therapy in severe disease, 186 
primigravidae with persistent diastolic blood pressures of over 110 mmHg or 
diastolic blood pressures of over 100 mmHg with proteinuria of a t least 0.5 gm in  24 
hours were commenced on oral labetalol.
All patients were assessed for fetal wellbeing prior to commencement. If there was 
any sign of fetal compromise, delivery was expedited and the patients were not 
included in the study.
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The starting dose was 200 mg tid increasing to 1600 mg a day. If blood pressure 
control was not achieved a vasodilator was added. Initially this was hydrallazine 25 
mg tid increasing to 200 m g/day as previously described. Then nifedipine was used at 
a starting dose of 10 mg bd increasing to 40 mg/day. Subsequently, nifedipine slow 
release 10 mg bd has been used.
Results
The patient group is seen in table 10.7. The parameters confirm tha t the patients had 
severe preeclampsia by m ost criteria. After commencement of labetalol, adequate 
blood pressure control was achieved in the majority of patients. Thirty three had a 
fall of diastolic blood pressure down into the normal range (less th an  90 mmHg), a 
fu rther 81 of the patients had their blood pressure reduced into the m oderate 
hypertensive range between 9 0 -  100 mmHg (Fig. 10.7). In some of these patients long 
term  control was achieved and they were managed as outpatients (Fig. 10.8). Fifty 
eight patients achieved adequate blood pressure control initially, I although they required 
increasing doses and the addition of vasodilator substances to help m aintain the 
blood pressure. In these patients, control was only achieved for around 10 days of 
therapy. In 12 patients blood pressure control could not be achieved within 48 hours 
of commencement of therapy and these patients were then  delivered. The average 
dose of labetalol was 1201±320 mg (Range 600-1600 mg). As the study progressed, it 
became obvious tha t it was better to add nifedipine to the regime when the labetalol 
dose was 1200 mg rather than  increase the labetalol alone, (fig 10.9)
In the 43 patients th a t received nifedipine as a second line drug, fu rther blood 
pressure control was achieved with further prolongation of the pregnancy for 
another seven days (fig 10.10). Smoother control was achieved especially when 
nifedipine slow release 10 mg bd was used.
In the overall study, the average length of treatm ent was 15.6 days leading to a 
delivery gestation of 33.5 weeks (Table 10.8). It was not possible to predict those who 
would respond well to therapy and it did not appear to correspond to the other 
parameters of disease severity such as proteinuria, uric acid or platelet count.
After commencement of therapy, there was no change in uric acid, plasm a creatinine 
or creatinine clearance although there was a slight deterioration ju s t  prior to 
delivery (Table 10.9). The average proteinuria did not change although in  some 
patien ts the proteinuria disappeared whereas in others it steadily worsened. 
Generally if the proteinuria was less than  1.5 gm /24 hours and the blood pressure 
was controlled, proteinuria would disappear. As was found in the m ild/m oderate 
study, the platelet count rose after treatm ent was started. Sometimes th is  was 
dramatic (Fig. 10.11)
Close monitoring of the fetus was carried out throughout the study. If there was
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evidence of fetal compromise as demonstrated by cardiotocograph abnormality, no 
improvement was seen even when blood pressure was controlled. In these situations, 
delivery was expedited for the benefit of the fetus no m atter what the m aternal blood 
pressure was.
There was 1 intrauterine death in a patient who suffered an  abruption a t 30 weeks. 
The patient was normotensive at the time after 2 weeks of antihypertensive therapy. 
There were 3 other birth related deaths, 1 a neonatal death a t 4 days following a birth 
a t 28 weeks and 2 other babies tha t died around the age of 3 m onths because of 
problems with long term  ventilation.
Discussion
This study demonstrates tha t is possible to lower the blood pressure even in severe 
preeclampsia. In some patients, the blood pressure returned to normal and control 
appeared to be easy. This may call into question w hether these patien ts had 
significant disease. However, there was no correlation between the severity of the 
disease a t entry and the ease of blood pressure control. With most of the patients, 
control or stabilisation was achieved. This allowed the option to continue the 
pregnancy with a reduced risk  to the mother. Many of these patien ts could be 
returned home and followed at daycare. This obviously has benefits to the patient. 
Prolongation of the pregnancy allows a more controlled timing of delivery and 
increased m aturity of the fetus. The effects of this regime will be discussed later in 
this chapter.
One of the fears of antihypertensive therapy has also been the potential harm  it 
might bring to the fetus (Lieberman et aL, 1978; Vink, Moodley and Philpott, 1980; 
Witter, King and Blake, 1981; Dagbjartsson et a l, 1985; Dagbjartsson, Kjellmer and 
Rosen, 1987). There was no apparent affect seen in  th is study as m easured by 
cardiotocograph and ultrasound. If antihypertensive drugs do have an  effect on the 
fetus, it is likely th a t it would be on the cardiovascular system. With new direct 
m ethods of studying fetal/p lacental blood flow (Fitzgerald and Drumm, 1977; 
Campbell et a l, 1983; Hanretty and Rubin, 1989), it is possible to investigate the 
effect of therapy on the maternal and fetal cardiovascular system.
Special Investigations
Various specific investigations were carried out into the effect of antihypertensive 
therapy on the mother and fetus apart from the routine investigations reported in  
Chapter 6.
Doppler assessm ent o f the Effect o f Antihypertensive Treatm ent 
If antihypertensive therapy is used to lower the blood pressure and reduce the 
m aternal risks, pregnancies can be prolonged allowing the fetus to reach greater 
maturity. The reduction of blood pressure does not treat the underlying disease and
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continuing monitoring of the mother and fetus is necessary. The main concern about 
antihypertensive therapy is the potential effects on the fetus, either directly or by a 
reduction in uteroplacental blood flow.
As described in Chapter 3, various studies have demonstrated both the risks and the 
lack of problems from the used of antihypertensive drugs.
Doppler u ltrasound examination is a non-invasive procedure th a t perm its the 
assessm ent of both m aternal and fetal cardiovascular system. Abnormalities of 
Doppler waveforms have been reported in pregnancies complicated by hypertension. 
The aim of this study was to monitor the effects of acute and chronic blood pressure 
reduction on the maternal and fetal circulations using Doppler ultrasound.
Acute Study
Eight primigravid patients with acute hypertension in  the th ird  trim ester of 
pregnancy were recruited. All had a diastolic blood above 105 mmHg for 30 m inutes 
on bed rest in the semirecumbent position. The patients remained in th is  position 
and were given 10 mg oral nicardipine, a calcium channel blocker. The blood 
pressure , pulse rate, cardiotocograph and Doppler waveform analysis of the  
uteroplacental, m aternal brachial and fetal umbilical arteries were carried out 
before and during the 60 minutes following the administration of the drug.
Chronic Study
Fifteen primigravid patients with mild preeclampsia were recruited. All had  an 
average daily diastolic blood pressure of greater than  100 mmHg and a gestation 
between 30 and 36 weeks. They were treated with the beta-blocker Pindolol, with a 
starting dose of 5 mg twice daily increasing to a maximum of 10 mg three times a  day 
or until the average daily diastolic blood pressure was less than 100 mmHg. The same 
investigations as in the acute study were carried out before, the day following and on 
alternate days of pindolol therapy.
Control Group
There was no control group of patients for the acute study. For the chronic study, 15 
primigravid patients with untreated mild preeclampsia were used as controls. All 
had an average daily diastolic blood pressure of between 90 mmHg and 99 mmHg and 
a gestation between 30 and 36 weeks. They were monitored using the  identical 
methods as described above.
Doppler Waveform Analysis
Doppler ultrasound examination was performed using a continuous wave system 
(Doptek, Chichester, UK). A 150 Hz high pass filter was used to eliminate low 
frequency signals caused by vessel wall movement. During all Doppler studies, 
patients adopted a semirecumbent position with a 15 degree left lateral tilt to avoid 
caval compression. Umbilical artery and uteroplacental Doppler waveforms were
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recorded. Doppler waveforms were obtained from the left m aternal brachial artery 
located in  the antecubital fossa. The systolic/diastolic ratio (SD) was calculated 
when five representative consecutive wave forms had been obtained from each vessel 
studied.
Doppler assessm ent o f the Effect o f Antihypertenstue Treatment.
Acute Study
Administration of nicardipine was associated with a significant fall in the diastolic 
blood pressure by 30 minutes (Table 10.10). Diastolic blood pressures a t 45 minutes 
and 60 m inutes were also significantly lower compared with pretreatm ent values. As 
regards the Doppler readings, the only significant finding w as a  rise in  the 
uteroplacental SD at 30 minutes. This change were not evident at 60 minutes.
Chronic Study
Following the administration of pindolol (Table 10.11), there was a  significant fall 
in blood pressure seen within 24 hours bu t this control was not as good by 72 hrs. 
Control varied after this depending on whether the patients could tolerate higher 
doses of pindolol. The main reason for withdrawal of patients was m arked beta- 
agonist side effects such as tremor. By 8 days, the num ber of patients remaining in 
the study make the results more difficult to interpret. The only significant change in 
Doppler measurements was a rise in the uteroplacental SD at 3 days. This change was 
no longer evident by 5 days.
When the control group were studied (Table 10.12), it can be seen th a t conservative 
management made little difference to the blood pressure, which rose steadily over 
the study period. With respect to Doppler indices, there was a significant rise in the 
uteroplacental SD at 5 days and the umbilical SD at 7 days.
Discussion
It would be surprising if therapy to lower blood pressure was not associated with 
m aternal and fetal circulatory changes. The magnitude of such changes and their 
effect on fetal wellbeing m ust be influenced by the pharmacological properties of the 
drugs used, the rate of onset of antihypertensive action and the inherent ability of 
the mother and fetus to compensate for drug induced circulatory changes.
Most of the reported adverse fetal effects of antihypertensive therapy have been 
associated with acute lowering of maternal blood pressure. In the acute study, a rise 
in  uteroplacental SD was seen 30 m inutes after administration of nicardipine b u t 
this was short lived and was not reflected in changes seen in the umbilical blood flow 
param eters or fetal heart rate monitoring. It may be th a t the m aternal and  fetal 
circulations th a t were studied were able to rapidly compensate for the effect of acute 
blood pressure lowering. These findings do not exclude the possibility th a t some 
patien ts with hypertension in  pregnancy (particularly those w ith a reduced
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circulating blood volume) may not be able to compensate for the circulatory changes 
induced by acute antihypertensive therapy. Consequently, they m ay show a 
sustained change in uteroplacental an d /o r fetoplacental Doppler indices and fetal 
h eart ra te  abnorm alities. All pa tien ts we studied showed norm al baseline 
uteroplacental and umbilical artery Doppler indices throughout the study period. It 
may be argued that such patients have a relatively stable cardiovascular system and 
lowering m aternal blood pressure is unlikely to produce changes in fetoplacental or 
uteroplacental blood flow velocities. In addition, even if no Doppler changes are 
detected, th is  does not m ean th a t there has been no change in m aternal or fetal 
cardiovascular function. F urther studies are indicated to assess  the effect of 
an tihypertensive  th erapy  on p a tien ts  w ith abnorm al fe top lacen ta l and 
uteroplacental waveform patterns, particularly when the umbilical artery shows 
absent end-diastolic frequencies.
In conclusion, data is accumulating tha t if required, the use of antihypertensive 
therapy in  pregnancy has no detrimental effect on either fetal wellbeing or neonatal 
outcome if the  fetus is in good condition before treatm ent. Although acute 
adm in istra tion  of nicardipine and chronic adm inistra tion  of pindolol was 
associated with a change in  the uteroplacental SD ratio, there was no change in 
umbilical artery or m aternal brachial artery SD ratios. The rise in  uteroplacental 
SD ratio was clinically insignificant since it was transient and was not associated 
with evidence of either maternal or fetal compromise.
10.6 Development of Management Protocols.
After all these studies, an  attem pt was made to standardise the  m anagem ent 
approach and produce protocols th a t are simple to use. Inevitably, these protocols 
are under constant review. The final conclusions will be described although it is 
realised tha t these also may change in the future.
It is sometimes not possible to distinguish between the two forms of pregnancy 
hypertension. However, it is easy to separate the patients into those th a t present 
before 20 weeks and those tha t present for the first time at a later gestation. The later 
group are obviously not a “pure group” b u t the potential risks and therefore the 
management of these patients are similar. Antihypertensive therapy is only part of 
the overall management and should not be considered in isolation. Lowering blood 
pressure does ju s t that, it does not cure the patient. The assessm ent and monitoring 
of the mother and baby is the most important part of any therapeutic regime. If there 
is any sign of maternal or fetal compromise, delivery should be expedited.
Patients presenting before 20 weeks or Chronic hypertension
If it was possible, any patien t with chronic hypertension and  who w as on 
antihypertensive therapy was seen prior to pregnancy and the need of treatm ent
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assessed. The patient may have mild disease and not require therapy and there are 
some drugs which are contraindicated. Any change of therapy should be balanced 
against the reason why the patient was given it in first place. If enalapril is the only 
drug that controls the blood pressure, then it may be better to continue this therapy 
even with the knowledge tha t it may cause problems. The need for therapy should be 
reassessed after the patient has become pregnant as blood pressure may fall in the 
first and second trimesters and need for therapy will be reduced.
If the patient’s blood pressure is stable prior to pregnancy, she is continued on her 
medication and then reassessed in the first trimester. If the blood pressure has fallen 
below 140/90 mmHg, the therapy is stopped and restarted only if the blood pressure 
rises again to over 150/100 mmHg. (Table 10.13) -
If the hypertension is diagnosed in the first trimester, the patient should be assessed 
for renal disease as this is often discovered for the first time during pregnancy. As 
long as the blood pressure is less than  150/100 mmHg, the patient is observed 
without therapy as it will normally drop by 18-20 weeks.
All patients with chronic hypertension in the GRMH are followed closely in  the 
Outpatient Daycare Assessment Unit (Chapter 7). They are seen on a regular basis 
and monitored for both m aternal and fetal wellbeing. (Table 10.13) If the blood 
pressure rises above 150/100 mmHg, antihypertensive therapy is started. Close 
monitoring as an  outpatient is continued as long as stabilisation of the  blood 
pressure is achieved. When treating chronic hypertension, the drug used probably 
does not m atter very much. Although the use of antihypertensive drugs is unproven, 
it is our policy to treat patients if the blood pressure rises above 150/100 mmHg. The 
drug normally used is labetalol. This preparation has the advantage th a t it can  be 
used in the acute situation as well as the chronic setting. It can be given by the 
intravenous route as well as orally. This m eans tha t medical staff only require to 
learn one regime for all patient groups. The starting dose is 200 mg eight hourly, 
increasing to 200 mg six hourly and then 300 mg six hourly. If control is not achieved 
or is lost at this dose, nifedipine, a calcium channel blocker, is added at dose of 10 mg 
retard twice a day increasing to 20 mg twice a day.
Patients presenting after 20 weeks.
Preeclampsia is a multisystem disease and the blood pressure is one aspect of it. All 
hypertensive patients are reviewed by the hypertensive team  under the direction of 
the author. Only patients with a persistent blood pressure over 150/100 mmHg were 
considered for therapy. In the last 9 years, 3885 patients with hypertension in 
pregnancy have been assessed and only 649 of these have been started on regular 
doses of antihypertensive drugs. This constitutes only 16.7% of the hypertensive 
patients or 1.7% of the pregnancy population (Table 10.14. Approximately a further
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300 (0.8%) have been given single doses of either labetalol, nicardipine or 
hydrallazine. Therefore, even if a ‘liberal’ approach to antihypertensive therapy is 
used the numbers treated are small. This is comparable with the rate of around 16% 
of patients given magnesium sulphate in some centres in  the United States.
The regimen developed for the management of patients with preeclampsia in  GRMH 
is the same as previously described for chronic hypertension. Over 60% of the cases 
treated were controlled on labetalol alone with a further 35% patients requiring a 
vasodilator, usually nifedipine (Fig. 10.9). As with all therapies, about 5% of cases 
were treatm ent failures and progressed to delivery because of poor blood pressure 
control. An integral part of the care of these patients, was the continuing close 
monitoring of the mother and fetus using a standard protocol (Table 10.13) The 
m other was monitored by platelet count, uric acid, urinalysis as well as regular blood 
pressure estimations. The average daily blood pressure (of four readings) was used as 
an  assessm ent of blood pressure control and the need to change therapy. The 
occasional elevated reading was ignored. The fetus was m onitored using the 
cardiotocograph and ultrasound estimation of fetal weight, biophysical profile and 
Doppler blood flow. Delivery was carried out when an adequate gestation was 
reached or when there was signs of either fetal distress or deterioration of the 
m aternal condition. The average length of therapy continued to be 15 days, ranging 
from 24 hours to 8 weeks as first found in the initial studies.
The hypertensive crisis
Severe hypertension is a crisis for the mother, fetus, paediatrician and obstetrician. 
The aim of therapy was to stabilise the m other to reduce the risks to her and allow 
either prolongation of the pregnancy or delivery of the fetus in a  controlled way. Any 
patient with a blood pressure above 160/110 mmHg, was given 200 mg of Labetalol. A 
fall of around 10/20 mmHg should be achieved within 60 mins. A further 200 mg was 
given as required. Alternatively, a slow intravenous injection of 50 mg labetalol was 
almost always successful in  reducing blood pressure. This w as followed by an 
infusion by a slow infusion pum p delivering a solution containing 300 mg of 
labetalol in 60 ml, or 5 mg per ml if further therapy was required. This infusion was 
started a t 12 m l/h r and increased or decreased depending on the blood pressure 
response. Control was normally achieved at a rate of between 24/48 m l/h r and we did 
not see any evidence of fetal distress in response to this regime. It is the author’s 
experience tha t once a patient was started on an intravenous infusion to control the 
blood pressure, delivery was required as it was rare to transfer control to  oral 
therapy.
The policy was to stabilise a ll patients with blood pressures above 160/110 mmHg 
prior to delivery or patient transfer as these are the times of great risk to the mother.
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This is particularly true if a  general anaesthetic with intubation is to be given. 
Therapy was continued after delivery as long as blood pressure control is required.
A single oral dose of nifedipine 10 mg or nicardipine 10 mg can also be used as the 
acute studies showed it to be effective. Occasionally, sublingual nifedipine was 
associated with sudden hypotensive reactions and oral therapy was safer.
Delivery
Delivery was carried out if there was any maternal or fetal reason. This was done in 
the best way on the best day. It was usually possible to plan this in collaboration with 
the paediatricians. If the patient is beyond 34 weeks, a vaginal delivery was aimed at. 
Before this gestation, or if there are signs of fetal distress, caesarean section would 
seem sensible to improve the fetal chances of survival. We found tha t the presenting 
gestation was the most important param eter affecting the fetal outcome. No baby 
bom  after 30 weeks gestation from a hypertensive mother has died in the last eight 
years. Most perinatal deaths are associated with low birth weight and early gestation 
as was discussed in Chapter 6.
Post delivery
After delivery, vigilance should be m aintained. Many of the m aternal deaths 
associated with th is condition occur after delivery. The dosage of hypertensive drug 
would usually be reduced in a stepwise process until it can be stopped. If the drugs are 
suddenly stopped, rebound hypertension can occur with the concomitant risks to the 
mother. Most of the drugs used are excreted in the breast milk but appear to be safe to 
use in b reast feeding mothers. Some patients became more hypertensive after 
delivery and were more difficult to control. In these situations enalapril was 
sometimes used. The starting dose was 2.5 mg twice a day, increasing in  steps until 
control was achieved. If patients did not settle after delivery, the diagnosis was 
reconsidered and the patient referred for further investigation and management.
The effect o f this therapy
Has th is therapy and these protocols been beneficial? The effects of therapy on the 
patient population cannot be separated from the other changes in  the management 
protocol, particularly the m atem al/fetal monitoring. The sum m ary of the results 
for the years 1980-89 are shown in table 10.14. The num bers of patien ts with 
persistent hypertension (diastolic blood pressure persistently above 90 mmHg) has 
remained constant over th is time. Overall only 15.27% of hypertensive patients 
received antihypertensive therapy. However, in the last 5 years th is has been about 
20% of the patients. Prophylactic anticonvulsants were used in  less th a n  100 
patients. Despite this the rate of eclampsia in hypertensive patients was only 9/4317 
or 1/438 during this period. This has reduced further to 1/577 since 1982, bu t this 
change was not significant.Therefore the change of m anagement regimes has not
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reduced the progression to eclampsia, but the risk appears to be small.
Perinatal mortality was only 7.2/1000 for all hypertensives over these ten years 
reducing to around 3/1000 in the last few years. If the years 1980-82 are compared to 
years 1983-89, there has been a statistically significant decrease from 14.07 to 4.25 
per 1000 hypertensives (pcO.OOl). Since the incidence of hypertension has not 
changed, the rate of hypertensive deaths per 1000 of all deliveries has also fallen 
(Fig. 10.13). Comparisons with the Scottish figures show th a t GRMH ra tes were 
higher earlier in  the decade bu t now have fallen to similar levels to the Scottish 
figures. This is in spite of the fact tha t apart from 1983, the GRMH figures for total 
PND rates have been consistently higher th an  the Scottish figures (pcO.OOl) (Fig.
10.14). If the percentage of PND associated with hypertension is considered (Fig.
10.15) it can be seen tha t the results from GRMH were higher in 1980-82 bu t since 
then  have been consistently lower. This was statistically significant (p<0.001). It can 
be concluded that there has been an dramatic improvement in the figures tha t are not 
seen in Scotland as a whole.
If the gestation at delivery is studied, it can be seen that there has been a reduction in 
the incidence of delivery of babies before 30 weeks (p<0.005), and a smaller change in 
the incidence of delivery less than  35 weeks (p<0.05) (Fig. 10.16). Prolongation of the 
pregnancy from below 30 weeks would allow increased m aturity for the fetus with 
improved survival. If the total perinatal mortality is split into stillbirth and early 
neonatal death (Fig. 10.17), it can be seen that there has been a reduction in stillbirth 
(p<0.05) and a more significant drop in neonatal deaths ( (p<0.005). (Statistics 
calculated by comparing years 1980-82 and 1983-89, Fishers exact test). Therefore 
the reduction appears to be related to stillbirth as well as neonatal death. This 
implies that, not only has prolongation of pregnancy reduced prematurity, b u t also 
improved monitoring may have led to judicious delivery. Perinatal death is now 
almost completely related to the sick premature baby (Chapter 6).
10.7 Discussion
Reluctance to adm inister antihypertensive drugs in pregnancy h as  arisen  from 
reports of possible detrimental effects on the fetus and neonate as discussed in 
Chapter 3. If antihypertensive therapy is going to be of benefit, it is when it allows 
stabilisation of the m other and prolongation of pregnancy.
These studies suggest tha t antihypertensive drugs are effective in lowering the blood 
pressure in pregnancy, although the num bers requiring treatm ent are relatively 
small. Delivery rem ains the only cure for established preeclam psia and  drug 
treatm ent should only be used to lower blood pressure to minimise the risks for the 
m other and help reduce the need to deliver the prem ature infant. The combined 
alpha/beta blocker labetalol appears to be well tolerated. It has the advantage th a t it
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can be used in the acute as well as the chronic situation but studies suggest that other 
drugs could also be used.. Lowering the blood pressure may moderate the progression 
of the disease but it does not stop it.
Severe preeclam psia presenting in  the m id-trim ester is associated with high 
perinatal morbidity and mortality. Aggressive management with early delivery may 
resu lt in  neonatal death or long term  disability from com plications of the 
prematurity. Conversely, attempts to prolong the pregnancy may result in  fetal death 
or asphyxial death in utero. It was seen in Chapter 6 tha t if the fetus is already 
compromised, there appears to be no benefit in prolonging the  pregnancy and 
delivery should be expedited. Therefore, even when blood pressure is stabilised, close 
monitoring of both the mother and the baby should be continued.
If antihypertensive drugs are of benefit, it should be apparent th a t more babies are 
now being saved. Without a properly controlled study, either with a  randomised 
group of patients receiving labetalol or not, or looking a t good cohort studies of 
before and after the addition of labetalol to the pharmacological armoury, it is 
impossible to say w hether the presence of labetalol has been detrim ental or 
beneficial. It would appear that there has been a dramatic improvement in perinatal 
mortality which has not been matched in the rest of Scotland. There is now a lower 
percentage of babies being lost in GRMH associated with hypertension th an  in  the 
rest of Scotland. There has also been reduction in delivery prior to 30 weeks. The 
reduction in perinatal death is as m uch due to a reduction in stillbirth rate  as 
neonatal loss. This would imply th a t the increased monitoring and judicious 
delivery, as well as antihypertensive therapy, have contributed in  lowering 
perinatal mortality.
Once delivery has been carried out, the m other may need continuing therapy for a 
num ber of weeks. If blood pressure does not settle following delivery, the diagnosis 
may need to be altered and the patient referred for further assessment.
10.8 Conclusions
The main conclusions from this chapter are:
1) A stepwise management protocol is easy to setup and practice.
2) Most p a tien ts  are low  risk  and  do not require h o sp ita lisa tion , 
antihypertensive drugs or anticonvulsants.
3) The risk of eclampsia is low.
4) Blood pressure can be controlled with ease in the majority of patients.
5) If the fetus is well, the pregnancy can be prolonged for an average of 15 days.
6) If there is evidence of fetal compromise, therapy has no benefit.
7) Premature delivery and perinatal m ortality can be reduced by using these 
regimes.
Chapter 11
D iscu ss io n
and
C on clu sio n s
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11.1 Discussion
Hypertension is a common abnormality occurring in about 15% of all pregnancies. 
Despite a general improvement in fetal and m aternal outcome, it is still a  major 
cause of maternal and fetal mortality and morbidity in this country and throughout 
the world.
A critical review of literature was carried out to assess the current state of knowledge 
concerning the presentation and management of pregnancy hypertension. Areas 
were then  chosen where there was either a lack or a discrepancy of knowledge and 
where further investigation might be fruitful. The aim was to clarify some aspects of 
the aetiology and presentation of the condition and to see whether it was possible to 
develop management protocols tha t could improve the outcome for mother and baby. 
The main areas of study were selected to assess various aetiological factors; look for 
special m arkers of increased risk in patients presenting with the condition; study 
various methods of monitoring both the m other and baby for signs of progression of 
the disease; assess the role of intervention therapy using antihypertensive drugs; and 
investigate the effect of th is therapy on the disease process and outcome of 
pregnancy.
The initial critical review of the available literature showed there were m ajor 
problems in  the definition of pregnancy hypertension. There w as no universal 
agreement on the method of diagnosis of hypertension or what level of systolic or 
diastolic blood p ressu re  m erited special care or intervention. There w as 
disagreement on whether the rise in blood pressure from a booking visit or the 
absolute level of blood pressure was more dangerous. The other problem of blood 
pressure measurement was the method of m easuring the diastolic blood pressure. 
The American literature generally accepts Phase V Korotkov sound diastolic whereas 
the British literature tends to favour the IV Korotkov sound. This obviously is a 
problem and there may be a difference of 5 - 10 mmHg of mercury between the IV and 
V sound. There is also a dispute over which position the patient should be in  while 
taking blood pressure. The importance of proteinuria was well documented although 
it was difficult to know w hat relationship proteinuria had to m aternal and fetal 
outcome. Oedema did not appear to be an important factor and therefore should be 
ignored in the assessm ent of the condition. Parity was seen to be im portant in  the 
diagnosis of pure disease as a primigravid with proteinuric hypertension is far more 
likely to be a  true preeclamptic than  a parous woman with hypertension. However, 
the fact tha t parous women can also have preeclampsia tends to be ignored in  most 
literature.
Eclampsia has had a falling incidence throughout the world. This has had a limited 
effect on maternal mortality as its importance as a m arker of severity of disease has
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probably been overstated. The risk to both mother and baby is more related to the 
degree of preeclampsia than  to the occurrence of an eclamptic seizure itself.
The whole area of preexisting hypertensive disease and the role of superimposed 
preeclampsia was extremely confused. As blood pressure rises in  late pregnancy 
anyway it is very difficult to be sure w hether a patient has true  superim posed 
preeclampsia or ju s t a worsening degree of preexisting hypertensive disease. All 
these  com plications make the  nom enclature of hypertension in  pregnancy 
exceptionally difficult.
It was concluded, tha t for the purpose of our investigations and in reference to other 
studies, tha t the term 'preeclampsia' would be used solely for the primigravida w ith  
hypertension occurring for the first time during pregnancy and generally with 
proteinuria. All other forms of hypertension would be termed 'pregnancy-induced 
hypertension', u n less a known preexisting hypertension su ch  as  essen tial 
hypertension or renal disease was present.
In studying the available literature on the aetiology of pregnancy hypertension I 
found th a t there were major degrees of overlap as various people were investigating 
various epiphenomena which were interrelated. They then would associate cause and 
effect with these changes, despite the fact th a t they are probably ju s t  m arkers of 
disease process. There are, however, various absolutes which m erit fu rther 
investigation.
1) There was a definite suggestion tha t preeclampsia was a hereditary disorder 
(Chesley and Cooper, 1986).
2) The epidemiology of the disease suggests tha t it has a strong immunological 
basis since it affects primigravid ra ther th an  parous women (MacGillivray, 
1961) and factors such as blood transfusion appear to protect against disease 
development (Feeney, Tovey and Scott, 1977).
3) When the disease presents it appears to be associated with definite placental 
pathology which is not unique to preeclampsia b u t also is associated with 
intrauterine growth retardation (Sheppard and Bonnar, 1981).
4) In the presence of proteinuria there is a specific renal lesion which can  be 
used as an absolute diagnostic marker of preeclampsia (McCartney, 1964).
5) There is strong evidence th a t there is increased vascular reactivity which 
appears to be present prior to the development of the disease itself (Gant et 
a t, 1973).
6) This vascu lar reactivity may be associated w ith p rostag land in  and 
thromboxane imbalance (Downing, Shepherd and Lewis, 1980) which also 
would tend to increase platelet consumption, a sign which is well recognised 
in preeclampsia (Redman, Bonnar and Beilin, 1978).
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On investigating the current information on the risks of pregnancy hypertension to 
the mother and fetus, it became obvious that most of the literature was historical and 
th a t the risk  of death to the m other in the w estern world from hypertension in 
pregnancy is now not much greater than  the risk of dying in pregnancy in  general. 
However, it was also obvious tha t there had been little reduction in m aternal death 
from hypertension in pregnancy over the 20 years from 1960 to 1980 (Turnbull, 
1987).
As far as the baby is concerned, there has been a gradual improvement of outcome. 
This has mostly been due to improvement in neonatal care for the smaller baby. This 
produces a  clinical dilemma. Although the potential outcome of hypertension in 
pregnancy can be catastrophic, for both m other and baby, the majority of patients 
now do well.
The literature on the management of hypertension in  pregnancy was also mostly 
based on historical knowledge or came from centres seeing patient types quite 
different th an  those seen in Glasgow. Bed rest has rem ained the  m ainstay  of 
hypertension management since the 1950's (Hamlin, 1952). The use of sedation and 
anticonvulsants was geared towards the time when eclampsia was seen as the main 
risk to the mother. Antihypertensive drugs have only more recently been introduced 
in routine management of this condition. Delivery is still seen as the only option by 
m any in cases of severe hypertension with proteinuria and no attem pt is made to 
stabilise the condition or prolong pregnancy.
Antihypertensive drugs initially were thought to be dangerous and associated with 
intrauterine death. More recently, a large num ber of studies with a  wide variety of 
drugs have shown th a t antihypertensive drugs can be used w ithout harm  within 
pregnancy. Studies have been started on the use of aspirin as an  antiplatelet agent in 
trying to prevent the development of preeclam psia. The in itial re su lts  are 
encouraging but the outcome of the large multi-centre studies are still awaited.
It was obvious after this critical review of the literature that it was important;
1) to study the absolute risk of hypertension in pregnancy as seen in  our own 
hospital.
2) to assess the problems of disease presentation to see whether it was possible 
to distinguish those who are at increased risk of m atem al/fetal problems and 
those who are not.
3) to investigate the use of the routine investigations to see w hat information 
they can give us about disease development
4) to concentrate on certain areas of aetiological significance.
In order to investigate the changing risk to the m other and baby of hypertension in
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pregnancy I reviewed 50 years of eclampsia at the Royal Maternity Hospital. I chose 
eclampsia as a disease marker because it was ‘hard’ and I could be relatively sure of 
the accuracy of the diagnosis whereas the diagnosis of hypertension is less reliable. I 
found tha t there had been a dramatic fall in the incidence of eclampsia from the mid 
1930’s to the early 1980’s. Although this fall had been gradual and consistent, there 
was an  increased reduction at around 1950. This coincided with the advent of the 
National Health Service and also the introduction of bromethol as a  m ethod of 
prophylaxis and treatm ent in patients with severe hypertension an d /o r eclampsia. 
There were 537 cases of eclampsia from 1933 to 1942, similar to numbers still seen in 
the third world (Lopez Llera, Linares and Horta, 1976). There were only 19 between 
1973 and 1982, figures compatible with others seen in th is country (Templeton and 
Campbell, 1979). Over the study period, 45% of the eclampsias occurred antenatally, 
35% intrapartum  and 20% postpartum. In recent years, there h as been a relative 
increase in the proportion of postpartum  eclampsia.
There were 74 m aternal deaths in the first decade or about 14% of all eclamptics. 
There was only 1 m aternal death in the last decade which is about 5% of all 
eclamptics. Therefore, not only has the incidence of eclampsia fallen dramatically, 
the m aternal deaths from eclampsia have also fallen over th a t last 50 year period. 
This implies tha t the risk of eclampsia is now far lower in our practice th an  in  other 
parts of the world. This has implications concerning the treatm ent of preeclampsia. 
The majority of m aternal deaths were associated with antepartum  eclampsia and 
th is is usually related to the degree of preceding preeclampsia. Although the num ber 
of babies lost to mothers with eclampsia has fallen, one-third of the babies bom  to 
i m others with eclampsia in the last decade died. These figures are similar to the 
incidence in the first decade. This again is almost exclusively related to antepartum  
eclampsia, premature delivery or abruption. The conclusions from th is  study were 
tha t there has been a gradual improvement in the outcome of eclampsia over the last 
50 years. The last m aternal death  in  the Royal M aternity H ospital from 
hypertension in pregnancy was in 1964. This is almost in spite of any changes in 
therapy, although the use of bromethol and later other sedative drugs to try  and 
stabilise the eclamptic appear to have had some beneficial effect. It would appear to 
be logical to move away from sedative therapy and concentrate on antihypertensive 
therapy in the first instance. If anticonvulsant therapy is to be used, a  true  
anticonvulsant would appear to have some advantages.
I then  went on to study the presentation of the disease in the present day. Initially, I 
looked a t blood pressure variability. The serial study confirmed the normal fall in  
blood pressure in the second trimester, bu t the parous women did not have the same 
rise in the blood pressure in the third trimester. Therefore a diastolic blood pressure
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of 90 mmHg a t 32 weeks is more ‘abnorm al’ in a parous woman th a n  in a 
primigravida. A study at the antenatal clinic of 300 patients showed th a t over 60% of 
patients had a blood pressure variation of more than  5 mmHg in both systolic and 
diastolic blood pressure when 2 m easurem ents were taken 10 m inutes apart. The 
direction of variation depended on the level of blood pressure. There was a tendency 
to move towards the mean. I then  went on to study repeated blood pressure 
m easurem ents to see whether an average of several readings could give me a more 
accurate assessm ent. I again confirmed the blood pressure variations were quite 
m arked on repeated blood pressure  m easurem ents. Once 4 blood pressu re  
m easurem ents had been taken and meaned, a fifth blood pressure reading did not 
change tha t m ean by more than  about 1 - 2  mmHg. Therefore, an  average of 4 blood 
pressure readings appeared to give an accurate estimate of a patients’ ‘true’ blood 
pressure. Variation in blood pressure has been documented before (Redman, Beilin 
and Bonnar, 1977a; Mumaghan, 1987), bu t methods of correcting for it have not. I 
also studied the use of automated blood pressure monitoring and showed similar 
variations to th a t found by nursing staff. The Dinamap automatic blood pressure 
recording tended to measure the diastolic blood pressure at about 8 mmHg lower than  
th a t found by the attendant nursing staff. This is probably due to the difference 
between the m ethods of diastolic blood pressure determ ination. The Dinamap 
records a diastolic blood pressure between the IV and V sound, whereas the nursing 
staff are taught to use the IV sound. Following this, I routinely used an  average of 4 
blood pressure readings taken over a space of a few hours for outpatients and over the 
space of a day for inpatients as a m arker of a patient's blood pressure. I concluded 
that a single blood pressure reading should not be used as a method of diagnosis or of 
making management decisions. It would appear to be reasonable to use single blood 
pressure readings if epidemiological studies are being done.
Based on this philosophy, I conceived and developed an  outpatient day assessm ent 
area to assess patients thought to be a t risk of hypertension, with more accuracy. The 
day care unit started in a small way in 1981 and has gradually expanded to accept 
patients from all consultants in  Glasgow Royal M aternity Hospital. At the day 
assessm ent unit, not only was blood pressure monitored, bu t also uric acid levels, 
platelet counts and proteinuria were estimated in the assessm ent of m aternal risk. 
Fetal risk  was assessed by cardiotocography and ultrasound. I found tha t, in  the 
patients assessed at daycare, uric acid was rarely elevated and levels generally 
rem ained within the normal range. It was only after th is monitoring had been 
carried out and abnormalities discovered and assessed th a t the patien ts were 
selected for the possibility of admission to hospital, and for investigations of early 
intervention therapy, in an  attem pt to control the disease process. Using the 3
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param eters of blood pressure, uric acid and platelet count it was found that, If these 
were all within the normal range at day care, there was a  95% chance th a t these 
patien ts would rem ain norm al throughout the res t of the ir pregnancy. This 
constituted approximately 50% of all patients who attended the day care unit. If any 
of these param eters were elevated, the patients were then  seen back for repeated 
estimations at day care. It was generally found that they would progress to a  more 
severe form of the disease over a period of time varying from days to weeks. If, a t 
initial assessm ent, they were thought to be at high risk, with the presence of a 
diastolic blood pressure m easurement of over 100 mmHg, elevation of uric acid, a 
reduced platelet count or with the presence of proteinuria, these patients were 
brought back  to Daycare for closer monitoring. If the m atem al/fe ta l risk  was 
thought to very high, patients were admitted to hospital.
Overall I found tha t 60% of the patients referred to day care attended only once with 
the majority of them  returning to the antenatal clinic for routine care under their 
referring consultant. About 20% of the patients attended day care on a  regular basis 
for day care management because they were thought to be at high risk. A further 20% 
were admitted to hospital for more intensive care, either after the first Daycare 
attendance or after further day assessments. Therefore, the diagnosis of normality 
can be increased. The diagnosis of risk was still overused bu t greatly improved.This 
form of management has reduced the number of admissions and num ber of inpatient 
days spent because of hypertension. It has allowed more intensive monitoring and 
care to be given to patients who appear to require it.
The routine investigations of blood pressure, uric acid, platelet count, liver function 
tests and proteinuria were all assessed for evidence of association with each other 
and the outcome parameters of the pregnancy. It was found that the three m easures of 
renal involvement were not directly related. Using multiple regression analysis, I 
found tha t proteinuria appeared to be a specific abnormality unassociated with the 
other parameters. It seems likely tha t proteinuria is a marker of ‘true’ preeclampsia 
and therefore associated with higher risk. It was also inversely associated with the 
delivery gestation. This implies tha t the earlier the gestation a t presentation, the 
h igher the incidence of proteinuria. These findings m ake the  relevance of 
proteinuria difficult to  assess. If present, the  diagnosis is more likely to be 
preeclampsia and the gestation early. Both these factors will increase the risk to the 
fetus. The level of proteinuria does not appear to change the risk. Therefore, it would 
seem possible that the presence of proteinuria is associated with the pregnancies at 
higher risk rather than  proteinuria being a risk factor itself. Hence the association 
of proteinuria with increased perinatal mortality (Friedman and Neff, 1975).
Uric acid was associated negatively with platelet count and positively with
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abnormalities of Ast. These results suggest tha t elevations of uric acid are associated 
with general abnormalities of cellular dysfunction or damage as seen in increasing 
platelet consum ption and elevation of Ast. Therefore, uric acid is not purely a 
m arker of renal involvement in preeclampsia bu t it appears to be a  reasonably 
accurate m arker of systemic involvement. Patients with elevation of uric acid are 
more likely to have progressive problems and require closer monitoring. Chesley 
(1985) states tha t the presence of hyperuiicaemia is important for the accuracy of the 
diagnosis of preeclampsia. These findings would appear to support th is statement. 
The results concerning serum  albumin are interesting and support the idea of this 
being a m ultisystem  disorder. Albumin levels will a lter with changes in  liver 
function, renal function and haemodynamic changes, particu larly  capillary 
permeability. Many of the complications of the condition can be blamed on changes 
in serum albumin (Cope, 1961; Brown, Zammit and Lowe, 1989; Gallery, Hunyor and 
Gyory, 1979). Albumin replacement has been advocated in the management of this 
condition (Boekkooi, Verkeste and Peeters, 1991) b u t it is not w ithout hazard 
(Kirshon et a l, 1988). The factors tha t cause the reduction of the level of serum  
album in will tend to reduce any benefit th a t albumin infusion will bring. It was 
interesting tha t the level of albumin was independently inversely related to the birth 
weight. This supports the finding th a t patients with oedema have larger babies 
(MacGillivray and Campbell, 1980). This may be due to ‘oedema’ of the baby 
secondary to reduced maternal osmolality.
The outcome of the pregnancies was related to the gestation a t delivery. Babies 
delivered after 30 weeks did well. This would support the policy of trying to prolong 
the pregnancy in an attempt to improve the fetal outcome. The baby has to be in good 
condition before th is  is possible. This may also contribute to the ir improved 
outcome. Growth retardation is associated with later onset disease, not the  acute 
onset early disease.
It was disappointing th a t the booking param eters did not relate strongly to the 
disease param eters. It has previously been suggested th a t the level of booking 
haemoglobin affects the chances of developing preeclampsia (Murphy et aL, 1986). 
There appeared to be no association between booking haemoglobin and disease 
severity, bu t there was with weight centile.
More specific investigations were also carried out into the platelet-vessel wall 
interaction. Three separate studies were carried out into alterations of platelet size. 
The first investigation was to look at platelet size throughout normal pregnancy and 
I showed th a t platelet size tended to increase in pregnancy towards term. It was 
therefore important when monitoring the effect of hypertension in pregnancy to use 
gestation matched controls as the normals, something th a t had not been done in
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previous studies of hypertension in pregnancy and platelet size (Giles, 1981). I found 
th a t acute hypertension developing before 34 weeks was not associated with an 
increase of platelet size. Severe hypertension developing after 34 weeks was 
associated with increased platelet size, with some levels quite markedly increased 
above the normal level for th a t gestation. My conclusion from this was th a t patients 
developing preeclampsia at less than  34 weeks tend to have an  acute onset disease 
process without any prodromal signs. On the other hand, those developing severe 
preeclampsia later in  pregnancy would appear to have a longer disease development, 
which will lead to a  longer stim ulus to platelet activation and increased platelet 
turnover, leading to increasing platelet size.
In order to investigate this theory, I looked at two groups of patients thought to be at 
risk of worsening hypertension. One was a group of primigravidae and the other was 
a group of essential hypertensives. I have found th a t in the patients who had 
progressive disease they had progressing enlargement of platelet size, whereas those 
who remained stable had platelet size tha t remained within the normal range. I also 
showed th a t those whose platelet size was less th an  the m ean of the group did not 
develop severe preeclampsia. These figures suggest th a t all the patien ts who 
developed severe disease had evidence of early platelet consumption as illustrated by 
a higher th an  average initial platelet volume and increasing platelet volume with 
time. In most of the patients the increasing platelet size occurred prior to the onset of 
the hypertension itself. This confirmed th a t platelet consum ption is an  early 
manifestation of the condition (Redman, Bonnar and Beilin, 1978). This progressive 
development of platelet consumption could be the explanation of growth retardation. 
If the disease presents early, there has been no chance for the platelet deposits in  the 
placenta to cause growth problems.
Associated studies were carried out on prostacyclin levels. Again initial studies were 
conducted to look at the changing prostacyclin and thromboxane levels throughout 
pregnancy. In normal pregnancy I found the prostacyclin levels were higher in  the 
first trim ester and then  fell during the third trimester,. Thromboxane fell during the 
second and third trimester and further in the puerperium. Studies in hypertensive 
patients showed th a t in patients with severe disease, nearly all had unrecordable 
levels of prostacyclin (<5 ng/ml). About 50% of those with moderate disease also had 
unrecordable levels, although the other 50% had levels within the norm al range. 
Thromboxane did not appear to be elevated in patients with severe disease unless 
there was evidence of a large degree of platelet activity. I conclude from these studies 
tha t although the prostacyclin/thromboxane balance is disturbed it is mostly due to 
deficiency of prostacyclin, rather than  elevations of thromboxane.
A serial study was carried out in a group of high risk  primigravidae. It was
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discovered th a t the group of patients who went on to develop hypertension in 
pregnancy had a higher level of prostacyclin th an  average, which then  fell to 
unrecordable levels ju s t before hypertension appeared. This suggests tha t there was 
an  increased stim ulus in these patients to produce prostacyclin in early pregnancy. 
This ability to respond appeared to be exhausted leading onto development of the 
hypertension itself. This suggests tha t there was a substance, or substances which 
interfered with prostacyclin production.
These studies may well agree with the studies on platelet activation. Patients who 
present with early disease, with sudden preeclampsia and sudden fall in  platelet 
count, may well have absolute deficiency of prostacyclin. Those tha t develop severe 
disease over a period of time in later pregnancy initially have the ability to produce 
prostacyclin to protect themselves. This ability and protection slowly diminishes 
with time, increasing platelet consumption and leading to the development of severe 
preeclampsia. I feel tha t prostacyclin deficiency is not the underlying cause of the 
disease, bu t may well be responsible for many of the clinical m anifestations seen 
and the patient’s own ability to respond to the stim ulus and the disease process. 
Absolute deficiency of their ability to produce prostacyclin will lead to an  early onset 
severe disease often presenting at 28 - 30 weeks. Relative inability or an  exhaustion 
of the ability to produce prostacyclin will tend to produce progression to severe 
disease over time. Thromboxane does not appear to have an  early role in the disease 
and it is likely to be a marker of increased platelet activation.
These studies confirm the studies suggesting tha t there are abnormalities of platelet 
and prostacyclin interaction as described in Chapter 3. These have led onto the idea 
of using low dose aspirin as a treatment, either to prevent preeclampsia or attenuate 
its progress (Beaufils, Donsimoni and Colau, 1985; Wallenburg e ta l,  1986). The logic 
is th a t aspirin will act by blocking the action of the cyclo-oxygenase enzyme system. 
The problem is tha t it will affect both prostacyclin and thromboxane production. 
The use of ‘low dose’ aspirin is an  attem pt to prevent this. Most of the aspirin is 
metabolised in the liver. This m eans tha t only the platelets in the portal circulation 
are affected. More work is required to elicit whether this therapy really is of benefit. 
There is also the concern of the effect on platelet function. If bleeding time is 
prolonged beyond the physiological limits, there are potential risks w hen using 
epidural cannula. The multicentre studies are awaited with interest.
In the patients who were admitted to hospital with persistent high blood pressure, I 
investigated the role of antihypertensive therapy. I initially looked a t the acute 
hypertensive situation. I studied three separate  m edications; the  standard , 
hydrallazine 10 mg I.M.; 200 mg oral labetalol; and 10 mg oral nicardipine. These 
studies showed that all three medications could adequately reduce the diastolic blood
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pressure over a period of 30 minutes to 1 hour. This reduction was m aintained over a 
period of a t least 2 hours. The systolic blood pressure was not well controlled by 
either hydrallazine or nicardipine, bu t was by labetalol. These studies showed that 
oral medication, using either labetalol or nicardipine, is perfectly adequate in 
reducing blood pressure in the acute situation without resorting to parenteral drugs. 
This has become the standard method of treatm ent for patients with high blood 
pressure in  the Glasgow Royal Maternity Hospital. If they could take oral therapy, 
200 mg oral labetalol was the first line therapy.
A further randomised study was carried out using labetalol against bed rest in 
patients with mild to moderate disease. Because the entry criteria required the 
patients to have persistent hypertension after 4 days of hospital bed rest it was 
actually very difficult to collect the 120 patients used in the investigation. The 
majority of patients with mild to moderate disease did appear not to fulfil the given 
criteria. The results of the investigation showed that, after inclusion into the study, 
bed rest alone did not lower blood pressure or slow the progression of the disease. 
Labetalol therapy significantly reduced blood pressure and appeared to slow the 
progression of some of the disease parameters, assessed by blood pressure, platelet 
consumption and proteinuria. There was also an  increased num ber of patients in 
whom blood pressure was stabilised or reduced on therapy. This is not surprising as 
th a t was the point of the therapy. There was no difference in the outcome of the 
pregnancies between the two groups. Since the bed rest patien ts were given 
antihypertensive therapy if their blood pressure progressed to the severe stage, it is 
difficult to assess the potential benefit of early intervention therapy. It would appear, 
however, that if patients had a diastolic blood pressure below 100 mmHg they did not 
benefit from early therapy. In only 30% of the patients treated with bed rest alone, 
did the blood pressure rise to over 100 mmHg with time. These patients could be 
adequately controlled with antihypertensive drugs if th is was thought necessary. 
Therefore, patients with diastolic blood pressure between 90 and 100 mmHg were not 
thought to be a problem. However, they should be monitored relatively closely as 
outpatients. If their diastolic blood pressure rose further to above 100 mmHg, they 
should be admitted to hospital for closer assessment. Antihypertensive drugs should 
be used if th is  is thought necessary. There is no evidence th a t use of these 
medications causes any harm  to the mother or baby. This study agrees with others in 
the literature tha t showed no apparent benefit, bu t did show a significant increase in 
the num ber of patients stabilised, and a reduction of progression to severe disease 
(Sibai etaL , 1987; Pickles, Symonds and Pipkin, 1989).
A further study of patients with severe hypertension was also carried out. This was a 
group of 186 primigravidae with diastolic blood pressures over 100 mmHg with the
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presence of proteinuria of a t least 0.3 g /2 4  hours. Long term  reduction of blood 
pressure can be achieved in virtually all patients using either labetalol alone, or a 
combination of labetalol and a vasodilator, which initially was hydrallazine, bu t 
more recently was nifedipine. The average length of treatm ent was over 15 days. This 
suggests th a t a significant prolongation of pregnancy is possible in nearly all cases 
of hypertension in pregnancy. The study showed tha t there was no detriment to the 
fetal heart rate pa tterns or blood flow param eters as m easured by Doppler 
velocimetry w ith com m encem ent of therapy. However, a  breakdow n of the  
monitoring of the fetus showed tha t in looking at pregnancies presenting after 30 
weeks, virtually all the babies did well, w hereas the majority of the  perinatal 
mortality occurred with presentation less than  30 weeks. This is almost completely 
due to the fact tha t after 30 weeks, if there was any sign of abnormality on fetal 
monitoring, delivery could be expedited. These babies now do well in  m odem  
neonatal units. In babies presenting at less than 30 weeks, there was no evidence that 
fetal outcome was predicted by any additional form of m aternal monitoring, 
including uric acid, blood pressure, proteinuria, or platelet count. Poor fetal outcome 
was associated with evidence of fetal distress, i.e., abnormalities of fetal heart rate 
pa tte rn  or Doppler u ltrasound abnormality or u ltrasound evidence of growth 
retardation. Therefore, if a baby was well a t presentation, lowering the blood 
pressure was not detrimental to fetal wellbeing. Pregnancies could be continued for 
approximately 2 weeks. If, on the other hand , there was evidence of fetal 
compromise, controlling blood pressure did not appear to improve the  fetal 
condition. Babies may die in utero. This leads to a clinical dilemma in those patients 
who presented early. If they are delivered, the babies often died neonatally because of 
prematurity. With the improvement of the neonatal care units, these problems will 
further reduce. What is clear is tha t the fetal wellbeing is not directly related to the 
wellbeing of the mother. The fetus requires direct monitoring. Separate decisions are 
required in order to improve the outcome of the baby. Even if the results of the fetal 
monitoring were poor, successful outcomes were possible and the baby should rarefy 
be “written off.
Over the last 9 years 3,885 hypertensive patients have been reviewed. Only 7 patients 
have progressed to convulsion, giving a seizure rate of 1 in 577 hypertensive patients. 
I do not use prophylactic anticonvulsants unless there are obvious signs of severe 
progressive hypertension with evidence of imm inent eclampsia. These figures 
suggest tha t the incidence of eclampsia in patients with preeclampsia is very low, 
and therefore I feel there is no need for routine use of anticonvulsant therapy in  this 
patient group. However, I do have available a protocol for anticonvulsant therapy in 
labour ward to be used by the attendant staff if it is thought necessary (Ryan, Lange
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and Naugler, 1989).
In reviewing the results of these management changes, it is difficult to judge what 
benefits each may have brought. There is no doubt tha t the perinatal survival has 
improved over the years and now is at least as good as the rest of Scotland. Whether 
th is is due to improved monitoring, antihypertensive usage, a  specialised team, well 
practised protocols or a combination of some or all of these, is difficult to assess. 
These results do support the argument for specialist teams to manage these problems 
(Turnbull et aL, 1989).
Can a  more accurate diagnosis be made?
The primigravid proteinuric hypertensive is almost certainly preeclamptic. The 
presence of proteinuria, hyperuricaemia and /o r thrombocytopenia will increase the 
chances of significant disease. Intrauterine growth retardation is more likely in  the 
presence of abnorm alities of these m aternal param eters. In the  absence of 
proteinuria, hyperuricaemia or thrombocytopenia the hypertension will be almost 
certainly of a benign nature for both mother and baby.
11.2 Conclusions
1) A logical stepwise approach to the management of hypertension in pregnancy 
is possible.
2) The majority of patients who present with diastolics greater th an  90 mmHg 
are of low risk and can be managed as outpatient w ithout the  need for 
intervention.
3) Patients who have blood pressures persistently greater than  100 mmHg can be 
treated safely with antihypertensive therapy as long as the baby is well.
4) Prolongation of the pregnancy is generally possible.
5) This approach was associated with a  reduction of hospital adm ission, 
reduction of intervention and an overall reduction in the perinatal mortality 
rate associated with hypertension in pregnancy in our hospital.
6) Many of the benefits achieved are a resu lt of the development of the  
hypertensive team  and standardised protocols used  in  the  stepwise 
management of this condition. It is felt tha t these could be a model for other 
units to follow.
7) In the absence of proteinuria, hyperuricaem ia or throm bocytopenia the 
hypertension will be almost certainly of a benign nature for both m other and 
baby.
8) Our aetiological investigations suggest that, how a patient presents, how they 
progress and how severe they become, is largely dependent on the platelet- 
vessel wall interaction.
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These abnormalities are probably mediated through the prostacyclin system. This 
also may relate to the vascular activity in the hypertension which then ensues. There 
is evidence, however, from the studies with uric acid, tha t there may be widespread 
cellular abnormalities. These may be more widespread than  specifically against the 
platelet-vessel wall endothelium.
These studies have not established the trigger to the development of preeclampsia but 
have outlined the new areas of research which have developed from this work
11.3 The future.
The work in th is thesis reports the completion of the studies as outlined in the 
previously described objectives. I now have more understanding of the disease 
processes, presentation and management. These studies will allow a more accurate 
diagnosis of preeclampsia to be made. This will allow selection of the patients at 
risk for further study and to reduce the intervention in those not at risk.
However, it covers only a proportion of the questions raised by the literature review 
and the work carried out has raised an increasing num ber of questions. Additional 
studies into areas such as genetics, immunology, haematology and m em brane 
stability, in pregnancy hypertension, are being developed to increase, yet further, 
knowledge into this complex condition.
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7Field Bytes Field Bytes
Name 0-14 Unit Number 15-17
Date of Birth 18-20 Parity 21-22
Attendance Date 23-25 Attendance Number 26
LMP 27-29 BDD 30-32
Gestation 33 Date of Referral 34-36
BP at referral 37-38 Booking BP 39-40
Booking Gestation 41 28 week BP 42-43
Consultant 44 Referred From 45
Referred for 46 BP’s 1-5 47-56
Dinamap BP 57-58 Average BP 59-60
Urea 61 Urate 62
Haemoglobin 63 Platelet Count 64
Proteinuria 65 Cardiotocograph 66
Fetal Heart Rate 67 Place of Followup 68
Date of Followup 69-71 Diagnosis 72
Table 2.1
A byte map of the Daycare file showing all the data that was stored and available for 
analysis. The data was stored in compacted format. The whole record was only 72 
bytes long allowing over 3000 records stored on one floppy disc. This is the 
equivalent of 18 months data from Daycare.
VISIT 1 Consultant - LUNRN
Name - I NEILLV Para 0+0 Gestation 37+2 Date 18/09/89
Unit No. 134009 DOB 28/01/62 LMP 30/12/88 EDD 07/10/89
This patient was refered from the GENERAL PRACTITIONER on 13/09/89 
Reason for referal was PREGNANCV HVPERTENSION. Blood pressure was 150/085
Blood pressure at 12 weeks was 110/080 
Blood pressure at 28-30 weeks was 115/080
The patient was seen at Day Care on 18/09/89 5 days after referal
1) Blood Pressure - 140/080 Urea - 2.6
2) Blood Pressure - 130/082 Urate - 310
3) Blood Pressure - 140/085 Haemoglobin - 12.2
4) Blood Pressure - 142/088 Platelet Count - 240
5) Blood Pressure - 150/095 Proteinuria - None
Average Blood Pressure - 140/086 Card i otocograph - REACTIVE
Dinamap Blood Pressure - 000/000 Fetal Heart Rate - 150
The diagnosis at Day Assessment was Mild PIH 
Follow up will be at DRV CARE on 22/09/89 
< 4 days after the Day Care attendance)
Table 2.2
The print out from the Daycare programme that is placed into the case notes. This is 
a false name although the data is genuine. This allows the patient's consultant to 
have the full monitoring information. Despite having a blood pressure of 150/95 at 
the antenatal clinic, th is patient is clearly low risk  with a low average blood 
pressure and normal uric acid and platelet count. The significance of these tests will 
be discussed later.
9Diastolic Weeks Gestation
BP mmHg 24-27 28-32 33-34 35-36 37-38 39-41
65-74 8 7 6 4 5 5
75-84 10 8 6 6 4 3
85-94 9 9 8 6 5 5
>95 26 21 19 16 9 9
Table 3.1
F e t a l  loss ra tes per 1000 b irths associated with diastolic blood pressure and 
gestational age taken from a study of 35486 pregnancies by Friedm an and Neff 
(1977). The increase in fetal loss rate seen in  association with diastolic blood 
pressures above 95 mmHg was significant (p<0.01) in  all gestations although the 
difference was less in gestations above 36 weeks. This is true despite the fact the 
num bers in the earlier gestation group are inevitably small.
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No of No Of Perinatal M ortality
Women Perinatal Deaths rate/1000
Normotensive 10787 207 19.2
Preeclampsia Mild 2459 48 19.5
Moderate 610 11 18.1
Severe 830 28 33.7
Total 14686 294 20.0
Table 3.2
Data from the British Birth Survey showing th a t the perinatal m ortality is 
increased only in association with severe proteinuric preeclampsia (Chamberlain 
et aL, 1978). It is im portant to note th a t even in  these patients the perinatal 
mortality is only 175% of normal and in  96.6% of the pregnancies the  fetus 
survived.
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Weeks Gestation
Proteinuria No 24-27 28-32 33-34 35-36 37-38 39-41
None 15365 10 10 8 6 5 4
Trace 6631 14 11 11 10 8 10
+ 2712 14 6 10 16 11 6
++ 597 26 40 44 17 25 41
+++ 183 71 58 56 24 19 22
Table 3.3
Fetal loss rates per 1000 births associated with proteinuria without hypertension 
by gestational age taken from a study of 35486 pregnancies by Friedman and Neff 
(1977). The increase in fetal loss rate seen in association with proteinuria alone was 
seen in all gestations. The highlighted figures are significantly different (pcO.OOl). 
The relevance of these findings is difficult to assess. Unfortunately, the authors 
took a diastolic of 95 mmHg as the cut of point of hypertension. Some of these 
patients may have had a diastolic blood pressure of between 90 and 95 mmHg and 
would have been classified as severely hypertensive in  m any centres with the 
presence of proteinuria. The num bers associated with 3+’s of proteinuria were so 
small tha t the results were not statistically significant.
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D iastolic Proteinuria
BP mmHg None Trace + ++ +++ ++++ Total
<65 15.5 13.64 6.20 - - _ 13.60
65-74 9.30 8.06 5.58 32.86 41.54 - 8.84
75-84 6.20 7.44 6.20 19.22 - - 6.80
85-94 8.68 9.30 23.56f - 22.32 - 10.20
95-104 19.22f 17.36f 26.66f 55.80f 115.32f 143.22f 25.16
105+ 20.46f 27.90f 62.62f 68.82f 125.24f 110.98f 41.48
Total 8.60 9.46 12.94 23.22 41.96 56.76
Table 3.4
Fetal loss rate per 1000 births by diastolic blood pressure and proteinuria. This 
data was taken from a study of 58906 pregnancies by Friedman and Neff (1976). The 
figures marked with a t  are significantly increased (p<0.01). It can be seen that, 
although, each param eter appears to exert an independent influence, the diastolic 
blood pressure is the major factor associated with increased fetal loss.
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Preeclampsia
None Mild Proteinuric
Pregnancy (number) % % %
First (5124) 71.4 23.1 5.5
Second (4445) 86.1 12.5 1.4
Third (2726) 88.8 9.9 1.3
Four or more (3060) 88.6 10.2 1.2
Table 3.5
The percentage of patients with preeclampsia by parity. These are figures from 
Aberdeen quoted in MacGillivray (1983). After the first pregnancy, there appears to 
be a  constant background incidence of both mild and proteinuric disease. 
Therefore, the existence of preeclampsia in parous women is possible although less 
likely.
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Preeclampsia
None Mild Protein
Pregnancy % % %
First Subsequent 74.2 21.1 4.7
Second Subsequent 88.1 10.2 0.8
Third Subsequent 92.2 7.0 0.8
Fourth Subsequent 86.7 13.3 0
Table 3.6
Incidence of preeclampsia In the subsequent four pregnancies in 128 patients with 
preeclampsia in their first pregnancy. These figures are from Aberdeen quoted by 
MacGillivray (1983). The incidence of preeclampsia appears to be higher th an  
expected in the first subsequent pregnancy, being equal to the incidence in  
primigravida. After this, the incidence is no different th an  patien ts of sim ilar 
parity.
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Edema
Proteinuria
Systolic BP 
Diastolic BP
gm%
‘Stix’
0
no
<0.5
n il
<140
<90
1 2
pretibial generalised
0.5-2
+
140-160
90-100
2-5
++
160-180
>5
+++
>180
100-110 >110
Table 3.7
The definitions used by Organisation Gestosis. The patient is then  classified by 
score such as E 1P2 H2 for someone with pretibial edema, between 2-5 gm% of 
proteinuria and a blood pressure of 160-180/100-110 mmHg.
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A. GESTATIONAL HYPERTENSION AND/OR PROTEINURIA
Hypertension an d /o r proteinuria developing during pregnancy, labour or the 
puerperium  in a previously normotensive nonproteinuric women and subdivided 
into
1. Gestational hypertension fwithout proteinuria!
a) developing during pregnancy (antenatal)
b) developing for the first time in labour
c) developing for the first time in the puerperium
21 Gestational proteinuria (without hypertension)
a) developing during pregnancy (antenatal)
b) developing for the first time in labour
c) developing for the first time in the puerperium
31 Gestational proteinuric hypertension fpreeclampsiai
a) developing during pregnancy (antenatal)
b) developing for the first time in labour
c) developing for the first time in the puerperium
B. CHRONIC HYPERTENSION AND CHRONIC RENAL DISEASE
Hypertension a n d /o r  proteinuria in pregnancy in  a wom an w ith chronic 
hypertension or chronic renal disease diagnosed either before or during or 
persisting after pregnancy and subdivided into
1) Chronic hypertension (without proteinuria)
2) Chronic renal disease (proteinuria and hypertension)
31 Chronic hypertension with superimposed Preeclampsia
(Proteinuria developing for the first time during pregnancy in a woman with 
known chronic hypertension)
C. UNCLASSIFIED HYPERTENSION AND/OR PROTEINURIA
Hypertension and /o r proteinuria found after
a) at first “booking” examination after the 20th week
of pregnancy (140 days) in a woman without known chronic hypertension or 
chronic renal disease
or
b) during pregnancy, labour or the puerperium where information is 
insufficient to permit classification.
is provisionally regarded as unclassified and subdivided into
L Unclassified hypertension (without proteinuria)
2. Unclassified proteinuria fwithout hypertension)
3. Unclassified proteinuric hypertension (preeclampsia)
D. ECLAMPSIA
is regarded as one of the complications of the hypertensive disorders of pregnancy 
and should be included in a separate classification of complications.
HYPERTENSION IS DEFINED AS EITHER:
One measurement of DBP of 110 mmHg or above
Two consecutive measurements of DBP of 90 mmHg or above
PROTEINURIA DEFINED AS:
Total protein excretion of300 mg or more in 24 hours
Table 3.8
The definitions as used by the ISSHP (Davey and MacGillivray, 1988).
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Israel Europe
America
Iraq Asia
A frican
Non
Jews
Unknown Total
Cases 131 216 129 173 9 75 733
B irths 6464 12149 7250 20012 543 6171 32589
Rates 2.03 1.78 1.78 0.86 1.66 1.21 1.39
Table 3.9
The rates of preeclampsia in Israel, by country of origin, as found by Davies (1979). 
These differences may be due to m any other factors, including childhood 
environment, as well as racial variations.
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Total Preeclampsia Eclampsia
Triennium Number Rate Number Rate Number Rate
1970-72 43 18.7 14 6.1 29 12.6
1973-75 34 17.7 15 7.8 19 9.9
1976-78 29 16.6 16 9.1 13 7.4
1979-81 36 18.7 16 8.3 20 10.4
1982-84 25 13.3 11 5.8 14 7.4
1985-87 25 12.6 13 6.5 12 6.0
Table 3.10
Number of women who died from hypertensive diseases of pregnancy and the death 
rate per million maternities, 1970-87 in England and Wales (DHSS, 1969, DHSS, 
1974, DHSS, 1979, Turnbull et al., 1989). There had been no fall in  the rate of 
m aternal death between 1970-81. The fall seen in  the last two triennium  is 
encouraging.
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Causes Eclampsia Preeclampsia Total
Cerebral Haemorrhage 11 13 24
Cerebral Oedema 3 1 4
Cerebral infarction 0 2 2
Cerebral Cortical necrosis\ 1 0 1
Cerebral softening 1 0 1
Pulmonary com plication 10 4 14
Hepatic Necrosis 0 2 2
Other 0 3 3
Total 24 17 51
Table 3.11
The causes of the 54 maternal deaths associated with eclampsia or preeclampsia in 
England and Wales in years 1982-87 (Turnbull, 1987, Turnbull et aL, 1989). One of 
the patien ts with preeclampsia in  the triennium  1982-1984 did not have a 
postmortem and is not included in the figures. Thirty two of the 51 patients had 
evidence of cerebral lesions.
20
Antepartum Intrapartum Neonatal Total
Timing 149 43 105 297
% 50 15 35 100
Nonproteinuric Proteinuric Unrecorded
Severity 115 132 50 297
Rate 3/1000 10/1000 6/1000
Table 3.12
Perinatal mortality related to hypertension in  pregnancy in  Scotland between 
1977-81 (Common Services Agency., 1986). Sixty-five percent of the perinatal 
deaths occurred either antenatally or intrapartum . The risk of perinatal mortality 
for both proteinuric and nonproteinuric hypertension is well below the overall rate 
for the time which ranged from 18-12/1000.
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Decade Hospital Annex District Total Eclampsia Rate
33-42 32574 40995 73579 537
/100000
729f
43-52 32632 19009 51632 365 707
53-62 36606 10446 5368 52420 123 235t*
63-72 38725 18378 57103 74 130
73-82 36878 150 37028 19 51*
Total 177406 28974 65372 271752 1118 411
Table 4.1
A table of the deliveries and eclampsia over the last 50 years. The total num ber of 
deliveries were those supervised by the Glasgow Royal Maternity Hospital including those 
delivered in the annex and on district. The total numbers have halved since the first 
decade. The rate of eclampsia dramatically fell around 1950 at the time of the 
advent of the NHS and changes in management. There has been a further fall over 
the next two decades.
tStatistical difference between the rate in decades 33-42 and 53-62 (pcO.OOl)
* Statistical difference between the rate in decades 53-62 and 73-82 (p<0.005)
(Fishers Exact Test)
22
Decade Number Primigravida Multigravida
33-42 537 3921 (73%) 145 (27%)
43-52 365 256 (70%) 109 (30%)
53-62 123 80 (65%) 43 (35%)
63-72 73 56 (76%) 17 (23%)
73-82 19 14 (73%) 5 (26%)
Total 1117 789 (71%) 319 (29%)
Table 4.2
The ratio of eclampsia in primigravida to multigravida over the 50 year period of 
study. The ratio has remained more or less constant (Not significant by Fishers 
Exact Test). Around 30% of the eclamptics are multigravida.
(Figures from the years 1933-82 in the Glasgow Royal maternity Hospital)
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Decade Number Antenatal Intrapartum Postnatal
33-42 537 252 (47%) 192 (36%) 93 (17%)
43-52 365 156 (43%) 140 (38%) 69 (18%)
53-62 123 55 (45%) 37 (30%) 31 (25%)
63-72 73 26 (36%) 25 (34%) 22 (30%)
73-82 19 10 (52%) 4 (21%) 5 (26%)
Total 1117 499(44%) 398(36%) 2 2 0 (20%)
Table 4.3
The ratio of antenatal, intrapartum  and postpartum  eclamptics over the fifty years. 
There has been a steady decline in the numbers in each group.
(Figures from the years 1933-82 in the Glasgow Royal maternity Hospital)
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Decade Number Antenatal Intrapartum Postnatal
33-52 902 408 (45%) 332 (38%) 162 (17%)
p<0.05 p<0.05 p<0.001
53-82 215 91 (42%) 66 (31%) 58 (27%)
% reduction 76% 78% 80% 64%
Total 1117 499 (44%) 398 (36%) 220 (20%)
Table 4.4
Changes seen between the first two decades and the last three. The p values show the 
significance of the change. There has been a greater fall in the an tenatal and 
intrapartum  cases leading to a  relative increase in postpartum cases (pcO.OOl) 
(Fishers exact test)
(Figures from the years 1933-82 in the Glasgow Royal maternity Hospital)
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Decade
33-42 Delivery (Induction with bougies)
Stomach and colonic lavage
43-52 Stroganoff Therapy
Bromethol (IV or rectal)
Morphine
53-62 Barbiturates
63-72 Diazepam
Chlormethiazole
73-82 Hydrallazine
Labetalol
Table 4.5
This is a  list of the different treatm ents used over the fifty years and the decade tha t 
they were mostly used. Stomach and colonic lavage was carried out using 
magnesium sulphate. Stroganoff therapy was introduced in the late 1930’s  and was 
the mainstay of therapy in the early 1940’s. Newer sedation agents were introduced 
in the later decades. Antihypertensive therapy has only been used regularly in  the 
1970’s. These therapies represent the summary of the treatments used in  all cases of 
eclampsias delivered in the years 1933-82 in the Glasgow Royal Maternity Hospital. 
Not all the consultant team s used these therapies and there were other less used 
therapies tha t were used over this period.
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Decade Number Rate/1000 Antenatal Intrapartum Postnatal
Eclamptics
33-42 74 137 38 (51%) 27 (36%) 9 (13%)
43-52 44 120 25 (57%) 13 (30%) 6 (13%)
53-62 3 24 3 0 0
63-72 1 13 1 0 0
73-82 0 0 0 0 0
Total 122 109 67 (55%) 40 (33%) 15 (12%)
Table 4.6
The m aternal deaths associated with eclampsia over the fifty year period. Overall 
the rate is 109/1000 eclamptics or 11%. The last maternal death associated with 
eclampsia occurred in 1964.
(Figures from the years 1933-82 in the Glasgow Royal maternity Hospital)
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Decade Number Rate/1000 Antenatal Intrapartum Postnatal
Eclamptics
33-52 118 124 63(53%) 40(34%) 15(13%)
p<0.001
53-82 4 37 4 0 0
Total 122 109 67 (55%) 40 (33%) 15 (12%)
Table 4.7
The m aternal deaths associated with eclampsia, years 1933-52 compared with 
1953-82. The rate has significantly reduced. (Statistical difference pcO.OOl, Fishers 
exact test)
(Figures from the years 1933-82 in the Glasgow Royal maternity Hospital)
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Decade Stillbirth Neonatal 
Deaths
Total
Deaths
Perinatal
/1000
eclamptics
Perinatal
/1000
deliveries
33-42 164 64 228 424 3.1
43-52 80 36 116 317 2.2
53-62 27 6 33 268 0.6
63-72 3 7 10 135 0.2
73-82 3 4 7 368 0.2
Total 277 117 394 352 1.4
Table 4.8
The perinatal m ortality associated with eclampsia. Both the  ra te  per 1000 
deliveries in the hospital and the rate per 1000 eclamptics has steadily fallen 
throughout the decades. There has been an increase in the years 1973-82 bu t this is 
probably due to smaller numbers. If the last two decades are taken together, the 
trend is maintained (see table 4.9) This would imply tha t the reduction of perinatal 
loss related to eclampsia is due to both the reduction of the eclamptic rate and the 
improved survival of the babies of eclamptic mothers.
(Figures from the years 1933-82 in the Glasgow Royal maternity Hospital)
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Decade Stillbirth Neonatal
Deaths
Total
Deaths
Perinatal
/1000
eclamptics
Perinatal
/1000
deliveries
33-62 271 106 377 367 2.1
63-82 6 11 17 182 0.2
Total 277 117 394 352 1.4
Table 4.9
Difference between years 1933-62 and 1963-82. The stillbirth numbers have reduced 
by more than  the neonatal deaths resulting in  a relatively higher proportion of 
perinatal deaths being caused by neonatal deaths compared to stillbirths (pcO.OOl). 
The perinatal mortality in  the eclamptic group was also significantly reduced 
(pcO.OOl). (Fishers Exact Test)
(Figures from the years 1933-82 in the Glasgow Royal maternity Hospital)
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Number Age SD Range
Primigravida 186 21.5 4.3 16-35
Multigravida 115 26.3 4.9 18-40
Table 5.1
The details of the the 186 primigravid and 115 multigravid randomly selected 
patients who were followed serially throughout pregnancy for the norm al blood 
pressure changes. The Multigravida were significantly older than  the primigravida 
(p<0.005) (Student’s T* test).
31
Primigravida Multigravida Significance
Gestation BP SD BP SD
12 weeks 120.4 ± 17.0
72.4 ±11.2
118.0± 8.4 
71.0 ± 8.4
NS
NS
16 weeks 117.3 ± 12.7
69.3 ±10.2
115.0± 11.9 
67.2 ± 10.2
NS
NS
20 weeks 115.2 ± 16.8 
69.3 ± 8.8
111.6± 18.5 
67.7 ± 8.6
NS
NS
24 weeks 116.4 ± 17.9 
71.1 ± 9.2
112.1 ± 11.0 
65.8 ± 7.6
p<0.05
p<0.001
28 weeks 117.1 ± 17.0 
70.6 ± 9.8
113.4± 16.2 
66.4 ± 7.3
p<0.005
p<0.005
30 weeks 118.3 ± 14.1 
72.4 ±10.2
113.8± 11.5 
68.7 ± 7.8
p<0.05
p<0.005
32 weeks 118.3 ±13.2 
72.8 ± 8.9
114.3± 16.8 
68.6 ± 7.3
p<0.05
p<0.005
34 weeks 118.0 ± 13.1 
74.5 ±11.2
114.2± 16.7 
70.0 ± 8.4
p<0.001
p<0.001
36 weeks 117.1 ± 16.6 
75.2 ±10.8
114.1 ± 11.2
70.1 ± 10.6
NS
p<0.005
38 weeks 118.0 ± 17.0 
76.1 ±11.4
116.4± 11.0 
70.8 ± 9.9
NS
p<0.001
40 weeks 119.5 ± 11.0
75.5 ± 9.0
119.4± 10.8 
73.8 ± 10.0
NS
NS
Highest BP 
in Labour
118.7 ± 12.5 
74.0 ± 9.2
120.0 ± 15.8
76.0 ± 10.0
NS
NS
3rd day 
Postnatal
120.9 ± 19.4 
75.1 ±11.0
120.7 ± 11.7 
76.3 ± 8.3
NS
NS
Table 5.2
The m ean blood pressures and standard deviations from the m ean for a  serial study 
of 186 primigravida and 115 multiparous randomly selected patients attending the 
an tenatal clinic a t the Glasgow Royal M aternity Hospital. The graph of the  
m easurem ents is shown in Fig. 5.1. The previously documented fall in  blood 
pressure in the second trim ester is dem onstrated with a rise to w ards term  
(MacGillivray, Rose and Rowe, 1969). It was found th a t the parous women had a 
significantly lower systolic and diastolic blood pressure in mid-pregnancy.
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Mean SD Max Min Units
Age 22.34 4.56 28 16 Years
Booking Systolic 111.44 14.10 155 80 mmHg
Booking Diastolic 64.53 11.15 88 35 mmHg
Booking Height 160.38 6.1 180 141 cm.
Booking Weight 68.31 14.8 122 41.5 Kg.
Booking Gestation 9.74 2.27 13 6 Wfeeks
Booking Haemoglobin 12.8 1.0 16.4 9.6 gm /dl
Booking Hct 0.39 0.01 0.54 0.31 -
Table 6.1
The mean, standard deviation and range of the first trimester parameters of the 335 
primigravida studied. The patients were studied only if they were known to be 
normotensive in the first trim ester and developed the hypertension for the first 
time after 24 weeks gestation. None had  any history of hypertension prior to 
pregnancy.
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Data File: Primigravida/PIH
Source
Sum of 
Squares
Deg. of 
Freedom
Mean
Squares F-Ratio Prob>F
Model 34189.7 5 6837.9 63.2 0.000
Error 40867.5 378 108.1
Total 75057.2 383
Coefficient o f Determination (RA2) 0.5
Adjusted Coefficient (RA2) 0.4
Coefficient of Correlation (R) 0.7
Standard Error of Estimate 10.4
Durbin-Watson Statistic 1.9
Data File: Primigravida/PIH Dependent Variable: Booking Systolic
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 50.1 16.6 3.0 0.003
Booking Diastolic 0.8 0.0 16.0 0.000
Booking Height -0.0 0.1 -0.2 0.876
Booking Weight 0.1 0.0 2.3 0.021
Booking Haemoglobin 1.9 1.3 1.5 0.140
Booking Hct -45.1 48.4 -0.9 0.352
Table 6.2
These tables show the results of multiple regression analysis using booking systolic 
blood pressure as the dependent variable compared with booking diastolic blood 
pressure, height, weight haemoglobin and haematocrit. This dem onstrates a  close 
independent relationship between the booking systolic and the booking diastolic, 
with lesser bu t significant relationship with weight. The significance of the F Ratio 
dem onstrates th a t th is calculation is valid. The resu lts produce an  equation 
suggesting th a tS y s to l ic  BP=[50+ (0.8 x  Diastolic BP)+ (0.1 x weight in Kg)] mmHg
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Data File: Primigravida/PIH
Source
Sum of 
Squares
Deg.of
Freedom
Mean
Squares F-Ratio Prob>F
Model
Error
21472.1
26071.5
5
378
4294.4
69.0
62.3 0.000
Total 47543.6 383
Coefficient of Determination (RA2) 0.5
Adjusted Coefficient (RA2) 0.4
Coefficient of Correlation (R) 0.7
Standard Error of Estimate 8.3
Durbin-Watson Statistic 1.8
Data File: Primigravida/PIHDependent Variable: Booking Diastolic
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > i
Constant 22.0 13.3 1.6 0.100
Booking Systolic 0.5 0.0 16.0 0.000
Booking Height -0.1 0.1 -1.6 0.115
Booking Weight 0.1 0.0 2.1 0.033
Booking Haemoglobin -0.5 1.1 -0.4 0.655
Booking Hct 29.0 38.6 0.7 0.454
Table 6.3
These tables show the resu lts of multiple regression analysis using booking 
diastolic blood pressure as the dependent variable compared with booking systolic 
blood pressure, height, weight, haemoglobin and haematocrit. This demonstrates a 
close independent relationship between the booking systolic and the booking 
diastolic, with lesser but significant relationship with weight. The significance of 
the F Ratio dem onstrates th a t th is calculation is valid. The resu lts produce an  
equation suggesting th a tD ia s to lic  BP=[22+ (0.5 x  Systolic BP)+ (0.1 x  weight in  Kg)] 
mmHg
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Mean SD Max M in U nits
Systolic 144.59 16.01 200 125 mmHg
D iastolic 99.44 9.49 140 85 mmHg
Urea 3.31 1.08 7.5 1 m mol/1
Urate 291.33 80.24 650 90 m mol/1
Haemoglobin 12.54 1.05 17.8 9.2 gm /dl
Haematocrit 0.36 0.02 0.53 0.29 -
Platelet Count 234.08 77.66 669 62 x l0 9/ l
Alkaline Phos 318.64 113.26 860 100 u/1
AST 20.82 13.83 194 6 u/1
ALT 17.19 13.91 110 6 u/1
yGT 17.67 22.03 36 3 u/1
Albumin 32.99 3.31 43 23 gm/1
Proteinuria 0.48 2.46 21.9 0 gm s/24hrs
Birth Weight 3327 644 5050 690 gms
Birth Centile 56 24 >95 <5 %
Apgar 1 min 7.67 1.84 10 0 -
Apgar 5 min 9.24 1.20 10 0 -
Table 6.4
The m ean and range of all parameters studied in 335 primigravida studied. For each 
individual patient, the results are either the last taken prior to delivery or before 
antihypertensive therapy was commenced. The blood pressures used were the 
average of four blood pressure readings taken on the day of sampling, hence the 
lower limit of 85 mmHg. The average birth weight and birth weight centile shows 
th a t there is no evidence of an  increase incidence of growth retardation in  th is 
group. Birth weight centile was calculated using Scottish Birth centiles.
36
Data File: Primigravida/PIH
Sum of Deg.of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 43704.7 12 3642.1 28.4 0.000
Error 38464.6 300 128.2
Total 82169.3 312
Coefficient of Determination (RA2) 0.5
Adjusted Coefficient (RA2) 0.5
Coefficient of Correlation (R) 0.7
Standard Error of Estimate 11.3
Durbin-Watson Statistic 1.9
Data File: Primigravida/PIHDependent Variable: Last Systolic
'Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 46.4 22.8 2.0 0.043
Booking Systolic 0.2 0.1 3.3 0.001
Booking Diastolic -0.1 0.1 -1.7 0.089
Booking Height -0.2 0.1 -1.6 0.117
Booking Weight 0.0 o.O 1.0 0.334
Booking Haemoglobin -1.3 1.8 -0.7 0.456
Booking Hct 25.8 65.8 0.4 0.695
Last Diastolic 1.1 0.1 14.0 0.000
Last Urea 0.9 0.7 1.3 0.200
Last Urate 0.0 0.0 1.1 0.289
Last Haemoglobin -4.0 1.6 -2.4 0.016
Last Hct 133.6 59.8 2.2 0.026
Last Platelet 0.0 0.0 0.4 0.686
Table 6.5
These tables show the results of multiple regression analysis using the systolic 
blood pressure as the dependent variable compared with the booking param eters 
and the last measurements of diastolic blood pressure, urea, urate haemoglobin, 
haem atocrit and  platelet count. This dem onstrates a close independent 
relationship between the last systolic and the last diastolic blood pressure readings. 
There was a lesser bu t significant relationship with the booking systolic, the last 
haemoglobin and last haem atocrit. The relationship with haem oglobin and 
haem atocrit is in opposite directions. There is no significant relationship with 
either urea, urate or platelet count.The significance of the F Ratio dem onstrates 
tha t th is calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg.of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 16716.6 12 1393.0 32.1 0.000
Error 13003.2 300 43.3
Total 29719.8 312
Coefficient of Determination (RA2) 0.6
Adjusted Coefficient (RA2) 0.5
Coefficient of Correlation (R) 0.7
Standard Error of Estimate 6.6
Durbin-Watson Statistic 2.0
Data File: Primigravida/PIHDependent Variable: Last Diastolic
variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 39.0 13.2 3.0 0.003
Booking Systolic -0.1 0.0 -2.0 0.050
Booking Diastolic 0.1 0.0 2.9 0.004
Booking Height -0.0 0.1 -0.2 0.880
Booking Weight 0.0 0.0 0.5 0.612
Booking Haemoglobin 0.3 1.0 0.3 0.766
Booking Hct -9.9 38.3 -0.3 0.796
Last Systolic 0.4 0.0 14.0 0.000
Last Urea 1.0 0.4 2.5 0.013
Last Urate 0.0 0.0 2.2 0.029
Last Haemoglobin 2.1 1.0 2.2 0.029
Last Hct -59.2 34.9 -1.7 0.090
Last Platelet -0.0 0.0 -2.7 0.007
Table 6.6
These tables show the results of multiple regression analysis using the diastolic 
blood pressure as the dependent variable compared with the booking param eters 
and the last systolic blood pressure, urea, urate, haemoglobin, haem atocrit and 
platelet count. This demonstrates a close independent relationship between the last 
diastolic and the last systolic blood pressure readings. There is a lesser b u t 
significant relationship  with the booking diastolic, the la st u rea , u ra te , 
haemoglobin and platelet count. There is no significant relationship  with 
haematocrit. The significance of the F Ratio demonstrates th a t th is calculation is 
valid.
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Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 145.2 18 8.1 8.9 0.000
Error 252.1 277 0.9
Total 397.3 295
Coefficient of Determination (RA2) 0.4
Adjusted Coefficient (RA2) 0.3
Coefficient of Correlation (R) 0.6
Standard Error of Estimate 1.0
Durbin-Watson Statistic 1.8
Data File: Primigravida/PIHDependent Variable: Last Urea
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant -3.0 2.1 -1.4 0.157
Booking Systolic 0.0 0.0 0.1 0.923
Booking Diastolic -0.0 0.0 -1.0 0.300
Booking Height 0.0 0.0 1.3 0.187
Booking Weight -0.0 0.0 -1.3 0.182
Booking Haemoglobin -0.3 0.2 -2.1 0.041
Booking Hct 10.9 6.0 1.8 0.069
Last Systolic 0.0 0.0 1.7 0.098
Last Diastolic 0.0 0.0 1.6 0.105
Last Urate 0.0 0.0 6.7 0.000
Last Haemoglobin 0.0 0.1 0.0 0.973
Last Hct 0.7 5.3 0.1 0.888
Last Platelet 0.0 0.0 0.6 0.560
Last Aik Phos 0.0 0.0 0.1 0.921
Last Ast -0.0 0.0 -1.6 0.111
Last Alt 0.0 0.0 2.4 0.019
Last yGT 0.0 0.0 1.0 0.333
Last Albumin 0.0 0.0 0.6 0.548
Last Proteinuria 0.0 0.0 1.3 0.212
Table 6.7
These tables show the results of multiple regression analysis using urea as the 
dependent variable. This demonstrates a close independent relationship between 
the last urea and the uric acid. There is a lesser but significant relationship with the 
booking haemoglobin and last Alt. There is no significant relationship with any of 
the other param eters. This would imply tha t renal impairment, as m easured by 
urea level, is not related to the markers of disease activity. The significance of the F 
Ratio demonstrates that this calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 988739.0 17 58161.1 14.3 0.000
Error 1133506.5 278 4077.4
Total 2122245.5 295
Coefficient o f Determination (RA2) 0.5
Adjusted Coefficient (RA2) 0.4
Coefficient of Correlation (R) 0.7
Standard Error of Estimate 63.9
Durbin-Watson Statistic 2.1
Data File: Primigravida/PIHDependent Variable: Last Urate
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 405.7 138.5 2.9 0.004
Booking Systolic 0.2 0.4 0.5 0.635
Booking Diastolic -0.6 0.5 -1.3 0.193
Booking Height -0.0 0.7 -0.1 0.954
Booking Weight 0.0 0.3 0.1 0.931
Booking Haemoglobin 1.4 10.8 0.1 0.895
Booking Hct -321.3 401.4 -0.8 0.424
Last Systolic 0.2 0.3 0.5 0.625
Last Diastolic 1.2 0.6 2.2 0.031
Last Urea 25.1 3.7 6.7 0.000
Last Haemoglobin 3.5 9.5 0.4 0.711
Last Hct -113.7 351.7 -0.3 0.747
Last Platelet -0.1 0.1 -1.8 0.066
Last Aik Phos 0.1 0.0 1.7 0.083
Last Ast 1.2 0.5 2.6 0.009
Last Alt -0.5 0.5 -1.0 0.309
Last yGT 0.6 0.4 1.5 0.124
Last Albumin -6.8 1.3 -5.3 0.000
Last Proteinuria -1.0 1.6 -0.6 0.519
Table 6.8
These tables show the results of multiple regression analysis using urate  as the 
dependent variable. This demonstrates a close independent relationship between 
the last u rate  and urea. There is no relationship with any of the  booking 
param eters. There is a significant relationship with the last diastolic, platelet 
count and albumin, all recognised m arkers of disease severity. There is also a 
significant relationship to Ast. This suggests th a t changes in Ast, unlike Alt, are 
more directly related to the disease process. The significance of the F Ratio 
demonstrates tha t this calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg.of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 498.7 18 27.7 4.6 0.000
Error 1676.5 277 6.1
Total 2175.2 295
Coefficient o f Determination (RA2) 0.2
Adjusted Coefficient (RA2) 0.2
Coefficient of Correlation (R) 0.5
Standard Error of Estimate 2.5
Durbin-Watson Statistic 2.1
Data File: Primigravida/PIHDependent Variable: Last Proteinuria
'Variable Std. Err. t
Name Coefficient Estimate Statistic Prob>t
Constant 4.8 5.5 0.9 0.382
Booking Systolic -0.0 0.0 -0.1 0.894
Booking Diastolic -0.0 0.0 -0.3 0.771
Booking Height 0.0 0.0 0.6 0.522
Booking Weight -0.0 0.0 -0.8 0.415
Booking Haemoglobin -1.1 0.4 -2.6 0.010
Booking Hct 29.4 15.4 1.9 0.058
Last Systolic 0.0 0.0 1.2 0.244
Last Diastolic 0.0 0.0 1.5 0.142
Last Urea 0.2 0.2 1.3 0.212
Last Urate -0.0 0.0 -0.5 0.608
Last Haemoglobin 0.2 0.4 0.5 0.598
Last Hct -4.7 13.6 -0.3 0.729
Last Platelet -0.0 0.0 -0.5 0.620
Last Aik Phos -0.0 0.0 -1.2 0.227
Last Ast -0.0 0.0 -0.5 0.610
Last Alt 0.0 0.0 0.5 0.613
Last yGT -0.0 0.0 -0.3 0.728
Last Albumin -0.3 0.1 -5.0 0.000
Table 6.9
These tables show the results of multiple regression analysis using proteinuria as 
the  dependent variable. This dem onstrates a close independent negative 
relationship between the last proteinuria and albumin. Apart from a relationship 
with the booking haemoglobin, there is no independent relationship with any other 
parameter. This suggests th a t proteinuria is due to a specific abnorm ality 
independent of the rest of the disease process. The significance of the  F Ratio 
demonstrates tha t this calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg.of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 279.1 17 16.4 101.0 0.000
Error 46.0 283 0.2
Total 325.2 300
Coefficient o f Determination (RA2) 0.9
Adjusted Coefficient (RA2) 0.8
Coefficient of Correlation (R) 0.9
Standard Error of Estimate 0.4
Durbin-Watson Statistic 2.0
Data File: Primigravida/PIHDependent Variable: Last Haemoglobin
'Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant -0.3 0.6 -0.5 0.599
Booking Systolic 0.0 0.0 0.8 0.453
Booking Diastolic -0.0 0.0 -0.9 0.345
Booking Height 0.0 0.0 1.3 0.302
Booking Weight 0.0 0.0 0.5 0.589
Booking Haemoglobin 0.2 0.1 3.2 0.002
Booking Hct -5.3 2.5 -2.1 0.035
Last Systolic -0.0 0.0 -2.3 0.020
Last Diastolic 0.0 0.0 2.1 0.034
Last Urea -0.0 0.0 -0.1 0.913
Last Urate 0.0 0.0 0.4 0.685
Last Hct 33.4 1.0 34.4 0.000
Last Platelet -0.0 0.0 -0.6 0.575
Last Aik Phos -0.0 0.0 -1.2 0.250
Last Ast 0.0 0.0 0.2 0.854
Last Alt -0.0 0.0 -0.2 0.876
Last yGT 0.0 0.0 0.6 0.568
Last Albumin -0.0 0.0 -1.0 0.316
Last Proteinuria 0.0 0.0 0.4 0.678
Table 6.10
These tables show the results of multiple regression analysis using haemoglobin as 
the dependent variable. This dem onstrates a  close independent rela tionsh ip  
between the last haemoglobin and the booking haemoglobin and haematocrit, both 
the systolic and diastolic blood pressure, and the last haematocrit. There is no 
independent relationship with any other parameter. The significance of the F Ratio 
demonstrates tha t this calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg.of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 0.2 18 0.0 92.3 0.000
Error 0.0 277 0.0
Total 0.2 295
Coefficient of Determination (RA2) 0.9
Adjusted Coefficient (RA2) 0.8
Coefficient of Correlation (R) 0.9
Standard Error of Estimate 0.0
Durbin-Watson Statistic 2.0
Data File: Primigravida/PIH Dependent Variable: Last Hct
'Variable Std. Err. t
Name Coefficient Estimate Statistic Profo > t
Constant 0.0 0.0 0.6 0.541
Booking Systolic -0.0 0.0 -0.6 0.542
Booking Diastolic 0.0 0.0 1.0 0.339
Booking Height 0.0 0.0 1.1 0.266
Booking Weight -0.0 0.0 -1.1 0.262
Booking Haemoglobin -0.0 0.0 -2.5 0.013
Booking Hct 0.2 0.1 2.8 0.005
Last Systolic 0.0 0.0 2.6 0.010
Last Diastolic -0.0 0.0 -1.8 0.078
Last Urea 0.0 0.0 0.1 0.888
Last Urate -0.0 0.0 -0.5 0.624
Last Haemoglobin 0.0 0.0 34.3 0.000
Last Platelet -0.0 0.0 -0.6 0.560
Last Aik Phos 0.0 0.0 1.6 0.100
Last Ast 0.0 0.0 0.0 0.986
Last Alt -0.0 0.0 -0.3 0.748
Last yGT 0.0 0.0 0.3 0.786
Last Albumin 0.0 0.0 2.1 0.039
Last Proteinuria -0.0 0.0 -0.3 0.729
Table 6.11
These tables show the results of multiple regression analysis using haematocrit as 
the  dependent variable. This dem onstrates a close independent rela tionsh ip  
between the last haematocrit and the booking haemoglobin and haematocrit, the 
systolic blood pressure, the last haemoglobin and the last albumin. There is no 
independent relationship with any other parameter. The significance of the F Ratio 
demonstrates tha t this calculation is valid.
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Data File: Primigravida/PIH
Sum of D eg.of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 404712.3 18 22484.0 4.2 0.000
Error 1482319.6 277 5351.3
Total 1887031.9 295
Coefficient of Determination (RA2) 0.2
A d ju s ted  Coefficient (RA2) 0.2
Coefficient of Correlation (R) 0.5
Standard Error of Estimate 73.2
Durbin-Watson Statistic 1.8
Data File: Primigravida/PIH Dependent Variable: Last Platelet Count
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 709.0 157.3 4.5 o.OOO
Booking Systolic -0.7 0.4 -1.7 0.082
Booking Diastolic 0.2 0.5 0.5 0.652
Booking Height -1.2 0.8 -1.6 0.115
Booking Weight 0.7 0.3 2.3 0.024
Booking Haemoglobin 0.4 12.4 0.0 0.971
Booking Hct 89.9 461.7 0.2 0.846
Last Systolic 0.2 0.4 0.6 0.568
Last Diastolic -1.8 0.7 -2.7 0.007
Last Urea 2.7 4.6 0.6 0.560
Last Urate -0.1 0.1 -1.9 0.053
Last Haemoglobin -7.3 10.9 -0.7 0.503
Last Hct -235.9 404.7 -0.6 0.560
Last Aik Phos 0.0 0.0 1.2 0.249
Last Ast -1.3 0.5 -2.4 0.018
Last Alt 0.3 0.6 0.5 0.613
Last yGT -0.1 0.4 -0.2 0.815
Last Albumin 2.2 1.6 1.4 0.169
Last Proteinuria -0.9 1.8 -0.5 0.620
Table 6.12
These tables show the results of multiple regression analysis using the platelet 
count as the  dependent variable. This dem onstrates a close independent 
relationship between the last platelet count and the booking weight, the diastolic 
blood pressure, and the last Ast. There is no independent relationship with any 
other param eter including the systolic blood pressure. The significance of the F 
Ratio demonstrates tha t this calculation is valid.
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Normal = No further blood pressures greater than 90 mmHg
Mild = Blood pressures never going above 100 mmHg
Moderate = Blood pressures between 100 and 109 mmHg
Severe = Blood pressures >110 mmHg
or the presence of proteinuria.
Table 6.13
Definitions used in the followup of patients in the prediction study shown in the 
next 4 tables.
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Long Term Outcome
Daycare
D iastolic Number Normal Mild Moderate Severe
<90 846 293 434 109 10
90-100 197 0 33 98 66
>100 44 0 0 11 33
Total 1087 293 467 218 109
Table 6.14
The long term outcome compared with the average Daycare diastolic blood pressure 
of 1087 consecutive Primigravida attending Daycare for the first time after 24 
weeks. As will be discuss in Chapter 7, most patients had normal blood pressure.
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Long Term Outcome
Daycare 
Uric acid Number Normal Mild Moderate Severe
<250 153 109 22 22 0
250-370 782 184 442 120 36
>370 152 0 3 76 73
Total 1067 293 467 218 109
Table 6.15
The long term  outcome compared with the  Daycare uric acid level in  1087 
consecutive Primigravida attending Daycare for the first time after 24 weeks. It 
would appear tha t in this group of patients a level of 370 mmol/1 is too high to be the 
upper limit of normality as few patients have a level above this.
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Long Term Outcome
Daycare
Platelets Number Normal Mild Moderate Severe
>250 489 217 228 44 0
150-250 550 76 228 163 83
<150 48 0 11 11 26
Total 1087 293 467 218 109
Table 6.16
The long term  outcome compared with the platelet count in 1087 consecutive 
Primigravida attending Daycare for the first time after 24 weeks. It would appear 
tha t in this group of patients a level of 150 xl09/m l is too low to be the lower limit of 
normality as few patients have a level below this.
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Long Term Outcome
Daycare
Number Normal Mild Moderate Severe
Diastolic <90 846 293 434 109 10
and Urate <350 630 281 276 65 8
and Platelets >200 537 264 245 22 6
Table 6.17
The long term  outcome compared with the combination of results obtained at the 
first Daycare appointment. The cutoff levels were chosen as the best compromise of 
selectivity and specificity of diagnosis. Less than  50% of the patients had normal 
levels of all three parameters bu t these did well.
Data File: Primigravida/PIH
Sum of Deg.of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 1387873.8 18 77104.1 4.6 0.000
Error 4637996.7 277 16743.7
Total 6025870.5 295
Coefficient of Determination (RA2) 0.2
Adjusted Coefficient (RA2) 0.2
Coefficient of Correlation (R) 0.5
Standard Error of Estimate 120.4
Durbin-Watson Statistic 2.1
Data File: Primigravida/PIH Dependent Variable: Last Aik Phos
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 715.8 285.0 2.5 0.013
Booking Systolic -0.3 0.8 -0.4 0.671
Booking Diastolic -1.5 0.9 -1.7 0.092
Booking Height -1.9 1.3 -1.4 0.151
Booking Weight -0.2 0.6 -0.4 0.668
Booking Haemoglobin 24.1 21.9 1.1 0.273
Booking Hct -1034.7 814.4 -1.3 0.205
Last Systolic -0.1 0.7 -0.1 0.928
Last Diastolic 1.8 1.2 1.5 0.126
Last Urea 0.8 8.1 0.1 0.921
Last Urate 0.2 0.1 1.7 0.083
Last Haemoglobin -24.0 19.2 -1.2 0.214
Last Hct 1174.9 712.8 1.6 0.100
Last Platelet 0.1 0.1 1.2 0.249
Last Ast -0.2 0.9 -0.2 0.829
Last Alt -0.2 1.0 -0.2 0.842
Last yGT 3.2 0.8 4.2 0.000
Last Albumin -8.5 2.8 -3.1 0.002
Last Proteinuria -3.8 3.2 -1.2 0.227
Table 6.18
These tables show the resu lts of multiple regression analysis using alkaline 
phosphatase as the dependent variable. This demonstrates the close independent 
relationship between the last alkaline phosphatase and both the last yGT and the 
last albumin. There is no significant relationship with any of the other parameters.
The significance of the F Ratio demonstrates tha t this calculation is valid. 9
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Data File: Primigravida/PIH
Source
Model
Error
Sum of 
Squares
34683.7
17635.1
Deg. of 
Freedom
17
280
Total 52318.8 297
Mean
Squares
2040.2
63.0
F-Ratio
32.4
Prob>F
0.000
Coefficient of Determination (RA2) 0.7
Adjusted Coefficient (RA2) 0.6
Coefficient o f Correlation (R) 0.8
Standard Error of Estimate 7.9
Durbin-Watson Statistic 2.1
Data File: Primigravida/PIH Dependent Variable: Last Alt
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant -27.8 17.1 -1.6 0.105
Booking Systolic -0.0 0.0 -0.4 0.672
Booking Diastolic 0.1 0.1 1.8 0.076
Booking Height 0.1 0.1 0.8 0.412
Booking Weight 0.0 0.0 0.6 0.516
Booking Haemoglobin 1.1 o.5 2.0 0.042
Last Systolic -0.0 0.0 -0.0 0.982
Last Diastolic -0.0 0.1 -0.7 0.493
Last Urea 1.3 0.5 2.6 0.011
Last Urate -0.0 0.0 -1.1 0.287
Last Haemoglobin -0.2 1.2 -0.2 0.867
Last Hct -1.6 43.0 -0.0 0.971
Last Platelet 0.0 0.0 0.5 0.601
Last Aik Phos -0.0 0.0 -0.3 0.740
Last Ast 0.7 0.0 18.6 0.000
Last yGT 0.2 0.0 5.3 0.000
Last Albumin 0.0 0.2 0.1 0.890
Last Proteinuria 0.1 0.2 0.7 0.488
Table 6.19
These tables show the results of multiple regression analysis using Alt as the 
dependent variable. This demonstrates the close independent relationship between 
the last Ast, the last urea and the last GT. There a lesser relationship with the 
booking haemoglobin. There is no significant relationship with any of the  other 
parameters. The significance of the F Ratio demonstrates tha t th is calculation is
valid.
Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 34105.3 18 1894.7 28.0 0.000
Error 18771.5 277 67.8
Total 52876.8 295
Coefficient o f Determination (RA2) 0.6
Adjusted Coefficient (RA2) 0.6
Coefficient of Correlation (R) 0.8
Standard Error of Estimate 8.2
Durbin-Watson Statistic 2.1
Data File: Primigravida/PIH Dependent Variable: Last Ast
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 31.2 18.2 1.7 0.089
Booking Systolic -0.0 0.0 -0.5 0.599
Booking Diastolic -0.0 0.1 -0.8 0.419
Booking Height -0.0 0.1 -0.1 0.902
Booking Weight -0.0 0.0 -0.2 0.844
Booking Haemoglobin 1.7 1.4 1.3 0.211
Booking Hct -92.7 51.7 -1.8 0.074
Last Systolic 0.0 0.0 0.3 0.799
Last Diastolic 0.0 0.1 0.2 0.850
Last Urea -0.8 0.5 -1.6 0.111
Last Urate 0.0 0.0 2.6 0.009
Last Haemoglobin -0.0 1.2 -0.0 0.968
Last Hct 0.8 45.6 0.0 0.986
Last Platelet -0.0 0.0 -2.4 0.018
Last Aik Phos -0.0 0.0 -0.2 0.829
Last Alt 0.8 0.0 18.6 0.000
Last yGT -0.0 0.0 -1.0 0.319
Last Albumin -0.1 0.2 -0.6 0.527
Proteinuria -0.1 0.2 -0.5 0.610
Table 6.20
These tables show the results of multiple regression analysis using Ast as the 
dependent variable. This demonstrates the close independent relationship between 
the last Ast and the last uric acid, the last platelet count and the last Alt. There is no 
significant relationship with any of the other parameters. The significance of the F
Ratio demonstrates tha t this calculation is valid.
Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 11826.0 18 657.0 6.6 0.000
Error 27417.0 277 99.0
Total 39243.0 295
Coefficient o f Determination (RA2) 0.3
Adjusted Coefficient (RA2) 0.3
Coefficient of Correlation (R) 0.5
Standard Error of Estimate 9.9
Durbin-Watson Statistic 2.0
Data File: Primigravida/PIHDependent Variable: Last yGT
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 45.1 22.0 2.1 0.041
Booking Systolic 0.0 0.1 0.4 0.718
Booking Diastolic -0.1 0.1 -0.8 0.408
Booking Height -0.3 0.1 -3.0 0.003
Booking Weight 0.1 0.0 1.4 0.166
Booking Haemoglobin -0.5 1.7 -0.3 0.788
Booking Hct -12.0 62.8 -0.2 0.848
Last Systolic -0.1 0.1 -1.8 0.075
Last Diastolic 0.1 0.1 1.0 0.315
Last Urea 0.6 0.6 1.0 0.333
Last Urate 0.0 0.0 1.1 0.294
Last Haemoglobin 0.6 1.5 0.4 0.668
Last Hct 15.0 55.1 0.3 0.786
Last Platelet -0.0 0.0 -0.2 0.815
Last Alk Phos 0.0 0.0 4.2 0.000
Last Ast -0.1 0.1 -1.0 0.319
Last Alt 0.4 0.1 5.2 0.000
Last Albumin 0.1 0.2 0.7 0.495
Last Proteinuria -0.1 0.2 -0.3 0.728
Table 6.21
These tables show the results of multiple regression analysis using yGT as the 
dependent variable. This demonstrates the close independent relationship between 
the last yGT and the last alk phos and the last Alt. There is also a relationship with 
the booking height. There is no significant relationship with any of the other 
parameters. The significance of the F Ratio demonstrates tha t th is calculation is
valid.
Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 1134.9 18 63.1 8.2 0.000
Error 2133.2 277 7.7
Total 3268.2 295
Coefficient of Determination (RA2) 0.3
Adjusted Coefficient (RA2) 0.3
Coefficient of Correlation (R) 0.6
Standard Error of Estimate 2.8
Durbin-Watson Statistic 2.0
Data File: Primigravida/PIHDependent Variable: Last Albumin
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 28.1 5.9 4.7 0.000
Booking Systolic 0.0 0.0 1.1 0.291
Booking Diastolic -0.0 0.0 -1.6 0.111
Booking Height 0.1 0.0 1.9 0.054
Booking Weight -0.0 0.0 -0.5 0.592
Booking Haemoglobin 0.2 0.5 0.3 0.732
Booking Hct -16.0 17.5 -0.9 0.362
Last Systolic -0.0 0.0 -1.3 0.186
Last Diastolic 0.0 0.0 0.3 0.752
Last Urea 0.1 0.2 0.6 0.548
Last Urate -0.0 0.0 -4.8 0.000
Last Haemoglobin -0.4 0.4 -1.0 0.330
Last Hct 31.6 15.2 2.1 0.039
Last Platelet 0.0 0.0 1.4 0.169
Last Alk Phos -0.0 0.0 -3.1 0.002
Last Ast -0.0 0.0 -0.6 0.527
Last Alt 0.0 0.0 0.2 0.819
Last yGT 0.0 0.0 0.7 0.495
Last Proteinuria -0.3 0.1 -5.0 0.000
Table 6.22
These tables show the results of multiple regression analysis using albumin as the 
dependent variable. This demonstrates the close independent relationship between 
the last album in and the last urate, haem atocrit, alkaline phosphatase and 
negatively with the last proteinuria. There is no significant relationship with any 
of the other parameters. The significance of the F Ratio dem onstrates th a t th is 
calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 395.2 19 20.8 6.9 0.000
Error 826.1 275 3.0
Total 1221.3 294
Coefficient o f Determination (RA2) 0.3
Adjusted Coefficient (RA2) 0.3
Coefficient of Correlation (R) 0.6
Standard Error of Estimate 1.7
Durbin-Watson Statistic 2.0
Data File: Primigravida/PIH Dependent Variable: Delivery Gestation
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 37.4 3.9 9.7 0.000
Booking Systolic -0.0 0.0 -0.4 0.694
Booking Diastolic -0.0 0.0 -0.8 0.448
Booking Height 0.0 0.0 1.6 0.104
Booking Weight -0.0 0.0 -0.9 0.396
Booking Haemoglobin 0.5 0.3 1.7 0.097
Booking Hct -8.1 10.9 -0.7 0.460
Last Systolic -0.0 0.0 -1.6 0.102
Last Diastolic -0.0 0.0 -0.6 0.535
Last Urea -0.3 0.1 -3.2 0.002
Last Urate 0.0 0.0 0.7 0.454
Last Haemoglobin -0.1 0.3 -0.4 0.688
Last Hct -4.7 9.6 -0.5 0.627
Last Platelet 0.0 0.0 2.2 0.031
Last Alk Phos -0.0 0.0 -0.9 0.379
Last Ast -0.0 0.0 -0.7 0.508
Last Alt 0.0 0.0 0.4 0.678
Last yGT -0.0 0.0 -0.8 0.445
Last Albumin 0.1 0.0 1.4 0.151
Last Proteinuria -0.2 0.0 -3.6 0.000
Table 6.23
These tables show the results of multiple regression analysis using the delivery 
gestation as the dependent variable. This dem onstrates the close independent 
relationship between the delivery gestation and the last urea, platelet count and the 
last proteinuria. There is no significant relationship with any of the  o ther 
parameters. The significance of the F Ratio demonstrates tha t this calculation is 
valid.
55
Data File: Primigravida/PIH
Source
Sum of 
Squares
Deg. of 
Freedom
Mean
Squares F-Ratio Prob>F
Model 61416214.6 20 3070810.7 14.6 0.000
Error 56025446.2 267 209833.1
Total 117441660.8 287
Coefficient of Determination (RA2) 
Adjusted Coefficient (RA2) 
Coefficient of Correlation (R) 
Standard Error of Estimate 
Durbin-Watson Statistic
Data File: Primigravida/PIH Dependent Variable: Birth Weight
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant -4952.4 1237.6 -4.0 0.000
Booking Systolic 1.2 2.7 0.4 0.662
Booking Diastolic 3.0 3.3 0.9 0.374
Booking Height 18.0 4.8 3.7 0.000
Booking Weight 6.1 2.1 2.9 0.003
Booking Haemoglobin 85.1 79.4 1.1 0.284
Booking Hct -1762.9 2936.0 -0.6 0.549
Last Systolic 1.7 2.5 0.7 0.506
Last Diastolic -8.2 4.3 -1.9 0.055
Last Urea -69.6 29.8 -2.3 0.020
Last Urate 0.3 0.4 0.7 0.473
Last Haemoglobin -42.6 69.8 -0.6 0.542
Last Hct -12.0 2598.9 -0.0 0.996
Last Platelet -0.3 0.4 -0.8 0.414
Last Alk Phos -0.5 0.2 -2.2 0.030
Last Ast 0.9 3.4 0.3 0.786
Last Alt -2.5 3.5 -0.7 0.470
Last yGT -0.6 2.9 -0.2 0.838
Last Albumin -29.4 10.0 -2.9 0.004
Last Proteinuria -22.7 11.8 -1.9 0.055
Delivery Gestation 171.3 17.5 9.8 0.000
Table 6.24
These tables show the results of multiple regression analysis using the birth weight 
as the dependent variable. This demonstrates the close independent re la tionship  
between the birth weight and the delivery gestation as would be expected. There is 
also a relationship with the booking height and weight, last urea, alk phos and 
albumin. There is no significant relationship with any of the other parameters. The 
significance of the F Ratio demonstrates tha t this calculation is valid.
0.5
0.5
0.7
458.1
1.8
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Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>
Model 159770.4 21 7608.1 135.6 0.000
Error 14924.3 266 56.1
Total 174694.7 287
Coefficient of Determination (RA2) 0.9
Adjusted Coefficient (RA2) 0.9
Coefficient of Correlation (R) 1.0
Standard Error of Estimate 7.5
Durbin-Watson Statistic 2.1
Data File: Primigravida/PIH 
Variable
Dependent Variable: Weight Centile 
Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant 301.4 20.8 14.5 0.000
Booking Systolic 0.1 0.0 1.4 0.154
Booking Diastolic -0.1 0.1 -1.7 0.090
Booking Height -0.0 0.1 -0.5 0.597
Booking Weight -0.0 0.0 -0.2 0.819
Booking Haemoglobin -3.9 1.3 -3.0 0.003
Booking Hct 129.6 48.0 2.7 0.007
Last Systolic -0.0 0.0 -0.0 0.982
Last Diastolic 0.0 0.1 0.0 0.979
Last Urea -0.4 0.5 -0.9 0.373
Last Urate 0.0 0.0 1.3 0.189
Last Haemoglobin 0.4 1.1 0.4 0.721
Last Hct -31.2 42.5 -0.7 0.463
Last Platelet 0.0 0.0 0.3 0.749
Last Aik Phos -0.0 0.0 -1.3 0.194
Last Ast 0.0 0.1 0.5 0.596
Last Alt -0.1 0.1 -1.1 0.277
Last yGT -0.0 0.0 -0.6 0.546
Last Albumin -0.1 0.2 -0.3 0.729
Last Proteinuria 0.1 0.2 0.4 0.695
Delivery Gestation -9.9 0.3 -29.5 0.000
Birth Weight 0.0 0.0 46.5 0.000
Table 6.25
These tables show the results of multiple regression analysis using the weight 
centile as the dependent variable. The weight centiles were worked out for the 
Scottish tables of weight centiles. This dem onstrates the close independent 
relationship between the weight centile and the booking haem oglobin and 
haematocrit, and the delivery gestation and birth weight. There is no significant 
relationship with any of the other param eters. The significance of the F Ratio 
demonstrates tha t this calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg.of Mean
Source Squares Freedom Squares F-Ratio Prob,
Model 274.6 22 12.5 4.1 0.000
Error 815.3 265 3.1
Total 1089.9 287
Coefficient of Determination (RA2) 0.3
Adjusted Coefficient (RA2) 0.2
Coefficient of Correlation (R) 0.5
Standard Error of Estimate 1.8
Durbin-Watson Statistic 1.8
Data File: Primigravida/PIH Dependent Variable: Apgar 1 Minute
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob > t
Constant -25.2 6.5 -3.9 0.000
Booking Systolic -0.0 0.0 -0.3 0.760
Booking Diastolic 0.0 0.0 0.3 0.770
Booking Height 0.0 0.0 1.1 0.292
Booking Weight -0.0 0.0 -0.8 0.419
Booking Haemoglobin 0.3 0.3 0.8 0.412
Booking Hct 4.0 11.4 0.3 0.727
Last Systolic 0.0 0.0 0.8 0.434
Last Diastolic -0.0 0.0 -0.9 0.350
Last Urea -0.4 0.1 -3.4 0.001
Last Urate 0.0 0.0 1.8 0.066
Last Haemoglobin 0.0 0.3 0.1 0.909
Last Hct -4.1 10.0 -0.4 0.681
Last Platelet 0.0 0.0 1.0 0.325
Last Aik Phos -0.0 0.0 -0.7 0.472
Last Ast -0.0 0.0 -1.9 0.058
Last Alt 0.0 0.0 1.8 0.074
Last yGT 0.0 0.0 1.1 0.283
Last Albumin -0.0 0.0 -0.9 0.349
Last Proteinuria 0.1 0.0 1.4 0.152
Delivery Gestation 0.9 0.2 5.4 0.000
Birth Weight -0.0 0.0 -3.8 0.000
Weight Centile 0.1 0.0 4.1 0.000
Table 6.26
These tables show the results of multiple regression analysis using the Apgar at 
m inute as the dependent variable. This dem onstrates the close independent 
relationship between the Apgar at 1 minute and the last urea, delivery gestation, 
birth weight and weight centile. There is no significant relationship with any of the 
other param eters. The significance of the F Ratio dem onstrates th a t th is  
calculation is valid.
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Data File: Primigravida/PIH
Sum of Deg. of Mean
Source Squares Freedom Squares F-Ratio Prob>F
Model 211.9 23 9.2 11.5 0.000
Error 211.0 264 0.8
Total 422.9 287
Coefficient of Determination (RA2) 0.5
Adjusted Coefficient (RA2) 0.5
Coefficient of Correlation (R) 0.7
Standard Error of Estimate 0.9
Durbin-Watson Statistic 2.1
Data File: Primigravida/PIH Dependent Variable: Apgar 5 Minute
Variable Std. Err. t
Name Coefficient Estimate Statistic Prob, t
Constant 3.4 3.4 1.0 0.318
Booking Systolic 0.0 0.0 1.4 0.152
Booking Diastolic -0.0 0.0 -1.2 0.218
Booking Height -0.0 0.0 -0.3 0.768
Booking Weight -0.0 0.0 -0.1 0.956
Booking Haemoglobin -0.1 0.2 -0.8 0.443
Booking Hct 6.4 5.8 1.1 0.270
Last Systolic -0.0 0.0 -2.1 0.038
Last Diastolic 0.0 0.0 1.5 0.136
Last Urea 0.0 0.1 0.8 0.411
Last Urate -0.0 0.0 - 0.4 0.717
Last Haemoglobin -0.2 0.1 -1.1 0.268
Last Hct 4.5 5.1 0.9 0.376
Last Platelet -0.0 0.0 -0.5 0.644
Last Aik Phos 0.0 0.0 1.0 0.302
Last Ast 0.0 0.0 0.8 0.429
Last Alt -0.0 0.0 -1.8 0.074
Last yGT 0.0 0.0 0.3 0.800
Last Albumin -0.0 0.0 -1.8 0.076
Last Proteinuria 0.0 0.0 1.7 0.096
Delivery Gestation 0.1 0.1 1.2 0.234
Birth Weight -0.0 0.0 -0.5 0.613
Weight Centile 0.0 0.0 0.5 0.641
Apgar 1 Minute 0.4 0.0 13.1 0.000
Table 6.27
These tables show the results of multiple regression analysis using the Apgar at 5 
m inutes as the dependent variable. This dem onstrates the close independent 
relationship between the Apgar at 5 minutes and the Apgar at 1 m inute and the last 
systolic blood pressure. There is no significant relationship with any of the other 
parameters. The significance of the F Ratio demonstrates tha t th is calculation is 
valid.
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Presenting
<30 wks >30 wks Total P value
Total 57 129 186
Alive 36 123 159 <0.0001
Normal Umbilical Artery S/D  (106) 16(33) 68(73) 84 <0.0001
Normal Uteroplacental S/D 11 (33) 54(73) 65 <0.0001
Reactive Cardiotocograph 29 77 106 <0.05
Decelerative Cardiotocograph 16 14 30 <0.005
Normal amniotic fluid volume (142) 30(48) 75(94) 105 <0.05
<10th centile birthweight 27 38 65 <0.01
Delivered for fetal reasons 32 38 70 <0.001
Delivered for maternal indications 19 43 62 NS
Thrombocytopenia (<150xl03) 18 39 57 NS
Hyperuricaemia (>350 mmol/1) 49 113 162 NS
Proteinuria >5m g/24 hours 18 24 42 <0.05
Table 6.28
Summary of m aternal and fetal monitoring in all 186 pregnancies compared with 
gestation at presentation. Not all the tests were available over the nine year period. 
Doppler U ltrasound and liquor volume estim ations were available only in  the 
la tter half of the study. The relevant num bers of the tests  carried out are in  
brackets. It is clear th a t there is significantly worse monitoring resu lts in  those 
pregnancies presenting less than  30 weeks than  those presenting after th a t time. 
These tests tend to be those assessing the fetus wellbeing rather th an  the m aternal 
disease.
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Alive Demise Total P value
Total 38 19 57
Normal Umbilical Artery S/D  (33) 13 (23) 3(10) 16 <0.05
Normal Uteroplacental S/D  (33) 10 (23) 1(10) 11 <0.005
Reactive Cardiotocograph 27 2 29 <0.0001
Decelerative Cardiotocograph 10 6 16 NS
Normal am niotic fluid volume (48) 23 (32) 7(16) 30 <0.005
<10th centile birthweight 12 15 27 <0.01
Delivered for fetal reasons 16 16 32 <0.005
Delivered for maternal indications 13 6 19 NS
Thrombocytopenia (<150xl03) 10 8 18 NS
Hyperuricaemia (>350 mmol/1) 32 17 49 NS
Proteinuria >5m g/24 hours 10 8 18 NS
Delivered after 30 weeks 19 2 21 <0.005
Table 6.29
A com parison of m onitoring te s ts  compared with outcome in  pregnancies 
presenting less than  30 weeks gestation. Doppler Ultrasound and liquor volume 
estim ations were available only in the la tter half of the study. The relevant 
numbers of the tests carried out are in brackets. It is not surprising tha t there was a 
significant difference in tests  of fetal wellbeing between those tha t survived and 
those th a t did not. Differences are not seen in the traditional tests  of disease 
severity such as proteinuria, hyperuricaemia, and thrombocytopenia.
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Reasons why patients were referred
Diastolic blood pressure above 90 mmHg 
Proteinuria on stick testing 
Past history of hypertension in pregnancy 
Preexisting hypertensive problem 
Known renal disease
Table 7.1
The recommendations and the reasons for referral to the Daycare Unit. These 
criteria were not binding on the consultant obstetrician and were not decided upon 
by the author.
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Routine: Five blood pressure readings at hourly intervals
Abdominal palpation
Serum Uric Acid (Redman, Beilin and Wilkinson, 1976) 
Haemoglobin
Platelet Count (Redman, Bonnar and Beilin, 1978) 
Cardiotocograph
Follow-up: Ultrasound assessment
Estimation of fetal weight (Jeanty et a t, 1984)
Liquor volume estimation
Biophysical profile (Manning, Platt and Sipos, 1980)
Table 7.2
The monitoring tests  carried out at the Daycare Unit on the day of attendance. 
Results are available on the same day. The follow-up assessm ents are carried out in 
those patients returning to Daycare for a second attendance or if there is a 
particular risk to the pregnancy.
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Low risk
Average diastolic blood pressure < 90 mmHg 
Uric Acid < 350 mmol/1
Platelet count > 200 x 10®
Absence of proteinuria 
Reactive cardiotocograph 
Absence of IUGR
moderate risk
Average diastolic blood pressure >90 but <100 mmHg 
Uric Acid > 350but <450 mmol/1
Platelet count < 200 but >100 x  10® 
proteinuria < ++ or < 1.5gm/24hrs 
Reactive cardiotocograph 
Signs of IUGR but adequate liquor volume
high risk
Average diastolic blood pressure > 100 mmHg 
Uric Acid > 450 mmol/1
Platelet count < 100 x  10® 
proteinuria > ++ or > 1.5gm/24hrs 
Non-reactive cardiotocograph 
! Signs of IUGR or reduced liquor volume
Table 7.3
Risk categories used at Daycare for the assessm ent of the patients. To be low risk, 
a ll the parameters m ust be met. If any of the param eters in the moderate or high 
risk categoiy were met, tha t classified the patient into th a t group. Therefore, the 
patient was classified into the highest risk categoiy tha t any of the param eters met. 
Those a t low risk were referred back to the antenatal clinic, moderate risk patients 
were referred back to Daycare and the high risk patients were admitted to hospital.
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Referral diastolic BP Daycare diastolic BP 
Average 93±6 mmHg 83±8 mmHg
<90 278 2446
>90 and <100 2138 624
>100 and <110 566 86
>110 mmHg 174 0
Table 7.5
The average blood pressure and the incidence at four levels at time of referral and at 
the first Daycare attendance. Blood pressure was found to be lower with the 
majority being less than  90 mmHg at Daycare.
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No of Admissions No of Inpatient days
Hospital Deliveries adm issions /1000 Del inpatient days /1000 Del
A 9077 478 53 1353 149
B 8641 446 52 2628 304
D 7200 349 48 1283 178
GRMH 
Table 7.7
8609 256 30 804 93
A com parison of num ber of adm issions and inpatien t days sp en t due to 
hypertension in pregnancy in The Glasgow Royal Maternity Hospital and the three 
other large m aternity hospitals in the West of Scotland. These hospitals did not 
have a Daycare unit at the time of study. Figures are the totals for the years 1986/87.
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A
B
C
Group Study Number Age
Non-pregnant 20 22.3±3.2
Cross-sectional 208 21.5±4.3
Serial study 40 21.6±4.6
Range
18-26
16-35
17-28
Table 8.1
Patient Groups for the cross-sectional and serial studies of normal pregnancy.
The non-pregnant controls were recruited from the nursing staff w ithin the 
hospital. None had used hormonal contraceptive for the three m onths prior to 
sampling. The cross-sectional and the serial sampled patients were randomly 
selected from the Monday antenatal clinics at Glasgow Royal Maternity Hospital. 
All were normal a t inclusion into the study. The pregnancy outcome was also noted 
and no patient developed hypertension or intrauterine growth retardation.
There was no difference between groups as regards age (Students T  test).
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Group Study Number Age Range Gestation
D Prospective Primigravida 300 22.4±5.2 16-36 29.2±0.9 wks
E PIH (Cross-sectional Study) 141 25.2±5.2 14-38 34.4±5.2 wks
F Moderate PIH (Serial Study) 40 24.3±4.7 18-28 32.3±3.5 wks
G Ess. hypertension (Serial Study) 34 28.2±4.9 18-35 24 wks
Table 8.2
The four patient groups studied for changes in platelet size related to pregnancy 
induced hypertension (PIH) and essential hypertension.
Group D were randomly selected from primigravida attending the antenatal clinics 
a t Glasgow Royal m aternity Hospital. All were between 28 and 30 weeks when 
sampled. The outcome of their pregnancies were noted and compared with the 
results of the platelet studies.
Of the 141 patients with pregnancy-induced hypertension (PIH) (Group E), 107 had 
moderate PIH: (diastolic blood pressure 91-109 mm mercury on two occasions, 
without proteinuria); and 34 had severe PIH or preeclampsia: (diastolic blood 
pressure greater than  110 mm mercury with proteinuria of at least 0.3 gm /24 hours) 
at time of sampling.
Groups F and G were recruited from patients being managed in the Daycare Unit. 
This allowed serial sam pling of platelet size to be correlated w ith other 
manifestations of disease progression.
None of Group F were on any form of antihypertensive therapy when first selected 
for this study.
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Non-pregnant
Controls
1st Trimester 
2nd Trimester 
3rd Trimester 
27-33 weeks 
34-40 weeks
Number
20
26
87
40
55
Platelet Count MPV PDW
256.0±33.6 8.5±0.4 15.0+0.4
254.6+41.3
260.8±58.9
274.3167.5
257.6162.7
8.310.6 15.010.4 
8.410.9 15.010.4
8.411.0 15.510.5
8.911.1 15.810.6
Table 8.3
The cross sectional study of platelet size changes in normal pregnancy. (Groups 
A&B) The changes seen in m ean platelet volume (MPV) (p < 0.05) and platelet 
distribution width (PDW) (p < 0.001) are seen in the third trimester. In MPV this is 
only found after 34 weeks.
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Number Platelet Count MPV PDW
3rd Trimester 40 255.7±76.7 8.5±1.1 15.5±0.6
Labour 40 249.3±65.7 8.8±1.2 15.8±0.5
5th day postnatal 40 329.0±75.3 7.5±0.9 15.510.6
6th week postpartum 20 318.0±77.7 8.5±1.0 15.110.5
Table 8.4
The sequential study of platelet size in the third trimester, normal labour and 
puerperium. There is a further rise in  MPV and PDW during labour with a fall in 
MPV post-deliveiy coinciding with the rise in platelet count. Results have returned 
to normal by the 6th postnatal week.
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Outcome Number % Hct MPV PICt
A ll 300 100 35.5+2.1 8.5+0.5 268+35.8
Normal 216 70 35.5+2.0 8.6+0.5 277+35.7
Mild PIH 62 21 35.6+2.1 8.7+0.9 270+58.9
Moderate PIH 13 7 35.9+3.4 8.7+1.4 270+51.0
Severe 9 3 34.5+2.8 8.8+1.5 246+79.1
Table 8.5
The outcome of the pregnancies in the 300 primigravid patients screened at 28-30 
weeks. (Value + SD) There is a trend towards a lower haematocrit, larger MPV and 
lower platelet count in the patients who developed severe disease.
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Normal Mild Moderate Severe
106 32 8 8
110 30 5 1
NS NS NS p<0.02
MPV Number
>8.5 154
<8.5 146
Significance
Table 8.6
Outcome of the pregnancies in patients with MPV above or below the normal m ean 
for the gestation. Significantly more patients developed severe hypertension if the 
MPV was greater or equal to the m ean value (8.5). This produces a high sensitivity 
for severe disease of 8 /9  or 88.9%. Because the incidence of the severe disease is low, 
the specificity is only 145/291=49.8% and the positive predictive value is only 
8/154=51.9%.
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Number Platelet Count MPV PDW
Prior to 34 weeks
Normals 40 274.3+67.5 8.4±1.0 15.5±0.5
Moderate PIH 35 277.5±49.5 8.5±1.3 15.4±0.4
Severe PIH 14 148.8±24.0 8.7±0.3 15.4±0.5
At or after 34 weeks
Normal 55 257.6±62.7 8.9±1.1 15.8±0.6
Moderate PIH 72 271.3±79.1 9.0±1.4 15.8±0.6
Severe PIH 20 212.3±51.0 11.2±1.3 15.910.7
Table 8.7
Platelet changes in patients with moderate or severe PIH. If the disease presents 
prior to 34 weeks, the platelet count is reduced with no change in  MPV. A smaller 
reduction in count is seen with a large change in MPV after 34 weeks. The PDW did 
not change, implying th a t the whole population of platelets changed volume, not 
ju s t a  subpopulation.
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Outcome Number 24 wks 28wks 32wks 36wks
Stable 20 8.5+1.2 8.6+1.0 8.8+1.4 8.7+1.1
Moderate 8 8.7+1.0 8.7+1.1 8.9+1.3 9.1+1.3
Severe 6 8.6+1.2 9.1+1.4 9.7+1.2 10.2*1.2
Significance NS NS p<0.01 p<0.005
Table 8.8
Outcome of the 34 patients with essential hypertension sampled serially and the 
changes in the m ean platelet volume (MPV). The total num bers for each group 
reduce as gestation increases as patients are delivered. The significant differences 
were found between the severe group and those patients that remained stable.
!
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Outcome Number Atdiag 1 wk 2wk 3wks
Stable 17 8.6+1.1 8.8+1.2 8.9+1.3 9.0f 1.1
Moderate 14 8.8+1.2 9.0+1.2 9.1+1.4 9.2+1.2
Severe 9 8.8+1.3 9.1+1.4 10.0+1.2 11.2±1.2
Significance NS NS p<0.005 p<0.001
Table 8.9
Outcome of the 40 patients with mild pregnancy induced hypertension sampled 
serially and the changes in the m ean platelet volume (MPV). The timings are related 
to the time the diagnosis was made and the weeks after the diagnosis was made not 
to gestation. The total num bers for each group reduce as the weeks increase. The 
significant differences were found between the severe group and those patients tha t 
remained stable.
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Normal 
3rd Trimester 
Pregnancy
Mild/Moderate Severe
PIH PIH
Number
Primigravid
Parous
Mean Age 
(years±SD)
Mean±SD 
Gestation at time 
of first sample (wks)
Number with 
significant proteinuria 
(>0.3 gm /24 h)
40
23 (57.5%) 
17 (42.5%) 
25.2±5.8
35.2 + 4.0
0
26 
18 (69%) 
8 (31%) 
26.1±5.7
33.9 + 5.1
3(11%)
15
10 (66.6%) 
5 (33.3%) 
25.3±5.4
29.7 + 2.9
10 (66 .6%)
Number with 
IUGR*
0 3(11%) 10 (66 .6%)
Live Births 40 (100%) 26 (100%) 15 (100%)
' IUGR = Intra Uterine Growth Retardation = Birth Weight < 10th centile.
Table 9.1
Patient characteristics of those involved in the cross-sectional study of PGI2M and 
TxB2 in normal and hypertensive pregnancy. The severe patients not only had  a 
nigher incidence of IUGR b u t also presented earlier. There was no perinatal 
m ortality.
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Non 1st 2nd 3rd
pregnant Trimester Trimester Trimester
Postnatal
PG12M 15.9±0.68 19.9±0.96*** 15.5±1.05SI 16.4±1.2SI 13.6±1.99SI
TxB2 142+4.9 131±14.2* 133±14.9* 123±10.7** 119±6.3***
Number 44 29 3 1 29 21
*** p<0.01, ** p<0.02, * p<0.05 compared with non-pregnant.
** p<0.01, SI p<0.05, compared with 1st Trimester.
Table 9.2
Plasma levels of prostacyclin metabolites (PGI2M) and Thromboxane B 2 (TxB2 ) in 
non-pregnant women, the three trim esters of pregnancy and the puerperium . 
Results are mean±SEM.
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1st 2nd 3rd (1) (2)
Trimester Trimester Trimester
Norm al 19.1+2.5 13.1±1.2* 13.3±1.8*
PIH 17.6±2.5 18.2±2.1 12.2±3.4 <5.0*+
* p < 0.05 compared with 1st trimester of same group 
+ p < 0.05 compared with 2nd trimester of same group.
(1) = 32-36 weeks gestation (2) = 37-40 weeks gestation
Table 9.3
;The serial changes in the PGI2M in those who remained normotensive and those who 
developed PIH in the third trimester. The PIH group had higher levels in  the 2nd 
trim ester although this did not reach significance.
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1st 2nd 3rd (1) (2)
Trimester Trimester Trimester
Normal 125.0+8.8 94.8±13.8* 75.3±5.0**
PIH 131.5±12.6 82.2±12.6* 74.0+5.0* 113.6±10.4+
* p < 0.05 compared with 1st trimester of same group 
** p < 0.02 compared with 1st trimester of same group 
+ p < 0.05 compared with 3rd trimester of same group.
(1) = 32-36 weeks gestation (2) = 37-40 weeks gestation
Table 9.4
The serial changes in the TxB2 in those who remained normotensive and those who 
developed PIH in the third trimester. The PIH group had higher levels towards the 
end of pregnancy bu t this did not reach significance.
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Number
Age
Gestation 
Systolic BP 
Diastolic BP
Hydrallazine
15
23.4±3.4
31.3+3.5
155.32+15.3
106.43±8.5
Labetalol
15 
24.2±4.1 
32.1±3.9 
154.26±14.7
105.6717.6
Nicardipine
20
22.914.6
31.914.1
156.21115.8
106.2118.1
Table 10.1.
The patient groups in the acute hypertension study. The hydrallazine and labetalol 
groups were randomised separately. The nicardipine study was done a t a  Hater time. 
There was no difference in the parameters between any of the groups. Although the 
criteria for entry was a diastolic blood pressure of above 105 mmHg, some patients 
had a blood pressure below this a t commencement of the study. No patient had a 
diastolic blood pressure below 100 mmHg.
(Values are given as meansiSD)
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Labetalol Hydrallazine Nicardipine
Number 15 15 20
SelfAssessm ent 
Felt better 5 4 6
No change 9 5 6
Felt worse 1 <- p<0.05 -> 6 3
Side Effects 
Headache 0 4 2
Nausea 0 2 0
Peripheral Tremor 2 2 0
Scalp Tingling 3 0 0
Total with side effects 3 6 <- p<0.05 -> 2
Figure 10.2
The patients subjective assessment of the therapy given and the side effects reported 
when questioned for each of the study drugs. More patients felt either no better or 
worse after hydrallazine th an  with the other two drugs (p<0.05 for difference 
between labetalol and hydrallazine). This was usually  due to experiencing 
headache. The incidence of side effects was significantly higher with hydrallazine 
as compared to nicardipine (p<0.05)
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Labetalol Group Control group
Primigravida 38 36
parous 26 26
Total 64 62
Age 23.8 ±3.4 24.1 ±2.9
Gestation 34.86 ±2.23 35.22 ±2.14
Systolic BP 142.59 ± 10.02 139.78 ±9.13
Diastolic BP 97.46 ±7.6 95.02 ± 5.29
Rise in Sys BP 14.78 ±9.02 11.71 ±8.26
Rise in Dias BP 19.26 ± 13.33 16.16± 12.58
Plasma Urate 308.09 ±84.0 306.00 ±72.02
Platelet Count 220.13 ±50.0 239.41 ± 74.20
Table 10.3
The entry parameters of the randomised study of labetalol against bed rest in  mild 
to moderate Pregnancy Induced Hypertension. The rise in blood pressure was from 
the first trimester levels to the entry blood pressure.
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Labetalol
Group
Control
Group
Significance
Number Settled 33 9 p<0.0001
Number Stable 26 20 NS
Number worsened 5 33 p<0.001
Total 64 62
Number severe 3 13 p<0.005
Number Proteinuria 4 9 NS
Uric acid rise 32 31 NS
Platelet Count Fall 5 25 p<0.0001
Table 10.4
A comparison of the change in the parameters between the treated and the control 
groups.
Settled = Diastolic blood pressure fell below 90 mmHg
Stable = Diastolic blood pressure did not rise by more than
5 mmHg.
Worsened = Diastolic blood pressure rose by more than
5 mmHg.
Severe = Diastolic blood pressure rose above 110 mmHg.
Proteinuria = Greater than 0.3 gm /24 hours.
Uric acid rise = A rise of more than  15 mmol/1 (approx. 5%)
Platelet Count Fall = A fall of more than 25 x  10^ (approx 10%)
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Side Effect Number Withdrawals
Nasal Stuffiness 7 0
Slight Nausea 10 0
Peripheral Tremor 21 2
Scalp Tingling 18 O
Bronchospasm 1 1
Table 10.5
The side effects seen in the study group. The most common were peripheral tremor 
and scalp tingling. These were rarely bad enough to cause withdrawal from the 
study.
Labetalol Control Significance
Group Group
Delivery Gestation 38.78±1.35 38112 NS
Labour
Spontaneous 15 12 NS
Induced 40 38 NS
Elective Section 9 12 NS
Delivery
SVD 29 28 NS
Forceps 18 15 NS
Caesarean Section 17 19 NS
Birth Weight (Kg) 3.2110.86 3.2610.63 NS
Number < 10th Centile 12 11 NS
Placental weight 0.6210.15 0.6010.14 NS
Apgar <5 at 1 min. 6 5 NS
Apgar <7 at 5 min. 3 3 NS
Perinatal Death 0 0 NS
Table 10.6
The outcome of the pregnancies as assessed by gestation at delivery, onset of labour, 
delivery and neonatal wellbeing in the controlled trial of labetalol against bed rest.
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Parameter Mean Range
Number 186
Age 24.21±4.6 18-36
Gestation 31.42±3.2 24-34
Systolic BP 154.48+16.1 135-200
Diastolic BP 109.20±9.2 100-140
Systolic Rise 25.55±9.2 10-40
Diastolic Rise 27.93±10.2 10-60
Proteinuria 2.4+1.3 0.5-6.2
Urate 387.21±82.1 260-620
Platelet Count 174.90+66.4 32-265
Table 10.7
The patient group in the severe study. Blood pressure levels as well as the rise in 
blood pressure form the first trim ester reading are m arkedly elevated. The 
elevation of urate, the low platelet count and the degree of proteinuria confirm that 
these patients have significant disease.
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Parameter Mean Range
Labetalol dose 12011320 600-1600
Treatment length 15.619.2 1-36
Delivery gestation 33.513.1 28-38
Table 10.8
The average dose of labetalol given. 58 of these patients also received a vasodilator 
drug which was initially hydrallazine b u t latterly nifedipine. There was a wide 
range in treatm ent length, partly related to the desire to prolong the pregnancy for 
longer in the earlier gestations.
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Parameter Start Week 1 Week 2
Systolic BP 
Diastolic BP 
Proteinuria 
Urate
Creatinine Cl 
Platelets
154.48±16.1 
109.2Q±9.2 
2.4±1.3 
387.6±82.1 
109.4±23.1 
174.9±66.4
135.38±7.4
93.40±6.2
2 .0±2.1
402.4±92.1
106.7±25.2
206.7±43.2
135.84±10.1 
91.68±8.3 
3.2±2.4 
394.6±88.1 
94.8±35.6 
226.4±36.3
Table 10.9
The results of the treatm ent and the monitoring in the severe study. These results 
confirm the apparent platelet protective effect of labetalol therapy.
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Time (min) Pre 15 30 45 60
Systolic BP 155.5±8.7 156.6±14.6 144.9±13.2 145.4115.2 146.6110.6
Diastolic BP 108.0±4.3 96.6±5.6 94.917.8** 93.915.8** 93.714.5**
Brachial SD 3.2±1.1 3.6+1.6 3.712.1
Uteroplacental SD 1.6±0.5 1.8±0.8* 1.810.3
Umbilical SD 2.5±0.9 2.410.7 2.410.8
SD = Doppler systolic/diastolic ratio BP = blood pressure
* p<0.05 ** p<0.001 (Significance by Wilcoxon rank test for matched pairs.)
Table 10.10
Maternal blood pressure and brachial artery, uteroplacental and umbilical artery 
systolic/diastolic ratios pre and post nicardipine therapy (results are m ean ± 1 
standard deviation).
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Time Pre 1st Day 3rd Day 5th Day 7th Day 9th Day
Systolic BP 151.7±8.4 145.9±10.4 152.8±16.1 148.7±15.1 145.6±5.3 144.7±4.1 
Diastolic BP 105.414.1 95.617.5* 102.1111.8 97.9±12 99.4 ±10.3 93.2±5.3 
Brachial
SD 4.0±1.3 3.9±1.3 3.8±1.4 3.9±2.3 4.6±2.0 5.1±1.8
Uteroplacental
SD 1.8±0.4 1.9±0.3 2.0±0.4* 1.910.4 1.5±0.5 1.5±0.6
Um bilical
SD 2.6±0.9 2.7±0.7 2.710.8 2.8±0.8 2.410.4 2.711.0
SD = Doppler systolic/diastolic ratio BP = blood pressure
*p<0.05 (Significance by Wilcoxon Rank test for matched pairs)
Table 10.11
Maternal blood pressure and brachial artery, uteroplacental and umbilical artery 
systolic/diastolic ratios pre and post pindolol therapy (results are m e a n ll  
standard deviation).
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Time Pre 1st Day 3rd Day 5th Day 7th Day 9th Day
Systolic BP 138.5±8.5 135±9.2 136.3±8.6 138.1±8.3 140.8±8.4 145.8±10.2
Diastolic BP 92.9±3.9 93.2±5.8 91.5±6.6 95.2±5.8 96.4±6.4 99.5±6.2
Brachial
SD 3.3±0.6 3.8±1.4 3.4±0.8 3.5±1.2 4.0±1.8 3.8±1.7
Uteroplacental
SD 1.9+0.4 2.0+0.5 2.1±0.4 2.310.3* 2.210.7 2.310.4
Umbilical
SD 2.410.3 2.410.2 2.410.3 2.410.4 2.710.6* 2.510.5
SD = Doppler systolic/diastolic ratio BP = blood pressure
*p<0.05 (Significance by Wilcoxon Rank test for matched pairs)
Table 10.12
The changes in m aternal blood pressure and brachial artery, uteroplacental and 
umbilical arteiy systolic/diastolic ratios in preeclamptic patients on no therapy 
(results are mean + 1 standard deviation).
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Prepregnancy
If patient is normotensive consider stopping all anti hypertensive drugs.
Aim to stop ACE inhibitors and diuretics if at all possible.
Less than 20 weeks
If the  patient is normotensive stop antihypertensive medication and  p u t into 
monitoring programme.
If presenting for the first time with hypertension, investigate for renal disease, then 
insert into monitoring programme.
Refer to the Outpatient Daycare Assessment unit for followup.
After 20 weeks.
Any patient tha t presents for the first time or with worsening BP after 20 weeks is 
presumed to have preeclampsia until monitoring suggests otherwise.
Monitoring
Mother:- Average of five blood pressure readings.
Serum uric acid 
Platelet count 
Urinalysis for protein 
Optional:- plasma creatinine
24 hour urine for protein 
Fetus:- Non stress test (cardiotocograph)
Ultrasound for weight and liquor volume.
Optional:- Doppler ultrasound 
Biophysical profile 
Criteria for antihypertensive usage 
If BP is persistently elevated above 150/100 mmHg.
start Labetalol 200 mg three times a day 
If BP not controlled increase to 200 mg four times a day
then increasing dosage up to 1200 mg a day 
If BP not controlled add in nifedipine 10 mg twice a  day 
then increasing up to 40 mg a day.
Hypertensive crisis
If BP greater than  160/110 mmHg give 200 mg oral labetalol 
o r 50 mg IV labetalol 
or 20 mg IV Hydrallazine 
Repeated oral doses or an infusion of labetalol can then be used
Table 10.13
Management protocol for the use of antihypertensive drugs in the Glasgow Royal 
Maternity Hospital.
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HEN DRVCflRE <1990> - MR IN MENU
1) TODRVS FILE
2) CLOSE FILE/PRINT DRTfi
3) RCCESS MASTER FILE
4> LIST FROM MASTER FILE
5) GESTATION CALCULATOR
6) CHRNGE TODRVS DATE
7) CHANGE TIME
8) CHECK DELIUERED PATIENTS
INPUT RNSHER
Figure 2.1
A “screendump” of the m enu for the Daycare programme. It was completely m enu 
driven and easy to use. All Daycare data from August 1984 was entered In ’real’ time.
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DRVCRRE C1988J - RESULT:
PRRfl O-i-O 
D0B28/01/62 
28uik
I ME I l_L_ V 
INIT MO 134009 
1 2uuk b rH H E B S ^  >  BR| 
nom GENERAL PRACTITIONER on 13/09/89 
ioson PREGNflNCV HVRERTEMSIOM BP150/085
GEST 37+2 
LMP30/12/88
O  O
DC da te 18/09/89 5 days a f ten ne fera I
CONSULTANT LUNAN UISIT 1
1 > BP — 140/080 Urea — 2 - 5
2 > BP — 130/082 Urate — 3 10
3 C* BP — 140/085 Haemog1ob i n — 12.2
4 > BR — 142/088 R 1 a-te let Count— 240
5 > BP — 150/095 Pr-o to i nun i a — Mono
Aw BR — 140 S O 86 CTO — REACTIUE
DM BR — OOO/OOO FHR — 150
i agnosis Mild RIH
/U-DAV CARE on 22/09/89C4 day
■ SPflCEl
Figure 2.2
A “screendump” of the Daycare data screen displaying the available data. This is a 
false name and number, bu t the data is genuine. This patient had a single BP greater 
th an  95 mmHg diastolic a t the outpatient clinic. Therefore, she is, by definition, 
mildly preeclamptic. She is being seen again at Daycare to see if her blood pressure 
problems are progressive. This will be explained fully in Chapter 7.
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120 SYSTOLIC
Lying ---------
110
Sitting
100
DIASTOLIC
—o
20 24 28 40 Post­
natal
Weeks of pregnancy
Figure 3.1
The blood p ressu re  changes th roughou t norm al pregnancy tak en  from 
MacGillivray (MacGillivray, 1961). There is little difference between lying and 
sitting as far as diastolic blood pressure is concerned, bu t a m arked difference in 
systolic blood pressure.
There is a fall into the second trimester and and then a rise towards term. The blood 
pressure at term is little different from the non-pregnant blood pressure.
Figure 3.2
The classic renal lesion of preeclampsia. The glomerulus shows pouting of the 
glomerular loop into the neck and the first coil of the proximal tubule (Sheehan and 
Lynch, 1973).
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Latent Essential Hypertension ?
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Figure 3.3 '
The incidence of moderate and severe preeclampsia changes with age. There is an  
increase of moderate hypertension with increasing age. This is probably related to 
the background incidence of essential hypertension (Nelson, 1955).
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p<0.001p<0.05 p< 0.1 p<0.01
18 22 26 28 30 32 34 36 38 40
WEEKS OF GESTATION
Figure 3.4
A comparison of the dose of angiotensin II required to produce a pressor response in 
120 primigravida who remained normotensive (black circles) and 72 who became 
hypertensive in later pregnancy (open circles). There was a significant difference 
seen from 22 weeks, where those that developed hypertension appeared to be more 
sensitive (Gant e ta l ,  1973).
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210 patients screened with All infusion test 
44 patients found positive
21 aspirin
21 
No PIH
0
23 placebo
11
PIH No PIH
Figure 3.5
The results from a randomised study of aspirin in 44 primigravida who were found 
to be sensitive to angiotensin II infusion. It shows tha t aspirin appears to prevent 
the development of preeclampsia bu t also tha t only 50% of the untreated  patients 
developed the disease (Walleriburg etaL, 1986).
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INTERVILLOUS SPACE
Spiral
arteries
c  S p i r a l
I arteries
JphysiologicalJ 
■structural changes-*- 
j (0  500 pm) |
Narrow \
se g m en t —•-] Basal artery1/3 M Basal artery
Radial arteryRadial artery Musculo-eiastic
(0150-250/z m) \ PRE-ECLAMPSIANORMOTENSION |
Figure 3.6
An a rtis t’s im pression of the spiral arteries of the u te ru s  in  norm al and 
preeclam ptic pregnancy. Normally there is a dilatation of the  artery  from 
trophoblastic invasion destroying the muscle coat. In preeclampsia, th is dilatation 
does not occur. This will lead to reduced placental perfusion and may explain the 
increase incidence of growth retardation found in  preeclam psia (Robertson, 
Brosens and Dixon, 1976).
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HEREDITARY IMMUNO-COMPATABILITY
VASCULAR REACTIVITY PLACENTATION
PIH PIH IUGR
No IUGR IUGR No PIH
Figure 3.7
A suggested relationship between pregnancy induced hypertension and intrauterine 
growth retardation. If the placental lesion is present, IUGR will be apparent bu t 
there will be no blood pressure problems unless there is a vascular sensitivity. The 
reverse would also be true.
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mmHg
130 i
120
1 1 0 -
1 0 0 -
90 -
80 -
1 2  1 6  2 0  2 4  2 8  3 2  3 6  4 0  L bP N
Gestation
Primigravida ------ • -----  Multigravida
Figure 5.1
The serial blood pressure measurements in 186 primigravida and 115 m ultiparous 
randomly selected patients attending the antenatal clinic a t the Glasgow Royal 
Maternity Hospital. The graph demonstrates a fall in blood pressure in  the second 
trim ester with a rise towards term. It was found tha t the parous women had a 
significantly lower systolic and diastolic blood pressu re  in  m id-pregnancy 
(Significance shown in Table 5.2).
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1 0 0 -
80 -
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2nd Clinic Systolic
&  Z 7 *. 7 7
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Systolic Blood Pressure
Figure 5.2
A graph of the two systolic blood pressure m easurem ents taken in  365 randomly 
selected patients at the antenatal clinic by the same observer using a random zero 
sphygmomanometer. There was a normal distribution and no difference between 
the m ean or range of the two readings.
Each column corresponds to the num ber of patients with a reading between the 
given figure and 9 mmHg above, e.g. the first column is the num ber of all readings 
between 70-79 mmHg.
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200-1
Number
1st Clinic Diastolic E3 2nd Clinic Diastolic
150-
100 -
50 -
3 0  40  5 0 60 70 80  90  100
Diastolic Blood Pressure
1 1 o
Figure 5.3
A graph of the two diastolic blood pressure measurements in 365 randomly selected 
patients taken at the antenatal clinic by the same observer using a random  zero 
sphygmomanometer. There was a normal distribution and no difference between 
the mean or range of the two readings.
Each column corresponds to the num ber of patients with a reading between the 
given figure and 9 mmHg above, e.g. the first column is the num ber of all readings 
between 30-39 mmHg.
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S3 Clinic DiastolicsM Clinic Systolics
Number
- 4 0 - 3 5 - 3 0 - 2 5 - 2 0 - 1  5-1 0 - 5  0 5 10 15 20 25  30 35 40 45
Difference between blood pressures
Figure 5.4
A graph showing the difference between two consecutive readings taken 10 m inutes 
apart in 365 randomly selected patients at the antenatal clinic by the same observer 
using a random zero sphygmomanometer. There was a wide disparity between the 
consecutive readings and less than  40% of the patients had readings w ithin 5 
mmHg. The difference could either be up or down.
Each column corresponds to the num ber of patients with a difference between the 
given figure and 4 mmHg above, e.g. the first column is the number of patients where 
the second reading is between 36-40 mmHg less than  the first reading.
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Systolic Blood Pressure
Figure 5.5
A graph of the first two systolic blood pressure m easurem ents taken  in  1000 
consecutive Daycare patients by the attendant nursing staff using a m ercuiy 
sphygmomanometer. There was a normal distribution and no difference between 
range of the two readings. There was a small bu t highly significant difference in the 
means. (131.2±12.9 mmHg v 128.7±12.8 mmHg, p<0.001 (Student’s T Test))
Each column corresponds to the num ber of patients with a  reading between the 
given figure and 9 mmHg above, e.g. the first column is the num ber of all readings 
between 70-79 mmHg.
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Number
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0  2st DC Diastolic
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Diastolic Blood pressure
Figure 5.6
A graph of the first two diastolic blood pressure m easurem ents taken  in  1000 
consecutive Daycare patients by the attendant nursing staff using a m ercury 
sphygmomanometer. There was a normal distribution and no difference between 
range of the two readings. There was a small but significant difference in the means. 
(84.8±10.8 mmHg v 83.5±10.3 mmHg, p<0.005, (Student’s TTest))
Each column corresponds to the num ber of patients with a reading between the 
given figure and 9 mmHg above, e.g. the first column is the num ber of all readings 
between 30-39 mmHg.
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Difference between DC Blood Pressures
Figure 5.7
A graph showing the differences between the first blood pressures readings taken in 
lOOO consecutive Daycare patients by the attendant nursing staff using a mercury 
sphygmomanometer. There was a wide variation in the consecutive readings and in 
less than  50% of the patients was the second blood pressure within 5 mmHg of the 
first. The difference could either be up or down.
Each column corresponds to the num ber of patients with a difference between the 
given figure and 4 mmHg above, e.g. the first column is the number of patients where 
the second reading is between 36-40 mmHg less than the first reading.
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zero o n e  two three  four five six seveneigh t  nine
Figure 5.8
The incidence in percent of Diastolic blood pressure readings ending in the quoted 
digits in  the combined group of the first and second Daycare readings by the 
attendant midwives. There appears to be a predominance of readings ending in zero 
and five and a reluctance to give a reading ending in 1,4,6 or 9 mmHg.
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Figure 5.9
A “Box and Whiskers” graph of the changes in systolic blood pressure taken in  1000 
consecutive Daycare patients by the attendant nursing staff using a m ercury 
sphygmomanometer. The data represents the differences separated depending on 
the first systolic blood pressure.
The results demonstrate tha t for the higher blood pressures there is a tendency for 
the blood pressure to fall (a positive difference) and to rise with the lower blood 
pressures. These differences are all highly significant (p<0.001) although there is an 
obvious overlap.
The graph shows the median (horizontal line), confidence limits of the m ean (the 
Box), SDx3 (the whiskers) and the outliers (the small boxes)
Figure 5.10
A “Box and W hiskers” graph of the changes in diastolic blood pressure taken in 
1000 consecutive Daycare patients by the attendant nursing staff using a mercury 
sphygmomanometer. The data represents the differences separated depending on 
the first diastolic blood pressure.
The results demonstrate tha t for the higher blood pressures there is a tendency for 
the blood pressure to fall (a positive difference) and to rise with the lower blood 
pressures. These differences are all highly significant (pcO.OOl) although there is an 
obvious overlap.
The graph shows the median (horizontal line), confidence limits of the m ean (the 
Box), SDx3 (the whiskers) and the outliers (the small boxes)
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Figure 5.11
The trend of the five diastolic blood pressure readings at Daycare. There was a  small 
bu t significant difference between the means of the first and second readings. These 
differences were only 2.5 mmHg for the systolic blood pressure and 1.3 mmHg for 
the diastolic blood pressure. There was no difference between the later readings 
(Readings are in mmHg±SD).
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Figure 5.12
The differences in the consecutive averages of the diastolic blood pressures seen at 
Daycare. After the first three readings, adding a fourth reading does not 
significantly change the average result achieved (Values are mmHg±SD).
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Figure 5.13
The percentage of patients with a difference between consecutive averages of more 
than  5 mmHg. Only 2% of the patients still had differences of greater th an  5 mmHg 
between the averages of 3 and 4 readings. This implies that the average of 3 readings 
give accuracy in 98% of patients. The addition of a  fourth reading improves th is 
accuracy to almost 100%. A fifth reading does not appear to give any benefit.
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Figure 5.14
The incidence of the differences between the diastolic blood pressures found 
between the Dinamap and the nurse at Daycare. It can be seen that there are marked 
differences and most of the Dinamap readings are lower than  the nurses readings. 
The average difference was 8.3±3.4 mmHg. This is probably related to the fact th a t 
the Dinamap is oscillatory and m easures a diastolic blood pressure  between 
somewhere between the fourth and fifth Korotkoff sounds.
The graph shows the cumulative num ber of patients were the difference was as 
stated, e.g. the first column shows the num ber of patients with a difference of 
greater th an  20 mmHg, the next column shows the num ber of patients with a 
difference of greater than  15 mmHg, including those greater than  20 mmHg
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Figure 5.15
The trend in the 10 Dinamap blood pressure readings. There is a significant 
reduction from the first blood pressure readings to the rest (Values are mmHg±SD).
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Figure 5.16
The trend of pulse rate over the ten Dinamap readings. There was no evidence tha t 
there was any anxiety a t the beginning of the readings th a t would have explained 
the higher first BP reading. In fact, the pulse significantly rose over the first four 
readings. (Values are Heart Rate±SD)
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Figure 5.17
A graph showing the differences between the first two blood pressures readings 
taken  in 1000 consecutive Daycare patients by the Dinamap blood pressure 
recorder. There was a wide variation in the consecutive readings and in less th an  
40% of the patients was the second blood pressure within 5 mmHg of the first. The 
difference could either be up or down.
Each column corresponds to the num ber of patients with a difference between the 
given figure and 4 mmHg above, e.g. the first column is the number of patients where 
the second reading is between 36-40 mmHg less than the first reading.
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Figure 5.18
The incidence in percent of Diastolic blood pressure readings ending in the quoted 
digits in  the combined group of the first and second Daycare readings by the 
Dinamap. As expected, there is no predominance for any given readings.
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Figure 5.19
The differences in the consecutive averages of the diastolic blood pressures seen 
using the Dinamap. After the first six readings, adding a seventh reading does not 
significantly change the average result achieved. (Values are mmHg±SD)
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Figure 5.20
The percentage of patients with a difference between consecutive averages of more 
than  5 mmHg using the Dinamap. Only 3% of the patients still had differences of 
greater than  5 mmHg between the averages of 6 and 7 readings. This implies tha t the 
average of 6 readings using the Dinamap gives An accurate result in  97% of patients. 
The use of 8 readings improves th is accuracy to almost 100%. A n in th  or tenth  
reading does not appear to give any benefit.
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Figure 7.1
The num ber of attendances at Daycare. 62% had only one attendance. This is made 
up of those who are referred back to the Antenatal Clinic and a few th a t were 
admitted directly to hospital. The rest attended Daycare for further assessment.
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Figure 7.2
A graph of the num ber of admissions, Daycare Attendances and those managed at 
the normal outpatient clinic. Daycare has dramatically reduced the admissions to 
hospital bu t has led to an increased number that are monitored.
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Figure 8.1
The changes in platelet size in normals, moderate pregnancy induced hypertension 
and severe disease. The increase in platelet size is only seen in the patients with late 
onset severe disease.
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Figure 9.1
Prostacyclin levels in  40 normal third trim ester pregnancies, 26 patien ts with 
moderate PIH (preeclampsia) and 15 patients with severe preeclampsia. Almost all 
severe and 50% of the m oderate patients had prostacyclin levels below the 
measurable range.
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Figure 9.2
Thromboxane levels In 40 normal third trim ester pregnancies, 26 patients with 
moderate PIH (preeclampsia) and 15 patients with severe preeclampsia. There was a 
significant increase in the moderate patients bu t no change in  the severe patients 
who tended to present a t an  earlier gestation. This may well relate to the results 
seen in the platelet size studies where only in the milder late onset disease did 
platelet size increase.
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Figure 9.3
The serial changes in  prostacyclin and throm boxane in  those patien ts who 
remained normotensive. These results confirmed the cross-sectional study which 
showed elevated prostacyclin levels in  early pregnancy, th en  falling w ith 
advancing gestation.
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Figure 9.4
The serial changes In prostacyclin and throm boxane in  those patien ts who 
developed pregnancy induced hypertension. The prostacyclin appeared to fall prior 
to the  hypertension developing in half the patients. Thromboxane rose after 
development of the hypertension.
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Figure 10.1
The effects of 200 mg labetalol, 10 mg oral nicardipine and 10 mg IM hydrallazine 
on hypertensive patients in pregnancy. All three drugs showed a statistically 
significant reduction in diastolic blood pressure by 30 mins which persisted for the 
rest of the two hour monitoring period (p<0.001) , Labetalol was the only drug to 
show a statistically significant reduction in systolic blood pressure a t 60 m inutes 
(pcO.OOl), bu t all had achieved a reduction by 2 hours (p<0.001).
(Wilcoxon rank  sum  test for matched pairs)
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Figure 10.2
The pulse changes seen in the acute antihypertensive study. Both hydrallazine and 
nicardipine cause a tachycardia (Statistically significant between 30-60 m inutes, 
pcO.OOl). Labetalol caused a small initial rise, bu t th is did not reach statistical 
significance. There was no difference between the groups after 90 minutes.
(Wilcoxon Rank sum  test for matched pairs)
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Figure 10.3
The num ber of patients controlled a t given dose of labetalol. Few patients were 
controlled on 100 mg bd. Soon after the start of the study, the starting dose was 
raised to 200 mg tid as most patients appeared to require this am ount to achieve 
adequate control.
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Figure 10.4
The effect of labetalol on blood pressure. The systolic and diastolic blood pressures 
were found to be significantly reduced by day two in the treated group (pcO.Ol, 
Wilcoxon Rank Sum  test) compared with pretreatm ent levels. However, no 
significant difference was found between the two groups until day nine of treatm ent 
(Mann Whitney U test).
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Figure 10.5
The changes seen in the creatinine clearance in the randomised m ild/m oderate 
study. This was a m arked improvement seen in the first few days in  the treated 
group. The difference between the treated and non-treated groups was statistically 
significant on days 3-7 (p<0.005). This difference was not maintained.
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Figure 10.6
The platelet count in the randomised study. There was a small insignificant rise in 
the platelet count after commencement of labetalol. The platelet count fell in the 
un treated  group. The difference reached significance after the seventh day of 
treatment (p<0.005).
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Figure 10.7
The num ber of patients who were controlled in the severe study. The majority 
settled into the normal range (less than  90 mmHg) or were stabilised (maintained 
between 90-100 mmHg). There were a small num ber of patients where control was 
not achieved, blood pressure rose further and delivery was necessary.
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Figure 10.8
If blood pressure control is achieved with labetalol, long term  control can  be 
maintained and the patients can let home to return  for Daycare management. The 
figure shows an random  example of one patient where long term  control was 
achieved. This is possible in around 20% of the patients.
140
Number
6 0 0  8 0 0  1 2 0 0  1 6 0 0  + V asodilator
Final Drug Regime
Figure 10.9
The final drug dosage and the incidence of the usage of vasodilators in the severe 
study. Over 40% of the patients were given vasodilators drugs as well as labetalol. In 
the majority of the cases, nifedipine was the vasodilator used.
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Figure 10.10
The effect of second line therapy with nifedipine. In patients where there is loss of 
control with labetalol alone, a further 7 days of control can often be achieved.
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Figure 10.11
The effect of labetalol on the platelet count In a single patient. Not all the patients 
had such a dramatic response, b u t the platelet count tended to improve after 
labetalol was commenced.
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Figure 10.12
The gestation a t presentation of all those seen at the GRMH with hypertension in 
pregnancy. Most of the patients are between 32-40 weeks. These patients are easy to 
manage as the delivery option is available. A significant num ber of the patients 
present below 32 weeks. These are the patients th a t would benefit m ost from 
intervention therapy.
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Figure 10.13
The PND associated with hypertension per 1000 of all deliveries in the Glasgow 
Royal Maternity Hospital and in Scotland for the years 1980-89. For the years 
1980-82, the rates in  GRMH were higher than  for Scotland, bu t there has been no 
difference in the years since.
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Figure 10.14
The PND in the Glasgow Royal Maternity Hospital and in Scotland for the years 
1980-89. In the all years apart from 1983, the rate for GRMH have been higher than  
tha t in Scotland as a  whole (p<0.001)
(Wilcoxon rank sum  test)
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Figure 10.15
The percentage of the total PND th a t were associated with hypertension in  the 
Glasgow Royal Maternity Hospital and in Scotland for the years 1980-89. In the 
years 1980-82 the rates were higher in GRMH, bu t in the years 1983-89, the 
percentage for GRMH has been significantly less th an  for the rest of Scotland
(p<0.01)
(Wilcoxon Rank sum  test)
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Figure 10.16
The incidence of delivery under 35 and 30 weeks in  pregnancies in  GRMH booked 
patients affected by hypertension in pregnancy. Figures are shown for num ber of 
deliveries per 1000 hypertensives in  the  hospital per year. There w as an  
improvement around 1983 with a reduction in deliveries less than  30 weeks. If the 
years 1980-82 are compared with 1983-1989, the rate of delivery less than  30 weeks 
has significantly reduced (p<0.005). There has also been a small b u t significant 
change in the rate under 35 weeks (p<0.05).
(Fishers exact test)
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Figure 10.17
A graph of the changes in the stillbirth and neonatal death rates per 1000 of all 
deliveries in GRMH booked patients associated with hypertension in pregnancy. 
When compared with the rates for 1980-82, there has been a significant reduction 
for both stillbirth (p<0.05) and neonatal death (p<0.005) in the years 1983-89. The 
reduction in overall perinatal death rate is also significantly reduced (pcO.OOl) 
(Fishers exact test)
The Daycare Programme
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The Daycare Programme
The basis of good research is documentation. From the very beginning of these 
studies, I used computers to store data in a form that would allow easy analysis. The 
development of these systems was an  integral part of the work. It allowed the 
collection and evaluation of a large amount of data. The initial computers used were 
BBC microcomputers with attached disc drives. There was no database available 
th a t appeared to be able to serve our purposes. I then  decided to write my own 
programmes for the computers. These were all written in BBC Basic, a  high level 
structured language with procedures and functions. It has particularly good file 
handling and colour graphic capabilities. There was three m ain programmes 
written; the Daycare programme, the Platelet size database and the Dinamap 
interface programme. There were m any other sm aller programmes w ritten to 
collect data, analysis the files and finally to transfer the data into IBM compatible 
Dbase files or Mac compatible FileMaker files. This allowed an  upw ard 
compatibility of the databases with the improvement of the computer facilities as 
the more more powerful machines became available.
Listed below is the Daycare programme. This was the mainstay of the hypertensive 
database allowing storage of data on the thousands of attendances through the 
Daycare unit. This programme was designed, developed and written totally by the 
author.
T he D aycare P rog ram m e
0 REM DAYCARE PROGRAM
1 REM Copyright JJ WALKER 1990 
10 ONERRORGOTO30000
20 MODE 7 
30 PROC_DATA 
40 PROCJNFO 
90 REPEAT
95 axes%=0:gotit%=0 
100 ANS$=FN_MENU(12330)
120 IF ANS$="S" THEN PROC_SPECIAL
121 IF ANS$="1" THEN PROC_NEW
122 IF ANS$="2" THEN PROC_ENDOFDAY
123 IF ANS$="3" THEN PROC_AXESFIL:ANS$=M"
124 IF ANS$="4" THEN PROCJJST
125 IF ANS$="5" THEN PROC_GESTATION
126 IF ANS$="6" THEN PROC_DATECHANGE
127 IF ANS$="7" THEN PROC_TIME 
130 UNTIL ANS$="E" OR ANS$="8"
140 PROC_SAVECURRENT
145 IF ANS$="8" THEN CHAIN"PATCHCK"
150 END 
160 :
170 DEFPROC_SPECIAL
171 LOCAL ANS$
172 CLS 
174 pw$=H"
151
176 PROC_DH(5,2,CHR$129+'THIS IS THE SPECIAL FUNCTIONS")
178 PROC_DH(5>6,CHR$129+"WHAT IS THE PASSWORD ?")
180 A$=GET$:pw$=pw$+A$
:PROC_DH(5,10,CHR$130+STRING$(LENpw$,"*")):IF LENpw$<5 THEN 180 
182 IF pw$o"JIMMY" THEN ENDPROC
184 REPEAT
185 ANS$=FN_MENU(12331)
186 IF ANS$="1" THEN PRINT"1) ERASE CURRENT FILE Y/N?":A$=GET$:IF 
A$="Y" THEN PROC_ERASE
188 IF ANS$="2" THEN PRINT"2) ERASE LAST DATE Y/N?":A$=GET$:IF A$="Y" 
THEN PROC_ERASEDATE 
190 IF ANS$="3" THEN INPUT"Ram No ";ram%
192 IF ANS$="4" THEN axes%=0:PROC_ERASEPATIENT:RUN 
194 UNTIL A$="E"
196 ENDPROC 
198 :
200 DEFFN_MENU(restore%)
202 RESTORE restore%
205 READ ADD$,num%
210 PROC_HEAD
215 FOR quest%=1 TO num%
217 READ quest$
220 PROC_DH(5,quest%*2,CHR$129+STR$quest%+") "+quest$)
230 NEXT
240 READ answer$
250 =FN_ANSWER(answer$)
290 :
300 DEFPROC_NEW
310 CLS:IF TDDATE$<>"00/00/00" THENPROC_DISPLAY:ENDPROC 
315 ADD$="DATE INPUT":PROC_HEAD
320 IFTDDATE$="00/00/00" THEN PROC_DH(0,1,CHR$130+"CURRENT FILE 
EMPTY")
330 PROC_DH(0,1,CHR$130+"CURRENT FILE CONTAINS "+TDDATES)
340 IF D%=0 THEN PROC_DH(0,4,CHR$129+"INPUT DAYS DATE (00/00/00)") 
350 TDDATE$=FN_DATE(21,7,85,86):D%=FN_CALCDATE(TDDATE$)
355 PROC_DISPLAY 
360 ENDPROC 
370 :
400 DEFPROC_DATECHANGE 
410 CLS
415 PROC_DH(3,3,"APRESENT DATE IS "+TDDATES)
420 PROC_DH(3,5,"QINPUT NEW DATE")
450 TDDATE$=FN_DATE(21,7,85,86):D%=FN_CALCDATE(TDDATE$ 
:PROC_SAVECURRENT 
460 ENDPROC 
1000 DEFPROC_BASICDATA
1010 CLS:ADD$="BASIC DATA":HEAD$="D/C "+TDDATE$:PROC_HEAD
1020 miss%=0:change%=0:alr%=0:first%=1
1030 PROC_DH(0,0,CHR$129+"PATIENT "+STR$(P%+1))
1040 PRINTTAB(0,2);"NAME (A SMITH)"
1045 IFNAME$(P%)oSTRING$(15," ")THENPRINTTAB(20,2)NAME$(P%); 
:gg%=1 :first%=0
1050 IFNAME$(P%)oSTRING$(15," ")THENPRINTTAB(20,2)NAME$(P%); 
:GOTOFN_OK(1060,1070)
1060 NAME$(P%)=FN_NAMEINPUT(20,2)
1070 PRINTTAB(0,4);"UNIT NUMBER "
1080 IFVAL(UNIT$(P%))o0THENPRINTTAB(20,4)UNIT$(P%);:G0T01090
152
1085 UNIT$(P%)=FN_INPUT(20l4,6,num$)
1090 PRINTTAB(35,4);:GOTOFN_OK(1085,1100)
1100 IFLEN(UNIT$(P%))=5 THEN UNIT$(P%)=" "+UNIT$(P%)
1110 IF change%=0 AND miss%=0 AND VALDOB$(P%)=0 THENPROC_ALREADY 
ELSE GOTO1130
1112 IF alr%=1 THEN first%=0
1120 miss%=1 :GOTO 1080
1130 PRINTTAB(0,6);”DATE OF BIRTH"
1140 IFVAL(D0B$(P%))o0THENPRINTTAB(20,6);D0B$(P%);
:GOTOFN_OK(1145,1150)
1145 DOB$(P%)=FN_DATE(20,6,40,75)
1150 PRINTTAB(0,8);"PARITY (0+0)";TAB(20,8);PARITY$(P%); 
:GOTOFN_OK(1160,1190)
1160 PARITY$(P%)=FN_INPUT(20,8,3,num$+"+")
1170 IFLEN(PARITY$(P%))<>3 OR MID$(PARITY$(P% ),2,1)o"+'THEN1160 
1180 GOTOFN_OK(1160,1190)
1190 PRINTTAB(0,10);"LMP "
1200 IFVAL(LMP$(P%))o0THENPRINTTAB(20,10);LMP$(P%);
:GOTOFN_OK(1205,1210)
1205 LMP$(P%)=FN_DATE(20,10,85,86)
1207 IF VALGEST$(P%)>0 THEN GOTO 1220
1210 GEST$(P%)=FN_GEST(LMP$(P%),TDDATE$)
:EDD$(P%)=FN_CALCEDD(LMP$(P%),0,VALRIGHT$(TDDATE$,2))
1220 IF VALGEST$(P%)>44 OR VALGEST$(P%)<4 THEN VDU7 
:PRINTTAB(28,10)"WRONG":GOTOFN_OK(1230,1205)
1230 PRINTTAB(0,12);"EDD "
1240 IFVALEDD$(P%)<>0 THENPRINTTAB(20,12);EDD$(P%);
:GOTOFN_OK(1250,1260)
1250 EDD$(P%)=FN_DATE(20,12,85,86)
1260 PRINTTAB(0,14);"GESTATION "
1270 IFVALGEST$(P%)o0THENPRINTTAB(20,14);GEST$(P%);
:GOTOFN_OK(1275,1280)
1275 GEST$(P%)=FN_INPUT(20,14,2,num$):GOTOFN_OK(1275,1280)
1280 PRINTTAB(0,16)"WHICH ATTENDANCE"
:IFVAL(ATTN0$(P%))o0THENPRINTTAB(20,16);ATTN0$(P%);:alr%=1 
:GOTOFN_OK(1290,1300)
1290 ATTNO$(P%)=FN_INPUT(20,16,2,num$):GOTOFN_OK(1290,1300)
1300 PRINTTAB(5,18)"ARE THESE CORRECT ?";:gg%=0:GOTOFN_OK(1310,1320) 
1310 change%=1 :GOT01050 
1320 change%=0:
1325 IF ATTNO$(P%)="1" AND first%<>1 THEN alr%=1
1327 IF ATTNO$(P%)="1" AND first%=1 THEN alr%=0
1328 IF alr%=1 THEN gg%=1 ELSE gg%=0 
1330 PROC_DISPLAY1
1340 IFalr%=1 OR change%=1 THENG0T01375 
1350 CLS:PRINTTAB(0,1);"CONSULTANT "
1360 FORD%=0 TO 7:PRINTTAB(20,(1+D%));D%;") ";CONS$(D%):NEXT 
1370 CON$(P%)=FN_ANSWER("01234567")
1375 VDU28,0,24,39,6
1380 CLS:PRINTTAB(0,1);"CONSULTANT ";TAB(20);CONS$(VAL(CON$(P%))); 
:GOTOFN_OK(1350,1390)
1390 VDU28,0,24,39,9
1400 PRINTTAB(0,1);"Source";TAB(0,3)"of referal"
1410 IFalr%=1 OR change%=1 THEN1430
1420 FOR D%=0 TO 3:PRINTTAB(18,(1+(D%*2)));D%;")";REF1$(D%):NEXT 
:REFERAL$(P%,1 )=FN_ANSWER("0123")
1425 VDU28,0,24,39,9
153
1430 CLS:PRINTTAB(0,1);"Source of referal ";TAB(18,1) 
;REF1$(VAL(REFERAL$(P%,1)));:GOTOFN_OK(1420,1440)
1440 VDU28,0,24,39,11
1450 IFalr%=1 OR change%=1 THEN1480
1460 PRINTTAB(0,1);"Reason";TAB(0,3)"for referal"
1470 FOR D%=0 TO 5:PRINTTAB(14,(1+D%));D%;")";REF2$(D%):NEXT 
:REFERAL$(P%,2)=FN_ANSWER("012345")
1475 VDU28,0,24,39,11
1480 CLS:PRINTTAB(0,1);"Referal Reason";TAB(15,1) 
;REF2$(VAL(REFERAL$(P%,2)));:GOTOFN_OK(1470,1490)
1490 VDU28,0,24,39,13
1500 PRINTTAB(0,1 );"Referal Date"
1510 IFVALREFDATE$(P%)<>0 THENPRINTTAB(20,1);REFDATE$(P%); 
:GOTOFN_OK(1520,1530)
1520 REFDATE$(P%)=FN_DATE(20,1,85,86)
:IF VALLEFT$(FN_GEST(REFDATE$(P%),TDDATE$),2)<0 THEN VDU7 
:PRINTTAB(28,1)"WRONG":GOTOFN_OK(1530,1520)
1530 PRINTTAB(0,3);"Referal BP "
1540 IFVALREFBP$(P%)<>0 THENPRINTTAB(20,3);REFBP$(P%); 
:GOTOFN_OK(1545,1550)
1545 REFBP$(P%)=FN_BP(20,3)
1550 PRINTTAB(0,5);"Booking BP"
1560 IFVALBKBP$(P%)<>0 THENPRINTTAB(20,5);BKBP$(P%);
:GOTOFN_OK(1565,1570)
1565 BKBP$(P%)=FN_BP(20,5)
1570 PRINTTAB(0,6);"Booking Gestation"
1580 IFVALBKGEST$(P%)o0THENPRINTTAB(20,6);BKGEST$(P%); 
:GOTOFN_OK(1590,1600)
1590 BKGEST$(P%)=FN_INPUT(20,6,2,num$)
:IF VALBKGEST$(P%)>VALGEST$(P%) THEN 1590 ELSE GOTOFN_OK(1590,1600) 
1600 PRINTTAB(0,8);"BP AT 28/30 WKS"
1610 IFalr%=1 OR VALGEST$(P%)<28 THENPRINTTAB(20,8);BP28$(P%); 
:GOTOFN_OK(1620,1630)
1620 BP28$(P%)=FN_BP(20,8)
1630 PRINT'TAB(5)"ARE THESE CORRECT ?";:gg%=0:GOTOFN_OK(1640,1650)
1640 change%=1 :GOTO1340
1650 IF axes%=0 THEN PROC_SAVECURRENT
1655 IF axes%=1 THEN PROC_SAVE
1660 VDU28,0,24,39,3:CLS
1670 ENDPROC
1680 :
2000 DEFPROC_DINAREADINGS
2010 ENDPROC
4000 DEFPROC_ENDOFDAY
4030 PROC_ENDMENU
4040 IF ANS$="1" THEN PROC_PRINT
4050 IF ANS$="2" THEN PROC_NEXT:ENDPROC
4060 IF ANS$="3" OR ANS$="E"THENANS$="":ENDPROC
4070 GOTO4030
4080 DEFPROC_ENDMENU
4085 MODE 7:ADD$="END OF DAY':HEAD$="DAYCARE":PROC_HEAD 
4090 PROC_DH(5,4,CHR$129+"1) PRINT RECORD SHEETS")
4100 PROC_DH(5,6,CHR$129+"2) CLOSE TODAYS FILE")
4110 PROC_DH(5,8,CHR$129+"3) RETURN TO DAYCARE PROGRAM")
4120 ANS$=FN_ANSWER("1234")
4130 ENDPROC
4140
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4150 DEFPROC_NEXT 
4160 PROC_DOWNLOAD 
4170 PROCCLEARCURRENT 
4175 ok%=1
4180 PROC_SAVECURRENT
4200 MODE 7:RUN
4201 DEFPROC_ERASE
4205 GOTO4170
4206 DEFPROC_ERASEDATE
4207 DAT%=OPENUP("DTINX88")
4208 INPUT#DAT%>DATinput%,DATIength%
4209 PTR#DAT%=0
4210 DATinput%=DATinput%-DATIength%
4211 PRINT#DAT%,DATinput%
4212 CLOSE#DAT%
4213 ENDPROC 
4215 ENDPROC
4220 DEFPROC_DOWNLOAD
4230 FILE$=LEFT$(TDDATE$,2)+MID$(TDDATE$,4,2)+RIGHT$(TDDATE$,2)
4235 FOR dr%=0 TO 4 STEP 4
4240 DAT%=OPENUP(":"+STR$dr%+".DTINX88")
4250 INPUT#DAT%>DATinput%,DATIength%
4260 PTR#DAT%=DATinput%-DATIength%
4270 INPUT#DAT%,date$
:IF date$=RIGHT$(FILE$,6) THEN PR I NT" DATA ALREADY DOWNLOADED":GOTO4430 
4275 IF dr%=0 THEN fdr%=2 ELSE fdr%=5 
4280 ATT%=OPENUP(":"+STR$fdr%+".DC/FL88")
4290 INPUT#ATT%,input%Jlength%
4300 PTR#DAT%=DATinput%
4310 PRINT#DAT%,RIGHT$(FILE$,6),input%
4315 CLS
4316 P%=-1 
4320 REPEAT 
4322 P%=P%+1
4325 PR0C_DH(5,5,"AD0WNL0ADING PATIENT ”+STR$(P%+1))
4330 PTR#ATT%=lnput%
4340 PROC_BPUT
4350 input%=input%+length%
4360 UNTIL P%=8 OR LEFT$(NAME$(P%+1),3)=" "
4370 last%=lnput%-length%
4380 PRINT#DAT%,last%
4390 DATinput%=PTR#DAT%:PTR#DAT%=0 
4400 PRINT#DAT%,DATinput%
4410 PTR#ATT%=0:PRINT#ATT%,input%
4415 NEXT 
4420 CLOSE#0 
4430 :
4440 ENDPROC 
4450 :
4500 DEFPROCJNDEX
4510 DAT%=OPENUP("DTINX88")
4520 ATT%=OPENUP(":2.DC/FL88")
4522 PTR#DAT%=18 
4525 next%=11 
4530 REPEAT
4535 INPUT#DAT%Jdate$lin%,end%
4536 REPEAT
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4540 PTR#ATT%=next%+23
4542 d$="":
4543 FOR Y%=1 TO 3
4544 p$=STR$BGET#ATT%:IF LENp$=1 THEN p$="0"+p$
4545 d$=d$+p$
4546 NEXT
4547 PRINTdate$,d$
4599 CLOSE#0
4600 STOP
4630 DEFPROC_BLANK(P%)
4640 NAME$(P%)="
" :UN IT$( P%)=" 000000" :LMP$(P%)="00/00/00":EDD$(P%)="00/00/00" 
:GEST$(P%)="0+0"
4642 CON$(P%)="0":REFERAL$(P%f0)="00/00/00":REFERAL$(P%,1)="0" 
:REFERAL$(P%,2)="0"
4650 RESULTS$(P%,0)="0.0":RESULTS$(P%>1 )="000"
:RESULTS$(P%,2)="00.0":RESULTS$(P%J3)="000"
:RESULTS$(P%,4)="0":CTGAN$(P%)="0"
4652 FUAN$(P%,0)="0":FUAN$(P%,1)="0":FUAN$(P%l2)="00/00/00"
4660 DIAGAN$(P%)="0":REFDATE$(P%)="00/00/00" 
:REFBP$(P%)="000/000":FORX%=0 TO 6:DCBP$(P%,X%)="000/000":NEXT 
:BKBP$(P%)="000/000"
4662 BKGEST$(P%)="0":BP28$(P%)="000/000":PARITY$(P%)="0+0"\ 
:ATTNO$(P%)="0":DOB$(P%)="00/00/00"
4670 FHR$(P%)="000"
4680 ENDPROC
4682 DEFPROC_CLEARCURRENT
4683 LOCAL P%
4684 FORP%=0 TO 8:PROC_BLANK(P%):NEXT 
4690 TDDATE$="00/00/00"
4700 ENDPROC 
4705 :
4710 DEFPROC_BPUT
4720 FORX%=1 TO 15:BPUT#ATT%,ASCMID$(NAME$(P%)JX%,1):NEXT 
4730 FORX%=1 TO 5 STEP2:BPUT#ATT%,VALMID$(UNIT$(P%),X%,2):NEXT 
4740 FORX%=1 TO 7 STEP3:BPUT#ATT%,VALMID$(DOB$(P%),X%,2):NEXT 
4750 FORX%=1 TO 3 STEP2:BPUT#ATT%,VALMID$(PARITY$(P%),X%,1):NEXT 
4760 FORX%=1 TO 7 STEP3:BPUT#ATT%,VALMID$(TDDATE$>X%I2):NEXT 
4770 BPUT#ATT%,VALATTNO$(P%)
4780 FORX%=1 TO 7 STEP3:BPUT#ATT%,VALMID$(LMP$(P%),X%,2):NEXT 
4790 FORX%=1 TO 7 STEP3:BPUT#ATT%)VALMID$(EDD$(P%),X%,2):NEXT 
4800 BPUT#ATT%,VALGEST$(P%)
4810 FORX%=1 TO 7 STEP3:BPUT#ATT%,VALMID$(REFDATE$(P%),X%,2):NEXT 
4820 FORX%=1 TO 5 STEP 4:BPUT#ATT%fVALMID$(REFBP$(P%)fX%>3):NEXT 
4830 FORX%=1 TO 5 STEP 4:BPUT#ATT%,VALMID$(BKBP$(P%)fX%,3):NEXT 
4840 BPUT#ATT%,VALBKGEST$(P%)
4850 FORX%=1 TO 5 STEP 4:BPUT#ATT%fVALMID$(BP28$(P%)fX%,3):NEXT 
4860 BPUT#ATT%,VALCON$(P%)
5010 BPUT#ATT%JVALREFERAL$(P%>1)
5020 BPUT#ATT%,VALREFERAL$(P%,2)
5030 FORY%=0 TO 6 
5040 FORX%=1 TO 5 STEP 4 
:BPUT#ATT%,VALMID$(DCBP$(P%,Y%),X%,3):NEXT 
5050 NEXT
5060 BPUT#ATT%,(VAL(RESULTS$(P%,0))*10)
5070 BPUT#ATT%,(VALRESULTS$(P%,1)/3)
5080 BPUT#ATT%,(VAL(RESULTS$(P%,2))*10)
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5090 BPUT#ATT%f(VALRESULTS$(P%,3)/2)
5100 BPUT#ATT%fVALRESULTS$(P%l4)
5110 BPUT#ATT%,VALCTGAN$(P%)
5120 BPUT#ATT%,VAL(FHR$(P%))
5130 BPUT#ATT%,VALFUAN$(P%,1)
5140 FORX%=1 TO 7 STEP 3:BPUT#ATT%,VALMID$(FUAN$(P%,2),X%,2):NEXT 
:BPUT#ATT%,VALDIAGAN$(P%)
5150 ENDPROC 
5160 :
5170 DEFPROC_PRINT
5180 CLS:IF TDDATE$="00/00/00" THEN
PROC_DH(2,4,CHR$129+'THERE IS NO DATA ON FILE"):PROC_SPACE:ENDPROC 
5190 PROC_DH(2,4,CHR$129+"PRINTING RECORDS FOR "+TDDATE$)
5210 PROC_DH(5,8,CHR$131 +"DO YOU WISH TO CONTINUE ?") 
:AN$=FN_ANSWER("YN"):IF AN$="N'THEN ENDPROC 
5240 FOR P%=0 TO 8:PROC_CASE:NEXT 
5270 CLS:PROC_DH(5,8,CHR$131+"REPEAT PROCESS ?")
5280 AN$=FN_ANSWER("YN")
5290 IF AN$="Y"THEN GOTO5180 ELSE ENDPROC 
5300 DEFPROCCASE 
5310 VDU15
5320 IF LEFT$(NAME$(P%),5)=" " THEN ENDPROC
5330 CLS:PROC_DH(8,10,""+NAME$(P%))
5340 PROC_DH(8,14f”DO YOU WISH TO PRINT"):A$=GET$
5345 IF A$="N” ENDPROC
5346 IF VALATTNO$(P%)>1 THEN CLS:PROC_DH(Of4,"FOR M+NAME$(P%)) 
:PROC_DH(0,8,"FIRST ATTENDANCE DATE 00/00/00 ")
:first$=FN_DATE(13,11,84,86)
5350 MODE 0 
5360 VDU2
5370 PRINP'VISIT ";ATTNO$(P%);TAB(50);"Consultant - ” 
;CONS$(VAL(CON$(P%))):PRINT
5380 PRINT"Name - ";NAME$(P%);TAB(30);"Para ";PARITY$(P%);TAB(40) 
;"Gestation ";GEST$(P%);TAB(60);"Date ”;TDDATE$
5390 PRINTM,Unit No. ";UNIT$(P%);TAB(20);"DOB ";DOB$(P%);TAB(40) 
;"LMP ";LMP$(P%);TAB(60);"EDD ";EDD$(P%)
5400 PRINT,MThis patient was refered from the 
";REF1$(VAL(REFERAL$(P%,1)));" on "
;REFDATE$(P%)
5410 PRINP'Reason for referal was ";REF2$(VAL(REFERAL$(P%,2)))
Blood pressure was M;REFBP$(P%)
5420 LATER%=FN_LATER(REFDATE$(P%),TDDATE$)
5430 PROC_ANCSUM
5440 PRINP'The patient was seen at Day Care on ";TDDATE$;H"
;LATER%;" days after referal"
5445 IF VALATTNO$(P%)>1 THEN PRINT'"Previous attendances :"
:extra%=1 :PROC_PATIENT:extra%=0:PRINT'"Todays attendance 
5450 PRINT:FORX%=0 TO 3:PRINTTAB(5);X%+1;") Blood Pressure - " 
;DCBP$(P%,X%);TAB(40);TEST$(X%);TAB(60);"- ";RESULTS$(P%,X%):NEXT 
5460 PRINTTAB(5);5") Blood Pressure - " 
;DCBP$(P%,4);TAB(40);TEST$(4);TAB(60);H- " 
;PROT$(VAL(RESULTS$(P%,4)))
5470 PROC_AVERAGEBP
5480 PRINT"Average Blood Pressure - "
;DCBP$(P%,6);TAB(40);"Cardiotocograph";TAB(60);"- "
;CTG$(VAL(CTGAN$(P%)))
5490 PRINP'Dinamap Blood Pressure - ";DCBP$(P%,5);TAB(40)
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;"Fetal Heart Rate ";TAB(60);"- ";FHR$(P%)
5500 PRINT'The diagnosis at Day Assessment was HDIAG$(VAL(DIAGAN$(P%))) 
5510 FU%=FN_LATER(TDDATE$,FUAN$(P%,2))
5520 PRINT"Follow up will be at ";FU$(VAL(FUAN$(P%,1)));H on " 
;FUAN$(P%,2)'" ( ";FU%;" days after the Day Care attendance)"
5530 MODE 7 
5540 VDU3 
5550 GOTO5330 
5560 :
5570 DEFPROC_ANCSUM
5580 PRINT'"Blood pressure at M;BKGEST$(P%);" weeks was ";BKBP$(P%) 
5590 PRINTBIood pressure at 28-30 weeks was ";BP28$(P%)
5600 ENDPROC 
5640 :
5650 DEFPROCJJST 
5660 PROC_LISTMENU 
5670 IFANS$="1 "THENPROC_ALL 
5680 IFANS$="2"THENPROC_BIRTH 
5690 IFANS$="3"THENCHAIN"WEEKRVU"
5700 I FANS$="4"THEN CHAIN"FILCHEK"
5710 IFANS$="5"THEN
5720 IFANS$="E'THEN CLS:ENDPROC
5725 GOTO5660
5730 DEFPROC_LISTMENU
5740 MODE 7iADD$="PROGRAM":CLOSE#0:HEAD$="LISTING":PROC_HEAD 
5750 PROC_DH(5,2,CHR$129+"1) LIST ALL PATIENTS")
5760 PROC_DH(5,4,CHR$129+"2) LIST ALL DELIVERED PATIENTS")
5770 PROC_DH(5,6,CHR$129+"3) WEEKLY REVIEW")
5780 PROC_DH(5,8,CHR$129+"4) LIST ALL DATES")
5790 PROC_DH(5,10,CHR$129+"5) LIST SELECTED PATIENTS")
5799 ANS$=FN_ANSWER("12345")
5800 ENDPROC 
5810 :
6000 DEFPROC_AXESFIL
6010 axes%=1 :PROC_CLEARCURRENT
6030 PROC_AXMENU
6040 IFANS$="1 "THENPROC_PATIENT
6050 IFANS$="2"THENPROC_ACCESSDAY
6060 IFANS$="3"THENPROC_PRINT
6070 IFANS$="4"THENCHAIN"DINARED"
6075 IFANS$="5"THENCHAIN"WEEKRVU"
6077 IFANS$="6"THENCHAIN"SPACECK"
6120 IFANS$="E"THENCLS:PROC_INFO:ENDPROC 
6130 GOTO6030 
6140 :
6150 DEFPROC_AXMENU
6155 MODE 7 :AD D$="P ROG RAM" :C LOS E#0: H EA D$="ACC ESS": P ROC_H E AD 
6160 PROC_DH(5,2,CHR$129+"1) FIND PATIENT")
6170 PROC_DH(5,4,CHR$129+"2) FIND DATE")
6180 PROG_DH(5,6,CHR$129+"3) PRINT CURRENT FILE")
6220 PROC_DH(5,8,CHR$129+"4) READ DINADATA")
6230 PROC_DH(5,10,CHR$129+"5) WEEKLY REVUE")
6235 PROC_DH(5,12,CHR$129+"6) SPACE CHECK")
6240 ANS$=FN_ANSWER("123456")
6250 ENDPROC 
6260 :
6270 DEFPROC_ACCESSDAY
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6280 ADD$="DATE ACCESSM:PROC_HEAD 
6290 PROC_DH(0,8f"WHICH DATE 00/00/00 ")
:TDDATE$=FN_DATE(13,11,84,86)
6300 FILE$=LEFT$(TDDATE$,2)+MID$(TDDATE$,4,2)+RIGHT$(TDDATE$,2) 
6310 PROC_FINDDATE(FILE$,1)
6320 IF date%>0 ORdate%<0 THENPROC_DH(0,15,"DATE NOT ON FILE "):VDU7 
:PROC_DH(0,17," INPUT ANOTHER DATE ?"):Y$=GET$ ELSE GOTO 6330 
6325 IF Y$="Y" THEN CLS:GOTO 6290 ELSE ENDPROC 
6330 IN PUT#DAT%,begin%,end%:CLOSE#DAT%
6335 IF ram%=0 THEN dr%=2 ELSE dr%=5 
6340 PROC_OPEN(FILE$,2,dr%)
6350 P%=0
6360 FOR patient%=begin% TO end% STEP 80 
6370 address%(P%)=patient%
6380 NAME$(P%)=""
6390 PROC_BGET 
6410 P%=P%+1 
6420 PAT%=P%
6430 NEXT 
6440 CLOSE#ATT%
6450 gotit%=-1 :PROC_DISPLAY 
6460 ENDPROC 
6470 :
6480 DEFPROC_PATIENT
6485 IF extra%=1 THEN NAME$=NAME$(P%):last$=TDDATE$:GOTO6510 
6490 CLS:ADD$="PATIENT SEARCH":PROC_HEAD
6500 PRINTTAB(3,3)''DO YOU KNOW THE ATTENDANCE DATE ?":Y$=GET$
:IF Y$='YTHEN PROC_ACCESSDAY:ENDPROC 
6505 CLS
6510 PROC_SELECT:start%=begin%
6512 blt%=0:att%=0
6515 IF extra%=1 THEN GOTO6570
6520 PRINTTAB(0,2);"NAME (A SMITH)"
6540 CLS:PRINTTAB(0,2)"INPUT NAME (A SMITH)"
6550 NAME$=FN_NAMEINPUT(20,2)
6560 IFLEFT$(NAME$,2)=" "THEN NAME$=RIGHT$(NAME$,LENNAME$-2) 
6570* FX15.1
6580 YEAR$="0008"+RIGHT$(first$,2)
6590 PROC_OPEN(YEAR$,2,5)
6600 INPUT#ATT%,finish%
6610 IF extra%=1 THEN print$="Y":G0T06615
6611 CLS:PROC_DH(5,5,CHR$129+"PATIENT ATTENDANCE SUMMARY")
6612 PROC_DH(5,7,CHR$129+"DO YOU WISH TO PRINT SUMMARY?")
6613 print$=GET$
6615 temp%=P%
6620 REPEAT
6630 gotit%=0:again%=0:P%=9
6640 NAME$(P%)="":address%(P%)=start%:PTR#ATT%=address%(P%) 
6650 FORX%=1 TO 15:NAME$(P%)=NAME$(P%)+CHR$(BGET#ATT%):NEXT 
6660 gotit%=INSTR(NAME$(P%),NAME$)
6665 IF gotit%>0 THEN NAME$(P%)="":PROC_BGET:PROC_PATSUM
6670 start%=start%+80
6680 UNTIL start%>=end% OR start%>=finish%
6685 CLOSE#0
6690 IF extra%=1 THEN P%=temp%:ENDPROC
6692 VDU3
6710 PROC_SPACE
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6711 MODE 7
6712 PROC_DH(0,5,mAANOTHER PATIENT ?")
6713 CLOSE#0 
6715 P%=temp%
6720 ENDPROC 
6730 :
6740 DEFPROC_ALL 
6750 CLS:PROC_SELECT 
6755 page%=0:number%=0 
6760 patient%=begin%
6770 PRINT'"PRINTER Y/N?":Y$=GET$
6775 PRINT'"FIRST VISITS ONLY ?":fst$=GET$
6780 MODE 3:PROC_OPEN("0008"+YR$,2)
6790 IFY$="Y" THEN VDU2
6800 PRINTTAB(18)"ALL ATTENDANCES BETWEEN ";first$;" AND ";last$
6810 REPEAT:P%=0:number%=number%+1 
6820 NAME$(P%)='"':address%(P%)=patient%:PROC_BGET 
6830 IF page% MOD 55=0 AND page%>0 THEN VDU3,7:PROC_SPACE 
:IF Y$=”Y'THENVDU2
6835 IF fst$="Y" AND VAL(ATTNO$(P%))>1 THEN GOTO6850 
6840 page%=page%+1 :PRINTnumber%;") " 
;NAME$(P%),UNIT$(P%),ATTDATE$(P%),"Visit "
;ATTNO$(P%),"at ";GEST$(P%);H weeks"
6850 patient%=patient%+80 
6860 UNTILPTR#ATT%>end%
6870 CLOSE#ATT%:VDU3:PROC_SPACE:MODE 7:ENDPROC 
6880 :
6890 DEFPROC_SAVE
6895 FOR dr%=2 TO 5 STEP 3
6900 PROC_OPEN("000888",2,dr%)
6905 PTR#ATT%=address%(P%)
6910 PROC_BPLIT 
6920 CLOSE#ATT%
6925 NEXT 
6930 ENDPROC 
6940 :
7040 DEFPROC_SELECT
7045 IF extra%=1 THEN VDU3:GOTO 7062
7050 PRINTTAB(0,2)"FIRST DAY 00/00/00":DATE$=FN_DATE(20,2,84,86) 
:first$=LEFT$(DATE$t2)+MID$(DATE$,4,2)+RIGHT$(DATE$f2)
7052 YR$=RIGHT$(first$,2)
7060 PRINTTAB(0,4)"LAST DAY 00/00/00":DATE$=FN_DATE(20,4,84,86) 
:last$=LEFT$(DATE$,2)+MID$(DATE$,4,2)+RIGHT$(DATE$,2)
7062 YR$=RIGHT$(first$,2)
7070 PROC_FINDDATE(first$,1)
7080 SP%=SP%-DATIength%
7090 IFSP%=0 THEN SP%=18
7100 PTR#DAT%=SP%:INPUT#DAT%,DUMMY1$,begin%
7110 CLOSE#DAT%
7120 PROC_FINDDATE(last$,SP%/DATIength%)
7130 SP%=SP%-DATIength%
7140 PTR#DAT%=SP%:INPUT#DAT%,DUMMY1$,dummy%Jend%
7145 IF extra%=1 THEN VDU2 
7147 CLOSE#DAT%:ENDPROC 
7150 :
7160 DEFPROC_BYTESELECT(byte%fexpression$,end%)
7170 REPEAT
7180 match%=0
7190 PTR#ATT%=SP%+byte%
7200 BYTE%=BGET#ATT%
7210 IF EVAL(expression$)THENmatch%=1 :SP%=SP%-80
7220 SP%=SP%+80
7230 UNTIL SP%=end% OR match%=1
7240 ENDPROC
7250 :
7260 DEFFN_DATESELECT(byte%)
7270 PTR#ATT%=SP%+byte%
7280 =FN_BACK(3,2,"/")
7290 :
7300 DEFPROC_FINDDATE(dt$,st%)
7310 PROC_OPEN(dt$,1 ,ram%)
7320 INPUT#DAT%,DATinput%lDATIength%
7330 SP%=DATIength%
7340 REPEAT
7350 PTR#DAT%=SP%:INPUT#DAT%,DAT$:date%=FN_LATER(dt$,DAT$)
7351 IF DAT$="000000" THEN SP%=SP%+DATIength%:GOTO 7370
7352 PRINTTAB(2,15)CHR$141 CHR$129"SEARCH DATE ";DAT$ 
:PRINTTAB(2,16)CHR$141CHR$129"SEARCH DATE ";DAT$
7353 IF date%>-5 THEN SP%=SP%+DATIength%:GOTO 7370
7355 IF date%<0 THEN SP%=SP%+(DATIength%*INT(ABSdate%/4))
7370 UNTILdate%>=0 OR SP%>=DATinput%
7380 ENDPROC 
7390 :
7400 DEFPROC_OPEN(dt$,W%,dr%)
7410 IF dr%=5 AND ram%=0 THEN dr%=2 
7420 IF dr%=4 AND ram%=0 THEN dr%=0
7430 IF W%=1 THEN DAT%=OPENIN(":M+STR$dr%+M.DTINX88") ELSE 
ATT%=OPENUP(":"+STR$dr%+".DC/FL88")
7470 ENDPROC 
7480 :
7490 DEFPROC_BIRTH
7495 CLS:PROC_SELECT :SP%=begin%
7500 PRINT"'PRINTER Y/N":Y$=GET$
7510 PRINT'"FIRST ATTENDANCE ONLY Y/N":att$=GET$:MODE 3
7520 IF Y$=''Y"THENVDU2
7530 PROC_OPEN("000086",2,5)
7550 P%=0 
7560 REPEAT
7570 date$=FN_DATESELECT(27)
7580 IF att$="Y" THEN PROC_BVTESELECT(26,"BYTE%=1",end%) ELSE 
match%=1
7590 date%=VALFN_GEST(date$,TDDATE$)
7600 IF date%>44 AND match%=1 THEN
address%(P%)=SP%:PROC_BGET:PRINTSTR$((SP%-11)/80+1);") "
;NAME$(P%),UNIT$(P%)/'Attended
7602 PRINTATTDATE$(P%),"EDD was ”;EDD$(P%)
7610 SP%=SP%+80 
7620 UNTIL SP%=end%
7630 CLOSE#ATT%:VDU3:ENDPROC 
7640 :
7650 DEFPROC_BGET
7660 PTR#ATT%=address%(P%)
7670 NAME$(P%)='"':FORX%=1 TO 15
:N AM E$(P%)=N AM E$( P%)+CH R$(BG ET#ATT%) :N EXT
7680 UNIT$(P%)=FN_BACK(3,2,''")
7690 DOB$(P%)=FN_BACK(3,2,7")
7700 PARITY$(P%)=FN_BACK(2,1 
7710 ATTDATE$(P%)=FN_BACK(3,2,7")
7720 ATTNO$(P%)=STR$(BGET#ATT%)
7730 LMP$(P%)=FN_BACK(3,2,7")
7740 EDD$(P%)=FN_BACK(3,2,7")
7750 GEST$(P%)=STR$(BGET#ATT%)
7760 REFDATE$(P%)=FN_BACK(3,2,7")
7770 REFBP$(P%)=FN_BACK(2,3,7")
7780 BKBP$(P%)=FN_BACK(2,3,7")
7790 BKGEST$(P%)=STR$(BGET#ATT%)
7800 BP28$(P%)=FN_BACK(2,3,7")
7810 CON$(P%)=STR$(BGET#ATT%)
7820 IFVALCON$(P%)>7 THEN CONS^/oKO"
7830 REFERAL$(P%,1)=STR$(BGET#ATT%)
7840 IFVALREFERAL$(P%,1 )>3 THENREFERAL$(P%,1)="0" 
7850 REFERAL$(P%,2)=STR$(BGET#ATT%)
7860 IFVALREFERAL$(P%,2)>5 THENREFERAL$(P%,2)="0" 
7870 FORY%=0 TO 6:DCBP$(P%,Y%)=FN_BACK(2,3IT):NEXT 
7880 RESULTS$(P%,0)=STR$(BGET#ATT%/10)
7890 RESULTS$(P%,1 )=STR$(BGET#ATT%*3)
7900 RESULTS$(P%,2)=STR$(BGET#ATT%/10)
7910 RESULTS$(P%>3)=STR$(BGET#ATT%*2)
7920 RESULTS$(P%,4)=STR$(BGET#ATT%)
7930 IFVALRESULTS$(P%,4)>5 THEN RESULTS$(P%,4)="0" 
7940 CTGAN$(P%)=STR$(BGET#ATT%)
7950 IFVALCTGAN$(P%)>3 THENCTGAN$(P%)="0"
7960 FHR$(P%)=STR$(BGET#ATT%)
7970 FUAN$(P%,1 )=STR$(BGET#ATT%)
7980 IFVALFUAN$(P%,1 )>3 THENFUAN$(P%,1)="0"
7990 FUAN$(P%,2)=FN_BACK(3,2,7")
8000 DIAGAN$(P%)=STR$(BGET#ATT%)
8010 IFVALDIAGAN$(P%)>4 THENDIAGAN$(P%)="0"
8020 ENDPROC 
8030 :
8040 DEFFN_BACK(x%,n%,slash$)
8050 LOCALX%:tot$="”
8060 FORX%=1 TO x%
8070 t$=STR$(BGET#ATT%)
8080 IFLENt$<n% THEN t$="0"+t$:GOT08080 
8090 tot$=tot$+t$:lFX%<x% THEN tot$=tot$+slash$
8100 NEXT 
8110 =tot$
8120 :
8130 UNIT$(P%)=FN_BACK(3,2,"")
8140 DOB$(P%)=FN_BACK(3,2,7")
8150 PARITY$(P%)=FN_BACK(2,1 
8160 ATTDATE$(P%)=FN_BACK(3,2,7")
8170 ATTNO$(P%)=STR$(BGET#ATT%)
8180 LMP$(P%)=FN_BACK(3,2f7")
8190 EDD$(P%)=FN_BACK(3,2,7")
8200 GEST$(P%)=STR$(BGET#ATT%)
8210 REFDATE$(P%)=FN_BACK(3,2,7")
8220 REFBP$(P%)=FN_BACK(2,3,7")
8230 BKBP$(P%)=FN_BACK(2>3 ,7”)
8240 BKGEST$(P%)=STR$(BGET#ATT%)
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8250 BP28$(P%)=FN_BACK(2,3f'7")
8260 CON$(P%)=STR$(BGET#ATT%)
8270 IFVALCON$(P%)>7 THEN CON$(P%)="0"
8280 REFERAL$(P%,1)=STR$(BGET#ATT%)
8290 IFVALREFERAL$(P%,1 )>3 THENREFERAL$(P%,1)="0"
8300 REFERAL$(P%,2)=STR$(BGET#ATT%)
8310 IFVALREFERAL$(P%,2)>5 THENREFERAL$(P%I2)="0,,
8320 FORY%=0 TO 6:DCBP$(P%,Y%)=FN_BACK(2f3,7"):NEXT 
8330 RESULTS$(P%,0)=STR$(BGET#ATT%/10)
8340 RESULTS$(P%,1 )=STR$(BGET#ATT%*3)
8350 RESULTS$(P%,2)=STR$(BGET#ATT%/10)
8360 RESULTS$(P%,3)=STR$(BGET#ATT%*2)
8370 RESULTS$(P%,4)=STR$(BGET#ATT%)
8380 IFVALRESULTS$(P%,4)>5 THEN RESULTS$(P%,4)=,,0"
8390 CTGAN$(P%)=STR$(BGET#ATT%)
8400 IFVALCTGAN$(P%)>3 THENCTGAN$(P%)="0H 
8410 FHR$(P%)=STR$(BGET#ATT%)
8420 FUAN$(P%,1 )=STR$(BGET#ATT%)
8430 IFVALFUAN$(P%,1 )>3 THENFUAN$(P%J1)=M0"
8440 FUAN$(P%,2)=FN_BACK(3,2>7")
8450 DIAGAN$(P%)=STR$(BGET#ATT%)
8460 IFVALDIAGAN$(P%)>4 THENDIAGAN$(P%)="0"
8470 ENDPROC
8500 DEFFN_BACK(x%,n%,slash$)
8510 LO C A LX% :tot$=""
8520 FORX%=1 TO x%
8530 t$=STR$(BGET#ATT%)
8540 IFLENt$<n% THEN t$="0"+t$:GOTO8540 
8550 tot$=tot$+t$:IFX%<x% THEN tot$=tot$+slash$
8560 NEXT 
8570 =tot$
9000 DEFPROC_PATSUM
9001 IF att%>0 THEN GOTO 9045
9002 IF extra%=1 THEN VDU2:GOTO9040 
9010 MODE SiVDUIO.I.e.O.O.O
9015 IF print$="Y" THEN VDU2
9016 PRINTTAB(20)"PATIENT ATTENDANCE SUMMARY"
9017 PRINT
9020 PRINTNAME$(P%);TAB(16);"PARA ";PARITY$(P%);TAB(28);"UNIT NO " 
;UNIT$(P%);TAB(45);"DOB ";DOB$(P%);TAB(60);"LMP ";LMP$(P%)
9025 PRINT
9030 PRINT"BOOKING BP AT "BKGEST$(P%);"wk BP was ";BKBP$(P%) 
and at 28wk BP ”;BP28$(P%)
9035 PRINT"'CONSULTANT H;CONS$(VALCON$(P%))
9040 PRINT"' DATE";TAB(9)"Gest";TAB(13)" Av BP";TAB(22);"Urea";TAB(27) 
;"Uric";TAB(32);"Haem";TAB(37)"Plat";TAB(42)" CTG";TAB(52)"FHR" 
;TAB(57)"Diagnosis":att%=2 
9045 IF print$="Y" THEN VDU2
9050 PRINTATTDATE$(P%);TAB(10)GEST$(P%);TAB(13)DCBP$(P%,6) 
;TAB(22)RESULTS$(P%,0);TAB(27);RESULTS$(P%,1 );TAB(32) 
;RESULTS$(P%,2);TAB(37)RESULTS$(P%,3);TAB(42)CTG$(VALCTGAN$(P%)) 
;TAB(52)FHR$(P%);TAB(57)LEFT$(DIAG$(VAL(DIAGAN$(P%))),9)
9060 ENDPROC
10000 DEFPROC_RESULTS
10010 M%=0:IF axes%=1 THEN TDDATE$=ATTDATE$(P%)
10020 ADD$="RESULTS":HEAD$="DAYCARE (1988)":PROC_HEAD 
10030 PROC_DH(0,0,STR$(P%+1)+" "+CHR$131+NAME$(P%)+"
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+ UNIT$(P%))
10040 PROC_DH(5,3,CHR$129+"1) BASIC DATA")
10050 PROC_DH(5,5,CHR$129+"2) BLOOD PRESSURES”)
10060 PROC_DH(5,7,CHR$129+”3) BIOCHEMISTRY/HAEMOTOLOGY")
10070 PROC_DH(5,9,CHR$129+”4) URINALYSIS”)
10080 PROC_DH(5,11 ,CHR$129+"5) CARDIOTOCOGRAPH")
10090 PROC_DH(5,13,CHR$129+"6) FOLLOWUP/DIAGNOSIS")
10100 PROC_DH(5,15,CHR$129+”7) FULL DISPLAY")
10110 IF axes%<>0 PROC_DH(5,17,CHR$129+”8) PRINT INFORMATION") 
10115* FX15.1
10120 AN$=FN_ANSWER("12345678”)
10130 IFAN$="1 "THENPROC_BASICDATA
10140 IFAN$="2"THENM%=1 :PROC_DCBP
10150 IFAN$="3"THENM%=1 :PROC_BIOCHEM
10160 IFAN$="4"THENM%=1 :PROC_PROT
10170 IFAN$="5"THENM%=1 :PROC_CTG
10180 IFAN$="6"THENM%=1 :PROC_FUDIAG
10190 IFAN$="7"THENPROC_DISPLAY1 :PROC_DISPLAY2
10205 IFAN$=”8" AND axes%=1 THENPROC_CASE
10210 I FAN$=" E'TH EN AN$="" :EN DP ROC
10230 GOTO10020
10240 :
10250 DEFPROC_DISPLAY
10260 IFPAT%=0 THEN PROC_BASICDATA
10270 ADD$=TDDATE$:HEAD$=”DAYCARE":PROC_HEAD
10280 M%=0
10290 FORP%=0 TO PAT%-1
10300 IF NAME$(P%)=" " OR NAME$(P%)=”" THEN
PAT%=P%:P%=8:GOT010320
10310 IF gotit%>0 AND axes%=1 THEN
PROC_DH(0,P%*2,STR$(P%+1)+CHR$133+NAME$(P%)+" "+UNIT$(P%)+" " 
+ATTDATE$(P%))
ELSEPROC_DH(0,P%*2,STR$(P%+1 )+CHR$133+NAME$(P%)+"
+ UNIT$(P%))
10320 NEXT
10330 IFPAT%=9 THEN pat%=PAT%-1 :GOTO10350 ELSE pat%=PAT%
10340 IF gotit%>0 AND axes%=1 THEN
PROC_DH(0,P%*2,STR$(P%+1 )+CHR$129+"NEXT SAMPLE FOR SAME PAIENT")
10350 IF gotit%=0 AND axes%=1 THEN PROC_DH(2,P%*2,CHR$131+"NO MORE 
SAMPLES FOR THIS PATIENT")
10351 IF axes%=0 THENPROC_DH(0,PAT%*2+1,STR$(PAT%+1)+CHR$129 
+"ADD ANOTHER PATIENT")
10360 IF gotit%=0 AND axes%=1 THEN 
P$=FN_ANSWER(LEFT$("123456789",pat%)) ELSE 
P$=FN_ANSWER(LEFT$("123456789",pat%+1))
10370 IFP$="E"THENCLS:ENDPROC 
10375 IFP$="S"THENPROC_SPECIAL 
10380 P%=VAL(P$)-1
10390 IFP%=PAT% AND axes%=1 THEN again%=1 :ENDPROC 
10395 IFP%=PAT% AND axes%=0 THEN 
PAT%=PAT%+1 :PROC_BASICDATA:GOT010270 
10400 PROC_RESULTS
10410 IFM%=1 AND axes%=0 THENM%=0:PROC_SAVECURRENT 
10415 IFM%=1AND axes%=1 THENM%=0:PROC_SAVE 
10420 GOTO10270 
10430 :
10440 DEFPROC_BIOCHEM
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10450 CLS:PROC_DH(0,1 ,STR$(P%+1 )+CHR$129+NAME$(P%)+"
+ UNIT$(P%))
10460 FORT%=0 TO 3:PRINTTAB(0,4+(T%*2));T%+1 ;")"+CHR$129 
;TEST$(T%);TAB(20);CHR$131 ;RESULTS$(P%>T%):NEXT 
10470 AN$=FN_ANSWER("1234"):an%=VALAN$-1 
10480 IFAN$="E"THENAN$="":ENDPROC 
10490
RESULTS$(P%,an%)=FN_INPUT(21,4+(an%*2),4,num$+"."):G0T010470 
10500 :
10510 DEFPROC_DISPLAY1
10520 CLS:VDU28,0,24,39,3:PRINTTAB(0,1)NAME$(P%);TAB(16,1);"PARA " 
;PARITY$(P%);TAB(28,1);"GESTE";GEST$(P%)
10530 PRINTTAB(0,2);"UNIT NO "
;UNIT$(P%);TAB(16,2);''DOB";DOB$(P%);TAB(28l2);"LMP";LMP$(P%)
10540 VDU28,0,24,39,6 
10550 ENDPROC 
10560 :
10570 DEFPROC_DCBP
10580 CLS:PROC_DH(0,1 ,STR$(P%+1 )+CHR$129+NAME$(P%)+H 
"+UNIT$(P%))
10590 FORT%=0 TO 4:PRINTTAB(0,4+(T%*2));T%+1;") Blood Pressure 
;CHR$131;TAB(20);DCBP$(P%,T%):NEXT
10600 PRINTTAB(0,14),,Av Blood Pressure :";CHR$129;TAB(20);DCBP$(P%,6) 
10610 AN$=FN_ANSWER("12345")
10620 IFAN$="E"THENAN$="":ENDPROC
10630 DCBP$(P%,VAL(AN$)-1 )=FN_BP(20,4+((VAL(AN$)-1 )*2))
10640 PROC_AVERAGEBP
10650 PRINTTAB(20,14);DCBP$(P%,6):G0T010610 
10660 :
10670 DEFPROC_AVERAGEBP 
10680 SYST%=0:DIAST%=0:NUM%=0 
10690 FORX%=0 TO 4
10700 IF VALDCBP$(P%,X%)=0 THEN 10720 
10710 SYST%=SYST%+VAL(LEFT$(DCBP$(P%,X%),3)) 
:DIAST%=DIAST%+VAL(RIGHT$(DCBP$(P%,X%)>3)):NUM%=NUM%+1 
10720 NEXT
10730 IFNUM%=0 THEN DCBP$(P%,6)="000/000":ENDPROC 
10740 SYST%=SYST%/NUM%:SYST$=STR$(SYST%) 
:DIAST%=DIAST%/NUM%:DIAST$=STR$(DIAST%)
10750 IFLENSYST$<3 THEN SYST$="0”+SYST$:GOTO10750 
10760 IFLENDIAST$<3 THEN DIAST$=H0"+DIAST$:GOTO10760 
10770 DCBP$(P%,6)=SYST$+7"+DIAST$
10780 ENDPROC 
10790 :
10800 DEFPROC_PROT
10810 CLS:PROC_DH(0,1 ,STR$(P%+1 )+CHR$129+NAME$(P%)+"
+ UNIT$(P%))
10820 PRINTTAB(5J4);CHR$132;"URINALYSIS WARD TESTING"
10830 FORT%=0 TO 5:PRINTTAB(10,5+(T%*2));T%+1;") ";PROT$(T%):NEXT 
10840 PRINTTAB(20,5+(VAL(RESULTS$(P%,4))));"A<==";
:GOTOFN_OK(10850,10900)
10850 PRINTTAB(20,5+(VAL(RESULTS$(P%,4))));"
10860 AN$=FN_ANSWER("12345")
10870 I FAN$="E"THENAN$="":ENDPROC ELSE an%=VALAN$-1
10880 PRINTTAB(20,5+(an%*2));"A<==";:GOTOFN_OK(10820,10890)
10890 RESULTS$(P%,4)=STR$(an%)
10900 ENDPROC
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10910 :
10920 DEFPROCCTG
10930 CLS:PROC_DH(0,1 ,STR$(P%+1 )+CHR$129+NAME$(P%)+"
+ UNIT$(P%))
10940 PRINTTAB(1,4);"CARDIOTOCOGRAPH RESULTS"
10950 FORT%=0 TO 3:PRINTTAB(0,5+(T%*2));T%+1;") ";CTG$(T%):NEXT 
10960 PRINTTAB(20f5+(VAL(CTGAN$(P%))));"A<==";
:GOTOFN_OK(10970,11030)
10970 PRINTTAB(20,5+(VAL(CTGAN$(P%))));"
10980 AN$=FN_ANSWER("1234")
10990 IFAN$="E"THENAN$="":ENDPROC ELSE an%=VALAN$-1
11000 PRINTTAB(20,5+(an%*2));"A<==";:GOTOFN_OK(10940,11010)
11010 CTGAN$(P%)=STR$(an%)
11020 PRINTTAB(5,15);"QBASAL FETAL HEART RATE6" 
:FHR$(P%)=FNJNPUT(30,15,3,num$):GOTOFN_OK(11020,11030)
11030 ENDPROC 
11040 :
11050 DEFPROC_FUDIAG
11060 CLS:PROC_DH(0,1 ,STR$(P%+1 )+CHR$129+NAME$(P%)+"
+ UNIT$(P%))
11070 PRINTTAB(5,4);"DIAGNOSIS"
11080 FORT%=0 TO 4:PRINTTAB(0,6+(T%*2));T%+1;") ";DIAG$(T%):NEXT 
11090 PRINTTAB(30,6+(VAL(DIAGAN$(P%))*2));"A<==";
:GOTOFN_OK(11110,11150)
11100 PRINTTAB(30,6+(VAL(DIAGAN$(P%))*2));"
11110 AN$=FN_ANSWER("12345")
11120 IFAN$="E"THENAN$="":GOTO4540 ELSE an%=VALAN$-1 
11130 PRINTTAB(30,6+(an%*2));"A<==";:GOTOFN_OK(11070,11140)
11140 DIAGAN$(P%)=STR$(an%)
11150 CLS:PROC_DH(0,1 ,STR$(P%+1 )+CHR$129+NAME$(P%)+"
+ UNIT$(P%))
11160 FORT%=0 TO 3:PRINTTAB(0,6+(T%*2));T%+1;") ";FU$(T%):NEXT 
11170 PRINTTAB(5,4);"FOLLOW UP "
11180 PRINTTAB(30,6+(VAL(FUAN$(P%,1))*2));"A<==";
:GOTOFN_OK(11190,11240)
11190 PRINTTAB(30,6+(VAL(FUAN$(P%,1))*2));"
11200 PRINTTAB(8,15);:AN$=FN_ANSWER("1234")
11210 IFAN$="E"THENAN$="":GOTO4630 ELSE an%=VALAN$-1 
11220 PRINTTAB(30,6+(an%*2));"A<==";:GOTOFN_OK(11160,11230)
11230 FUAN$(P%,1 )=STR$(an%)
11240 PRINTTAB(0,15)"FOLLOW UP DATE : A";FUAN$(P%,2);
:GOTOFN_OK(11250,11260)
11250 FUAN$(P%,2)=FN_DATE(20,15,85,86)
11260 ENDPROC 
11270 :
11330 :
11340 DEFPROC_ALREADY 
11350 UNIT$="":ALR%=0
11360 PRINTTAB(0,6)"HAS THIS PATIENT ATTENDED BEFORE":AN$=GET$
11370 IFAN$="N" THEN ATTNO$(P%)="1":PRINTTAB(0,6)"
":ENDPROC
11380 PRINTTAB(0,8)"ATTENDANCE DATE "
11390 ATTDATE$=FN_DATE(20,8,85,86)
11400 ATT$=LEFT$(ATTDATE$,2)+MID$(ATTDATE$,4,2)+RIGHT$(ATTDATE$,2) 
11410 DAT%=OPENIN":4.DTINX88"
11420 INPUT#DAT%,DATInput%,DATIength%
11430 ATT%=OPENIN":5.DC/FL88"
166
11440 SP%=DATinput%-DATIength%
11450 REPEAT 
11460 PTR#DAT%=SP%
11470 INPUT#DAT%fDAT$
11471 date%=FN_LATER(ATT$,DAT$)
11472 IF DAT$="000000" THEN SP%=SP%-DATIength%:GOTO 11490
11473 IF date%<5 THEN SP%=SP%-DATIength%:GOTO 11490
11474 IF date%<0 THEN SP%=SP%+(DATIength%*INT(ABSdate%/2))
11475 IF date%>0 THEN SP%=SP%-(DATIength%*INT(ABSdate%/2))
11490 UNTI LDAT$=ATT$
11500 INPUT#DAT%,begin%,end%:CLOSE#DAT%
11510 REPEAT
11520 PTR#ATT%=begin%:PATIENT$=H"
11530 FORX%=1 TO 15:PATIENT$=PATIENT$+CHR$(BGET#ATT%):NEXT 
11540 IFNAME$(P%)=PATIENT$ THEN GOTO 11565 
11550 UNIT$=FN_BCK(3,1,2,"")
11560 IFUNIT$(P%)=UNIT$ THEN GOTO 11570 ELSE GOTO 11770 
11565 UNIT$(P%)=FN_BCK(3,1,2,"")
11570 DOB$(P%)=FN_BCK(3,1,2,7”)
11580 ALR%=1 :gg%=1 
11590 PARITY$(P%)=FN_BCK(2,1,1,”+”)
11600 DT$=FN_BCK(3,1,2,7")
11610 ATTNO$(P%)=STR$(BGET#ATT%+1)
11620 LMP$(P%)=FN_BCK(3,1,2,7")
11630 EDD$(P%)=FN_BCK(3,1,2,7")
11640 RUBBISH=BGET#ATT%
11645 diff%=FN_LATER(TDDATE$,EDD$(P%))
:IF diff% MOD 7 =0 THEN term%=40 ELSE term%=41
11646 GEST$(P%)=STR$(term%-(diff% DIV 7))+STR$(diff% MOD 7)
11650 REFDATE$(P%)=DT$
11660 OLDDT$=FN_BCK(3,1,2,7")
11670 REFBP$=FN_BCK(2,1,3,7")
11680 BKBP$(P%)=FN_BCK(2,1,3,7")
11690 BKGEST$(P%)=FN_BCK(1,1,2,"")
11700 BP28$(P%)=FN_BCK(2,1,3,"/")
11710 CON$(P%)=STR$BGET#ATT%
11720 REFERAL$(P%,1 )=STR$BGET#ATT%
11730 REFERAL$(P%,1 )="3"
11740 REFERAL$(P%,2)=STR$BGET#ATT%
11750 FOR Y%=0 TO 6:AVBP$=FN_BCK(2,1,3,7"):NEXT 
11760 REFBP$(P%)=AVBP$
11770 begin%=begin%+80:UNTILbegin%=end%+80 
11780 CLOSE#ATT%
11790 PRINTTAB(0,6)"
11800 IFALR%=0 THENPRINTTAB(0,6)" PATIENT NOT FOUND":PROC_SPACE 
11820 PRINTTAB(0,6);"
11830 PRINTTAB(0,8);"
11840 PRINTTAB(0,9);"
11850 ENDPROC 
11860 :
11870 DEFPROC_DISPLAY2
11880 PRINTBKGEST$(P%);"wk BPQ";BKBP$(P%);"£28wk BPQ";BP28$(P%) 
11890 PRINP'From ";REF1$(VAL(REFERAL$(P%,1)));" on ”;REFDATE$(P%) 
11900 PRINP'Reason ";REF2$(VAL(REFERAL$(P%,2)));"EBP";REFBP$(P%) 
11910 LATER%=FN_LATER(REFDATE$(P%),TDDATE$)
11920 PRINP'DC date ";TDDATE$;" ";LATER%;" days after referal"
11930 PRINP'CONSULTANT ";CONS$(VALCON$(P%));TAB(30);"VISIT "
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;ATTNO$(P%)
11940 FORX%=0 TO 3:PRINTTAB(0);X%+1;") BP 
;DCBP$(P%,X%);TAB(19);TEST$(X%)
;TAB(33);"-A";RESULTS$(P%,X%):NEXT
11950 PRINT"5) BP - M;DCBP$(P%,4);TAB(19);TEST$(4);" - " 
;PROT$(VAL(RESULTS$(P%,4)))
11960 IF VALRIGHT$(DCBP$(P%f6),3)<90 THEN PRINT"Av BP -E" 
;DCBP$(P%,6)
;TAB(18);"6CTG - n;CTG$(VALCTGAN$(P%)) ELSE PRINT'Av BP -A" 
;DCBP$(P%,6)
;TAB(18);"£CTG - M;CTG$(VALCTGAN$(P%))
11970 PRINT’DN BP - ";DCBP$(P%,5);TAB(19);"FHR - ”;FHR$(P%)
11980 PRINT'Dlagnosis n;DIAG$(VAL(DIAGAN$(P%)))
11990 FU%=FN_LATER(TDDATE$,FUAN$(P%,2))
12000 PRINT"F/U-";FU$(VAL(FUAN$(P%,1)));'' on ";FUAN$(P%,2)
;"(";FU%;" days later)"
12010 PROC_SPACE 
12020 VDU28.0,24,39,3 
12030 ENDPROC 
12040 :
12042 DEFPROC_DATA 
12045 ram%=0
12047 HEAD$="NEW DAYCARE (1990) ":ADD$="LOADING DATA":PROC_HEAD
12048 P%=0:axes%=0:ok%=0:gg%=0:extra%=0:first%=0 
12049* K.100LD|MGOT030130|M
12055 PROC_DH(0,5,"ACOLLECTING DATA")
12060
DIMCONS$(7),REF1$(3),REF2$(5)lTEST$(4),CTG$(3)JFU$(3),DIAG$(4)
,UNIT$(9),LMP$(9),EDD$(9),GEST$(9)lCON$(9),REFERAL$(9l2)
12070 DIMRESULTS$(9,4),CTGAN$(9),FUAN$(9,2),DIAGAN$(9),REFDATE$(9) 
,REFBP$(9),DCBP$(9,6),BKBP$(9),BKGEST$(9),BP28$(9)
12080 DIMPARITY$(9)>ATTNO$(9),NAME$(9),PROT$(5),DOB$(9)>FHR$(9) 
,ATTDATE$(9),address%(9),day$(7),mon$(12)
12090 FORD%=0 T07:READ CONS$(D%):NEXT 
12100 FORD%=0 T03:READ REF1$(D%):NEXT 
12110 FORD%=0 T05:READ REF2$(D%):NEXT 
12120 FORD%=0 T04:READ TEST$(D%):NEXT 
12130 FORD%=0 T03:READ CTG$(D%):NEXT 
12140 FORD%=0 T03:READ FU$(D%):NEXT 
12150 FORD%=0 T04:READ DIAG$(D%):NEXT 
12160 FORD%=0 T05:READ PROT$(D%):NEXT 
12170 FORD%=1 TO 12:READ mon$(D%):NEXT 
12180 FORD%=0 TO 6:READ day$(D%):NEXT
12182 let$="QWERTYUIOPLKJHGFDSAZXCVBNM-' "
12183 num$="1234567890."
12190 ENDPROC
12200 :
12210 DATA BLACK,LUNANfMACNAUGHTONfMCEWANfWALKER,LAUGHLAND,HOWAT 
.KENNEDY
12220 DATA ANTE NATAL CLINIC,GENERAL PRACTITIONER ANTE NATAL WARD 
.DAYCARE
12230 DATA ESSENTIAL HYPERTENSION,PREGNANCY HYPERTENSION,PAST HISTORY
12240 DATA PROTEINURIA,ON TREATMENT,SMALL FOR DATES
12250 DATA Urea,Urate,Haemoglobin,Platelet Count,Proteinuria
12260 DATA Not Done,REACTIVE,NONREACTIVE,ABNORMAL
12270 DATA ANTE NATAL CLINIC,ADMISSION,DAY CARE,INDUCTION
12280 DATA Normal,Mild PIH,Moderate PIH,Severe PIH
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12290 DATA Essential Hypertension 
12300 DATA None,Trace,+,++,+++,++++
12310 DATA January,February,March,April,May, June.July,August,September 
,October,November,December
12320 DATA Monday ,T uesday,Wednesday .Thursday,Friday,Saturday,Sunday
12330 DATA MAIN MENU,8,TODAYS FILE,CLOSE FILE/PRINT DATA 
ACCESS MASTER FILE,LIST FROM MASTER FILE,GESTATION CALCULATOR 
.CHANGE TODAYS DATE,CHANGE TIME,CHECK DELIVERED PATIENTS,12345678S
12331 DATA SPECIAL,4,ERASE CURRENT FILE,ERASE LAST DATE 
.CHANGE DRIVE,ERASE PATIENT,1234E
12370 DEFPROCJNFO
12375 PROC_DH(0,5,"ALOADING CURRENT FILE")
12380 INFO%=OPENIN"CURRENT"
12390 LOCALP%
12400 FOR P%=0 TO 8
12405 PROC_DH(0,10,"EPATIENT - M+STR$P%)
12410 INPUT#INFO%,NAME$(P%),UNIT$(P%),LMP$(P%),EDD$(P%) 
,GEST$(P%),CON$(P%),REFERAL$(P%,0),REFERAL$(P%,1)
,REFERAL$(P%,2)
12420 INPUT#INFO%,RESULTS$(P%,0),RESULTS$(P%,1),RESULTS$(P%,2)
,RESULTS$(P%,3),RESULTS$(P%,4),CTGAN$(P%),FUAN$(P%,0)
,FUAN$(P%,1)
12430 INPUT#lNFO%,FUAN$(P%,2),DIAGAN$(P%),REFDATE$(P%) 
,REFBP$(P%)
12440 FORX%=0 TO 6:INPUT#INFO%,DCBP$(P%,X%):NEXT
12450 INPUT#INFO%,BKBP$(P%),BKGEST$(P%),BP28$(P%),PARITY$(P%)
,ATTNO$(P%),DOB$(P%),FHR$(P%)
12460 NEXT:INPUT#INFO%,TDDATE$:CLOSE#INFO% 
:D%=FN_CALCDATE(TDDATE$)
12470 PAT%=0:FOR P%=0 TO 8:IF NAME$(P%)<>" "THEN
PAT%=PAT%+1
12480 NEXT
12485 IFR%o1THENPROC_TIME 
12490 ENDPROC 
12500 :
12510 DEFFN_BCK(byte%,times%,l%,slash$)
12520 tot$="M
12530 FOR x%=1 TO byte%
12540 IFtimes%=1 THEN t$=STR$(BGET#ATT%)
ELSE t$=STR$(VAL(CHR$(BGET#ATT%))*times%)
12550 IF LENt$<l% THEN t$="0"+t$:GOTO 12550 
12560 tOt$=tot$+t$
12570 IF x%<byte% THEN tot$=tot$+slash$
12580 NEXT 
12590 =tot$
12600 :
12690 DEFPROCjSAVECURRENT
12695 IF TDDATE$="00/00/00" AND ok%=0 THEN ENDPROC 
12697 CLS:PROC_DH(5,5,"QSAVING CURRENT DATA")
12700 INFO%=OPENUP"CURRENT"
12710 LOCAL P%
12720 FOR P%=0 TO 8
12725 PROC_DH(5,8,"EPATIENT "+STR$(P%+1))
12730 PRINT#INFO%,NAME$(P%),UNIT$(P%),LMP$(P%),EDD$(P%) 
,GEST$(P%),CON$(P%),REFERAL$(P%,0),REFERAL$(P%,1),REFERAL$(P%,2) 
,RESULTS$(P%,0),RESULTS$(P%,1),RESULTS$(P%,2),RESULTS$(P%,3) 
,RESULTS$(P%,4),CTGAN$(P%),FUAN$(P%,0,FUAN$(P%,1)
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12740PRINT#INFO%>FUAN$(P%,2),DIAGAN$(P%),REFDATE$(P%)
,REFBP$(P%)
12760 FORX%=0 TO 6:PRINT#INFO%,DCBP$(P%,X%):NEXT
12770 PRINT#INFO%,BKBP$(P%),BKGEST$(P%)fBP28$(P%),PARITY$(P%)
>ATTNO$(P%),DOB$(P%),FHR$(P%)
12780 NEXT
12790 PRINT#INFO%,TDDATE$
12800 CLOSE#INFO%
12810 ENDPROC 
12820 :
13000 DEFPROC_ERASEPATIENT
13001 first%=0
13010 ADD$=MERASE PATIENT":HEAD$="DAYCARE":PROC_HEAD 
13020 FORP%=0 TO PAT%-1
13030 PROC_DH(0,P%*2,STR$(P%+1 )+CHR$133+NAME$(P%)+H "
+ UNIT$(P%))
13040 NEXT
13050 PROC_DH(0,P%*2ICHR$133+''INPUT PATIENT TO ERASE") 
:A$=FN_ANSWER("123456789")
13060 IF A$="E" THEN PROC_SAVECURRENT:ENDPROC 
13065 CLS
13070 PROC_DH(0,5," ERASING PATIENT "+A$)
13075 A$=STR$(VALA$-1)
13080 INFO%=OPENIN"CURRENT"
13090 LOCALP%
13100 FOR P%=0 TO 8
13104 IF P%=VALA$ AND first%=1 THEN P%=VALA$+1
13105 IF P%=8 THEN PROC_BLANK(8):GOTO13170 
13110 PROC_DH(0,10," READING PATIENT - "+STR$P%)
13120 INPUT#INFO%,NAME$(P%),UNIT$(P%),LMP$(P%),EDD$(P%) 
>GEST$(P%)ICON$(P%)>REFERAL$(P%I0),REFERAL$(P%,1),REFERAL$(P%>2) 
13130 INPUT#INFO%,RESULTS$(P%>0),RESULTS$(P%,1),RESULTS$(P%>2) 
>RESULTS$(P%,3),RESULTS$(P%,4),CTGAN$(P%)JFUAN$(P%,0)
,FUAN$(P%,1)
13140 INPUT#INFO%,FUAN$(P%f2)>DIAGAN$(P%),REFDATE$(P%) 
,REFBP$(P%)
13150 FORX%=0 TO 6:INPUT#INFO%,DCBP$(P%,X%):NEXT
13160 INPUT#INFO%>BKBP$(P%),BKGEST$(P%)JBP28$(P%),PARITY$(P%)
,ATTNO$(P%),DOB$(P%),FHR$(P%)
13165 IF first%=0 AND P%=VALA$ THEN first%=1 :P%=P%-1 
13170 NEXT
13175 INPUT#INFO%,TDDATE$:CLOSE#INFO%:D%=FN_CALCDATE(TDDATE$) 
13180 PAT%=0:FOR P%=0 TO 8:IF NAME$(P%)<>" "THEN
PAT%=PAT%+1 
13192 PRINTP%
13200 NEXT
13205 CLS
13210 GOT013020
13220 NEXT
13300 DEFPROC_BLANK
20000 DEFPROC_TIME
20010 CLS:ADD$="TIME CHECK":PROC_HEAD
20020 MIN$=STR$((TIME DIV 6000)MOD 60)
:HR$=STR$((TIME DIV 360000)MOD 24)
20030 IFLENHR$<2THENHR$="0"+HR$
20040 IFLENMIN$<2THENMIN$="0"+MIN$
20050 PROC_DH(0,5,"ATHE TIME IS "+HR$+":"+MIN$+" OK?")
170
:AN$=INKEY$(6000)
20060 IF AN$="Y"THEN R%=1 :ENDPROC 
20070 IFAN$o"N" THEN 20020  
20080 CLS:PROC_DH(8l5 l"AlNPUT TIME")
20090 PRINTTAB(0,9);"HOURS (00)”
20100 HOUR$=FNJNPUT(20,9,2,num$)
20110 PRINTTAB(0,11 );"MINUTES (00)"
20120 MIN$=FN_INPUT(20,11,2,num$)
20130 TIME=((VALHOUR$*60+VALMIN$)*60)*100 
20140 GOT020020 
20150 ENDPROC 
20160 :
20170 DEFFN_NAMEINPUT(X%,Y%)
20180 NAME$=FNJNPUT(X%,Y%,15,let$)
20190 IFMID$(NAME$,2f1)<>” " OR MID$(NAME$,3,1)=” " THEN NAME$=H" 
20200 NAME$=NAME$+STRING$(15-LEN(NAME$)," ")
:GOTOFN_OK(20180,20210)
20210 =NAME$
20220 :
20230 DEFFN_CALCEDD(d$,w%,y%)
20240 L0CALd%,e%,y%
20245 y%=VALRIGHT$(d$,2)
20250 d%=FN_CALCDATE(d$)
20260 e%=d%-w%+280
20270 IF e%>365 THEN y%=y%+1 :e%=e%-365
20280 =FN_CALCDAY(e%,STR$y%)
20290 :
20300 DEFFN_OK(g%,n%)
20301 IF gg%=1 THEN =n%
20305 LOCALk$:PRINT;CHR$136;” Y/N";:k$=FN_YN:VDU127,127,127 
:IFk$="N"THEN=g% ELSE =n%
20310 :
20320 DEFFN_DATE(X%,Y%,low%,high%)
20325 high%=90
20330 LOCAL D$,add$,key%,valid$
20340 D$="":valid$="1234567890"
20350 PRINTTAB(X%,Y%);"../../..";STRING$(9,CHR$(8));" ";:*FX15,1 
20360 key%=GET:lFkey%=13 AND D$="" THEN =D$
20370 IFkey%=47 THEN GOTO20360
20380 IFkey%=13 AND LEND$=8 THEN GOTO20440
20390 IFkey%=127 AND (LEND$ MOD 3<>0) THEN D$=LEFT$(D$,LEN(D$)-1) 
:PRINTCHR$(key%);".";CHR$(8);:GOTO20360
20400 IFkey%=127 AND (LEND$ MOD 3=0) THEN D$=LEFT$(D$,LEN(D$)-2) 
:PRINTCHR$(key%);CHR$(key%);"./";CHR$(8);CHR$(8);:GOTO20360 
20410 IFLEN(D$)=8 ORINSTR(valld$,CHR$(key%))=0 VDU7:GOTO20360 
20420 PRINTCHR$(key%);:D$=D$+CHR$(key%)
:IFLEND$=2 OR LEND$=5 THEN D$=D$+7":PRINT7";
20430 GOTO20360
20440 IF VAL(MID$(D$,4,2))>12 THENVDU7:GOTO20350
20450 l%=VAL(RIGHT$(D$,2)) MOD 4:IFI%<>0 THEN add$="303232332323"
ELSE add$="313232332323"
20460 IFVAL(LEFT$(D$,2))>28+VAL(MID$(add$,VAL(MID$(D$,4,2)),1)) 
THENVDU7:GOTO20350
20470 IFVAL(RIGHT$(D$,2))>high% OR VAL(RIGHT$(D$,2))<low%
THENVDU7:GOTO20350
20480 GOTOFN_OK(20350,20490)
20490 =D$
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20500 :
20510 DEFFN_CALCDATE(d$)
20520 LOCALd%fadd$,alt%,l%
20530 add$="000031059090120151181212243273304334"
20540 IFLENd$=8THEN alt%=0 ELSE alt%=-1
20550 d%=VAL(LEFT$(d$,2))+VALMID$(add$,VALMID$(d$f4+alt%,2)*3-2f3) 
20560 IFVALRIGHT$(d$,2)MOD 4=0 AND VALMID$(d$,4+alt%,2)>2 
THENd%=d%+1 
20570 =d%
20580 :
20590 DEFFN_CALCDAY(d%,YR$)
20600 LOCALdS.addS.mon^o.day^o.mSjyo 
20610 l%=VAL(RIGHT$(YR$,2)) MOD 4
20620 IFI%<>0 THEN add$="000031059090120151181212243273304334" 
ELSE add$="000031060091121152182213244274305335"
20630 mon%=-1 :REPEAT:mon%=mon%+1 :UNTIL 
d%<VALMID$(add$,mon%*3+1,3) OR mon%=12
20640 day%=d%-VALMID$(add$,(mon%-1)*3+1,3):d$=STR$day%:IFLENd$=1 
THEN d$="0"+d$
20650 m$=STR$mon%:IF LENm$=1 THEN m$="0"+m$
20660 =d$+7"+m$+"/"+YR$
20670 :
20680 DEFFN_DAYNAME(date$)
20682 LOCAL y%,m%,d%,c%,a%,d$
20684 RESTORE20700
20686 y%=VAL(RIGHT$(date$f2)):d%=VAL(LEFT$(date$,2))
20688 m%=VAL(MID$(date$,4>2))-2:IF m%<1 THEN m%=m%+12:y%=y%-1 
20690 c%=(1900+y%) DIV 100
20692 a%=(260*m%-19) DIV 100 + y% DIV 4 + c% DIV 4 +d%+y%-c%*2 
20694 FOR D%=1 TO (INT((a%/7-INT(a%/7))*7+0.1))
20696 READ d$
20698 NEXT
20700 DATAMon.Tues.Wednes.Thurs.Fri.Satur.Sun 
20702 =d$+"day"
20704 :
20706 DEFFN_MONTHNAME(date$)
20708 LOCAL M%,m$:RESTORE 20714
20710 FOR M%=1 TO VAL(MID$(date$,4,2)):READ m$:NEXT
20712 =m$
20714 DATA January.February,March,April.May.June.July,August,September 
.October,November,December 
20716 :
20718 DEFFN_DAYNUMBER(date$)
20720 LOCAL d%,d$
20722 d%=VAL(LEFT$(date$,2))
20724 IF d%>3 AND d%<21 THEN=STR$d%+"th"
20726 d%=d% MOD 10
20728 IF d%=1 THEN =STR$d%+"st"
20730 IF d%=2 THEN =STR$d%+"nd"
20732 IF d%=3 THEN =STR$d%+"rd" ELSE =STR$d%+"th"
20734 :
20736 DEFFN_NAMEDAY(d%,YR$)
20738 LOCALd$,m$
20740 date$=FN_CALCDAY(d%,YR$)
20742 =FN_DAYNAME(date$)+" the "+FN_DAYNUMBER(date$)+" of " 
+FN_MONTHNAME(date$)+", 19"+YR$
20746 :
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20760 :
20770 DEFFN_LATER(f$,s$)
20780 LOCAL f%,s%
20790 f%=FN_CALCDATE(f$)+(VALRIGHT$(f$,2)*365) 
:s%=FN_CALCDATE(s$)+(VALRIGHT$(s$,2)*365)
20800 IF RIGHT$(f$,2)="84" AND f%>30719 THEN YR%=1 ELSE YR%=0 
20810 =s%-f%+YR%
20812 :
20814 DEFPROC_GESTLMP 
20816 CLS
20818 PRINTTAB(5,5)”LMP ":lmp$=FN_DATE(20,5,85,87)
20820 IF TDDATE$="00/00/00" THEN PRINTTAB(5,7)"TODAYS DATE " 
:TDDATE$=FN_DATE(20,7,86,87)
20824 PRINTTAB(5,10)"AGestation isQ H;FN_GEST(lmp$,TDDATE$)
20825 PRINT'"Q<R>eturn to menu E<A>gain":A$=GET$:IF A$="A" THEN GOTO 20816
20826 ENDPROC 
20828 :
20830 DEFFN_GEST(f$,s$):LATER%=FN_LATER(f$,s$)
:=STR$(LATER% DIV 7)+V'+STR$(LATER% MOD 7)
20840 :
20850 DEFFN_AGE(f$,s$):LATER%=FN_LATER(f$,s$):=LATER% DIV 365 
20855 :
20860 DEFPROC_HEAD:VDU26:CLS:X%=(34-(LEN(HEAD$)+LEN(ADD$)))/2 
20870 PROC_DH(X%,OlCHR$132+HEAD$+H - "+ADD$)
20880 PRINTTAB(X%+1,2);CHR$147+STRING$(LEN(HEAD$)
+ LEN(ADD$)+3,"|")
20890 VDU28,Ol24,39,3:ENDPROC 
20900 :
20910 DEFFN_YN:LOCALkey$:*FX15,1
20920 REPEAT:key$=CHR$(GET AND &DF):UNTIL INSTR("YN",key$):=key$
20930 :
20940 DEFPROC_SPACE:*FX15,1
20950 PRINT"TAB(7);CHR$132+"Press"+CHR$131+"SPACE"
+CHR$132+"to continue'':REPEAT:UNTIL GET=32:ENDPROC 
20960 :
20970 DEFPROC_DH(X%,Y%,A$):PRINTTAB(X%,Y%);CHR$141 ;A$
:PRINTTAB(X%);CHR$141;A$:ENDPROC
20980 :
20990 DEFFN_INPUT(X%>Y%,len%,valid$)
21000 LOCALinput$,key%
21010 input$='"'
21020 PRINTTAB(X%>Y%);STRING$(len%,".");STRING$(len%+1 ,CHR$(8));" 
:*FX15,1
21030 key%=GET:IFkey%=13 THEN =input$
21040 IFkey%=127 AND lnput$=,M,THEN =input$
21050 IFkey%=127 THEN input$=LEFT$(input$,LEN(input$)-1) 
:PRINTCHR$(key%);".";CHR$(8);:GOTO21030
21060 IFLEN(input$)=len% ORINSTR(valid$,CHR$(key%))=0 VDU7:GOTO21030 
21070 PRINTCHR$(key%);:input$=input$+CHR$(key%):GOTO21030 
21080 :
21090 DEFFN_BP(X%,Y%)
21100 LOCAL D$,key%,valid$
21110 D$=,,M:valid$=M1234567890"
21120 PRINTTAB(X%,Y%);".../...";STRING$(8,CHR$(8));" ";:*FX15,1 
21130 key%=GET:lFkey%=13 AND D$=,,H THEN =D$
21135 IFkey%=13 AND D$="000/000" THEN =D$
21140 IFkey%=47 THEN GOTO21130
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21150 IFkey%=13 AND LEND$=7 THEN GOTO21220
21160 IFkey%=13 AND LEND$=6 THEN D$=LEFT$(D$,4)+"0"+RIGHT$(D$,2) 
:PRINTTAB(X%,Y%)D$;:G0T021220
21170 IFkey%=127 AND LEND$<>4 THEN D$=LEFT$(D$,LEN(D$)-1)
:PRINTCHR$(key%);".";CHR$(8);:G0T021130
21180 IFkey%=127 AND LEND$=4 THEN D$=LEFT$(D$,LEN(D$)-2)
:PRINTCHR$(key%);CHR$(key%);"./";CHR$(8);CHR$(8);:G0T021130
21190 IFLEN(D$)=7 ORINSTR(valid$,CHR$(key%))=0 VDU7:G0T021130
21200 PRINTCHR$(key%);:D$=D$+CHR$(key%):IFLEND$=3 THEN
D$=D$+7":PRINT7";
21210 GOTO21130
21220 IF VAL(RIGHT$(D$,3))>=VAL(LEFT$(D$,3))THENVDU7:G0T021120 
21230 IF VALRIGHT$(D$,3)>250 OR VALLEFT$(D$,3)>250 
THEN VDU7:G0T021120
21240 IFVALRIGHT$(D$,3)=0 OR VALLEFT$(D$,3)=0 THENVDU7:G0T021120 
21250 GOTOFN_OK(21130,21260)
21260 =D$
21270 :
21280 DEFFN_ANSWER(A$):LOCAL key$:*FX15,1
21282* FX15.1
21285 VDU28,0,24,39,3
21290 A$=A$+"E"
21300 REPEAT
21310 MIN$=STR$((TIME DIV 6000)MOD 60):HR$=STR$((TIME DIV 
360000)MOD 24)
:SEC$=STR$((TIME DIV 100)MOD 60):SEC$=LEFT$(SEC$,2)
21320 IFLENSEC$ <2THENSEC$=,,0"+SEC$
21330 IFLENHR$<2THENHR$=''0"+HR$
21340 IFLENMIN$<2THENMIN$="0"+MIN$
21350
PROC_DH(0,19,CHR$131 +CHR$136+"INPUT"+CHR$137+"ANSWER"+CHR$132 
+"E TO EXIT"+"A"+HR$+":"+MIN$+":"+SEC$)
21360 key$=INKEY$(100):IFkey$="e"THENkey$="E"
21370 IFLENkey$=0 THEN 21310 
21380 UNTIL INSTR(A$,key$)
21390 =key$
21400 :
22000 DEFPROC_GESTATION
22010 CLS:PRINTTAB(8,2)"OGESTATION CALCULATOR"
22020 PRINTTAB(5,5)"A<L>MPQ<S>CANE<E>DDN<M>ENU"
22025 A$=GET$
22030 IF A$="L" THEN PROC_GESTLMP 
22035 IF A$="M" THEN ENDPROC 
22040 IF A$="E" THEN PROC_GESTEDD 
22050 IF A$="S" THEN PROC_GESTSCAN 
22060 GOTO 22010 
22100 DEFPROC_GESTEDD 
22110 CLS
22120 PRINTTAB(5,5)"EDD ":edd$=FN_DATE(20,5,85,87)
22130 IF TDDATE$="00/00/00" THEN PRINTTAB(5,7)"TODAYS DATE " 
:TDDATE$=FN_DATE(20,7,86,87)
22140 LATER%=FN_LATER(TDDATE$,edd$)
22145 IF LATER% MOD 7=0 THEN PRINTTAB(5,10)"AGestation isQ " 
;(40-(LATER% DIV 7));" + 0"
22150 IF LATER% MOD 7<>0 THEN PRINTTAB(5,10)"AGestation IsQ " 
;(40-(LATER% DIV 7+1));" + ";(7-LATER% MOD 7)
22160 PRINT'"A<A>gain Q<R>eturn to menu"
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22170 A$=GET$:IF A$="A" THEN GOTO 22110 
22180 ENDPROC 
22190 DEFPROC_GESTSCAN 
22200 CLS
22210 PRINTTAB(5,5),'SCAN DATE ”:scan$=FN_DATE(20,5,85f87)
22215 PRINTTAB(5,7)"SCAN GEST 00+0”
:gest$=FNJNPUT(20,7,4,"1234567890+"):IF LENgest$<>4 THEN 
VDU7 iGOT022215
22220 IF TDDATE$="00/00/00" THEN PRINTTAB(5,9)"TODAYS DATE " 
:TDDATE$=FN_DATE(20,9,86,87)
22230 LATER%=FN_LATER(scan$,TDDATE$)
22240 wk%=VALgest$:day%=VALRIGHT$(gest$,1)
22250 day%=day%+wk%*7
22260 PRINTTAB(5,10)"AGestation isQ ";(LATER%+day%) DIV 7;" +
";(LATER%+dav%) MOD 7
22270 PRINT"'A<A>gain Q<R>eturn to menu"
22280 A$=GET$:IF A$="A" THEN GOTO 22200 
22290 ENDPROC
30000 REM ERROR TRAP
30001 REPORT :PRINTERL
30004 IF ERL>=4500 AND ERL<=4550 THEN 
DINAinput%=DINAinput%+50:PROC_BACK:GOTO4170
30005 VDU26:MODE 7 
30010* FX2,0
30015 CLOSE#0:IF axes%o1 THEN PROC_SAVECURRENT 
30020 CLS:IF ERR=17 THENPROC_DH(0,10,CHR$131
+"YOU HAVE PRESSED THE"+CHR$132+"ESCAPE"+CHR$131+"KEY"):GOT030080 
30060 :
30065 IF ERL>4000 AND ERL <5600 THEN GOT030070 ELSE CLS 
30070 IF ERR<>17 THEN
PROC_DH(0,5fCHR$131+HTHE"+CHR$132+"ERROR"):REPORT 
:PROC_DH(0f10,CHR$131 +"HAS BEEN MADE IN LINE "+STR$ERL)
30080 PROC_DH(1,13,"ADO YOU WISH TO 
CONTINUE"+CHR$135+"==>"+CHR$130+"(Y)")
30090 PROC_DH(1,15,mADO YOU WISH TO ESCAPE "
+CHR$135+"==>"+CHR$130+"(N)")
30100 Y$=FN_YN
30110 IFY$="Y" AND axes%=0 THEN GOTO 110 
30120 IFY$="Y" AND axes%<>0 THEN RUN ELSE END 
30130 CLS:PROC_DH(1 ,7,"AY0U HAVE PRESSED THE" 
+CHR$132+"BREAK"+CHR$129+"KEY")
30140 PROC_DH(0,10,CHR$131 +"ALL DATA NOT SAVED HAS BEEN LOST")
30150 PROC_DH(1,13,"ADO YOU WISH TO 
CONTINUE"+CHR$135+"==>"+CHR$130+"(Y)")
30160 PROC_DH(1,15t"ADO YOU WISH TO ESCAPE "
+CHR$135+"==>"+CHR$130+"(N)")
30170 Y$=FN_YN
30180 IFY$="Y"THEN RUN ELSE END
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